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1 T-CELL	ACUTE	LYMPHOBLASTIC	LEUKEMIA	
	
“Several	cases	exist	with	a	great	excess	of	white	blood	cells	(…)	In	fact	I	believe	the	excess	of	
white	blood	cells	is	due	to	an	arrest	of	maturation	of	blood.	From	my	theory	on	the	origin	of	
blood	cells,	the	overabundance	of	white	blood	cells	should	be	the	result	of	an	arrest	of	the	
development	of	intermediate	cells.”	
-Alfred	Donné,	1844-	
	
This	text	is	the	first	description	of	leukemia	by	the	hand	of	a	French	physician	Alfred	Donné	in	
18441,	2	and	it	is	quite	remarkable	that	this	already	states	the	main	features	of	leukemia	and	its	
subtype	T-cell	acute	lymphoblastic	leukemia	(T-ALL).	T-ALL	is	a	malignant	disorder	in	which	the	
accumulation	of	several	oncogenic	events	 leads	to	a	differentiation	arrest	during	T-cell	devel-
opment	 in	the	thymus	and	to	an	overpopulation	of	 immature	T-cells	 in	the	blood	stream	and	
infiltration	 of	 lymphoblasts	 in	 the	 bone	marrow.	 These	 immature	 T-cell	 lymphoblasts	 do	 not	
have	the	potential	to	fight	infections	as	normal	T-cells	have	and	since	they	overpopulate	other	
cell	 types	 in	 the	 blood,	 these	 cells	 cannot	 function	 either.	 Clinical	 consequences	 of	 this	 per-
turbed	blood	cell	maturation	are	fatigue,	shortness	of	breath,	multiple	infections,	bruising	and	
easy	bleeding	and	the	presence	of	mediastinal	thymic	masses.	
In	 pediatric	 cancers,	 acute	 lymphoblastic	 leukemia	 is	 the	 most	 prevalent	 malignancy.	 T-cell	
acute	 lymphoblastic	 leukemia	 (T-ALL)	 represents	 10	 to	 15%	 of	 acute	 lymphoblastic	 leukemia	
(ALL)	patients.	The	cure	rates	in	T-ALL	patients	have	risen	tremendously	in	the	last	decades	due	
to	intensified	chemotherapy	protocols.	The	overall	survival	is	nowadays	over	80%	for	pediatric	
T-ALL	and	around	60%	for	adult	T-ALL3,	4.	Despite	the	quite	optimistic	survival	rates,	relapse	pa-
tients	and	patients	with	primary	resistant	T-ALL	have	a	very	bad	prognosis	and	also	the	 long-
term	side	effects	of	chemotherapy	are	not	to	be	neglected4.		
1.1 T-cell	development	
T-cells	are	essential	components	of	 the	 immune	system,	which	protects	 the	body	 from	 infec-
tious	agents	and	the	damage	they	can	cause.	Mature	T-cells	in	the	bloodstream	can	be	subdi-
vided	in	three	main	categories	with	specific	functions:	(1)	cytotoxic	CD8+	T-cells	detect	and	kill	
cells	that	are	infected	by	viruses	or	intracellular	pathogens;	(2)	T-helper	cells	(CD4+)	aid	in	the	
function	of	other	white	blood	cells	by,	for	example,	activating	B-cells	to	produce	antibodies	and	
activating	macrophages	infected	by	pathogens;	(3)	and	regulatory	T-cells	(CD4+)	are	involved	in	
the	suppression	of	lymphocytes	to	strictly	control	the	immune	response.	
Before	T-cells	can	perform	their	function	in	the	blood	stream,	they	have	to	go	through	a	very	
orchestrated	maturation	process	in	the	thymus,	which	includes	several	stages	of	proliferation,	
differentiation	and	selection	(Figure	1).	First,	multipotent	hematopoietic	progenitor	cells	have	
to	migrate	from	the	bone	marrow	to	the	thymus.	These	uncommitted	early	T-cell	progenitors	
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(ETPs)	are	characterized	as	CD34+CD1a-	and	some	of	these	cells	can	still	differentiate	into	sever-
al	hematological	 lineages	(lymphoid,	myeoloid	and	in	some	instances	erythroid	cells)5.	Due	to	
the	absence	of	either	the	CD4	or	the	CD8	receptor	at	the	membrane,	these	first	stages	of	T-cell	
development	are	also	 known	as	 “double	negative”	 thymocytes.	 To	 induce	T-cell	 specification	
and	proliferation,	 strong	NOTCH-signaling	 is	 required,	which	 is	 introduced	by	several	NOTCH-
ligands	(especially	Delta-like	ligand	4,	DLL4)	present	on	the	membrane	of	the	cortical	thymic	ep-
ithelial	cells6.	The	activation	of	NOTCH1-signaling	leads	to	a	subset	of	NOTCH1-primed	ETPs	that	
have	high	levels	of	CD7,	but	still	the	possibility	to	develop	into	natural	killer	(NK)	cells6,	7.	A	re-
cent	study	by	Van	de	Walle	et	al.	 further	elucidated	the	transcriptional	program	leading	to	T-
cell	 commitment,	 with	 the	 transcription	 factor	 ‘GATA	 binding	 protein	 3’	 (GATA3)	 as	 a	 main	
player.	GATA3	represses	some	of	the	NOTCH1	target	genes	(ex.	IGF1R,	DTX1	and	RUNX3)	lead-
ing	to	a	partial	reduction	in	NOTCH1	signaling8.	Next	to	that,	GATA3	represses	several	stem	cell	
genes	(ex.	LMO2	and	MEF2C)	and	genes	necessary	for	NK-lineage	development	and	is	also	in-
volved	in	the	upregulation	of	transcription	factors	necessary	for	the	next	stages	in	T-cell	devel-
opment	(for	example	BCL11B).	Finally,	the	completion	of	T-cell	commitment	is	marked	by	the	
expression	of	CD1a9.		
	
	
Figure	1.	Schedule	of	normal	T-cell	development	in	the	thymus.		CD34+	early	T-cell	progenitors	migrate	from	the	
bone	marrow	to	the	thymus.	 In	the	thymus,	several	environmental	cues	and	transcriptional	regulators	will	guide	
the	T-cell	through	the	different	stages	of	T-cell	development.	Mature	CD4+	αβ,	CD8+	αβ	and	γδ	T-cells	will	leave	the	
thymus	towards	the	blood	stream	and	secondary	lymphoid	organs.	(Based	on	figures	from	12,	13,	illustrations	from	
www.somersault1824.be)	
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After	 T-cell	 commitment,	 the	next	 step	 in	 T-cell	 development	 is	 called	β–selection	which	de-
pends	 upon	 successful	 V(D)J	 recombination	 of	 the	 T-cell	 receptor	 genes	 TCRγ	 and	 TCRδ	 or	
TCRβ.	These	rearrangements	are	orchestrated	by	the	‘Recombination	activated	gene’	(RAG)	re-
combinases	and	the	‘Interleukin	7	receptor‘	(IL7R)	and	result	in	the	joining	of	several	DNA	seg-
ments	through	recombination,	resulting	in	unique	T-cell	receptor	loci.	This	eventually	leads	to	a	
great	 diversity	 of	 antigens	 that	 can	be	detected	by	 T-cells.	 The	RAG	mediated	double	 strand	
breaks	place	the	cells	undergoing	V(D)J	recombination	in	a	vulnerable	position,	exposing	them	
to	unwanted	DNA	damage	and	 illegitimate	 recombination	events.	 To	avoid	 this,	 recombining	
cells	go	into	G1	arrest	until	correctly	assembled	premature	T-cell	receptors	(pre-TCRs)	are	pre-
sent	at	 the	membranes.	The	pre-TCR	consists	of	a	mature	TCRβ-chain	and	a	pre-Tα	chain,	as	
TCRα	rearrangements	only	happen	in	later	stages	of	T-cell	development.	This	pre-TCRα	chain	is	
encoded	by	the	NOTCH1-dependent	‘Pre	T-cell	Antigen	Receptor	α‘	(PTCRA)	gene	and	signaling	
through	this	pre-TCR	receptor	will	shift	the	cells	into	rapid	proliferation6.	Furthermore,	this	will	
lead	to	the	expression	of	CD4	and	CD8	membrane	receptors,	bringing	T-cell	development	in	the	
‘double	positive’	stage.	In	addition,	under	the	impulse	of	a	strong	NOTCH1	signal,	a	small	subset	
of	immature	thymocytes	will	undergo	rearrangements	of	the	TCRγ	and	TCRδ	loci	producing	γδ	
T-cells	with	functions	in	the	stress	response	in	epithelial	cells6,	10.	
As	indicated,	the	double	positive	αβ	T-cells	will	undergo	TCRα	gene	rearrangement.	Given	that	
cells	underwent	a	proliferative	burst	 immediately	after	β-selection,	 thymocytes	are	produced	
with	the	same	β-chain,	but	with	a	large	diversity	of	α-chains,	again	leading	to	an	increase	in	an-
tigen	detection.	A	mature	TCRαβ	receptor	and	the	markers	CD3,	CD4	and	CD8	mark	these	thy-
mocytes,	activating	positive	and	negative	selection	of	the	T-cells.	During	this	stage,	the	interac-
tion	of	the	T-cell	receptor	with	an	antigen	in	the	context	of	the	major	histocompatibility	com-
plex	(MHC)	will	be	evaluated	to	eliminate	autoreactive	T-cells	and	T-cells	without	a	functional	
TCR.	Under	impulse	of	the	downregulation	of	E2A	and	HEB,	this	will	eventually	lead	to	mature	
single	positive	(CD4+	or	CD8+)	TCRαβ	T-cells	that	will	leave	the	thymus	and	will	perform	a	pleth-
ora	of	functions	in	the	bloodstream	and	peripheral	immune	organs	(see	above)11.	
As	can	be	appreciated,	thymic	T-cell	development	is	a	tightly	regulated	process	in	which	several	
transcription	factors	play	a	key	role12-14.	Another	remarkable	event	during	T-cell	development	is	
the	rearrangement	of	the	T-cell	receptor	loci,	which	makes	this	process	prone	to	DNA	damage.	
It	 is	 therefore	 not	 surprising	 that	 this	 process	 can	 go	 astray,	 leading	 ultimately	 to	malignant	
transformation	of	immature	T-cells	towards	full	blown	T-cell	acute	lymphoblastic	leukemia.		
1.2 T-ALL	oncogenic	driver	genes	and	T-ALL	subtypes	
T-ALL	occurs	from	a	multistep	cancer	process	in	which	a	sequence	of	multiple	consecutive	on-
cogenic	events	 leads	to	clonal	expansion	of	developmentally	arrested	malignant	T-cells.	T-ALL	
patients	can	be	subdivided	into	several	genetic	subtypes	based	on	their	transcriptional	profiles	
and	presence	of	mutually	exclusive	driver	oncogenes15-18.		
These	genomic	pictures	of	heterogeneous	T-ALLs	emerged	from	several	studies	using	transcrip-
tome	profiling.	Ferrando	et	al.	was	able	to	couple	the	T-ALL	oncogenes	‘T-cell	leukemia	Home-
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obox	1’	(TLX1/HOX11),	‘T-cell	Acute	Lymphocytic	leukemia	1’	(TAL1)	and	‘LYL1	basic	helix-loop-
helix	family	member’	(LYL1)	to	specific	gene	expression	profiles	by	microarray	expression	profil-
ing.	Next	 to	 that,	 hierarchical	 clustering	of	 expression	profiles	 allowed	 the	 identification	of	 a	
new	subgroup	that	clustered	close	to	the	TLX1	group	and	was	marked	by	high	expression	levels	
of	 ‘T-cell	 leukemia	Homeobox	3’	 (TLX3/HOX11L2)15.	 A	 second	 important	 study	by	 the	 Soulier	
team	detected	a	subset	of	patients	with	an	unknown	disease	mechanism,	which	clustered	in	a	
separate	 group,	 but	 near	 the	TLX1	 and	TLX3	 samples.	 All	 patient	 samples	 in	 this	 cluster	 had	
markedly	elevated	expression	levels	of	HOXA	genes,	resulting	from	a	recurrent	cryptic	chromo-
somal	 rearrangement16.	 In	 addition,	 T-ALL	 samples	 with	 an	 immature	 immunophenotype	
(strong	CD34	expression)	also	marked	a	separate	cluster.	
These	two	papers	thus	detected	new	oncogenic	T-ALL	transcription	factors	by	means	of	gene	
expression	profiling	 and	 they	 discovered	 the	 subtype	 specific	 gene	 expression	pattern	 in	 the	
different	T-ALL	subtypes.	In	the	next	paragraphs,	these	subtypes	will	be	discussed	in	more	de-
tail	and	an	overview	can	be	found	in	Figure	2	and	Table	1.	
	
																	
	
	
Figure	2.	Schematic	overview	of	T-ALL	genetic	subtypes	in	relation	to	their	T-cell	developmental	stage.	T-ALL	oc-
curs	 from	malignant	development	of	 immature	T-cells.	The	genetic	subtypes	of	T-ALL	can	be	 linked	to	a	specific	
stage	of	differentiation	arrest.	(Based	on	a	figure	from	18,	illustrations	from	www.somersault1824.be)	
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1.2.1 Immature	T-ALL	
The	immature	T-ALL	subtype	is	marked	by	a	differentiation	arrest	during	the	very	early,	double	
negative,	stages	of	T-cell	development.	Remarkably,	thus	far	no	recurrent	specific	driver	onco-
gene	could	be	identified.	Immature	T-ALLs	exhibit	high	expression	of	CD34,	LMO2,	MEF2C	and	
LYL1,	together	with	myeloid	markers	CD13	and	CD3315,	16,	19.	In	comparison	to	other	T-ALL	sub-
types,	immature	T-ALL	patients	appear	to	have	fewer	deletions	of	the	CDKN2A	and	CDKN2B	lo-
cus	 and	 less	NOTCH1	 activating	mutations20.	 The	 prevalence	 of	 immature	 T-ALL	 is	 higher	 in	
adult	patients	compared	to	pediatric	cases	and,	remarkably,	some	of	the	oncogenic	mutations	
involved	 in	 immature	T-ALL	development	 (ex.	DNMT3A)	 are	only	present	 in	adult	T-ALL	 sam-
ples21.			
A	part	of	the	immature	T-ALL	cases,	with	a	differentiation	arrest	at	the	ETP-stage	of	T-cell	de-
velopment,	 can	 be	 further	 subclassified	 into	 early	 T-cell	 precursor	 ALL	 (ETP-ALL).	 ETP-ALL	 is	
characterized	by	the	absence	of	expression	of	CD1a	and	CD8,	weak	expression	of	CD5	and	the	
expression	of	 one	or	more	 stem	cell	 or	myeloid	markers	 (CD117,	CD34,	CD13,	CD33,	CD11b,	
CD65	and/or	HLA-DR),	resembling	a	bi-phenotypic	nature22.	Using	whole	genome	sequencing,	
Zhang	et	al.	established	a	comprehensive	genomic	picture	of	the	mutational	landscape	of	ETP-
ALL	 characterized	by	 inactivating	mutations	 in	 genes	 involved	 in	hematopoietic	 development	
(RUNX1,	GATA3,	BCL11B,	ETV6…),	activating	mutations	of	mediators	of	 cytokine	 receptor	 sig-
naling	and	RAS	signaling	(NRAS,	KRAS,	IL7R,	JAK1	…)	and	various	genetic	lesions	affecting	epige-
netic	regulators,	most	notably	the	‘Polycomb	Repressive	Complex	2’(PRC2)	components	EZH2,	
SUZ12	 and	 EED23.	 Of	 further	 interest,	 some	 adult	 ETP-ALL	 patients	 also	 show	 high	 levels	 of	
DNMT3A,	 IDH1	 and	 IDH2,	 which	 are	 known	 oncogenes	 in	 acute	 myeloid	 leukemia	 (AML)	 in	
keeping	with	the	bi-phenotypic	nature	of	ETP-ALL24.	
In	 addition	 to	 the	 early	 studies	 describing	 high	 expression	 levels	 for	 presumed	oncogenes	 in	
immature	T-ALL,	more	 recently	 yet	another	driver	gene	was	added	 to	 the	 list.	Unexpectedly,	
Goossens	et	al.	observed	T-cell	malignancies	with	 immature	characteristics	 in	a	mouse	model	
with	Zeb2	gain-of-function	in	a	p53	knock	out	genetic	background.	Together	with	the	finding	of	
rare	translocations	juxtaposing	ZEB2	 in	the	vicinity	of	the	BCL11B	 locus,	 leading	to	ZEB2	over-
expression	and	BCL11B	downregulation,	this	provided	strong	support	for	an	oncogenic	role	of	
ZEB2	 in	 immature	T-ALL	development.	Further	 functional	 studies	 illustrated	that	ZEB2	caused	
increased	IL7R/JAK/STAT	signaling	driving	thymocyte	proliferation	and	survival25.		
1.2.2 TLX1	and	TLX3	driven	T-ALL	
Five	to	ten	percent	of	pediatric	and	30%	of	adult	T-ALL	cases	has	an	ectopic	expression	of	the	
TLX1	oncogene.	TLX1	(HOX11)	is	a	homeobox	gene	involved	in	the	development	of	the	spleen	
during	embryogenesis	and	is	not	expressed	in	thymocytes.	Translocations	of	the	TLX1	gene	to	
the	 regulatory	 regions	of	 the	 T-cell	 receptor	 genes	 TCRα/TCRδ	or	 TCRβ	have	been	described	
(t(7;10)(q34;q24)	t(10;14)(q24;q11)),	leading	to	the	overexpression	of	TLX126.	The	lymphoblasts	
of	these	patients	showed	an	arrest	at	the	early	cortical	CD1a+	stage	during	T-cell	development,	
prior	to	the	CD4+CD8+	double	positive	stage	and	were	all	committed	to	the	αβ–lineage15,	27.		
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The	oncogenic	role	of	TLX1	in	T-ALL	was	studied	in	more	detail	by	De	Keersmaecker	et	al.,	using	
a	 TLX1	 overexpressing	mouse	model.	 After	 a	 long	 latency,	 these	mice	 developed	 T-cell	 neo-
plasms	with	a	high	degree	of	aneuploidy	and	defects	in	the	mitotic	checkpoints.	Furthermore,	it	
was	 shown	 that	 TLX1	 overexpression	 caused	 inhibition	 of	 T-cell	 differentiation	 and	 required	
additional	 genetic	 events	 for	 further	 T-ALL	 oncogenesis	 such	 as	Notch1	 activating	 and	 Pten,	
Tp53	and	Bcl11b	inactivating	mutations28.	A	remarkable	finding	was	done	by	Durinck	et	al.	who	
studied	the	genome-wide	binding	of	TLX1	in	T-ALL	and	observed	an	unexpected	attenuation	of	
NOTCH1-signaling	 through	 TLX1	 binding	 at	NOTCH1	 regulatory	 sequences	 as	 well	 as	 several	
NOTCH1	targets,	including	NOTCH329.	This	could	explain	the	high	frequency	of	NOTCH1	activat-
ing	mutations	in	TLX1	T-ALL	as	NOTCH1	signaling	is	critical	for	cell	survival.	
Another	homeobox	gene,	TLX3	(HOX11L2),	is	ectopically	expressed	in	approximately	20-25%	of	
pediatric	T-ALL	patients	and	5%	of	adult	T-ALL	cases,	defining	yet	another	T-ALL	subtype30,	31.	
The	overexpression	of	TLX3	 is	mostly	caused	by	a	cryptic	t(5;14)(q35;q32)	translocation	juxta-
posing	TLX3	nearby	the	BCL11B	locus31.	Furthermore,	also	translocations	of	TLX3	to	TCRα/TCRδ	
(t(5;14)(q32;q11))	 and	CDK6	 (t(5;7)(q35;q21))	have	been	described	 in	T-ALL	patients32,	33.	 The	
TLX3	patients	show	a	broader	range	of	differentiation	arrest	as	immature	and	TLX1	T-ALL.	Sev-
eral	cases	have	a	more	immature	immunophenotype	as	compared	to	TLX1	T-ALL,	but	others	are	
then	linked	to	more	mature	αβ	or	γδ	lineages27,	34,	35.	
An	 elegant	 study	 discovered	 that	 TLX1	 and	 TLX3	 positive	 T-ALLs	 showed	 a	 low	 frequency	 of	
TCRα	rearrangements	and	high	repressive	H3K27me3	histone	marks	at	the	TCRα	locus.	This	led	
to	the	discovery	that	TLX1	and	TLX3	interact	with	ETS1,	resulting	in	the	epigenetic	silencing	of	
the	TCRα	locus	and	the	specific	tumor	differentiation	stage36.		
1.2.3 TAL-rearranged	T-ALL	
The	 TAL-rearranged	 (TAL-R)	 subtype	 represents	 T-ALLs	 arising	 through	 overexpression	 of	
E2A/HEB	transcription	factors	due	to	unscheduled	constitutive	TAL1,	LYL1	or	LMO2	activation	
during	thymopoiesis.	TAL1	was	first	discovered	through	the	rare	translocations	t(1;14)(p32;q11)	
and	 t(1;7)	 (p32;q35))37,	 leading	 to	 the	 juxtaposition	 of	 TAL1	 near	 strong	 enhancers	 of	 the	
TCRα/TCRδ	or	TCRβ	loci.	Subsequently,	a	highly	recurrent	cryptic	interstitial	1p32	deletion	was	
detected	in	25%	of	T-ALL	cases,	placing	TAL1	under	the	control	of	the	STIL	promotor37.	The	class	
B	 helix-loop-helix	 (bHLH)	 protein	 TAL1	binds	 LIM-domain	only	 proteins	 (LMO1	or	 LMO2)	 and	
overexpression	of	these	LMO	genes	themselves	is	a	second	mechanism	linked	to	this	T-ALL	sub-
type.	Typically,	LMO1/2	activation	is	detected	in	10%	of	T-ALL	cases	and	results	from	TCR	medi-
ated	 illegitimate	 recombination	 events	 producing	 various	 translocations	 (t(11;14)(p13;q11),		
t(7;11)(q35;p13),	t(11;14)(p15;q11)	or	t(7;11)	(q35;p15))38,	39.	In	addition,	interstitial	11p13	de-
letions	have	also	been	detected,	removing	a	negative	regulatory	element	of	LMO240.	TAL-R	T-
ALL	cases	are	arrested	at	a	relatively	 late	stage	during	T-cell	development	and	therefore	pre-
sent	a	more	mature	CD3+CD4+CD8+	double	positive	phenotype	from	the	αβ	T-cell	lineage27.		
Further	studies	have	unraveled	the	mode	of	action	of	the	TAL1	transcription	factor.	TAL1	was	
shown	to	be	part	of	a	large	complex,	called	the	TAL1-complex,	containing	also	LMO2,	RUNX1,	
E2A	and	HEB41-43.	Members	of	this	complex	could	interact	with	the	histone	acetylase	p300	lead-
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ing	to	the	activation	of	target	genes	including	MYB	and	TRIB2	44,	45.	Furthermore,	this	complex	
activates	miRNA-223,	which	inhibits	the	expression	of	FBXW7,	a	known	tumor	suppressor	gene	
in	T-ALL	that	acts	through	the	inhibition	of	NOTCH1	signaling46.	
1.2.4 HOXA	driven	T-ALL	
The	HOXA	 subgroup	 is	 typically	marked	 by	 cases	with	 illegitimate	 TCR	 rearrangement	 driven	
HOXA	 gene	 cluster	 activation.	 The	 prototypical	 rearrangement	 is	 a	 pericentric	 inversion	 of	
chromosome	7	(inv(7)(p15q34))	which	was	shown	to	activate	several	HOXA	cluster	genes,	most	
notably	HOXA9,	HOXA10	and	HOXA11,	and	presents	with	a	mature	immunophenotype	of	either	
the	αβ-	 or	 the	 γδ-lineage16,	47.	 In	 addition	 to	HOXA	 cluster	 rearranged	 cases,	HOXA	gene	up-
regulation	could	also	result	from	other	oncogenic	events	through	e.g.	formation	of	the	CALM-
AF10	 (t(10;11)(p13;q14)	 or	 the	 SET-NUP214	 (del(9q34))	 fusion	 protein48,	 49.	 The	 CALM-AF10	
protein	interacts	with	DOT1L,	an	H3K79	methyltransferase	that	is	required	for	HOXA	activation,	
while	SET-NUP214	was	shown	to	act	as	a	transcriptional	cofactor	for	HOXA	genes49,	50.	Further-
more,	a	small	subset	of	T-ALL	cases	that	cluster	in	this	subgroup	carries	MLL-rearrangements51,	
52.	The	MLL-ENL	and	MLL-AF10	fusion	proteins	also	interact	with	DOT1L	leading	to	the	activa-
tion	of	 the	HOXA	 genes53.	These	 indirect	HOXA	 activated	cases	have,	 in	comparison	 to	HOXA	
cluster	rearranged	cases,	an	immature	or	a	γδ	immunophenotype.	
1.2.5 A	quest	to	link	T-ALL	subtypes	to	prognosis	
In	the	last	decade,	several	studies	have	been	published	trying	to	link	T-ALL	patients	from	a	spe-
cific	subgroup	to	a	good	or	bad	prognosis.	There	was	first	of	all	a	specific	focus	on	the	ETP-ALL	
cases	 as	 they	 were	 linked	 to	 a	 very	 poor	 prognosis	 and	 a	 high	 risk	 of	 relapse	 in	 multiple	
studies19,	21,	22	56.	However,	in	recent	years,	these	findings	couldn’t	be	validated,	as	in	new	clini-
cal	studies	there	was	a	similar	outcome	for	both	ETP-ALL	and	non	ETP-ALL	patients57-59.	One	of	
the	possible	reasons	could	be	the	intensified	treatment	protocols	in	these	recent	studies,	which	
already	led	to	a	very	good	survival	rate	for	all	T-ALL	patients.	The	TLX1	patients	were	linked	to	a	
favorable	outcome,	 as	patients	with	CD1a+	lymphoblasts	 (most	of	TLX1	 T-ALL	patients)	 had	a	
good	survival	prognosis	due	to	the	low	expression	of	anti-apoptotic	genes	during	the	early	cor-
tical	stages	of	T-cell	development15,	54.	On	the	other	hand,	TLX3	patients	were	first	linked	to	a	
poor	outcome,	but	also	this	could	not	be	confirmed	by	others15,	27,	30,	60-62.	The	difficulty	to	iden-
tify	 specific	patients	with	a	bad	prognosis	 in	 the	 last	 studies	might	be	due	 to	 the	 increase	 in	
overall	survival	of	T-ALL	cases	due	to	intensified	treatment	protocols.	However,	the	prognosis	
for	relapse	patients	in	T-ALL	remains	extremely	poor,	it	might	be	crucial	to	identify	the	specific	
oncogenic	mechanism	that	leads	to	these	relapses.			
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Table	1.	Summary	of	the	most	frequent	oncogenic	driver	events	for	T-ALL	subtypes.	
	 Mechanism	of	activation	 Frequency	 Ref	
Immature	T-ALL	
No	specific	oncogenic	driver	event	
TLX1/3	T-ALL	
TLX1	 Translocations	to	TCRα/TCRδ	or	TCRβ	 5-10	%	of	pediatric	T-ALL	
30	%	of	adult	T-ALL	
15,	 26,	
54	
TLX3	 Translocation	to	BCL11B	locus		 20-25	 %	 of	 pediatric	 T-
ALL	
5	%	of	adult	T-ALL	
31-33	
	
TAL-rearranged	T-ALL	
TAL1	 Interstitial	 deletion	 placing	 TAL1	 under	 the	
control	of	the	STIL	promoter	
25	%	 37	
LMO2	 Translocations	to	TCRα/TCRδ	or	TCRβ	
Deletion	 to	 remove	 negative	 regulatory	 ele-
ment	
6	%	
3	%	
38,	39	
HOXA	T-ALL	 	 	 	
HOXA	 inv(7)(p15q34)	
	
3	%	 16,	47	
CALM-AF10	 t(10;11)(p13;q14)	leads	to	a	novel	fusion	pro-
tein	
5-10	%	 48,	55		
SET-NUP214	 del(9q34)	leads	to	a	novel	fusion	protein	 3	%	 49	
	
1.3 Cooperative	genetic	defects	in	T-ALL	formation		
As	indicated	above,	T-ALL	oncogenesis	 is	a	multistep	process.	 In	addition	to	the	inappropriate	
activation	of	the	above-mentioned	proto-oncogenes	as	initiating	event,	further	genetic	altera-
tions	are	required	to	breach	other	tumor	suppressing	signaling	pathways	in	order	for	the	cells	
to	become	fully	malignant.	Decades	of	research,	including	most	notably,	recent	whole	genome	
sequencing	 efforts,	 have	 provided	 a	 detailed	 view	 on	 the	 plethora	 of	 oncogenes	 and	 tumor	
suppressors	 implicated	 in	 this	 complex	 process63.	 Of	 these,	 one	 of	 the	most	 frequently	 per-
turbed	pathways	 is	 controlled	by	NOTCH1,	known	 to	play	multiple	crucial	 roles	 in	controlling	
normal	 T-cell	 development10,	64-70	with	 overactivation	 of	NOTCH1-signaling	 being	 observed	 in	
over	 half	 of	 T-ALL	 patients71.	 In	 addition,	 deletions	 of	 the	 cell	 cycle	 regulators	 CDKN2A	
(p16/INK4A)	or	CDKN2B	 (p14/ARF)	are	also	highly	recurrent	genetic	defects	detected	 in	up	to	
70%	of	the	cases72.	Like	in	most	other	cancer	entities,	sequencing	studies	have	revealed	loss	of	
function	mutations	 in	epigenetic	regulators	 including	PHF6,	UTX,	SUZ12	and	EZH223,	73,	74.	Fur-
ther	important	oncogenic	events	are	the	inactivation	of	WT175	and	PTEN76,	77	or	the	overexpres-
sion	of	MYB78,	79	and	IL7R80,	81.	An	overview	of	the	most	frequent	oncogenic	events,	next	to	the	
T-ALL	subtype	driving	events,	can	be	found	in	Table	2.	
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Table	2.	Cooperative	genetic	defects	in	T-ALL.	The	most	frequent	oncogenic	events	detected	in	T-ALL	irrespective	
of	the	T-ALL	subtype	driver	events.	(Based	on63)	
	 Oncogenic	lesion	 Frequency	 Ref	
Oncogenes	
NOTCH1	 Activating	mutation	 >	60	%	 71	
IL7R	 Activating	mutation	 10	%	 80,	81	
JAK1/3	 Activating	mutation	 10-25	%	 23,	82	
MYB	 t(6;7)(q23;q24)	
Duplication	
3	%	
8	%	
78,	79	
Tumorsuppresor	genes	
CDKN2A/2B	 9p21	deletion	 >	70	%	 72	
PHF6	 Inactivating	 mutation	 or	 dele-
tion	
20-40	%	 74	
FBXW7	 Inactivating	mutation	 10-30	%	 83,	84	
RUNX1	 Inactivating	 mutation	 or	 dele-
tion	
10-20%	 85,	86	
EZH2	 Inactivating	 mutation	 or	 dele-
tion	
10-15%	 23	
PTEN	 10q23	deletion	
Inactivating	mutation	
10-15	%	
10-15	%	
76,	77	
BCL11B	 Inactivating	 mutation	 or	 dele-
tion	
10	%	 87	
SUZ12	 Inactivating	 mutation	 or	 dele-
tion	
10	%	 23	
WT1	 Inactivating	 mutation	 or	 dele-
tion	
10	%	 75	
	
	
	
The	NOTCH1	oncogene	
The	NOTCH1-signaling	pathway	is	highly	conserved	across	species,	transmitting	signals	from	the	
cellular	 environment	 directly	 into	 changes	 in	 gene	 expression.	 NOTCH1	 is	 a	 heterodimeric	
transmembrane	 receptor	 that	 is	 activated	 through	 Serrate-like	 (JAG1	 or	 JAG2)	 or	 Delta-like	
(DLL1,	DLL4)	ligands.	Upon	interaction	of	the	receptor	with	one	of	its	ligands,	a	conformational	
change	occurs,	leading	to	the	proteolytic	cleavage	of	the	receptor	by	an	ADAM	metalloprotease	
and	a	γ-secretase	complex.	This	cleavage	releases	the	intracellular	part	of	the	receptor	(ICN1),	
containing	a	nuclear	 localization	signal	(NLS).	 In	the	nucleus,	 ICN1	functions	as	a	transcription	
factor	in	complex	with	RBPJκ,	aiding	in	the	DNA	binding,	and	with	the	co-activating	ligand	of	the	
Mastermind-like	family	(MAML)88.	This	complex	activates	a	plethora	of	genes,	including	c-MYC,	
HES1,	DTX1	and	IL7R,	through	the	recruitment	of	chromatin	remodeling	complexes	and	histone	
acetyltransferases	 (CBP/p300)89.	 FBXW7,	 an	 E3-ubiquitin	 ligase,	 terminates	NOTCH1-signaling	
due	 to	 the	 recognition	 of	 the	 PEST-domain	 in	 ICN1,	 which	 leads	 to	 its	 proteasomal	
degradation84.	In	the	absence	of	ICN1,	RBPJκ	associates	with	co-repressors	that	recruit	histone	
deacetylases	(HDACs),	repressing	the	activation	of	NOTCH1	target	genes90.	(Figure	3)		
Notch	signaling	 is	 involved	 in	development	and	cellular	processes	 in	several	 tissues,	 including	
epithelial,	 endothelial,	 neuronal,	 bone,	 blood	 and	 muscle	 cells91	 and	 as	 already	 mentioned,	
	
	
	
18	
NOTCH1-signaling	is	an	important	regulator	of	T-cell	development.	Strong	NOTCH1	signaling	is	
first	required	for	T-cell	lineage	specification,	while	subsequent	signaling	needs	to	be	downregu-
lated	to	inhibit	natural	killer	cell	formation8.	After	T-cell	commitment,	NOTCH1	is	again	neces-
sary	in	the	steps	leading	to	the	β-selection	checkpoint	and	the	γδ	T-cell	development.		
											
	
Figure	3.	NOTCH1-signaling	pathway.	The	 interaction	of	 the	NOTCH1	receptor	on	the	surface	of	 the	early	T-cell	
progenitors	(Receiving	Cell)	with	the	DLL4	ligand	expressed	on	the	surface	of	thymic	stroma	cells	(Sending	Cell)	re-
sults	in	proteolytic	cleavage	of	the	receptor.	The	intracellular	domain	of	NOTCH1	(ICN1)	is	released	from	the	mem-
brane	and	 translocates	 to	 the	nucleus,	where	 it	 interacts	with	RBPJ	and	MAML1.	This	complex	activates	 the	ex-
pression	of	NOTCH1	target	genes,	leading	to	cell	differentiation,	T-cell	lineage	commitment,	proliferation	and	sur-
vival.	The	termination	of	NOTCH1	signaling	is	mediated	by	FBXW7.	The	NOTCH1	signaling	pathway	can	be	thera-
peutically	 targeted	 through	 GSI	 (γ-secretase	 inhibitor)	 based	 blocking	 of	 the	 γ-secretase	 cleavage,	 antibodies	
blocking	 the	NOTCH1-receptor	or	 the	 small	peptide	SAHM1	 inhibiting	 the	 ICN1-transcriptional	 complex.	 	 (Based	
on63,	illustration	from	www.somersault1824.be)	
In	over	half	of	the	T-ALL	patients,	an	overactivation	of	the	NOTCH1-signaling	pathway	is	driving	
the	 immature	T-cells	to	an	oncogenic	proliferation.	The	role	of	NOTCH1	in	T-ALL	was	first	de-
scribed	 by	 a	 rare	 t(7;9)(q34;q34.3)	 translocation,	 leading	 to	 the	 constitutive	 activation	 of	
NOTCH192.	Much	later,	the	high	frequency	of	NOTCH1	mutations	was	detected	through	the	dis-
covery	of	several	hot	spot	activating	mutations.	First	of	all,	there	are	the	missense	mutations	or	
small	indels	in	the	heterodimerization	domain	(HD).	Secondly,	nonsense	mutations,	insertion	or	
deletions	can	lead	to	a	partial	or	complete	removal	of	the	PEST	domain,	which	inhibits	the	deg-
radation	of	ICN1	by	FBXW7	in	the	nucleus.	Several	patients	were	also	identified	with	a	combi-
HD
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nation	of	mutations	in	both	the	HD	and	the	PEST	domain71.	Inactivating	mutations	or	deletions	
of	FBXW7	also	increase	the	NOTCH1-signalling	and	frequently	occur	in	T-ALL.	These	mutations	
interfere	with	the	interaction	of	FBXW7	and	ICN1,	decreasing	ICN1	degradation,	but	additional-
ly	also	blocking	degradation	of	c-MYC,	one	of	the	major	NOTCH1	downstream	targets83,	84.	Also	
several	translocations	leading	to	the	overexpression	of	c-MYC	have	been	detected	in	T-ALL	pa-
tients93,	94	and	recently	the	focal	duplication	of	a	c-MYC	enhancer	was	proven	oncogenic	in	5	%	
of	T-ALL	cases95	(see	Box	1).	
The	effect	of	oncogenic	NOTCH1	signaling	can	be	linked	to	several	direct	NOTCH1	target	genes	
involved	in	anabolic	pathways	and	cell	growth,	with	MYC,	IL7R,	PTCRA	and	IGF1R	as	major	ef-
fectors96-99.	Activated	NOTCH1	also	affects	cell	growth	by	interacting	with	the	PI3K/AKT/mTOR	
pathway100.		Next	to	the	effects	on	cell	growth,	NOTCH1	promotes	G1/S	cell	cycle	progression	
through	 the	 upregulation	 of	 CDK4	 and	 CDK6101	 and	 the	 downregulation	 of	 p27/KIP	 and	
p18/INK4C102.	By	activating	NF-κB,	NOTCH1	might	also	be	involved	in	increased	cell	survival103.	
Furthermore,	NOTCH1	can	control	several	epigenetic	modulators	of	gene	expression104.		
	
All	of	the	above	clearly	indicates	that	NOTCH1	is	an	important	effector	in	T-ALL	oncogenesis	in	
over	half	of	T-ALL	patients	thus	putting	NOTCH1	as	a	major	target	for	precision	drugging.	Gam-
ma-secretase	inhibitors	(GSIs)	were	the	first	compounds	of	choice,	leading	to	a	decrease	in	in-
Box	1.	A	NOTCH1-controlled	long	range	MYC	enhancer95.	
In	2014,	 the	 Ferrando	 team	detected	 a	 focal	 duplication	 located	1.4	Mb	downstream	of	
the	MYC	oncogene	in	5	%	of	T-ALL	cases.		Interestingly,	this	region,	which	is	devoid	of	pro-
tein	coding	genes,	appeared	to	be	bound	by	the	intracellular	NOTCH1	complex	in	T-ALL	cell	
lines.	Further	analysis	of	regulatory	factors	and	epigenetic	histone	marks,	revealed	the	ac-
tive	 enhancer	 features	 of	 this	 region	 (ex.	 P300	 occupancy,	 high	 H3K27ac	 and	 high	
H3K4me1/H3K4me3	ratio).	Next	to	that,	3C-analysis	(Chromosome	Conformation	Capture)	
confirmed	the	association	of	the	MYC	promoter	and	this	enhancer	and	reporter	assays	re-
vealed	an	enhancer	dose	dependent	activation	of	the	promoter.	This	enhancer	was	named	
the	NOTCH-bound	MYC	enhancer	(N-Me).	
In	vivo	N-Me	knockout	(N-Me-/-)	mice	were	viable,	but	with	a	reduced	thymus	size	and	cel-
lularity.	 In	the	 thymus,	 there	appeared	an	accumulation	of	double	negative	T-cells	and	a	
reduction	in	double	positive	and	CD4+	and	CD8+	single	positive	cells.	Furthermore,	hetero-
zygous	N-Me	in	a	NOTCH1-induced	tumor	model	could	delay	tumor	development,	whereas	
N-Me	knockout	could	fully	inhibit	tumor	initiation.	This	shows	a	strong	dose	dependent	ef-
fect	of	the	N-Me	enhancer	on	the	NOTCH1-leukemia	initiation,	with	the	N-Me	regulation	
of	MYC	expression	as	a	major	cause.		
With	 this	study,	 the	oncogenic	effect	of	a	 focal	duplication	 in	a	 region	devoid	of	protein	
coding	genes	was	proven.	This	was	the	first	enhancer	that	showed	to	have	major	 impact	
on	T-ALL	development	and	marks	the	importance	of	non-coding	regions	in	gene	regulation.		
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tracellular	NOTCH1105.	The	first	clinical	trials	of	these	GSIs	showed	at	first	an	anti-leukemic	ef-
fect,	but	soon	resistance	to	this	compound	was	encountered106.	Another	disadvantage	of	this	
treatment	 was	 the	 dose-limiting	 gastrointestinal	 toxicity,	 resulting	 from	 the	 inhibition	 of	
NOTCH1	and	NOTCH2	in	the	intestinal	progenitor	cells107.	Various	drug	combinations	with	GSIs	
were	 tested	 to	 look	 for	 drugs	 that	 could	 alleviate	 the	 side	 effects	 and	 glucocorticoids	 were	
identified	as	a	candidate.	Combination	regimens	with	chemotherapy	or	drugs	 targeting	other	
pathways	 involved	 in	T-ALL	 (ex.	NF-κB	signaling103,	PI3K-AKT-mTOR	 inhibitors108	and	HDAC	 in-
hibitors109)	could	also	be	used.	Other	therapeutic	options	would	be	the	use	of	an	antibody	that	
specifically	blocks	 the	NOTCH1	 receptor110,	 the	 inhibition	of	 the	ADAM	metalloprotease111	or	
the	inhibition	of	the	ICN1-RBPJκ-MAML1	transcriptional	complex	by	a	peptide	called	SAHM1112.	
Further	 research	 to	 the	downstream	effectors	of	NOTCH1	oncogenesis	might	 lead	 to	 the	dis-
covery	of	new	drugging	targets.		
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2 NONCODING	RNAS	
	
“Only	a	small	proportion	of	the	RNA	made	in	the	nucleus	of	animal	and	higher	plant	cells	serves	
as	a	template	for	the	synthesis	of	protein.	This	RNA	is	characterized	by	its	ability	to	assume	a	
form	which	protects	it	from	intracellular	degradation.	Most	of	the	nuclear	RNA,	however,	is	
made	on	parts	of	the	DNA	which	do	not	contain	information	for	the	synthesis	of		
specific	proteins.”	
-Henry	Harris,	1965-	
	
In	1964,	Henry	Harris	discovered	that	a	large	amount	of	RNA	molecules	in	the	nucleus	were	not	
transferred	to	the	cytoplasm	where	translation	takes	places1.	This	led	to	the	comment	one	year	
later	in	a	book	chapter	in	“Evolving	Genes	and	Proteins”2,	describing	for	the	first	time	the	exist-
ence	of	noncoding	RNAs.	H.	Harris	saw	these	noncoding	transcripts	as	a	part	of	evolution	and	
assumed	these	molecules	would	undergo	mutations	and	evolve	into	messenger	RNAs	(mRNAs).	
However,	 science	only	needed	a	 few	more	years	 to	appreciate	 the	existence	and	 function	of	
noncoding	RNAs	as	R.W.	Holley	was	awarded	with	the	Nobel	Prize	for	his	research	that	led	to	
the	identification	of	the	structure	and	sequence	of	the	transfer	RNA	(tRNA)	for	alanine3-5.		
2.1 Discovery	and	diversity	of	noncoding	RNAs	
In	the	 late	1950s,	Francis	Crick	hypothesized	about	the	flow	of	genetic	 information	and	came	
with	 the	 idea	he	 called	 “The	 central	 dogma”.	 This	 theory	 states	 that	DNA	 is	 transcribed	 into	
RNA,	which	is	then	translated	into	protein,	the	molecule	with	the	active	function,	and	that	the	
information	cannot	be	 transferred	back	 from	protein	 to	nucleic	acid6.	 It	was	 just	a	 few	years	
later	 that	 the	 first	 RNA	molecule	with	 a	 function	by	 itself	was	described	by	R.W.	Holley,	 the	
tRNA3,	4.	A	tRNA	is	the	adaptor	between	the	mRNA	and	the	amino	acid	sequence	of	proteins,	
following	 the	genetic	 code.	Other	 important	 functional	noncoding	RNAs,	 the	 ribosomal	RNAs	
(rRNAs),	were	discovered	in	the	1980s	and	it	appeared	that	they	were	also	involved	in	protein	
synthesis	as	important	components	of	the	ribosomal	ribonucleoprotein	complex.	This	led	to	the	
discovery	that	RNA	molecules	can	have	a	catalytic	function,	calling	them	ribozymes7-9.		
Since	 the	 discovery	 of	 DNA,	 RNA	 and	 proteins,	molecular	 biology	 research	 has	 boomed	 and	
more	 functional	 noncoding	 RNA	molecules	were	 discovered	 to	 be	 involved	 in	 several	 crucial	
pathways	 in	the	cell.	Most	of	these	RNAs	are	now	characterized	as	small	noncoding	RNAs,	as	
they	are	not	longer	than	200	nucleotides.	DNA	replication	makes	use	of	the	small	noncoding	Y	
RNAs	 for	 their	 interaction	with	 chromatin	 and	 initiation	proteins10 and	 these	 Y	RNAs	 are	 re-
quired	for	cell	proliferation	in	tumors11.	Furthermore,	small	nuclear	RNAs		(snRNAs)	are	part	of	
the	spliceosome,	having	a	role	in	pre-mRNA	splicing12	and	small	nucleolar	RNAs	(snoRNAs)	are	
involved	 in	 the	 RNA-editing	 process13,	 14.	 Piwi-interacting	 RNAs	 (piRNAs)	 are	 necessary	 for	
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spermatogenesis	and	 function	by	guiding	the	PIWI	proteins	 to	 transposons	to	 induce	their	si-
lencing15.	 Another	 example	 of	 small	 ncRNAs	 are	 microRNAs	 which	 are	 involved	 in	 post-
transcriptional	gene	regulation,	this	type	of	ncRNAs	will	be	discussed	in	more	detail	in	section	
2.2.	 Very	 recently,	 the	 involvement	 of	 a	 short	 guide	 RNA	 (gRNA)	 was	 discovered	 in	 the	
CRISPR/Cas	system	in	the	prokaryotic	immune	defense.	This	system	uses	a	Cas	endonuclease	to	
cleave	viral	DNA	and	the	gRNA	is	necessary	for	the	guidance	of	the	endonuclease	complex	to	
the	viral	DNA16-18.		
Another	important	noncoding	RNA	is	the	Telomerase	RNA	Component	(TERC).	The	telomerase	
ribonucleoprotein	is	responsible	for	the	maintenance	of	the	telomere	length	at	the	end	of	the	
chromosomes.	 The	 TERC	RNA	of	 this	 complex	 is	 over	 500	 nucleotides	 in	 size	 and	 has	 a	 dual	
function.	It	acts	as	a	scaffold	for	several	proteins	of	the	complex	and	it	also	contains	the	tem-
plate	RNA	sequence	for	DNA	synthesis	by	the	Telomerase	Reverse	Transcriptase	(TERT)19.	In	the	
last	 decade,	 much	 work	 has	 been	 done	 on	 the	 so-called	 long	 noncoding	 RNAs	 (lncRNAs),	
noncoding	 RNA	 molecules	 with	 a	 length	 of	 at	 least	 200	 nucleotides,	 and	 several	 of	 these	
lncRNAs	have	been	discovered	with	a	broad	diversity	of	 functions.	One	a	example	 is	 the	XIST	
lncRNA	that	is	involved	in	dosage	compensation	by	recruiting	the	PRC2-complex	that	enhances	
epigenetic	silencing	of	one	X-chromosome20,	21.	The	role	of	lncRNAs	in	the	cell	and	in	cancer	is	
discussed	in	more	detail	in	section	2.3.			
With	the	discovery	of	several	functional	noncoding	RNAs	it	became	clear	that	the	genome	was	
more	than	just	DNA	coding	for	proteins	(2%)	and	‘junk’	DNA	(98%).	The	group	of	John	Mattick	
further	 established	 the	 importance	 of	 the	 noncoding	 DNA.	 They	 showed	 that	 the	 ratio	 of	
noncoding	DNA	to	the	full	genomic	sequence	could	explain	the	complexity	of	species,	with	low	
complex	 species	 having	 relatively	 less	 noncoding	DNA	 and	with	Homo	 sapiens	on	 top	 of	 the	
list22.	This	was	a	response	to	the	G-value	paradox,	which	states	that	there	is	no	relationship	be-
tween	the	amount	of	coding	genes	and	the	species	complexity23.	With	this,	 it	 is	hypothesized	
that	the	key	to	the	complexity	of	organisms	lies	to	a	large	extent	in	the	size	of	the	genome	from	
which	noncoding	RNAs	are	transcribed.	One	of	the	recent	estimates	is	that	less	than	2%	of	the	
genome	is	coding	for	proteins	and	at	least	75%	is	actively	transcribed	into	noncoding	RNAs24.	In	
the	next	parts,	the	role	of	miRNAs	and	lncRNAs	in	the	normal	cellular	processes	and	in	cancer	
development	will	be	discussed	in	more	detail.	
2.2 MicroRNAs	
2.2.1 MicroRNA	biogenesis	and	function	
In	1993,	the	Ambros	team	described	microRNAs	(miRNAs)	for	the	first	time	after	the	identifica-
tion	of	lin-4	in	C.	elegans25.	From	the	year	2000	on,	the	process	of	miRNA	biogenesis	was	stud-
ied	in	depth	and	it	was	shown	that	miRNAs	play	an	important	role	in	development	and	disease.	
MicroRNAs	are	defined	as	short	noncoding	RNAs	with	a	length	of	approximately	21	nucleotides	
that	function	as	post-transcriptional	repressors	of	their	target	genes26-28.	They	bind	with	their	
seed	sequence	(mostly	nucleotides	2	to	8	starting	from	the	5’	end	of	the	miRNA)	to	a	comple	
mentary	sequence	in	the	3’	untranslated	region	(3’UTR)	of	the	target	mRNA29.	The	importance	
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Figure	4.	MicroRNA	biogenesis.	MicroRNAs	are	transcribed	by	RNA	Pol	II	in	the	nucleus	into	pri-miRNAs.	The	pri-
miRNAs	are	processed	by	the	RNase	III	enzyme	DROSHA	into	pre-miRNA	that	is	exported	to	the	cytoplasm	by	Ex-
portin-5.	 In	 the	 cytoplasm	 the	 pre-miRNA	 is	 processed	 by	 another	 RNase	 III	 enzyme	 DICER	 forming	 a	 miRNA-
duplex.	One	strand	is	 loaded	into	the	RISC	complex	together	with	the	Argonaute	proteins	and	the	miRNA	guides	
the	RISC	complex	to	its	target	mRNA(s).	The	RISC	complex	inhibits	the	mRNA	function	through	translation	inhibi-
tion,	mRNA	degradation	and/or	mRNA	destabilization.	(Figure	adapted	from	31,	32)	
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of	miRNAs	in	gene	regulation	is	suggested	by	the	large	amount	of	possible	target	genes	particu-
lar	 miRNAs	 have	 and	 the	 variety	 of	 different	 miRNAs	 that	 can	 bind	 the	 3’UTR	 of	 specific	
mRNAs30.		
MicroRNAs	 are	 transcribed	 from	 intra-	 or	 intergenic	 regions,	 leading	 to	 large	primary	miRNA	
(pri-miRNA)	transcripts	consisting	of	several	hairpin	structures.	These	transcripts	are	processed	
in	the	nucleus	by	the	ribonuclease	DROSHA	to	single	hairpin	structures,	called	precursor	miR-
NAs	(pre-miRNA).	Pre-miRNAs	are	transported	to	the	cytoplasm	and	processed	by	another	ri-
bonuclease,	DICER,	forming	a	mature	double	stranded	miRNA.	One	strand,	the	guide	strand,	is	
incorporated	into	the	‘RNA-induced	silencing	complex’	(RISC)	and	guides	RISC	to	the	3’UTR	of	
its	target	mRNA.	The	RISC	complex	negatively	regulates	the	mRNA	through	either	the	inhibition	
of	translation,	mRNA	destabilization	and/or	the	degradation	of	the	mRNA31.	The	effect	of	one	
miRNA	on	the	expression	of	a	particular	mRNA	can	be	modest,	but	due	to	the	multiple	seed	se-
quences	for	different	miRNAs	in	the	3’UTR	of	the	mRNA,	the	combined	effect	of	several	miRNAs	
can	have	a	significant	result	on	the	overall	mRNA	expression	(see	Figure	4).		
The	post-transcriptional	regulation	by	several	miRNAs	of	one	target	mRNA	allows	strict	regula-
tion	in	time	and	context.	It	is	thus	not	a	surprise	that	miRNAs	have	been	detected	as	key	play-
ers	in	several	fundamental	processes	in	the	cell,	such	as	development,	differentiation,	prolifera-
tion	and	cell	death,	but	this	also	implies	that	deregulation	of	miRNA	expression	can	lead	to	dis-
ease	and	cancer	development.	
2.2.2 MicroRNAs	in	cancer	
MicroRNAs	are	involved	in	several	processes	in	normal	cellular	development,	in	which	they	can	
target	 tumor	 suppressor	genes	 (as	oncomiRs)	or	proto-oncogenes	 (as	 tumor	 suppressor	miR-
NAs).	If	this	strict	process	of	miRNA-controlled	target	gene	expression	is	disturbed,	cancer	de-
velopment	can	occur.	Several	different	oncogenic	events	in	this	process	have	been	described	in	
a	plethora	of	cancer	types	(Figure	5).		
The	downregulation	of	tumor	suppressor	miRNA	function	can	be	caused	by	the	genetic	loss,	ep-
igenetic	silencing	or	transcriptional	repression	of	the	miRNA	gene	or	through	a	general	down-
regulation	of	the	miRNA	biogenesis	pathway	(ex.	reduced	DICER	 levels33,	or	a	mutation	 in	Ex-
portin-5	 leading	 to	a	 reduced	nuclear	export	of	 the	pre-miRNA34).	 Furthermore,	 the	 targeted	
mRNAs	can	escape	repression	from	a	specific	miRNA	as	a	result	of	a	mutation	in	the	seed	se-
quence	or	through	expression	of	an	isoform	with	a	reduced	3’UTR.	Recent	discoveries	also	de-
tected	that	other	noncoding	RNAs	can	influence	the	miRNA	action.	These	ncRNAs,	called	“com-
peting	endogenous	RNA”	 (ceRNA),	 compete	 for	 the	miRNA	binding,	 leading	 to	an	 increase	 in	
expression	of	the	target	gene35.		
The	miRNA	cluster	miR-15a/16-1	was	 the	 first	miRNA	cluster	described	 to	have	a	 tumor	sup-
pressive	role.	This	locus	is	deleted	in	more	than	half	of	chronic	lymphocytic	leukemia	(CLL)	pa-
tients	(del(13q14)),	with	one	of	its	primary	targets	being	the	BCL2	oncogene36,	37.	The	let-7	clus-
ter	is	another	example	of	which	the	tumor	suppressor	miRNA	members	show	reduced	expres-
sion	 levels	 in	 different	 cancer	 types38.	 Known	 targets	 of	 this	 cluster	 are	 the	RAS	 oncogenes,	
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	Figure	5.	Deregulation	of	miRNAs	 in	 cancer	development.	The	reduction	of	a	miRNA	that	functions	as	a	tumor	
suppressor	can	lead	to	tumor	formation.	This	reduction	can	occur	due	to	changes	at	the	miRNA	gene	locus	or	 in	
the	miRNA	transcriptional	regulation.	 Inhibition	of	the	general	miRNA	biogenesis	machinery	also	reduces	miRNA	
functions.	The	overexpression	of	oncomiRs	can	occur	from	genetic	changes	(translocation	or	amplification	of	the	
region)	or	increased	transcription	due	to	oncogenic	transcription	factors.	(Figure	adapted	from	32)	
	
MYC	and	HMGA39-41.	 It	was	also	shown	that	both	tumor	suppressor	miRNA	clusters	described	
above	are	repressed	by	the	MYC	oncogene42.		
The	overexpression	of	oncogenic	miRNAs	or	oncomiRs	can	be	caused	by	the	loss	of	repressive	
epigenetic	marks,	activation	resulting	from	translocation	and	increased	expression	due	to	acti-
vated	oncogenic	transcription	factors.	The	miR-17~92	cluster	(oncomiR-1)	is	a	prototypical	on-
cogenic	miRNA	 cluster43,	 44.	 This	 cluster	 contains	 6	 different	miRNAs	 and	 has	 two	 paralogue	
clusters	that	are	deregulated	in	several	cancer	types.	The	overexpression	of	this	cluster	is	due	
to	gain	or	amplification	of	the	miRNA	cluster	locus,	the	direct	activation	of	the	MYC	oncogene	
or	the	decreased	repression	by	the	tumor	suppressor	gene	TP5345-48.	This	cluster	plays	an	im-
portant	regulatory	role	in	different	pathways	in	the	cell,	such	as	in	cell	cycle	and	proliferation,	
development,	angiogenesis	etc.	Some	important	targets	of	the	miR-17~92	cluster	are	the	tumor	
suppressor	genes	PTEN,	BIM	and	p21	(CDKN2A)48,	49.	
Several	comprehensive	reviews	have	been	published	on	the	role	of	miRNAs	in	cancer	develop-
ment32,	49-52.	Not	surprisingly,	several	oncomirs	and	tumor	suppressor	miRNAs	have	been	identi-
fied	to	play	an	important	role	in	T-ALL	development	as	well.	A	detailed	overview	of	this	can	be	
found	in	the	review	in	the	next	part	of	this	introduction.		
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2.3 Long	noncoding	RNAs	
2.3.1 Long	noncoding	RNAs	emerging	from	the	dark	side	of	the	genome	
It	was	already	known	for	a	long	time	that	functional	RNAs	were	part	of	the	cellular	machinery	
(see	section	2.1).	Technological	developments	driven	by	the	human	genome	project	at	the	be-
ginning	of	the	twenty-first	century53,	54,	including	tiling	microarrays	for	gene	expression	analysis	
and	 novel	 sequencing	 technologies55,	 56,	 fueled	 the	 discovery	 of	 novel	 long	 noncoding	 RNA	
(lncRNA)	 genes.	 Since	 then,	 several	 microarray	 hybridization	 and	 deep	 sequencing	 analyses	
provided	further	in	depth	studies	and	now	it	is	estimated	that	at	least	roughly	75%	of	the	hu-
man	genome	 is	 transcribed24.	While	 this	 finding	 is	overwhelming,	most	 lncRNAs	remain	 func-
tionally	unannotated	and	 it	 remains	to	be	determined	how	many	 lncRNAs	effectively	execute	
specific	cellular	functions.		
More	 evidence	 supporting	 the	 transcription	 of	 ncRNAs	 came	 from	 the	 epigenetics	 field	 that	
profiled	 specific	histone	markers	across	 the	genome	and	discovered	methods	 to	detect	open	
(or	active)	chromatin.	Several,	but	not	all,	of	the	previously	detected	ncRNAs	were	character-
ized	by	DNase1	hypersensitivity,	active	chromatine	marks	(ex.	H3K4me3	marks	at	the	promoter	
and	 H3K36me3	 marks	 along	 the	 transcriptional	 region)	 and	 the	 binding	 of	 transcription	
factors57-61.	These	chromatin	signatures	led	to	the	discovery	that	there	is	some	species	conser-
vation	of	chromatin	marks	and	the	promoter	regions	of	lncRNAs,	although	sequence	conserva-
tion	is	very	low57,	62.		
Even	 before	 these	 large	 scale	 studies,	 some	 lncRNAs	 were	 already	 discovered.	 In	 the	 early	
1990s	H19	and	XIST	were	detected	as	 lncRNAs	with	a	role	 in	epigenetic	regulation20,	21,	63	and	
also	 the	 TERC	 RNA	 of	 the	 telomerase	 complex	 was	 well	 known19.	 Since	 2010,	 research	 on	
lncRNAs	has	accelerated,	 leading	 to	 the	discovery	of	multiple	 lncRNAs	with	a	 large	variety	of	
functions	as	well	as	the	discovery	of	potential	disease	biomarker	lncRNAs.		
2.3.2 Long	noncoding	RNA	characteristics		
Long	noncoding	RNAs	are	arbitrarily	defined	as	RNA	molecules	with	a	length	of	at	least	200	nu-
cleotides	and	without	protein	coding	potential.	Several	algorithms,	for	example	CPC64,	CPAT65	
and	PhyloCSF66,	can	confirm	this	lack	of	protein	coding	potential.	LncRNAs	share	several	charac-
teristics	with	mRNAs,	as	most	of	them	are	multi-exonic	and	transcribed	by	RNA	polymerase	II,	
giving	them	the	5’	Cap-structure	and	3’	poly-A	tail.	In	comparison	to	mRNAs	however,	lncRNAs	
generally	have	lower	expression	levels	and	show	tissue	or	cell	type	specific	expression	patterns.	
The	 latter	 characteristic	 offers	 perspectives	 for	 lncRNAs	 as	 potential	 targets	 for	 therapy,	 as	
their	specific	expression	pattern	might	avoid	off-target	effects	of	specific	lncRNA	inhibitors.	
One	possible	classification	of	lncRNAs	is	based	on	the	location	of	the	lncRNA	gene	in	compari-
son	 to	 protein	 coding	 genes	 (Figure	 6).	 Intergenic	 lncRNAs	or	 ‘lincRNAs’	 do	not	 overlap	with	
protein	coding	genes.	As	 these	 lincRNAs	are	quite	easy	 to	define,	 the	 first	described	 lncRNAs	
were	 intergenic,	 for	 example	 XIST20,	 21,	 H1963,	 and	 MALAT167.	 Like	 miRNAs	 and	 snoRNAs,	
lncRNAs	can	also	be	located	in	introns	of	protein	coding	genes.	One	example	of	this	category	is	
COLDAIR,	one	of	the	first	described	lncRNAs	in	plant	biology,	which	is	located	in	the	first	intron	
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of	 the	 Flowering	 Locus	 C	 (FLC)	 gene	 and	 is	 necessary	 for	 the	 epigenetic	 repression	 of	 FLC	
through	the	recruitment	of	PRC2	(Polycomb	Repressive	Complex	2)68.	The	third	class	of	lncRNAs	
includes	the	lncRNA	genes	that	overlap	with	a	known	protein-coding	gene	in	the	antisense	di-
rection,	of	which	HOTAIR	 (HOX	transcript	antisense	RNA)	 is	a	well-known	example.	HOTAIR	 is	
located	 in	 the	HOXC	 locus	 and	 regulates	 the	 repression	of	 the	HOXD	 locus	 through	PRC2	 re-
cruitment69.	Some	lncRNAs	have	also	been	detected	that	overlap	with	a	protein-coding	gene	in	
the	sense	direction,	with	an	exon	of	the	protein-coding	gene	located	in	an	intron	of	the	lncRNA	
gene	(sense-overlapping	lncRNAs,	for	example	SOX2-OT70).	Another	category	includes	lncRNAs	
of	which	 the	 transcription	 start	 site	 is	 located	 in	 the	 vicinity	of	 a	protein-coding	 gene,	 but	 is	
transcribed	from	the	opposite	strand.	These	lncRNAs	are	called	bi-directional	lncRNAs.		
	
	
Figure	6.	Long	noncoding	RNA	classes.	LncRNA	genes	can	be	classified	based	on	their	location	according	to	protein	
coding	genes:	intronic	lncRNAs,	intergenic	lncRNAs,	antisense	lncRNAs,	bi-directional	lncRNAs	or	sense-overlapping	
lncRNAs.	(Figure	based	on	71)	
	
2.3.3 Long	noncoding	RNA	functions	
Long	noncoding	RNAs	have	been	described	in	several	processes	of	the	cellular	machinery,	main-
ly	acting	as	guides,	scaffolds	or	decoys	(Figure	7).	Guiding	lncRNAs	bind	to	transcription	factors	
or	epigenetic	 regulators	and	"guide"	them	to	a	genomic	 location	 (ex.	XIST	and	the	epigenetic	
regulator	PRC2),	 scaffolds	bring	several	proteins	 together	 in	one	complex	 (ex.	TERC	 in	 the	te-
lomerase	complex)	and	decoys	bind	to	proteins	by	which	they	inhibit	the	binding	of	the	protein	
to	the	DNA	(ex.	GAS5	and	the	glucocorticoid	receptor).		
Many	lncRNAs	identified	so	far	are	implicated	in	transcriptional	regulation.	Of	particular	inter-
est,	many	lncRNAs	have	been	shown	to	interact	with	the	PRC2-complex,	thus	possibly	guiding	
PRC2	 to	 a	 specific	 locus	 on	 the	 genome,	 leading	 to	 the	 epigenetic	 silencing	 of	 that	 locus	 by	
PRC2-mediated	H3K27	trimethylation72,	73.	Another	class	of	lncRNAs	are	the	so-called	enhancer	
RNAs	or	eRNAs.	These	eRNAs	are	transcribed	from	enhancer	sites	and	aid	in	the	attraction	of	
transcription	factors	to	the	enhancers	and	the	transcription	start	site	of	the	nearby	gene.	Fur-
thermore,	eRNAs	can	also	help	in	the	chromatin	looping	bringing	the	enhancer	site	closer	to	the	
transcription	start	site74,	75.	However,	these	eRNAs	are	nowadays	more	and	more	considered	as	
a	separate	entity	of	RNA	molecules	as	several	eRNAs	appear	to	have	some	characteristics	devi-	
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Figure	7.	Long	noncoding	RNA	functions.	(A)	LncRNAs	can	interact	with	chromatin	modifying	complexes	and	guide	
them	to	specific	loci	on	the	genome.	(B)	LncRNAs	can	be	scaffolds,	bringing	several	proteins	into	one	complex.	(C)	
Enhancer	RNAs	are	transcribed	from	enhancer	loci	and	can	aid	in	chromatin	looping,	bringing	transcription	factors	
in	 close	 proximity	 of	 the	 promoter	 of	 a	 neighboring	 gene.	 (D)	 CircRNAs	or	 ceRNAs	bind	miRNAs,	 titrating	 them	
away	from	their	mRNA	target,	leading	to	an	increased	mRNA	expression.	
ating	from	general	lncRNAs	(ex.	some	are	only	50	nucleotides	in	length	and	most	of	them	are	
single-exonic).	Nevertheless,	the	role	of	eRNAs	is	still	a	matter	of	debate	and	further	investiga-
tions	are	required	to	clarify	to	what	extent	they	are	the	result	of	divergent	RNA	Pol	II	mediated	
transcription	from	the	target	locus	rather	than	an	RNA	with	a	specific	functional	role	in	enhanc-
er	biology.	In	the	end,	both	might	be	true,	and	some	enhancer	RNAs	might	be	critically	involved	
in	enhancer	functions	whereas	others	might	be	transcriptional	by-products.	(Figure	7C)	
Also	in	several	post-transcriptional	steps	lncRNAs	can	be	involved,	for	example	in	splicing	con-
trol	 (ex.	MALAT1)	or	RNA-editing.	One	 interesting	class	of	 lncRNAs	comprises	the	competitive	
endogenous	RNAs	(ceRNAs).	These	ceRNAs	contain	several	miRNA	binding	sites	that	can	keep	
		
	
	
35	
miRNAs	away	from	their	normal	mRNA	target,	leading	to	the	enhanced	expression	of	the	mRNA	
target.	The	PTENP1	pseudogene	of	the	tumor	suppressor	gene	PTEN	is	an	example	of	a	ceRNA	
as	 it	acts	as	a	decoy	for	miRNAs	that	target	the	PTEN	gene,	 implying	also	a	tumor	suppressor	
role	for	PTENP135,	76.	(Figure	7D)	
LncRNAs	have	been	studied	in	different	developmental	processes,	as	they	are	known	to	have	a	
very	 specific	 expression	 patterns.	 One	 landmark	 study	 by	 the	 group	 of	 John	 Rinn	 made	 18	
knockout	 mouse	 models	 of	 intergenic	 lncRNAs	 that	 were	 conserved	 between	 humans	 and	
mice77.	Three	homozygous	knockout	models	were	incompatible	with	life,	showing	an	important	
role	for	the	 lncRNA	in	viability	 (Fendrr-/-,	Peril-/-	and	Mdgt-/-)	and	two	other	 lncRNA	knockouts	
had	 a	major	 impact	 on	 development	 (linc-Pint-/-	 and	 linc-Brn1b-/-).	 In	 Table	 3,	 an	 overview	 is	
presented	of	some	of	the	lncRNAs	with	a	role	in	the	cell	and	in	organ	development.		
Table	3.	Long	noncoding	RNAs	in	normal	development.	(A	list	of	abbreviations	can	be	found	at	the	beginning	of	
this	thesis.)	
lncRNA	 Function	 Mechanism	 Mouse	models	 Ref.	
Fendrr	 ?	 Interacts	with	PRC2	 Knockout	 is	 perinatally	
lethal	due	to	respirato-
ry	defects		
(defects	 in	 lung	 matu-
ration	and	vasculature)	
62,	 77,	
78	
H19	 Allelic	 imprinting	 at	 the	
IGN	 locus	 (Imprinted	
Gene	Network)	
Interacts	with	MBD1	 that	 brings	 ad-
ditional	histone	methyl-transferases	
Knockout	 results	 in	
overweight	
63,	 79,	
80	
HOTAIR	 Inactivation	 of	HOXD	 lo-
cus	 and	 some	 imprinted	
loci	
Recruits	PRC2	(H3K27	trimethylation)	
Interacts	with	the	LSD1	complex	
(H3K4	demethylation)	
Deletion	 leads	to	spine	
and	 bone	 malfor-
mation	
69,	 81,	
82	
HOTTIP	 Activation	 of	 5’	 HOXA	
genes	
Recruits	 the	WDR5/MLL	 complex	 by	
chromosomal	 looping	 to	 the	 HOXA	
locus	
(H3K4	trimethylation)	
Knockdown	 shortens	
forelimbs	
83	
MALAT1	 Alternative	splicing	
Transcription	control	
Interaction	with	SRSF1	modulating	 it	
by	phosphorylation	
Modulates	 nuclear	 speckle	 associa-
tion	of	various	splicing	factors	
Interaction	 with	 chromatin	 readers	
at	genome	loci	
Knockdown	 has	 no	 ef-
fect	 on	 mouse	 devel-
opment	
84-87	
NEAT1	 Nuclear	 paraspeckle	
formation	
Interacts	 with	 paraspeckle	 proteins	
and	transcriptional	repressors	
Knockout	 leads	 to	 loss	
of	 paraspeckles,	 but	
has	no	phenotype	
58,	 88-
90	
TERC	 Telomere	maintenance	 Scaffold	for	the	telomerase	complex	
Template	for	telomere	extension	
Knockout	leads	to	early	
aging	
19,	91	
XIST	 Inactivation	 of	 one	 of	
the	X	chromosomes	
Recruits	PRC2	(H3K27	trimethylation)	 Partial	 deletion	 is	 em-
bryonic	 lethal	 in	 fe-
male	mice	
21,	 92,	
93	
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2.3.4 Long	noncoding	RNA	deregulation	in	cancer		
Together	 with	 the	 discovery	 of	 lncRNAs	 playing	 a	 role	 in	 normal	 cell	 homeostasis,	 several	
lncRNAs	were	discovered	with	a	differential	expression	pattern	 in	one	or	more	cancer	 types.	
Some	identified	cancer-related	lncRNAs	also	had	a	function	in	normal	development,	but	several	
were	 only	 expressed	 in	 that	 specific	 cancer	 type,	making	 them	 ideal	 candidates	 for	 targeted	
therapy.	Furthermore,	lncRNAs	were	described	as	biomarkers	for	cancer	type,	stage	or	progno-
sis.	Still	most	of	the	cancer-associated	lncRNAs	are	only	identified	based	on	expression	profiling	
and	have	unknown	action	mechanisms.	However,	with	 the	 small	 amount	of	 lncRNAs	 that	do	
have	a	known	role	in	cancer	development,	it	became	clear	that	they	can	have	a	role	in	different	
cancer	pathways	that	contribute	to	the	hallmarks	of	cancer	(see	Figure	8,	Table	4)94,	95.		
																		 	
Figure	8.	Long	noncoding	RNAs	associated	with	hallmarks	of	cancer.	LncRNAs	have	been	discovered	in	the	several	
processes	that	lead	to	cancer	development.	(Figure	based	on	95,	96)	
The	deregulated	expression	of	 lncRNAs	 in	cancer	 is	mostly	due	 to	a	change	 in	 transcriptional	
regulation	as	several	lncRNAs	are	regulated	by	known	oncogenes	and	tumor	suppressor	genes.	
However,	there	are	also	lncRNAs	that	are	upregulated	by	different	mechanisms.	For	example,	
the	NBAT1	 (Neuroblastoma-Associated	Transcript	1)	gene	contains	a	high-risk	neuroblastoma	
single	nucleotide	polymorphism	(SNP),	decreasing	its	expression	and	leading	to	higher	prolifer-
ation	and	invasion	of	neuroblastoma	cells97.		
To	gain	 insight	 into	 lncRNA	function,	 ‘guilt-by-association’	analysis	can	offer	a	first	glimpse	by	
comparing	the	expression	pattern	of	a	specific	lncRNA	with	all	protein	coding	genes	and	linking	
the	lncRNA	to	specific	oncogenic	pathways57.	However,	this	only	provides	a	correlation	and	 in	
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Suppression
Tumor Invasion &
Metastasis8
Litmitless Replicative
Potential
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angiogenesis
Evading
Apotosis
TERC, TERRA
MALAT1, HULC,
HOTAIR, SCHLAP
ANRIL, GAS5,
linc-p21
MEG3, PCAT1
MEG3, PCGEM1
HOTAIR,  lincRNA-p21
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vitro	and	in	vivo	studies	should	be	performed	to	further	assess	the	role	of	the	lncRNA	in	the	on-
cogenic	 process.	 Challenges	 for	 in	 vitro	 studies	 include	 low	 success	 rates	 of	 shRNA/siRNA-
mediated	knockdown	as	the	RNAi	machinery	is	present	in	the	cytoplasm	and	most	lncRNAs	are	
localized	 in	 the	 nucleus,	 but	 also	 the	 uncertainty	 of	 the	 annotation	 of	 lncRNA	 transcript	 se-
quence	and	cis-regulatory	functions	make	overexpression	challenging.	Furthermore,	poor	spe-
cies	conservation	for	many	lncRNAs	often	precludes	in	vivo	studies.	These	challenges	and	solu-
tions	are	discussed	 in	more	detail	 in	 the	 review	 in	 the	next	part	of	 this	 introduction.	Despite	
these	 challenges,	 several	 lncRNAs	 could	 convincingly	 be	 linked	 to	 several	 cancer	 processes,	
such	as	the	melanoma-specific	 lncRNA	SAMMSON	 (as	discussed	in	Box	2	 in	more	detail)98.	An	
overview	of	a	selection	of	lncRNAs	with	a	role	in	cancer	can	be	found	in	Table	4.	It	should	how-
ever	be	 stated	 that	 some	 lncRNAs	have	different	 functions	 in	different	 cancer	 types	 and	not	
everything	could	be	included.	An	overview	of	lncRNAs	with	a	specific	role	in	T-ALL	can	be	found	
in	the	review	in	the	last	part	of	this	introduction.	
	
	
	
Box	2.	SAMMSON:	a	melanoma-specific	lncRNA	with	therapeutic	potential98.	
The	SAMMSON	lncRNA	is	focally	amplified	in	10%	of	melanoma	cases	together	with	the	MITF	
oncogene.	Next	to	that,	it	appeared	to	be	expressed	in	over	90%	of	melanoma	cases,	as	a	re-
sult	of	 SOX10-mediated	 transcription,	without	a	correlation	to	MITF	expression.	SAMMSON	
was	 also	 exclusively	 expressed	 in	 melanoma	 samples	 of	 the	 ‘The	 Cancer	 Genome	 Atlas’	
(TCGA)	cohort.	
In	vitro	knockdown	of	the	lncRNA	reduced	the	clonogenicity	of	melanoma	cultures	and	forced	
overexpression	of	SAMMSON	could	rescue	this	effect.	This	indicates	that	SAMMSON	exerts	a	
pro-survival	function	 in	trans.	Further	 in	vitro	experiments	showed	that	SAMMSON	interacts	
with	p32,	a	protein	involved	in	mitochondrial	metabolism,	and	enhances	its	mitochondrial	lo-
calization	and	function.		
Intravenous	 treatment	 of	 a	 patient-derived	 xenograft	 (PDX)	melanoma	model	with	 an	 LNA	
GapmeR	targeting	SAMMSON	could	suppress	the	growth	of	melanoma	tumors,	decrease	cell	
proliferation	and	increase	apoptosis.	Most	 interestingly,	as	SAMMSON	 is	melanoma	specific	
expressed,	this	treatment	did	not	cause	any	adverse	reaction	in	mice.	The	therapeutic	use	of	
these	antisense	drugs	targeting	SAMMSON	might	be	additive	to	the	BRAF	inhibitors	used	to-
day	as	cells	that	acquired	BRAF	inhibitor	resistance	are	still	in	need	of	SAMMSON	signaling.		
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Table	 4.	 Long	 noncoding	 RNAs	 with	 an	 oncogenic	 or	 tumor	 suppressor	 role	 in	 cancer.	 Inspired	 by	 recent	
reviews96,	99.	(A	list	of	abbreviations	can	be	found	at	the	beginning	of	this	thesis.)		
	
lncRNA	 Cancer	assocation	 Mechanism	 Phenotype	 Ref.	
ANRIL	 High	 expression	 in	 prostate	 can-
cer,	 gastric	 cancer	 and	 leukemia	
(cancer-associated	SNP)	
Silencing	of	p15	by	PRC2	and	
CBX7	recruitment	
é proliferation		 100-106	
CCAT1	 Oncogenic	 in	 gastric,	 colorectal	
and	gall	bladder	cancer	
MYC	 regulation	 by	 chromatin	
loops	
Sponge	for	miR-218-5p,	increas-
ing	BMI1	expression	
é proliferation	
é invasion	
107-110	
CRNDE	 Upregulated	 in	 colorectal	 cancer,	
glioma,	liver	cancer,	medulloblas-
toma	…	
Interacts	 with	 PRC2,	 reduces	
miR-384	 and	 miR-186	 expres-
sion	
é cell	growth	
é invasion	
ê cell	growth	
ê cell	cycle	pro-
gression	
111-115	
GAS5	 Downregulated	 in	 breast,	 pros-
tate,	 gastric,	 cervical	 and	 renal	
cell	cancers	
Inhibits	DNA	binding	of	the	glu-
cocorticoid	receptor	
é cell	arrest	
é apoptosis	
≠						cell	metabo-
lism	
116-121	
H19	 Oncogenic	in	several	cancer	types	
(liver,	breast,	bladder,	prostate...)	
Interacts	with	MBD1	that	brings	
additional	 histone	methyltrans-
ferases	(imprinting)	
é proliferation	
ê apoptosis	
79,	 80,	
122	
HOTAIR	 Overexpressed	in	liver	cancer	and	
metastatic	 breast,	 lung	 and	 pan-
creatic	cancers	
Silencing	 of	 HOXD	 and	 other	
genes	 through	 PRC2	 and	 LSD1	
binding	
é metastasis	 82,	 123-
128	
HULC	 Biomarker	for	liver	cancer	 Activated	 by	 CREB	 and	 sponge	
for	miRNAs	
é proliferation	
é invasion	
ê apoptosis	
129-132	
Linc-PINT	 Downregulated	 in	 colorectal	 can-
cer		
Activated	by	p53,	interacts	with	
PRC2	for	gene	silencing	
é 	apoptosis	
ê 	proliferation	
133	
LincRNA-
p21	
Downregulated	 in	 several	 cancer	
types	(lung,	cancer,	lymphoma	…)	
Activated	by	p53,	interacts	with	
hnRNP-K	for	gene	silencing	
é 	apoptosis	 134	
MALAT1	 Overexpressed	 in	 several	 cancer	
types	 (colorectal,	 breast…).	 SNP	
linked	 to	 hepatocellular	 carcino-
ma.		
Alternative	splicing	 é metastasis	
é proliferation	
67,	 84,	
135	
MEG3	 Downregulated	 in	 several	 cancer	
types	(prostate,	bladder	cancer…)	
Downregulates	MDM2	 and	 up-
regulates	p53.	
Recruits	 PRC2	 for	 gene	 silenc-
ing.	 Regulates	 TGF-β	 pathway	
genes.	
ê 	proliferation 136-139	
NBAT1	 SNP	 in	 high-risk	 neuroblastoma	
reduces	expression	
Silencing	of	REST	by	PRC2	 ê 	proliferation	
ê 	invasion	
97	
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Table	4	(Continued).	Long	noncoding	RNAs	with	an	oncogenic	or	tumor	suppressor	role	in	cancer.	Inspired	by	re-
cent	reviews96,	99.	(A	list	of	abbreviations	can	be	found	at	the	beginning	of	this	thesis.)		
	
lncRNA	 Cancer	assocation	 Mechanism	 Phenotype	 Ref.	
NEAT1	 Upregulated	 in	 several	 cancer	
types	 (prostate	 and	 liver	 cancer,	
leukemia	…)	
Paraspeckle	 formation	 and	
gene	regulation	
Replication	 stress	
response	
ê 	 chemosensi-
tivity	
é 	proliferation	
é 	invasion		
88,	140	
PCA3	 Biomarker	for	prostate	cancer	 Androgen	 receptor	 signaling	
modulation	
é 	cell	survival	 141,	142	
PCAT1	 Upregulated	 in	 prostate	 cancer	
with	disease-associated	SNPs	
Recruits	 PRC2	 for	 gene	 silenc-
ing.	 Inhibits	 homologous	 re-
combination.	 Activates	 c-MYC	
and	inhibits	BRCA2.	
é 	proliferation	 143-145	
PCGEM	 Upregulated	in	prostate	cancer	 Androgen	 receptor	 transcrip-
tional	 activation	 and	 c-MYC	 ac-
tivation	
é 	cell	growth	 146-149	
PTENP1	 Deleted	 in	melanoma,	colon	can-
cer	and	prostate	cancer	
Sponge	 for	 miRNAs	 targeting	
the	 tumor	 suppressor	 gene	
PTEN	
ê 	proliferation	
ê 	migration	
ê 	invasion	
ê 	tumor	growth	
35,	150	
SAMMSON	 Upregulated/amplified	 in	 mela-
noma	
Interaction	with	p32	to	regulate	
mitochondrial	metabolism	
é 	cell	viability	 98	
SCHLAP1	 Upregulated	in	prostate	cancer	 Interacts	with	SWI/SNF	complex	
and	 inhibits	 its	 binding	 to	 the	
genome	
é metastasis	
é invasion	
151	
XIST	 Downregulated	in	breast,	ovarian	
and	 cervical	 cancer,	 testicular	
cancer,	 leukemias	 and	 lympho-
mas	
PRC2	recruitment	to	silence	one	
X-chromosome	
X-chromosome	 an-
euploidy	
21,	 152-
155	
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2.4 LncRNAs	and	trying	to	see	the	forest	for	the	trees	
Since	 the	 discovery	 of	 lncRNAs,	 the	 scientific	 area	 has	 been	 divided	 between	 ‘believers’	 and	
‘non-believers’	of	their	importance.	One	major	concern	that	was	raised	was	the	lack	of	species	
conservation	of	these	lncRNAs.	However,	it	was	stated	that	these	lncRNAs	could	fold	into	spe-
cific	secondary	and	tertiary	structures	and	that	these	structures	are	more	 important	than	the	
sequence	itself156.	Furthermore,	promoters	of	lncRNAs	appeared	to	show	a	higher	level	of	con-
servation	 than	 the	 transcript	 itself,	 implying	 that	 modulation	 of	 transcription	 of	 the	 lncRNA	
might	be	more	important	than	the	transcript	itself157-159.	The	Mattick	team	on	the	other	hand	
showed	that	the	number	of	noncoding	RNAs	was	positively	correlated	to	the	complexity	of	the	
organism,	implying	that	this	noncoding	part	of	the	genome	was	responsible	for	the	evolution	of	
complex	organisms22,	however	this	not	fully	explains	the	low	lncRNA	conservation	between	e.g.	
human	and	mice.			
Some	 teams	also	 looked	 into	 the	probability	 that	 these	 lncRNAs	might	actually	be	coding	 for	
small	peptides	as	it	was	discovered	that	several	lncRNAs	interact	with	ribosomes160-162.	In	addi-
tion,	putative	open	reading	frames	in	the	lncRNAs	bound	by	ribosomes	resemble	small	peptides	
that	evolved	very	recently	in	evolution,	which	could	imply	that	lncRNAs	are	only	an	intermedi-
ate	step	to	the	development	of	novel	proteins163.	However,	others	observed	that	even	though	
lncRNAs	are	bound	by	ribosomes,	these	ribosomes	do	not	act	 in	the	same	way	as	for	mRNAs	
and	also	true	functional	lncRNAs,	like	TERC,	and	small	RNAs	involved	in	splicing	were	bound	by	
ribosomes.	Therefore,	 it	was	concluded	that	ribosomes	are	not	able	to	make	a	distinction	be-
tween	lncRNAs	and	mRNAs	for	binding164.	It	was	also	suggested	that	the	ribosomal	interaction	
would	lead	to	the	degradation	of	the	lncRNA162.	In	recent	years	however,	several	micropeptides	
were	detected	that	are	less	than	100	amino	acids	long	and	some	of	these	were	translated	from	
lncRNAs,	for	example	CRNDEP,	an	84	amino	acid	peptide	translated	from	the	CRNDE	lncRNA165-
167.	These	micropeptides	were	not	detected	in	previous	studies,	given	the	general	assumption	
that	proteins	should	at	least	contain	100	amino	acids	and	the	protein	purification	methods	that	
discard	these	smaller	fractions.		
Also	 several	 other	 concerns	 arose.	 For	 example,	 some	 lncRNAs	 appeared	 to	 be	 part	 of	 the	
3’UTR	of	mRNAs	of	which	a	specific	transcript	was	not	yet	detected,	due	to	its	low	expression61,	
168.	Some	lncRNAs	were	also	discovered	to	be	read-through	transcripts	from	neighboring	genes	
due	to	spurious	Pol	II	transcription169.	Furthermore,	several	groups	identified	lncRNAs	or	eRNAs	
of	which	only	the	act	of	transcription,	but	not	the	sequence,	is	necessary	to	enhance	the	tran-
scription	of	a	nearby	gene	(see	Box	3)157,	170,	171.	One	way	to	test	this	is	to	perform	two	knockout	
strategies:	full	deletion	of	lncRNA	and	promoter	or	insertion	of	a	poly-A	signal	next	to	the	tran-
scription	start	site.	If	only	the	first	set-up	has	a	phenotype,	the	sequence	of	the	lncRNA	has	no	
impact	on	it.	
After	more	 than	a	decade	of	 lncRNA	research,	 it	becomes	clear	 that	both	 the	 ‘believers’	and	
‘non-believers’	have	some	interesting	viewpoints	and	both	might	be	right	to	some	extent.	Sev-
eral	of	the	detected	noncoding	transcripts	appear	to	be	by-products	of	neighboring	gene	regu-
lation157,	170.	However,	these	studies	only	looked	at	the	potential	cis-effects	of	lncRNAs	and	do	
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not	 rule	 out	 possible	 trans	 effects	 of	 the	 transcript.	 The	 recent	 discovery	 of	 the	 SAMMSON	
lncRNA,	that	might	be	targeted	for	melanoma	therapy,	proves	on	the	other	hand	that	there	are	
lncRNAs	with	a	role	in	cell	biology	and	shows	the	importance	of	further	focus	on	the	discovery	
of	cancer-specific	lncRNAs	for	targeted	therapy.	As	lncRNA	research	is	a	relatively	recent	field,	
several	 novel	 insights	 in	 lncRNA	 biology	 will	 still	 be	 gained	 in	 the	 coming	 years,	 with	 novel	
technologies	as	a	major	driver	of	new	findings.		
	
2.5 Translating	noncoding	RNAs	to	the	patient		
In	recent	years,	precision	oncology	has	rapidly	emerged	and	gained	much	attention.	Insights	in-
to	 patient	 tumor	 specific	 genetic	 lesions	 of	 expressed	mRNAs	 opened	 the	 way	 for	 targeted	
therapies	using	immunotherapy	and	small	molecules.	Given	the	high	tissue	specificity	of	many	
lncRNAs	and	addiction	of	cancer	cells	to	some	oncogenic	lncRNAs,	novel	opportunities	for	RNA	
based	therapies	using	antisense	technologies	are	emerging	(ex.	siRNAs,	ASO	and	ribozymes)172,	
173.	 The	 ASO	 technology	 (antisense	 oligonucleotides)	 is	 being	 tested	 for	 several	 mRNAs	 and	
miRNAs	by	 IONIS	pharmaceuticalsTM,	with	some	mRNA-targeting	ASOs	already	FDA	approved.	
However,	the	delivery	of	the	antisense	molecules	to	the	specific	tissues	remains	challenging.	
Box	3.	Cis-regulation	by	lncRNAs:	when	the	sequence	doesn’t	matter.	
The	Lander	team	and	the	Olson	team	studied	the	mechanism	of	cis-regulation	of	lncRNAs	on	
their	neighboring	genes	and	published	their	findings	in	Nature	in	2016.			
In	 the	 first	 study,	 neither	 the	 sequence	 nor	 the	 transcription	 of	 3	 cis-acting	 lncRNAs	 influ-
enced	the	expression	of	the	neighboring	genes.	It	appeared	that	only	the	DNA	regulatory	el-
ements	 in	 the	 promoter	 of	 the	 lncRNA	 locus	 were	 responsible	 for	 the	 modulation	 of	 the	
neighboring	gene	expression.	For	another	lncRNA,	the	5’	splice	site	and	the	process	of	tran-
scription,	but	not	the	lncRNA	sequence,	were	important	for	its	cis-regulatory	function.	From	
none	of	the	lncRNA	loci	included	in	this	study,	the	sequence	mediated	the	effect	on	expres-
sion	level	of	neighbouring	genes.	However,	this	doesn’t	state	that	the	lncRNA	transcripts	do	
not	have	an	effect	other	than	gene	regulation	as	this	phenomenon	was	also	detected	for	sev-
eral	protein	coding	genes.156	
The	Olsen	group	focused	on	Hand2,	 a	regulator	of	heart	development,	and	 its	bidirectional	
lncRNA	Uph.	In	vivo	experiments	indicated	that	Uph	transcription	is	necessary	for	embryonic	
survival	and	Hand2	regulation,	but	in	vitro	knockdown	of	Uph	did	not	alter	Hand2	expression.	
This	again	implies	that	the	sequence	of	the	transcript	is	not	of	importance	for	cis-regulatory	
effects.	 Furthermore,	 it	was	 shown	 that	Uph	 transcription	was	necessary	 for	 the	H3K4me1	
and	 H3K27ac	 marks	 of	 the	 locus	 by	 recruitment	 of	 GATA4	 and	 for	 the	 RNAPII	 elongation	
along	the	Hand2	locus.169		
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Several	 lncRNAs	are	known	to	be	specifically	expressed	 in	a	certain	cancer	 type,	without	any	
expression	 in	 healthy	 tissue.	One	 example,	PCA3	 is	 now	 already	 used	 in	 the	 clinic	 as	 a	 non-
invasive	biomarker	for	the	detection	of	prostate	cancer	as	it	is	only	present	in	the	urine	of	af-
fected	patients141.	The	tissue	specific	expression	pattern	of	lncRNAs	also	makes	them	interest-
ing	candidates	for	targeted	therapy,	as	side	effects	should	be	minimal	when	the	lncRNA	is	not	
expressed	in	healthy	tissue.	This	is	also	the	current	mindset	for	a	lot	of	lncRNA	researchers,	in	
which	they	want	to	find	ectopically	expressed	lncRNAs	for	a	specific	disease	(ex.	SAMMSON98).		
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Abstract	
In	the	last	decade,	the	role	for	noncoding	RNAs	in	disease	was	clearly	established,	starting	with	
microRNAs	and	later	expanded	towards	long	noncoding	RNAs.	This	was	also	the	case	for	T-cell	
acute	 lymphoblastic	 leukemia,	 which	 is	 a	 malignant	 blood	 disorder	 arising	 from	 oncogenic	
events	during	normal	T-cell	development	in	the	thymus.	By	studying	the	transcriptomic	profile	
of	protein	coding	genes,	several	oncogenic	events	leading	to	T-ALL	could	be	identified.	In	recent	
years,	 it	 became	 apparent	 that	 several	 of	 these	 oncogenes	 function	 via	microRNAs	 and	 long	
noncoding	RNAs.	 In	 this	 review,	we	give	a	detailed	overview	of	 the	 studies	 that	describe	 the	
noncoding	RNAome	in	T-ALL	oncogenesis	and	normal	T-cell	development.		
3.1 Background	
3.1.1 The	noncoding	RNAome	
For	decades,	it	was	thought	that	only	2%	of	the	human	genome	was	functional	given	its	coding	
potential	for	proteins.	The	remaining	98%	of	the	genome	was	considered	‘junk	DNA’.	More	re-
cently,	many	studies	have	indicated	that	a	large	portion	(up	to	75%	or	more)	of	the	human	ge-
nome	is	actively	transcribed	while	not	coding	for	proteins	[1].	These	so-called	noncoding	RNAs	
consist	 of	 several	 distinct	 families	 including	microRNAs,	 small	 nuclear	 RNAs,	 PIWI-interacting	
RNAs	and	long	noncoding	RNAs.	 Interestingly,	the	detection	of	noncoding	RNAs	 led	to	a	solu-
tion	 for	 the	G-value	paradox	 that	 states	 that	 there	 is	 no	 correlation	between	 the	 amount	of	
coding	 genes	and	 the	 complexity	of	 the	organism	 [2],	while	we	do	observe	a	 correlation	be-
tween	the	complexity	of	the	organism	and	the	ratio	of	the	amount	of	noncoding	genes	to	the	
total	genomic	DNA.	This	 finding,	 indirectly,	suggests	that	the	 increasing	amount	of	noncoding	
RNA	genes	in	the	genome	of	organisms	can	account	for	their	complexity	[3].	In	the	last	decade,	
the	role	of	several	of	these	noncoding	RNA	families	has	been	intensively	studied	and	key	func-
tions	in	both	normal	development	and	disease	were	determined.		
MicroRNAs	
The	Ambros	team	described	the	identification	of	the	first	microRNA	(miRNA)	lin-4	in	C.	elegans	
in	1993	[4].	However,	only	from	the	beginning	of	this	century,	the	process	of	miRNA	biogenesis	
was	studied	in	depth	showing	that	miRNAs	play	an	important	role	in	development	and	disease.	
MicroRNAs	are	short	non-coding	RNAs	of	approximately	22	nucleotides,	that	function	as	post-
transcriptional	repressors	of	their	target	genes.	MiRNA	biogenesis	starts	with	transcription	by	
RNA	POLII	of	a	primary	miRNA	(pri-miRNA),	an	RNA	molecule	consisting	of	one	to	several	hair-
pin	 structures	 [5,	 6].	 This	 pri-miRNA	 is	 subsequently	 cleaved	 to	 one	 hairpin	 by	 the	 enzyme	
Drosha	leading	to	the	formation	of	a	precursor	miRNA	(pre-miRNA),	which	is	then	translocated	
to	the	cytoplasm	by	Exportin-5	and	processed	by	the	Dicer	complex	to	a	mature	double	strand-
ed	miRNA	[6[7-12].	In	order	to	execute	its	gene	regulatory	function,	one	strand	is	incorporated	
into	the	‘RNA-induced	silencing	complex’	(RISC)	thus	guiding	RISC	to	its	target	messenger	RNA	
(mRNA)	through	complementary	base	pairing	between	the	3’UTR	of	the	target	mRNA	and	the	
miRNA.	In	most	cases,	this	interaction	will	eventually	lead	to	mRNA	degradation	or	inhibition	of	
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protein	translation	(for	further	details	on	miRNA	biogenesis	we	refer	to	a	review	by	Ha	&	Kim	
[13]).	Remarkably,	 it	has	also	been	shown	that	the	miRNA	interaction	with	mRNAs	during	cell	
cycle	arrest	can	recruit	translation	activators	instead	of	translation	repressors	[14].		
Typically,	3'UTRs	of	protein	coding	genes	harbor	multiple	bona	fide	seed	sequences	for	differ-
ent	miRNAs.	While	the	overall	effect	of	a	given	miRNA	on	mRNA	levels	or	translation	may	be	
modest,	action	of	multiple	miRNAs	on	a	single	3'UTR	may	significantly	alter	the	mRNA	or	pro-
tein	level	of	a	gene.	At	the	same	time,	the	nature	of	this	regulatory	process	creates	the	possibil-
ity	of	time	and	context	specific	gene	regulation,	which,	amongst	others,	is	critical	in	normal	de-
velopment	and	cellular	functions.	As	such,	it	is	not	surprising	that	microRNAs	are	implicated	in	
various	diseases,	including	cancer	[15-17].	Indeed,	miRNAs	can	act	as	oncogenes	by	repressing	
the	expression	of	tumor	suppressors	in	the	cell.	The	prototypical	miRNA	oncogene	is	the	miR-
17∼92	cluster	(oncomiR-1)	encompassing	6	different	miRNAs	that	are	overexpressed	in	several	
cancer	entities	[18].	This	polycistron	is	directly	activated	by	the	MYC	transcription	factor	or	re-
pressed	by	p53	 [19-21]	and	controls	a	plethora	of	 target	genes	 including	PTEN,	BIM	 and	p21	
(CDKN1A),	 thereby	broadly	 impacting	on	 the	phenotype	of	 cells	 [22,	23].	One	of	 the	 first	de-
scribed	tumor	suppressor	miRNAs	is	encoded	by	the	miR-15a/16-1	cluster	and	this	locus	is	af-
fected	by	 recurrent	13q14	deletions	 in	more	 than	half	of	 chronic	 lymphocytic	 leukemia	 (CLL)	
cases	with	the	BCL2	oncogene	as	a	primary	target	[24,	25].	Following	these	landmark	discover-
ies,	many	additional	miRNAs	have	been	identified	to	act	as	oncomirs	or	tumor	suppressor	miR-
NAs	 (reviewed	 in	 [16,	 26,	 27]).	 Recent	 studies	 also	 linked	 another	 class	 of	 small	 noncoding	
RNAs,	the	PIWI-interacting	RNAs	(piRNAs)	to	cancer.	PiRNAs	were	detected	to	be	upregulated	
in	several	cancer	types,	which	could	be	linked	to	a	poor	prognosis.	The	specific	mechanism	of	
action	of	piRNAs	 in	 cancer	biology	 should	however	be	 further	 investigated	 to	 find	out	 if	 and	
how	they	are	driving	cancer	development	[28,	29].	
Given	the	role	for	miRNAs	in	several	cancer	types	and	promising	preclinical	studies,	further	ini-
tiatives	towards	implementing	miRNA-based	therapies	using	miRNA	mimics	or	miRNA	antisense	
inhibitors	are	taken	(eg.	Mirna	Therapeutics	-	www.mirnatherapeutics.com	and	miRagen	Ther-
apeutics	-	www.miragentherapeutics.com).	Remaining	challenges	are	the	risk	of	a	miRNA	to	act	
as	both	an	oncogene	or	tumor	suppressor	depending	on	the	cancer	type,	off-target	effects	and	
the	 bioavailability	 of	miRNA	mimics/inhibitors	 (reviewed	 in	 [30]).	 Further,	miRNAs	 or	miRNA	
signatures	can	be	used	for	prognostic	evaluation	of	cancer	entities,	as	 it	was	for	example	de-
tected	that	miRNA	expression	profiles	of	acute	myeloid	leukemia	(AML)	patients	clustered	the	
samples	in	different	groups	that	could	be	linked	to	cytogenetic	risk	categories	[31].	
Long	noncoding	RNAs	
While	 the	 existence	of	 certain	 long	noncoding	RNAs	 (lncRNAs)	 such	 as	XIST	 (implicated	 in	 X-
chromosome	 inactivation)	 has	 been	 known	 for	 some	 time	 [32,	 33],	 the	 full	 recognition	 for	
lncRNAs	 towards	 functionally	 active	 molecules	 has	 only	 emerged	 more	 recently.	 Generally	
speaking,	lncRNAs,	in	contrast	to	miRNAs,	represent	a	functionally	very	heterogeneous	group	of	
RNA	molecules	that	are	defined	by	their	length	of	at	least	200	nucleotides	and	lack	of	protein-
coding	potential.	While	many	lncRNA	genes	share	characteristics	with	protein	coding	genes	in	
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relation	to	splicing	and	poly-adenylation,	many	lncRNAs	are	expressed	at	low	levels	and	show	
poor	 species	 conservation	 compared	 to	 protein	 coding	 genes.	 These	 characteristics	 have	
caused	skepticism	on	the	actual	functional	relevance	of	lncRNAs.	On	the	other	hand,	their	com-
plex	secondary	and	tertiary	structures	hint	towards	functional	active	molecules	[34,	35],	a	no-
tion	 that	 is	 also	 further	 supported	by	 their	 remarkable	 tissue	or	 cell	 type	 specific	 expression	
pattern.	Indeed,	for	an	increasing	number	of	lncRNAs,	the	normal	function	and	its	putative	im-
plication	in	certain	diseases	has	been	reported,	but	for	the	vast	majority	of	lncRNAs	such	func-
tionalities	remain	to	be	discovered.	
The	total	number	of	annotated	lncRNAs	is	enormous	and	may	exceed	100,000	transcripts	[36].		
LncRNAs	can	be	classified	according	to	their	location	and	orientation	relative	to	protein	coding	
genes.	LncRNAs	overlapping	a	protein-coding	gene	are	categorized	as	‘sense’	or	‘antisense’	de-
pending	 on	 their	 transcriptional	 orientation	 compared	 to	 the	 protein-coding	 gene.	 ‘Intronic’	
lncRNAs	are	transcribed	from	an	intron	of	another	transcript,	whereas	‘intergenic’	lncRNAs	are	
located	 between	 two	 coding	 genes	 without	 any	 overlap.	 A	 fifth	 category	 is	 represented	 by	
those	 lncRNAs	that	are	transcribed	on	the	opposite	strand	of	a	protein	coding	gene,	with	the	
transcription	start	sites	located	less	than	1	kb	from	each	other.	These	lncRNAs	are	categorized	
as	‘bidirectional’.	(Reviewed	in	[37])		
At	 present,	 in-depth	 insights	 into	 the	 function	 of	 specific	 lncRNAs	 are	 rather	 limited.	 These	
studies	however	illustrate	the	broad	possible	cellular	functions	of	lncRNAs,	with	putative	func-
tions	in	transcription,	shaping	genome	architecture	or	epigenetic	regulation.	Modulation	(acti-
vation	or	repression)	of	transcription	by	lncRNAs	can	be	either	through	binding	and	regulation	
of	chromatin-modifying	complexes	(ex.	PRC2	recruitment	[38,	39])	or	transcription	factors	[40]	
or	by	inhibition	of	the	general	transcription	machinery	[41,	42].	Also,	a	specific	class	of	lncRNAs	
transcribed	 at	 enhancers,	 the	 so-called	 eRNAs,	 has	 been	 described	 [43,	 44].	 Post-
transcriptionally,	 lncRNAs	have	been	detected	to	aid	mRNA	processing	and	direct	splicing	[45,	
46]	 and	 also	 effects	 on	 translation	 or	mRNA	degradation	 have	 been	 encountered	 21307942.	
Some	lncRNAs	also	have	several	binding	sites	for	a	miRNA.	These	lncRNAs	are	called	competi-
tive	 endogenous	 RNAs	 (ceRNAs)	 as	 they	 titrate	miRNAs	 away	 from	 their	 conventional	 target	
mRNA	[47-49].	(Review	on	lncRNA	functions	in	[50])	
As	 indicated	above,	 long	non-coding	RNAs	play	a	role	 in	normal	cell	development,	but	also	 in	
several	types	of	heritable	diseases	and	cancer	[51].	One	of	the	most	well-characterized	and	de-
scribed	lncRNAs	in	cancer	is	the	‘metastasis-associated	lung	adenocarcinoma	transcript	1’	(MA-
LAT1),	a	rather	atypical	lncRNA	with	a	high	expression	and	species	conservation.	MALAT1	is	ex-
pressed	in	nuclear	speckles	and	plays	a	role	in	nuclear	organization,	transcription	and	alterna-
tive	splicing.	It	has	been	shown	that	MALAT1	is	upregulated	in	several	cancer	types,	enhancing	
cancer	metastasis	and	high	MALAT1	expression	is	correlated	with	poor	prognosis	[52].	Another	
example	of	an	oncogenic	lncRNA	involved	in	several	cancer	types	is	‘homeobox	transcript	anti-
sense	RNA’	(HOTAIR).	It	has	been	shown	that	HOTAIR	functions	in	the	recruitment	of	the	‘poly-
comb	 repressive	 complex	 2’	 (PRC2)	 to	 specific	 loci	 in	 the	 genome,	which	 leads	 to	H3K27	 tri-
methylation	and	transcriptional	silencing	of	these	loci	[53].				
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In	the	 last	years,	 it	was	shown	that	a	key	subset	of	 lncRNAs	 is	expressed	from	enhancer	sites	
[54].	Enhancers	are	 loci	on	 the	genome	that	are	bound	by	specific	 factors	 that	modulate	 the	
transcriptional	activity	of	a	nearby	gene.	These	loci	are	demarcated	in	the	genome	by	specific	
histone	 modifications	 (e.g.	 H3K27ac	 and	 H3K4me1)	 and	 binding	 of	 key	 transcription	 factors	
(e.g.	 p300	 and	 the	Mediator	 complex).	 The	 RNA	molecules	 expressed	 from	 these	 enhancers	
have	been	coined	enhancer	RNAs	(eRNAs)	and	are	between	50	and	2000	nucleotides	in	length.	
It	is	hypothesized	that	several	eRNAs	are	necessary	for	the	activity	of	enhancers,	by	recruiting	
transcription	factors	to	the	enhancers	and	aiding	in	the	chromosomal	looping	to	bring	the	en-
hancer	 bound	 transcription	 factors	 to	 the	 gene	 promoter	 [44,	 55].	 However,	 some	 concerns	
about	the	functionality	of	these	eRNA	transcripts	arose,	as	it	appears	that	only	the	act	of	tran-
scription,	but	not	the	sequence,	has	an	influence	on	the	function	of	the	enhancer	[56,	57].		
3.1.2 T-cell	acute	lymphoblastic	leukemia	
T-cell	acute	lymphoblastic	leukemia	(T-ALL)	is	a	hematological	malignancy	caused	by	oncogenic	
transformation	 of	 developing	 thymocytes.	 Normal	 T-cell	 development	 is	 a	 strictly	 regulated	
process	that	occurs	in	the	thymus.	Immature	thymocytes	enter	the	thymus	from	the	bone	mar-
row	and	migrate	through	several	thymic	niches	that	drive	specific	stages	of	T-cell	development	
[58-68].	During	these	stages,	specific	markers	are	present	at	the	membrane	of	these	immature	
thymocytes	and	genomic	 rearrangements	attribute	 to	 the	 formation	of	a	 functional	T-cell	 re-
ceptor,	leading	to	a	broad	range	of	different	mature	T-cell	types	characterized	by	a	specific	T-
cell	receptor.	During	these	stages	of	T-cell	development,	abnormal	activation	of	oncogenes	or	
inactivation	of	tumor	suppressor	genes,	can	lead	to	a	differentiation	arrest	and	an	uncontrolled	
expansion	of	immature	thymocytes	evolving	to	fully	transformed	T-ALL	lymphoblasts	[69].	
Different	genetic	lesions	have	been	identified	as	driving	events,	marking	specific	subgroups	of	
T-ALL	with	distinct	 gene	expression	patterns	 [70-74]:	 the	TAL-rearranged	 subgroup,	 the	TLX1	
subgroup,	 the	 TLX3	 subgroup	 and	 the	HOXA-overexpressing	 subgroup.	 Recently,	 a	 fifth	 sub-
group	with	a	poor	prognosis,	the	immature	T-ALL	subgroup,	has	been	added	with	an	early	T-cell	
progenitor	phenotype,	but	no	single	specific	oncogenic	driver	event.	This	subgroup	 is	marked	
by	 the	 overexpression	 of	multiple	 oncogenic	 factors	 as	MEF2C,	 LMO2,	 LYL1	 and/or	HHEX	 in	
several	patients.	To	establish	a	full-blown	leukemia,	several	other	oncogenic	effects	cooperate	
with	these	subtype	specific	driver	events.	For	example,	constitutive	activation	of	the	NOTCH1-
signaling	pathway	is	present	in	over	half	of	all	T-ALL	patients,	regardless	of	the	subtype,	indicat-
ing	 that	 hyperactive	NOTCH1	 signaling	 plays	 a	 central	 role	 in	 T-ALL	 biology	 [75].	 The	NOTCH	
signaling	 cascade	 is	 necessary	 in	 the	 early	 stages	 of	 T-cell	 development	 [58],	 but	 sustained	
NOTCH	activation	leads	to	the	malignant	transformation	of	thymocytes.	For	more	in	depth	in-
formation	on	T-ALL,	we	refer	to	several	good	reviews	[72,	76-78].	
Noncoding	RNAs	have	been	extensively	studied	in	leukemia	and	normal	hematopoiesis [79-85],	
here	we	will	focus	on	the	role	of	miRNAs	and	lncRNAs	in	T-ALL	and	T-cell	development.		
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3.2 Methodological	 approaches	 in	 miRNA	 and	 long	 noncoding	 RNA	 re-
search	
3.2.1 MicroRNAs	
Analytical	platforms		
MiRNA	expression	 studies	 have	 initially	 used	RT-qPCR	or	microarray	platforms,	which	 enable	
simultaneous	 detection	 of	 several	 hundreds	 of	 miRNAs.	 More	 recently,	 advances	 in	 next-
generation	sequencing	technology	made	it	also	possible	to	determine	the	expression	profiles	of	
miRNAs	by	means	of	small	RNA-sequencing.	A	major	advantage	of	small	RNA-sequencing	is	that	
also	novel	miRNAs	and	isomiRs	(miRNAs	with	small	variations	compared	to	a	reference	miRNA	
sequence)	get	detected	[86,	87].	The	recently	published	miRQC	study	gives	a	detailed	overview	
of	the	strengths	and	weaknesses	of	the	different	miRNA	detection	methods	and	platforms	[88].	
In	silico	target	gene	prediction	
After	the	identification	of	miRNAs	of	 interest,	their	potential	target	mRNAs	are	usually	 identi-
fied	based	upon	the	miRNA	seed	sequence,	a	seven-nucleotide	sequence	mostly	situated	at	po-
sitions	 2-7	 from	 the	 5’-end	 that	 can	 interact	 through	 complementary	 basepairing	 with	 the	
3’UTR	of	 the	miRNA.	 For	 this,	 several	 online	 tools	 can	be	used,	 including	miRDB	 (mirDB.org)	
[89],	 miRanda	 (microRNA.org)	 [90],	 TargetScan	 (targetscan.org)	 [91]	 and	 the	 recently	 devel-
oped	miSTAR	(mi-star.org)	[92],	which	also	enable	the	identification	of	all	miRNAs	that	poten-
tially	 target	 an	mRNA	of	 interest.	 The	disadvantage	of	 these	 in	 silico	prediction	algorithms	 is	
that	they	focus	on	the	interaction	between	the	5’	miRNA	seed	sequence	and	the	3’UTR	of	the	
miRNA,	but	it	has	been	shown	that	these	interaction	can	also	take	place	in	the	5’UTR	or	coding	
sequence	of	the	mRNA,	that	in	only	60%	of	the	cases	the	seed	interactions	are	perfectly	com-
plementary	(others	contain	bulged	or	mismatched	nucleotides)	and	that	sometimes	the	3’	end	
and	not	the	5’	end	of	the	miRNA	is	used	for	base	pairing	[93].	Furthermore,	these	methods	do	
not	take	 into	account	the	site	accessibility	as	other	RNA	binding	proteins	might	block	the	mi-
RNA	binding	site	[94].		
Wet	lab	validation	of	miRNA	target	genes	
Target	 prediction	 can	 also	 be	 achieved	 through	 several	 in	 vitro	methods.	 High-troughput	 se-
quencing	 methods	 used	 for	 miRNA-mRNA	 interaction	 detection	 are	 for	 example	 HITS-CLIP	
(High-throughput	sequencing	of	RNA	isolated	by	crosslinking	immunoprecipitation)	[95]	or	PAR-
CLIP	 (Photoactivatable	 Ribonucleoside-Enhanced	 Crosslinking	 and	 Immunoprecipitation)	 [96],	
which	are	methods	developed	to	identify	the	specific	binding	sites	of	RNA	binding	proteins.	In	
miRNA	research,	these	are	specifically	used	to	pull	down	the	RNA	that	interacts	with	proteins	
from	the	RISC-complex,	mostly	AGO2.	By	comparing	the	pulled	down	RNA	after	overexpression	
or	knockdown	of	a	miRNA	with	a	mock	control,	the	exact	interaction	partners	of	a	miRNA	can	
be	 identified	 [96-98].	 Next	 to	 these	 methods,	 all	 miRNA-mRNA	 interactions	 can	 be	 directly	
mapped	using	the	CLASH	(crosslinking,	 ligation	and	sequencing	of	hybrids)	technology	[93].	 In	
this	method,	 AGO-associated	miRNA-target	 duplexes	 are	 ligated,	 resulting	 in	 a	 chimeric	 RNA	
	
	
	
58	
molecule	that	is	subsequently	sequenced	immediately	revealing	the	exact	miRNA-mRNA	inter-
action	site [93].	While	these	methods	obtain	valuable	novel	information	on	miRNA	targets,	they	
are	however	labor	intensive	and	technically	challenging.	An	overview	of	other	in	vitro	methods	
can	be	found	in	the	review	by	Thomson	et	al.	[94].		
To	 validate	potential	miRNA-mRNA	 interactions,	 a	 luciferase	 reporter	 assay	 is	 the	method	of	
choice.	In	this	assay,	the	3’UTR	of	the	target	mRNA	is	cloned	next	to	a	reporter	gene	(e.g.	lucif-
erase)	 and	 a	 functional	miRNA-mRNA	 interaction	 should	 result	 in	 a	 decrease	of	 the	 reporter	
gene	 signal	 after	 overexpression	 of	 the	miRNA	 of	 interest.	 A	 direct	 interaction	 between	 the	
miRNA	and	the	3’UTR	of	 the	 target	gene	could	 then	be	confirmed	 if	 the	decrease	 in	signal	 is	
rescued	by	mutations	of	the	miRNA	binding	sites.		
This	reporter	assay	has	also	been	applied	in	3’UTR	library	screens	in	order	to	detect	possible	in-
teractions	of	 known	miRNAs	with	 a	 certain	 gene	of	 interest.	 In	 such	3’UTR	 library	 screens,	 a	
plasmid	containing	the	luciferase	report	gene	with	the	3’UTR	of	the	gene	of	interest	and	a	miR-
NA	library	are	transfected	together	in	HEK293T	cells	[99].	Subsequent	screening	of	the	lucifer-
ase	 signal	 intensity	 allows	 for	 the	 identification	of	potential	 functional	miRNA-mRNA	 interac-
tions,	which	also	need	to	be	validated	through	subsequent	mutagenesis	assays.		
In	vivo	studies	of	miRNA	function	in	T-ALL	development	
NOTCH1	activating	mutations	are	frequently	detected	 in	human	T-ALL	and	 it	has	been	shown	
that	NOTCH1	serves	as	a	potent	oncogene	that	can	drive	T-ALL	development	in	mice.	To	study	
the	role	of	miRNAs	in	T-ALL	in	vivo,	a	NOTCH1-sensitized	mouse	model	was	used	[100].	To	es-
tablish	this	model,	fetal	liver	cells	with	hematopoietic	progenitor	cells	(HPCs)	are	isolated	from	
pregnant	mice.	These	HPCs	are	then	transduced	with	ICN1	(active	NOTCH1)	and	a	vector	con-
taining	an	antagomiR	or	premiR.	After	irradiation	of	the	recipient	mice,	these	transduced	HPCs	
are	 injected	by	 tail	 vein	 injection.	 The	 leukemia	 onset	 of	 these	mice,	 compared	with	 control	
mice	(ICN1	+	a	negative	control	miRNA),	gives	an	indication	of	the	oncogenic	or	tumor	suppres-
sive	potential	of	the	tested	miRNA.	
Junker	 et	 al.	 showed	 that	 the	 leukemia	 onset	 of	 this	mouse	model	 is	 dependent	 on	Dicer1-
mediated	biogenesis	of	miRNAs	[101].	When	HPCs	with	 ICN1	overexpression	were	 injected	 in	
conditional	Dicer1	 knock	out	mice,	where	Dicer1	 is	 inactivated	when	 thymocytes	or	 leukemic	
cells	 transit	 from	the	double	negative	 to	double	positive	 (CD4+CD8+)	stage,	 there	was	no	 leu-
kemic	onset	compared	with	control	mice	that	all	developed	leukemia	in	less	than	100	days.		
3.2.2 LncRNAs	
Analytical	platforms		
In	some	early	studies,	lncRNAs	have	been	investigated	using	dedicated	microarrays	[102,	103].	
More	recently,	RNA	sequencing	has	become	the	method	of	choice,	particularly	given	the	signif-
icant	 tissue	and	 spatial	 specific	 expression	of	 lncRNAs.	RNA-sequencing	detection	of	 lncRNAs	
requires	a	higher	read	depth	in	comparison	to	protein	coding	mRNAs,	given	the	low	expression	
levels	 of	most	 lncRNAs	 [104].	 In	 addition	 to	 standard	 poly(A)	 RNA-sequencing,	 total	 RNA	 se-
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quencing	 (with	 ribosomal	RNA	depletion)	 is	 the	preferred	sequencing	 technique	 for	more	ex-
ploratory	studies,	as	it	appears	that	several	lncRNAs	don’t	have	a	poly(A)	tail	[105].	The	major	
advantage	of	RNA-sequencing	is	the	ability	to	detect	novel	lncRNAs	or	different	splicing	variants	
of	a	known	lncRNA	[104,	106].		
Guilt-by-association	analysis	
One	of	the	major	challenges	 in	 lncRNA	research	 is	the	selection	of	candidate	 lncRNAs	for	fur-
ther	functional	studies.	Guilt-by-association	analysis	has	been	applied	to	detect	potential	path-
ways	in	which	a	certain	lncRNA	of	interest	is	involved	[107,	108].	This	analysis	is	based	on	the	
correlation	of	the	candidate	lncRNA	expression	pattern	in	a	sufficient	large	number	of	(patient)	
samples	to	the	expression	of	all	protein	coding	genes.	Strong	positive	and/or	negative	correla-
tions	between	the	lncRNA	and	several	protein	coding	genes	could	hint	towards	the	involvement	
of	the	lncRNA	in	the	same	pathways	as	these	protein	coding	genes.	
In	vitro	studies	of	lncRNAs	
The	cellular	localization	of	the	lncRNA	can	be	determined	by	means	of	RNA-FISH	(fluorescence	
in	situ	hybridization)	or	cell	fractionation.	Nuclear	lncRNAs	are	probably	involved	in	gene	regu-
lation	or	 splicing	 control,	whereas	 cytoplasmic	 lncRNAs	might	have	a	plethora	of	other	 func-
tions	such	as	miRNA	sequestration,	regulation	of	translation	or	protein	complex	formation.	To	
detect	the	interaction	of	the	lncRNA	with	DNA,	other	RNAs	or	proteins,	several	techniques	have	
been	published.	These	are	based	on	the	use	of	biotinylated	oligonucleotides	complementary	to	
the	RNA	of	interest	to	pull	down	its	associated	DNA,	RNA	or	proteins	(ChIRP:	chromatin	isola-
tion	by	RNA	purification	[109];	CHART:	capture	hybridization	analysis	of	RNA	targets	[110];	RAP:	
RNA	antisense	purification	[111]).	On	the	other	hand,	lncRNAs	that	are	interacting	with	a	pro-
tein	of	interest	can	be	detected	by	means	of	RIP	(RNA	immunoprecipitation)[112].	These	tech-
nologies	and	many	more	are	nicely	 reviewed	by	Chu	et	al.	 [113].	Furthermore,	 the	change	 in	
transcriptional	profiles	after	lncRNA	knockdown	could	already	hint	towards	potential	roles	for	
the	lncRNAs.	However,	it	should	be	noted	that	knockdown	of	lncRNAs	is	not	always	as	straight-
forward	as	for	protein	coding	genes.	One	major	disadvantage	is	the	nuclear	location	of	several	
lncRNAs,	which	makes	 knockdown	by	 siRNAs	 less	efficient.	 The	use	of	 antisense	oligonucleo-
tides	(ASOs)	could	be	a	solution	for	this	problem	as	ASOs	activate	the	RNaseH	mechanism	in	the	
nucleus	to	cut	the	RNA	target.	The	use	of	the	CRISPR/Cas9	technology	to	knock	out	lncRNAs	al-
so	imposes	some	obstacles,	as	lncRNAs	might	overlap	with	protein	coding	genes	(sense	or	anti-
sense)	or	with	regulatory	elements	(ex.	enhancers).	CRISPRi	[91,	114],	using	an	inactivated	Cas9	
protein	linked	to	a	transcription	repressor,	could	be	a	possible	solution	to	inhibit	the	expression	
of	the	lncRNA.	Here,	the	guide	RNA	is	targeted	to	the	transcription	start	site	of	the	lncRNA,	in-
hibiting	its	expression.	
In	vivo	studies	of	lncRNAs	
The	lack	of	sequence	conservation	of	lncRNAs	between	human	and	mice	makes	it	very	difficult	
to	find	orthologous	lncRNAs	for	in	vivo	studies.	However,	for	several	lncRNAs	the	preservation	
of	 secondary	 structures,	 sequence	 domains	 or	 interacting	 proteins	 could	 be	 detected,	 as	 re-
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viewed	by	Johnsson	et	al.	[35].	One	remarkable	feature	detected	by	several	groups	is	that	the	
promoter	 of	 lncRNAs	 showed	 a	 higher	 degree	 of	 sequence	 conservation	 than	 the	 exons	 and	
that	 this	 promoter	 conservation	was	 similar	 to	 the	 promoter	 conservation	 of	 protein	 coding	
genes	[104,	107,	115,	116].	This	topic	is	also	reviewed	by	I.	Ulitsky	[117].		One	way	to	study	the	
oncogenic	 potential	 of	 lncRNAs	 in	 vivo	 without	 the	 knowledge	 of	 the	 mouse	 orthologous	
lncRNA,	is	the	use	of	xenografts	by	implanting	human	cell	lines	in	mice.	These	cell	lines	could	be	
modulated	by	means	of	 knockdown	or	overexpression	of	 the	 lncRNA	and	cancer	progression	
could	be	monitored.	In	T-ALL,	a	competition	assay	could	be	used	where	wild	type	and	modulat-
ed	cell	lines	with	specific	fluorescent	markers	are	mixed	and	consequently	injected	in	mice.	Af-
ter	a	few	weeks,	the	fluorescent	signal	ratios	can	then	be	measured	by	flow	cytometric	analysis	
of	the	blast	cells	[118].	
3.3 Oncomirs	and	tumor	suppressor	miRNAs	in	T-ALL	
3.3.1 T-ALL	miRNA	oncogenes	
MiR-19b	was	one	of	the	first	oncogenic	miRNAs	described	in	T-ALL	by	the	Wendel	team	[119].	
This	miRNA	is	part	of	the	above-mentioned	mir-17~92	cluster.	The	oncogenic	role	of	the	cluster	
in	T-ALL	was	strongly	 suggested	 through	 the	 finding	of	a	new	translocation	 t(13;14)(q32;q11)	
that	juxtaposed	the	miR-17~92	cluster	to	the	TCRA/D	locus	thereby	placing	it	under	the	imme-
diate	 control	 of	 the	 strong	 TCRA/D	 enhancer.	 This	 translocation	 occurred	 together	 with	 a	
t(9;14)(q34;q11)	translocation	that	contributes	to	the	aberrant	activation	of	the	NOTCH1	gene.	
The	coexistence	of	these	two	translocations	hinted	towards	the	collaboration	of	NOTCH1	and	
the	miR-17~92	cluster	in	T-ALL	development.	In	order	to	define	which	members	of	the	cluster	
effectively	 contributed	 to	 T-ALL	 formation,	 cytokine	 dependent	 FL5-12	 lymphocytes	 were	
transduced	with	individual	miRNAs	of	the	cluster	followed	by	IL-3	withdrawal.	In	these	assays,	
miR-19b	showed	the	strongest	oncogenic	capacity,	which	 is	 in	 line	with	the	fact	that	miR-19b	
shows	 the	 highest	 expression	 of	 all	 members	 of	 the	miR-17~92	 cluster	 in	 human	 T-ALL.	 A	
NOTCH1-sensitized	mouse	model	was	subsequently	used	to	confirm	the	oncogenic	role	of	miR-
19b	 in	vivo.	Finally,	 target	prediction	algorithms	 in	combination	with	 functional	validation	ex-
periments	 identified	 different	 components	 of	 the	 PI(3)K	 signaling	 pathway	 as	 direct	miR-19b	
targets,	including		PP2A,	PRKAA1,	BIM	and	PTEN.		
A	 few	 years	 later,	 Ye	 et	 al.	 performed	 a	 large	 bio-informatics	 screening	 to	 point	 out	 central	
hubs	in	the	T-ALL	network	[120].	To	this	end,	combinations	of	genes	and	miRNAs	known	to	be	
involved	 in	 T-ALL	were	 tested	with	 target	 prediction	 algorithms.	 Furthermore,	 possible	 tran-
scription	 factor	 regulatory	 relationships	 (feed	 forward	 and	 feedback	 loops)	were	 determined	
based	on	predicted	transcription	factor	binding	sites	near	T-ALL	genes	and	miRNAs.	This	led	to	a	
complex	network	that	contained	21	T-ALL	genes,	21	T-ALL	miRNAs	and	28	transcription	factors.	
The	main	hubs	in	this	in	silico	established	network	contained	4	miRNAs	of	the	miR-17~92	clus-
ter,	 again	 revealing	 an	 important	 role	 for	 this	 cluster	 in	 T-ALL.	 In	 addition,	 these	 authors	 re-
vealed	that	miR-19	could	regulate	NF-κB	signaling	through	direct	targeting	of	CYLD.		
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In	2011,	a	more	in	depth	study	was	performed	towards	identifying	oncogenic	miRNAs	targeting	
known	tumor	suppressor	genes	in	T-ALL	[121].	In	this	study,	miRNA	expression	data	was	com-
pared	with	an	unbiased	miRNA	library	screen,	computational	target	prediction	analyses	and	in	
vivo	modeling,	to	identify	the	most	promising	candidates.	Eventually,	this	resulted	in	the	identi-
fication	 of	 a	 network	 of	 5	 oncogenic	miRNAs	 (miR-19b,	miR-20a,	miR-26a,	miR-92	 and	miR-
223),	which	shared	a	panel	of	direct	tumor	suppressor	target	genes	previously	implicated	in	T-
ALL	biology	(IKZF1,	PTEN,	BIM,	PHF6,	NF1	and	FBXW7).	MiRNAs	with	the	same	target	genes	also	
showed	 a	 cooperative	 effect	 on	 cell	 viability.	 Three	 of	 these	miRNAs	 (miR-19b,	miR-20a	 and	
miR-92)	belong	to	the	oncogenic	miR-17~92	cluster,	whereas	miR-223	was	subsequently	shown	
to	 be	 activated	 by	 TAL1	 [122,	 123]	 and	NOTCH1	 [124],	 two	 important	 T-ALL	 oncogenes	 (dis-
cussed	below),	further	supporting	the	original	observations	of	this	study.	
In	subsequent	studies,	additional	miRNAs	with	an	oncogenic	role	in	the	development	of	T-ALL	
have	 been	 reported.	MiR-128-3p	 is	 highly	 expressed	 in	 T-ALL	 patients	 and	 has	 increased	 ex-
pression	in	T-ALL	samples	compared	to	healthy	donor	thymocytes.	MiR-128-3p	directly	inhibits	
the	expression	of	the	tumor	suppressor	PHF6	and	overexpression	caused	accelerated	leukemia	
onset	in	the	NOTCH1-sensitized	mouse	model	[99].	MiR-21	 is	highly	expressed	in	both	murine	
and	human	T-ALL	and	is	 involved	in	the	inhibition	of	apoptosis,	probably	by	regulating	Pdcd4,	
known	to	play	a	role	in	the	apoptosis	pathway	by	inhibition	of	BCL-xL	translation	[101].	Another	
example	is	miR-142-3p,	which	is	upregulated	in	T-ALL	patient	samples	compared	to	thymocytes	
of	healthy	donors	and	is	one	of	the	top	expressed	miRNAs	in	T-ALL	[121,	125].	MiR-142-3p	plays	
a	role	in	cell	proliferation	through	an	indirect	inhibition	of	cAMP	(cyclic	AMP)	and	PKA	(protein	
kinase	A),	an	inhibitor	of	T-cell	leukemia	proliferation.	Furthermore,	miR-142-3p	directly	targets	
glucocorticoid	receptor	alpha	(GRα),	with	high	miR-142-3p	 levels	being	 involved	 in	glucocorti-
coid	resistance	and	is	linked	to	poor	prognosis	[125].	MiR-149*	was	detected	as	being	upregu-
lated	in	T-ALL	cell	lines	and	bone	marrow	of	T-ALL	patients	in	comparison	to	peripheral	blood.	
This	miRNA	promotes	cell	proliferation	and	reduces	cell	apoptosis	and	might	perform	this	on-
cogenic	function	by	its	direct	targeting	of	JunB	[126].	
Finally,	other	studies	made	use	of	correlation	analyses	between	miRNA	and	mRNA	expression	
in	 T-ALL	patient	 samples	 to	detect	potential	 novel	 oncomiRs.	 For	 example,	 the	expression	of	
miR-590	 is	negatively	correlated	with	RB1	expression	and	 it	was	 found	that	miR-590	plays	an	
oncogenic	role	in	cell	proliferation	and	migration	and	invasion,	by	directly	targeting	RB1	[127].	
A	second	example	is	the	negative	correlation	between	miR-181a	and	EGR1,	a	tumor	suppressor	
in	several	other	cancer	entities.	The	miR-181a/EGR1	pair	probably	has	a	role	in	cell	cycle	regu-
lation	[128].	miR-181a	 is	also	 linked	to	the	NOTCH1	signaling	pathway	which	 is	discussed	fur-
ther	in	more	detail	[129].	
3.3.2 T-ALL	tumor	suppressor	miRNA	
The	Wendel	 team	 also	 conducted	 a	 screening	 for	miRNAs	with	 a	 tumor	 suppressor	 function	
[130].	They	selected	abundantly	expressed	miRNAs	in	thymocytes	from	healthy	donors	that	had	
at	least	a	10-fold	lower	expression	in	primary	T-ALL	samples.	Further	selection	was	performed	
by	in	vitro	proliferation	assays	after	overexpression	of	the	miRNAs.	This	approach	eventually	led	
	
	
	
62	
to	the	identification	of	5	miRNAs	(miR-29,	miR-31,	miR-150,	miR-155	and	miR-200)	with	tumor	
suppressive	effects	 in	vitro	and	 in	vivo.	To	identify	the	potential	mRNA	targets	by	which	these	
miRNAs	performed	their	tumor	suppressive	effect,	predicted	targets	with	higher	expression	in	
T-ALL	patients	as	compared	to	healthy	donors,	were	selected,	in	keeping	with	a	potential	onco-
genic	function	of	the	targets.	The	known	T-ALL	oncogene	MYB	(for	miR-150,	miR-155	and	miR-
200)	and	also,	a	potential	new	oncogene	in	T-ALL,	HBP1	(for	miR-29,	miR-31,	miR-155	and	miR-
200)	appeared	to	be	key	targets	of	this	tumor	suppressive	miRNA	network.	Remarkably,	it	was	
also	 shown	 that	 the	 oncogenic	 NOTCH1/c-MYC	 pathway	 inhibited	 the	 expression	 of	miR-31,	
miR-150	and	miR-155.	
To	further	evaluate	the	post-transcriptional	regulation	of	the	T-ALL	oncogene	MYB	by	miRNAs,	
the	Speleman	team	performed	a	miRNA	 library	screen	testing	the	putative	 interaction	of	470	
miRNAs	with	the	3’UTR	of	MYB	by	a	luciferase	reporter	assay.	Combined	with	mRNA	and	miR-
NA	expression	profiling	data	from	64	T-ALL	patient	samples,	miR-193b-3p	was	detected	as	a	di-
rect	negative	regulator	of	MYB.	MiR-193b-3p	was	also	lower	expressed	in	TAL-rearranged	T-ALL	
patients,	 in	keeping	with	MYB	upregulation	 in	 this	T-ALL	genetic	 subtype.	 Importantly,	 inhibi-
tion	 of	miR-193b-3p	 in	 the	NOTCH1-sensitized	mouse	model	 significantly	 increased	 leukemia	
onset	[131].	
In	another	study,	miR-204	was	detected	as	a	potential	tumor	suppressive	miRNA	as	it	was	low-
er	expressed	in	T-ALL	patient	samples	compared	to	normal	T-cells	from	peripheral	blood.	This	
was	 further	 supported	by	 the	observation	 that	miR-204	 could	 inhibit	 proliferation,	migration	
and	invasion	of	T-ALL	cell	lines	and	directly	targets	SOX4,	a	protein	involved	in	tumorigenesis	of	
AML	[132].		
3.3.3 T-ALL	subtype	specific	miRNAs	
As	indicated	above,	T-ALL	samples	can	be	classified	in	different	genetic	subtypes,	which	display	
unique	gene	expression	 signatures	 [70-74].	Although	different	 studies	have	 linked	miRNAs	 to	
specific	genetic	subtypes	of	human	T-ALL,	a	comprehensive	study	on	the	expression	of	subtype	
specific	miRNAs	in	human	T-ALL	remains	to	be	accomplished.		
One	of	the	first	papers	that	described	miRNAs	in	T-ALL	linked	high	expression	of	the	miR-17~92	
cluster	 to	 TLX1,	 TLX3	 and	NKX2-5	 overexpressing	 T-ALL	 primary	 samples	 and	 cell	 lines.	 This	
miRNA	cluster	seems	to	be	activated	by	these	transcription	factors	and	imposes	increased	cell	
survival	through	the	inhibition	of	E2F1	[133].	
Schotte	et	al.	linked	miR-196b	to	the	HOXA-overexpressing	subtype	with	MLL-rearrangements,	
CALM-AF10	or	SET-NUP214	fusions	or	inversion	on	chromosome	7	[134].	Since	miR-196b	is	lo-
cated	in	the	HOXA-locus,	this	 link	might	be	due	to	co-activation.	High	expression	of	miR-196a	
and	miR-196b	was	subsequently	also	linked	to	T-ALL	samples	with	an	early	immunophenotype	
and	concomitant	expression	of	CD34	and	CD33	[135].		
Furthermore,	miR-223	 has	 been	 linked	 to	 a	myeloid-like	 T-ALL	 phenotype[136],	 but	 has	 also	
been	 identified	 as	 a	 target	 of	 the	 TAL1	 transcription	 factor	 oncogene	 [122,	 123].	Moreover,	
high	expression	of	miR-221	and	miR-222	has	been	linked	to	the	poor	prognostic	subtype	of	hu-
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man	ETP-ALL,	and	it	was	discovered	that	miR-222	directly	inhibits	the	expression	of	the	proto-
oncogene	ETS1	 [137].	 In	 the	 same	 study,	miR-19a	 and	miR-363	were	detected	as	 specifically	
downregulated	in	ETP-ALL.	
3.3.4 miRNAs	in	the	NOTCH1	regulatory	network	
As	mentioned	in	the	introduction,	NOTCH1-activating	mutations	are	present	in	over	half	of	all	
T-ALL	patients.	A	plethora	of	canonical	NOTCH1	downstream	protein	coding	targets	have	been	
described	over	the	last	decade.	More	recently,	it	became	apparent	that	also	miRNAs	play	a	role	
in	the	NOTCH1	regulatory	network	in	the	context	of	T-ALL	development.	
Li	et	al.	described	miR-451	and	miR-709	as	possible	tumor	suppressor	miRNAs	in	murine	T-ALL.	
These	miRNAs	are	downregulated	in	T-ALL	and	show	a	dynamic	expression	pattern	during	nor-
mal	T-cell	development.	The	tumor	suppressor	role	of	these	miRNAs	was	further	established	by	
a	delayed	leukemia	onset	after	overexpression	of	miR-451	or	miR-709	in	the	NOTCH1-sensitized	
mouse	 model.	MiR-451	 and	miR-709	 directly	 target	 c-Myc,	 a	 known	 oncogene	 activated	 by	
NOTCH1	in	T-ALL.	Next	to	c-MYC,	miR-709	also	directly	targets	Ras-GRF1	and	Akt.	Motif	analysis	
followed	by	ChIP-sequencing	revealed	 the	positive	 regulation	of	 these	miRNAs	by	E2A,	which	
itself	 is	 inhibited	 by	NOTCH1	 signaling.	 The	NOTCH1/miR-451/c-MYC	 axis	 also	 plays	 a	 role	 in	
human	T-ALL	(miR-709	has	no	human	homologue)	[138].	
Later,	this	network	was	further	expanded	by	adding	a	feed	forward	loop	between	NOTCH1	and	
c-MYC	 that	was	 regulated	by	 the	 tumor	suppressive	miRNA,	miR-30a[139].	The	expression	of	
miR-30a	is	lower	in	T-ALL	patient	samples	with	hyperactive	NOTCH1	compared	to	NOTCH1	wild	
type	cases.	NOTCH1	signaling	activates	the	expression	of	c-MYC	and	c-MYC	inhibits	miR-30a	ex-
pression	[140].	Target	prediction	analysis	and	reporter	assays	then	demonstrated	that	miR-30a	
targets	NOTCH1.	This	implies	that	oncogenic	activation	of	NOTCH1	 leads	to	an	overexpression	
of	c-MYC,	followed	by	a	miR-30a	downregulation.	This	then	releases	the	inhibition	of	NOTCH1	
expression	by	miR-30a	[139].	
It	has	also	been	shown	that	NOTCH1-induced	murine	T-ALL	development	was	hampered	by	the	
deletion	 of	 the	miR-181a-1/b-1	 gene.	 Remarkably,	 the	 effects	 of	miR-181a-1/b-1	 change	 de-
pending	on	the	expression	level	of	Notch1.	If	the	expression	of	Notch1	 is	high,	the	deletion	of	
the	miR-181a-1/b-1	gene	strongly	delays	T-ALL	development,	whereas	the	deletion	 leads	to	a	
full	inhibition	of	T-ALL	if	Notch1	expression	is	lower.	miR-181a	regulates	Notch	signaling	by	in-
hibition	of	Nrarp,	which	is	a	negative	regulator	of	the	NOTCH1	downstream	signaling.	Further-
more,	miR-181a	was	also	necessary	in	early	T-cell	development,	where	it	inhibits	negative	regu-
lators	of	pre-T-cell	receptor	signaling	(ex.	Dusp5	and	Dusp6)	[129].	
MiR-223	was	 detected	 as	 differentially	 expressed	 in	murine	 Notch-modulated	 T-ALL	models.	
Motif	analysis	and	ChIP-sequencing	showed	the	binding	of	the	ICN1-complex	and	NF-κB	to	the	
promoter	of	miR-223,	which	leads	to	the	activation	of	transcription	of	this	miRNA.	MiR-223	it-
self,	further	negatively	regulates	FBXW7,	a	known	tumor	suppressor	gene	in	T-ALL.		In	contrast	
to	 this	 finding,	 γ-secretase	 inhibitor	 (GSI)	 treatment	 (which	 inhibits	 downstream	 NOTCH1-
signaling)	showed	upregulation	of	miR-223	in	GSI-resistant	T-ALL	cell	lines	[124].	These	contra-
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dictory	results	could	later	be	explained	by	the	activation	of	C/EBPα	after	GSI	treatment,	which	
can	activate	miR-223	as	well	 [141].	MiR-223	 is	 also	 important	 in	 the	TAL1	downstream	path-
way,	which	will	be	discussed	in	the	next	paragraph.		
3.3.5 miRNAs	up-	and	downstream	of	the	TAL1	oncogene	
TAL1/SCL	overexpression	is	one	of	the	major	oncogenic	events	in	T-ALL,	which	could	delineate	a	
specific	T-ALL	subtype.	Mansour	et	al.	 studied	the	downstream	miRNAs	of	TAL1	 [122].	 In	 this	
study	miR-223	 was	 the	 most	 promising	 candidate	 as	 it	 was	 most	 strongly	 differentially	 ex-
pressed	 upon	 TAL1-knockdown	 and	 direct	 binding	 of	 TAL1	 to	 the	 miR-223	 promoter	 was	
shown.	Next	to	that,	TAL1-positive	T-ALL	cells	needed	miR-223	for	their	sustained	cell	survival.	
They	also	showed	that	the	expression	of	TAL1	and	miR-223	is	strongly	correlated	during	normal	
T-cell	development,	implicating	that	the	expression	of	miR-223	is	high	in	early	T-cell	progenitors	
and	low	from	the	DN3a-stage	on	to	more	mature	T-cell	stages.	Furthermore,	it	was	proven	that	
miR-223	directly	inhibits	the	expression	of	FBXW7	and	in	this	way	supports	the	oncogenic	func-
tion	of	TAL1[121,	122].	By	means	of	TAL1-overexpression,	Correia	et	al.	also	showed	the	direct	
activation	 of	miR-223,	 but	 also	 direct	 repression	 of	miR-146b-5p	 by	 TAL1.	 Direct	 or	 indirect	
TAL1-regulated	miRNAs	were	predicted	(by	in	silico	analysis)	to	target	several	genes	in	the	TAL1	
downstream	pathways	[123].		
Because	several	T-ALL	patients	show	TAL1-overexpression	without	a	known	cause,	Correia	and	
colleagues	hypothesized	that	the	downregulation	of	miRNAs	that	target	TAL1	might	be	a	novel	
oncogenic	event	in	T-ALL.	Target	prediction	algorithms	revealed	several	miRNAs	with	potential	
binding	sites	 in	the	3’UTR	of	TAL1.	Five	of	these	miRNAs	(miR-101,	miR-520d-5p,	miR-140-5p,	
miR-448	 and	miR-485-5p)	 could	be	 validated	as	direct	 inhibitors	of	TAL1,	 of	which	4	miRNAs	
(not	miR-520d-5p)	where	lower	expressed	in	T-ALL	patient	samples	compared	to	normal	bone	
marrow	cells	[142]	.	
An	overview	of	the	described	miRNA-mRNA	interaction	can	be	found	in	Figure	9	and	in	Table	3.		
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Figure	9.	Overview	of	the	noncoding	RNAs	implicated	in	T-ALL.	miRNAs	(blue	text)	and	lncRNAs	(green	text)	stud-
ied	in	T-ALL	oncogenesis.	The	mRNAs	linked	to	the	ncRNAs	are	annotated	in	the	filled	circles.	Bonafide	oncogenes	
and	tumorsuppressor	genes	in	T-ALL	are	annotated	in	respectively	red	and	blue	background.	Dashed	lines	repre-
sent	indirect	interactions.	miRNAs	of	the	miR-17~92	cluster	are	highlighted	with	a	red	circle.		
	 	
	
	
	
66	
Table	3.	miRNAs	 implicated	 in	T-ALL	biology.	ONC:	oncogenic	miRNA,	TSG:	tumor	suppressor	miRNA,	ETP:	ETP-
ALL,	 TAL-R:	 TAL-rearranged	 T-ALL,	 IMM:	 Immature	 T-ALL,	 HOXA:	 HOXA-overexpressing	 T-ALL.	 The	 most	 recent	
miRBase	annotation	was	retrieved	using	the	miRBase	Tracker,	www.mirbasetracker.org	[143].	
	 miRBase	release	21	 Function	 Direct	targets	 Refs	
miR-19a	 hsa-miR-19a-3p	 ONC	
ETP	low	
CYLD	 [120,	137]	
miR-19b	 hsa-miR-19b-3p	 ONC	 BIM,	CYLD,	PP2A,	
PRKAA1,	PTEN	
[119-121]	
miR-20a	 hsa-miR-20a-5p	 ONC	 BIM,	PHF6,	PTEN	 [121]	
miR-21	 hsa-miR-21-5p	 ONC	 PDCD4	 [101]	
miR-26a	 hsa-miR-26a-5p	 ONC	 BIM,	PHF6,	PTEN	 [121]	
miR-29	 hsa-miR-29a-3p	 TSG	 HBP1	 [129]	
miR-30a	 hsa-miR-30a-5p	
hsa-miR-30a-3p	
MYC	repressed	
Targets	NOTCH1	
NOTCH1	 [139,	140]	
miR-31	 hsa-miR-31-5p	 TSG	 HBP1	 [130]	
miR-92	 hsa-miR-92a-3p	 ONC	 BIM,	 FBXW7,	
IKZF1,	NF1,	PTEN	
[121]	
miR-101	 hsa-miR-101-3p	 Targets	TAL1	 TAL1	 [142]	
miR-128-3p	 hsa-miR-128-3p	 ONC	 PHF6	 [99]	
miR-140-5p	 hsa-miR-140-5p	 Targets	TAL1	 TAL1	 [142]	
miR-142-3p	 hsa-miR-142-3p	 ONC	 cAMP,	GRα,	PKA	 [125]	
miR-146b-5p	 hsa-miR-146b-5p	 TAL1	repressed	 	 [123]	
miR-149*	 hsa-miR-149-3p	 ONC	 JunB	 [126]	
miR-150	 hsa-miR-150-5p	 TSG	 MYB	 [130]	
miR-155	 hsa-miR-155-5p	 TSG	 HBP1,	MYB	 [130]	
miR-181a	 hsa-miR-181a-5p	 ONC	 EGR1,	NRARP	 [128]	
miR-193b-3p	 hsa-miR-193b-3p	 TSG	
TAL-R	low	
MYB	 [131]	
miR-196a	 hsa-miR-196a-5p	 IMM	high	 ERG	 [135]	
miR-196b	 hsa-miR-196b-5p	 HOXA	high	
IMM	high	
ERG	 [134,	135]	
miR-200c	 hsa-miR-200c-3p	 TSG	 HBP1,	MYB	 [130]	
miR-204	 hsa-miR-204-5p	 TSG	 SOX4	 [132]	
miR-221	 hsa-miR-221-3p	 ETP	high	 	 [137]	
miR-222	 hsa-miR-222-3p	 ETP	high	 ETS1	 [137]	
miR-223	 hsa-miR-223-3p	 ONC	
Myeloid	high	
TAL-R	high	
NOTCH1	activated	
TAL1	activated	
FBXW7	 [121-124,	
136]	
miR-363	 hsa-miR-363-3p	 ETP	low	 	 [137]	
miR-448	 hsa-miR-448	 Targets	TAL1	 TAL1	 [142]	
miR-451	 hsa-miR-451a	 NOTCH1	repressed	 c-MYC	 [138]	
miR-485-5p	 hsa-miR-485-5p	 Targets	TAL1	 TAL1	 [142]	
miR-520d-5p	 hsa-miR-520d-5p	 Targets	TAL1	 TAL1	 [142]	
miR-590	 hsa-miR-590-5p	 ONC	 RB1	 [127]	
miR-92	 hsa-miR-92a-3p	 ONC	 BIM,	 FBXW7,	
IKZF1,	
NF1,	PTEN	
[121]	
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3.4 Long	non-coding	RNAs	implicated	in	T-ALL	
In	contrast	to	miRNAs,	lncRNAs	emerged	more	recently	on	the	cancer	scene	and	fewer	studies	
have	 been	 published	 so	 far.	Moreover,	 the	 possible	 functions	 of	 lncRNAs	 are	most	 probably	
very	diverse	as	exemplified	by	those	described	so	far	in	the	lncRNA	field.	Moreover,	modulating	
lncRNAs	and	identifying	their	function	can	be	notoriously	difficult	and	requires	extensive	inves-
tigations.	
3.4.1 NOTCH1	driven	lncRNAs	
The	 first	 comprehensive	 study	 of	 lncRNAs	 in	 T-ALL	 comprised	mRNA	 and	 lncRNA	 expression	
profiles	 of	 T-ALL	 cell	 lines	 and	 primary	 T-ALL	 patient	 samples	 by	means	 of	 deep	 total	 RNA-
sequencing.	Direct	NOTCH1-regulated	lncRNAs	were	determined	by	pharmacological	inhibition	
of	 the	NOTCH1	pathway	by	means	of	GSIs	 in	 two	T-ALL	cell	 lines	and	by	NOTCH/RBPJκ	ChIP-
sequencing.	Trimarchi	et	al.	prioritized	LUNAR1	(leukemia	induced	noncoding	activator	RNA	1)	
as	 a	 NOTCH1	 induced	 candidate	 oncogenic	 lncRNA	 for	 further	 functional	 analysis.	 This	 was	
based	on	its	strong	correlated	expression	with	IGF1R,	as	IGF1R	was	already	previously	linked	to	
T-ALL	development.	In	addition,	the	LUNAR1	locus	is	characterized	by	an	active	promoter	based	
on	the	chromatin	structure	as	determined	in	cell	lines	with	hyperactive	NOTCH1-signalling	and	
the	 transcript	 structure	 of	 LUNAR1,	 as	 determined	 by	 ‘Rapid	 Amplification	 of	 cDNA	 Ends’	
(RACE),	 has	 no	 protein	 coding	 potential.	 Hi-C	 and	 3C	 (chromosome	 conformation	 capture)	
proved	a	physical	interaction	between	the	LUNAR1	promoter	and	an	active	enhancer	in	the	last	
intron	of	its	neighboring	gene	IGF1R.	Also,	knockdown	of	LUNAR1	led	to	a	decrease	in	expres-
sion	of	IGF1R,	whereas	overexpression	of	LUNAR1	did	not	have	any	effect	on	IGF1R,	in	keeping	
with	a	cis-acting	role	of	LUNAR1.	Next,	in	depth	in	vitro	and	in	vivo	experiments	could	unravel	
the	mechanism	by	which	LUNAR1	has	an	oncogenic	role	in	T-ALL.	Xenograft	assays	with	a	mix	of	
human	T-ALL	 cells	with	or	without	 knockdown	of	LUNAR1	 revealed	 tumors	with	a	 significant	
loss	of	representation	of	cells	where	LUNAR1	was	depleted,	again	proving	an	oncogenic	role	of	
LUNAR1	in	T-ALL	development.	On	a	molecular	level,	Trimarchi	and	colleagues	could	show	that	
LUNAR1	is	involved	in	the	recruitment	of	the	Mediator	complex	and	RNA	Pol	II	to	the	enhancer	
located	 in	the	 last	 intron	of	 IGF1R,	 leading	to	full	 transcriptional	activation	of	the	 IGF1R	gene	
[118].			
In	a	parallel	study,	the	repertoire	of	NOTCH1-driven	lncRNAs	in	T-ALL	was	further	unraveled	by	
Durinck	et	al.,	through	characterization	of	lncRNAs	of	which	the	expression	was	affected	by	GSI	
treatment	of	T-ALL	cell	lines	and	under	control	of	NOTCH-signaling	in	CD34+	thymocytes	[102].	
By	means	of	RNA-sequencing	a	set	of	known	and	novel	lncRNAs	that	are	directly	regulated	by	
NOTCH1	 in	 both	 normal	 and	malignant	 T-cell	 development	were	 identified,	 with	 one	 of	 the	
most	prominent	NOTCH1	candidate	lncRNAs	apparent	from	both	in	vitro	model	systems	being	
the	previously	described	LUNAR1.	 Integration	of	the	obtained	RNA-seq	profiles	of	GSI-treated	
cell	lines	and	NOTCH1	stimulated	CD34+	T-cell	progenitors	with	NOTCH1	ChIP-sequencing	pro-
files	showed	that	the	majority	of	the	identified	NOTCH1-regulated	lncRNAs	showed	ICN1	bind-
ing	in	the	vicinity	of	their	promoter.	In	addition,	a	subset	of	those	was	also	bound	by	MED1	and	
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BRD4,	hinting	towards	a	potential	role	of	enhancer	RNAs	for	a	subset	of	the	identified	NOTCH1	
regulated	lncRNAs	[102].	
In	addition	to	the	above	studies	focusing	on	NOTCH1	controlled	lncRNAs,	yet	another	investiga-
tion	identified	NALT	(Notch1	associated	lncRNA	in	T-ALL)	as	a	lncRNA	involved	in	the	regulation	
of	NOTCH1	expression.	It	is	located	400	bp	upstream	of	the	NOTCH1	locus	in	the	antisense	di-
rection	 and	 is	 higher	 expressed	 in	 T-ALL	 patient	 bone	marrow	 compared	 to	 healthy	 control	
samples.	 In	 vitro	 and	 in	 vivo	 knockdown	experiments	 could	 further	 show	a	potential	 role	 for	
NALT	as	a	transcriptional	activator	involved	in	cell	proliferation	[144].	
3.4.2 T-ALL	subtype	specific	lncRNAs	
As	indicated	above,	gene	expression	studies	have	been	shown	to	allow	genetic	subgroup	classi-
fication.	To	explore	this	for	lncRNA	expression	profiles,	the	Speleman	team	screened	a	cohort	
of	 64	 primary	 T-ALL	 patient	 samples	 for	 expression	 of	 all	 protein	 coding	 genes	 and	 13,000	
lncRNAs	 [145].	 This	 cohort	 consisted	 of	 15	 immature,	 17	 TLX1/3,	 25	 TAL-rearranged	 and	 7	
HOXA	overexpressing	T-ALL	cases.	This	 study	allowed	defining	subsets	of	 lncRNAs	specific	 for	
each	 of	 the	 T-ALL	 genetic	 subtypes.	 	 Furthermore,	 the	 authors	 linked	 the	 lncRNA	expression	
pattern	 in	 these	 T-ALL	 subtypes	 to	 the	 different	 stages	 of	 healthy	 T-cell	 development	 in	 the	
thymus.	As	the	immature	T-ALL	subtype	lymphoblasts	occur	from	a	differentiation	arrest	early	
during	T-cell	development	 (CD34+	 thymocytes),	 it	appeared	that	several	 lncRNAs	that	are	up-
regulated	 in	 the	 immature	T-ALL	 subtype	are	also	higher	expressed	 in	 the	CD34+	 thymocytes	
compared	to	later	stages	during	T-cell	development.	These	lncRNAs	might	be	involved	in	nor-
mal	 T-cell	 development.	 On	 the	 other	 hand,	 lncRNAs	were	 identified	 in	 the	 immature	 T-ALL	
subtype	 group	with	 significantly	 higher	 expression	 in	 immature	 T-ALL	 as	 compared	 to	 CD34+	
thymocytes,	revealing	a	potential	oncogenic	role	during	T-ALL	development.	The	same	compar-
isons	could	be	made	for	the	TAL-rearranged	patients	that	resemble	a	later	differentiation	arrest	
during	T-cell	development,	the	double	positive	CD4+CD8+	stage	[103].	
3.5 Noncoding	RNAs	in	T-cell	development		
Normal	thymopoiesis	 is	a	tightly	regulated	developmental	process	that	 is	 initiated	with	CD34+	
early	T-cell	progenitors	 that	migrate	 from	the	bone	marrow	 towards	 the	 thymus.	Within	 this	
thymic	microenvironment,	discrete	developmental	stages	of	T	cell	development	can	be	identi-
fied	through	a	combination	of	cell	surface	markers	(CD34,	CD4,	CD8,	CD3	etc.)	and	each	of	the-
se	 stages	 contains	 a	 distinct	 transcriptional	 profile	 [58-68]	 	 (Figure	 10).	 As	 noncoding	 RNAs	
show	a	very	tissue	and	cell	type	specific	expression	pattern,	the	possible	 involvement	of	miR-
NAs	and	lncRNAs	in	the	clearly	distinct	steps	of	T-cell	development	is	quite	obvious.		
3.5.1 MiRNAs	in	T-cell	development	
Several	miRNAs	have	been	discovered	over	the	last	years	that	are	involved	in	normal	T-cell	de-
velopment	in	the	thymus.	Their	overall	relevance	was	nicely	illustrated	by	a	study	by	Cobb	et	al.	
that	showed	that	deletion	of	Dicer	in	early	T-cell	progenitors	in	mice	led	to	a	decrease	in	thymic	
cellularity	as	a	consequence	of	reduced	survival	of	the	αβ	T-cell	 lineage,	thus	revealing	a	role	
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for	miRNAs	 in	 the	double	negative	 to	double	positive	stage	 transition	 [146,	147].	 In	addition,	
miRNA	processing	by	Dicer	 is	also	necessary	 for	 the	positive	selection	of	 thymocytes	and	 the	
transition	 from	the	double	positive	 to	 the	CD8+	single	positive	stage,	as	 shown	 in	conditional	
Dicer	knock-out	mice	with	a	CD4-Cre	transgene	[148].	It	has	also	been	shown	that	miRNAs	and	
even	isomiRs	change	in	expression	during	T-cell	development,	 indicating	that	not	only	the	ex-
pression,	but	also	the	processing	of	the	miRNAs	is	altered	during	thymopoiesis	[149].	
Despite	their	clear	importance,	data	on	the	role	of	individual	miRNAs	is	rare.	MiR-181a,	howev-
er,	not	only	plays	a	role	in	NOTCH1-driven	T-ALL,	but	also	appears	to	be	involved	during	normal	
T-cell	development.	The	expression	of	miR-181a	is	high	at	the	double	positive	T-cell	stage	and	
decreases	during	development,	with	almost	no	expression	 in	differentiated	T-cells	 [150,	151].	
Furthermore,	 it	has	been	shown	that	miR-181a	 increases	 thymocyte	sensitivity	by	directly	 in-
hibiting	 the	expression	of	DUSP5,	DUSP6,	SHP2	 and	PTPN22	which	are	negative	 regulators	of	
TCR-signaling	[152].	miR-181a	also	appears	to	be	involved	in	the	regulation	of	positive	and	neg-
ative	selection	of	thymocytes	[151,	152].	(Figure	10)	
		
	
Figure	 10.	MicroRNAs	 involved	 in	 T-cell	 development	 in	 the	 thymus.	 Immature	T-cells	migrate	 from	 the	bone	
marrow	to	the	thymus	where	they	go	through	several	stages	of	differentiation	(early	T-cell	prognitors	(ETP),	dou-
ble	negative	T-cells	(DN),	double	positive	T-cells	(DP)	and	single	positive	T-cells	(SP)),	which	are	marked	by	different	
membrane	receptors	(CD34,	CD1a,	CD4,	CD8,	TCR	etc).	Mature	T-cells	leave	the	thymus	as	either	CD4+	or	CD8+	αβ	
T-cells	or	γδ	T-cells	and	perform	several	function	in	the	immune	defense	of	the	body.	MicroRNAs	play	a	role	during	
this	process,	with	proven	function	for	the	miR-17~92	cluster	and	miR-181a.	
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The	miR-17~92	 cluster	 inhibits	 the	expression	of	PTEN	 and	of	 the	pro-apoptotic	protein	BIM,	
which	 leads	 to	 T-cell	 survival	 at	 the	DN2	 stage	of	 T-cell	 development	 [153].	 It	 has	 also	 been	
shown	that	the	miR-17~92	cluster	is	necessary	for	cell	survival	at	the	double	negative	to	double	
positive	transition	of	T	cell	development	by	regulating	the	IL7R	receptor	surface	expression	and	
the	response	to	IL-7	[154].	Furthermore,	this	cluster	is	also	involved	in	positive	and	negative	se-
lection	of	thymocytes	[153].	Recently	it	has	been	shown	that	the	expression	of	the	miR-17~92	
cluster	is	regulated	by	TCR-signaling	and,	in	this	way,	indirectly	by	miR-181a.	The	expression	of	
miR-17~92	can	inhibit	CD69	expression,	which	is	also	activated	by	TCR-signaling.	With	this	feed	
forward	 loop,	 cell-to-cell	 variation	 in	 the	 thymocytes	 is	 regulated.	 This	 further	marks	 the	 im-
portance	of	miRNAs	during	normal	T-cell	development	[155].	(Figure	10)	
3.5.2 LncRNAs	in	T-cell	development	
As	 lncRNAs	 are	 known	 to	 be	 expressed	 tissue	 specifically,	 it	 should	 be	 no	 surprise	 that	 also	
lncRNAs	 are	 involved	 in	 this	 specific	 developmental	 process.	 However,	 not	 much	 is	 known	
about	 lncRNAs	involved	in	human	thymopoiesis.	Several	studies	profiled	either	sorted	thymo-
cytes	from	mice	or	differentiation	stages	of	mature	T-cells	[156,	157],	thereby	already	revealing	
fluctuations	in	lncRNA	expression	during	T-cell	development.		
The	T-ALL	oncogene	NOTCH1	is	also	necessary	for	T-cell	lineage	commitment	in	the	first	stages	
of	T-cell	development.	NOTCH1	signaling	is	high	in	the	CD34+	thymocytes,	but	drops	significant-
ly	during	the	β-selection	process	when	the	cells	differentiate	towards	CD4+CD8+	double	positive	
thymocytes.	In	addition	to	the	role	of	NOTCH1	in	lncRNA	expression	in	T-ALL	(see	above),	Dur-
inck	et	al.	also	examined	lncRNAs	in	T-cell	development[102].	Human	thymic	CD34+	progenitor	
T-cells	were	plated	on	an	OP9	stromal	cell	layer	that	expresses	the	NOTCH-ligand	DLL-1	(delta-
like	 ligand	1)[61],	 leading	 to	 activation	of	NOTCH1	 signaling.	RNA-sequencing	was	performed	
after	48	hours	of	co-culture	and	showed	a	clear	shift	in	lncRNA	expression.	Furthermore,	ex	vivo	
purified	 human	 thymocyte	 subsets	 (CD34+CD1-CD4+,	 CD34+CD1+CD4+,	 CD4+CD8+CD3-	 and	
CD4+CD8+CD3+)	were	profiled	on	an	expression	array.	The	NOTCH-regulated	 lncRNAs	selected	
from	the	co-culture	experiment	clearly	followed	the	expression	pattern	of	DTX1,	a	protein	cod-
ing	NOTCH1	 target	 gene	 that	 is	 expressed	 in	 CD34+	 thymocytes	 but	 not	 in	 CD4+CD8+	 double	
positive	T-cells.	With	this	study,	the	importance	of	NOTCH1	in	the	regulation	of	lncRNA	expres-
sion	during	T-cell	development	was	clearly	shown.	Expression	profiling	of	these	T-cell	subsets	
also	revealed	several	other	lncRNAs	with	dynamic	expression	patterns	during	human	T	cell	de-
velopment,	suggesting	that	these	also	have	specific	roles	during	the	T-cell	maturation	process	
[103].		
To	 elucidate	 the	 molecular	 mechanisms	 that	 control	 early	 hematopoietic	 lineage	 choices	 in	
human,	 Casero	 et	 al.	 performed	 RNA-sequencing	 on	 several	 stages	 of	 B-	 and	 T-cell	 develop-
ment	[158].	Also	here,	stage-specific	patterns	of	lncRNA	expression	were	identified	during	the	
different	stages	of	T-cell	development.	Remarkably,	cell-type	specific	 lncRNAs,	and	not	highly	
expressed	 lncRNAs,	were	 characterized	 by	 high	 densities	 of	 H3K4me1	 and	H3K4me3	 histone	
modifications	(marks	for	respectively	active	enhancers	and	promoters).	Another	interesting	dif-
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ference	between	lncRNAs	and	protein	coding	genes	was	detected	if	the	samples	were	clustered	
based	on	differentially	expressed	genes.	For	protein	coding	genes,	the	CD34+	thymic	progenitor	
cells	 segregated	with	 the	CD34+	populations	 in	 the	bone	marrow	and	not	with	more	mature	
(CD34-)	thymic	progenitor	cells.	However,	lncRNAs	clearly	made	the	distinction	between	thymic	
cells	 and	 bone	marrow	 derived	 cells.	With	 these	 data,	 the	 authors	 could	 show	 that	 the	 cell	
type-specific	nature	of	lncRNA	expression	could	be	used	to	define	developmental	relationships.		
Despite	the	low	amount	of	studies	describing	the	role	of	miRNAs	and	lncRNAs	in	early	T-cell	de-
velopment,	 they	 already	 suggest	 that	 noncoding	 RNAs	 complement	 protein	 coding	 genes	 in	
their	ability	to	guide	early	T-cell	progenitors	through	the	different	maturation	stages.		
3.6 Conclusions	and	future	perspectives	
The	role	for	miRNAs	and	long	noncoding	RNAs	has	been	described	in	several	cancer	entities	and	
in	developmental	processes.	However,	it	remains	a	challenge	to	define	the	functional	activities	
of	these	noncoding	RNAs,	especially	for	long	noncoding	RNAs	since	their	potential	mechanism	
of	action	can	be	very	broad.	Nevertheless,	the	oncogenic	roles	for	several	miRNAs	(ex.	the	miR-
17~92	cluster	[23])	and	lncRNAs	(ex.	MALAT1,	HOTAIR	…	[52,	53])	have	been	described	in	detail	
for	several	cancer	entities.		
In	 T-ALL,	 the	 role	 for	miRNAs	 is	 already	 explored	 in	 depth.	One	 landmark	publication	by	 the	
Wendel	team	could	link	several	miRNAs	to	protein	coding	genes	with	a	known	tumor	suppres-
sive	 role	 in	T-ALL,	also	showing	 the	cooperative	effect	of	 several	miRNAs	on	the	same	mRNA	
[121].	This	paved	the	way	for	several	other	studies	 that	could	expand	this	miRNA-mRNA	net-
work.	Also	in	T-cell	development,	there	seems	to	be	a	role	for	miRNAs,	however,	more	in	depth	
studies	should	be	performed	to	profile	the	miRNAs	that	have	key	roles	during	these	develop-
mental	steps.		
The	role	for	lncRNAs	in	T-ALL	and	T-cell	development	is	less	established	in	comparison	for	miR-
NAs.	 Nevertheless,	 the	 discovery	 of	 LUNAR1,	 a	 NOTCH1-activated	 lncRNA	 that	 regulates	 the	
expression	of	IGF1R	in	T-ALL	[118],	proves	that	there	are	lncRNAs	involved	in	the	oncogenic	de-
velopment	of	T-ALL.	Furthermore,	several	studies	identified	lncRNAs	with	a	specific	expression	
pattern	in	T-ALL	and	T-cell	development,	but	the	functional	mechanisms	of	these	lncRNAs	have	
not	been	discovered.	 	This	 is	partly	due	to	the	lack	of	species	conservation	of	 lncRNAs,	which	
makes	it	difficult	to	study	them	in	mouse	models,	but	also	because	a	detailed	study	describing	
an	 in-depth	 and	 full	 transcriptome	of	 all	 discrete	 stages	of	 human	T	 cell	 development	 is	 still	
missing.	Another	obstacle	 is	 the	broad	range	of	possible	 functional	mechanisms	that	 lncRNAs	
could	have,	which	 is	not	 the	case	 for	miRNAs,	and	 the	 lack	of	 robust	genetic	 tools	 in	human	
primary	hematopoietic	precursors	cells	to	functionally	study	the	role	of	individual	lncRNAs.		
As	more	and	more	functions	for	miRNAs	and	lncRNAs	are	discovered,	several	possible	pharma-
cological	inhibitory	mechanisms,	for	example	the	usage	of	anti-sense	oligonucleotides,	are	be-
ing	 tested	 to	 target	 these	 noncoding	 RNAs	 [159,	 160].	 The	 interesting	 feature	 of	 noncoding	
RNAs	is	that	their	expression	is	more	tissue	specific	than	most	protein	coding	oncogenes.	Drugs	
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targeting	these	tissue	specific	RNAs	could	then	result	 in	 less	off-target	effects	of	 the	therapy.	
Because	of	 this,	noncoding	RNA	research	with	a	 focus	on	 these	ectopic	expressed	noncoding	
RNAs	should	be	further	established,	taken	into	account	that	there	should	also	be	a	possibility	to	
identify	patients	in	clinic	that	could	benefit	from	these	specific	treatments.			
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Research	Objectives	
T-cell	acute	lymphoblastic	leukemia	(T-ALL)	patients	currently	present	with	an	overall	favorable	
prognosis	achieved	through	intense	chemotherapy	regimens.	Additional	challenges	that	are	still	
posed	today	concern	those	patients	that	present	with	therapy	resistance	or	relapse.	In	this	per-
spective	 it	will	be	crucial	 to	 further	unravel	 the	molecular	basis	of	T-ALL	biology	and	 identify	
novel	targets	for	development	of	 innovative	therapy	protocols.	Technological	advances	 in	the	
field	have	opened	new	possibilities	to	dissect	the	T-ALL	transcriptome	and	recent	findings	un-
derscore	 the	 importance	of	noncoding	RNA	molecules,	 such	as	miRNAs	and	 lncRNAs,	next	 to	
protein	coding	genes	in	various	cancer	entities	and	also	T-ALL.		
In	 this	 thesis,	my	 aim	was	 to	 landscape	 the	 expression	of	 these	 noncoding	RNAs	 in	 T-ALL	 to	
complement	the	previously	published	protein	coding	gene	expression	profiles.	In	this	way,	nov-
el	oncogenic	aspects	in	T-ALL	could	be	unraveled,	for	example	when	an	lncRNA	or	miRNA	is	de-
tected	in	a	known	T-ALL	oncogenic	pathway	or	when	it	could	point	at	complete	novel	oncogen-
ic	mechanisms.	This	would	lead	to	novel	insight	in	T-ALL	biology	and	potential	novel	therapeutic	
targets.	
AIM	1:	Defining	the	NOTCH1-regulated	lncRNAome	in	T-ALL	
In	more	than	half	of	T-ALL	cases	activating	mutations	in	the	NOTCH1-oncogene	have	previously	
been	identified	as	well	as	oncogenic	aberrations	in	genes	downstream	of	the	NOTCH1-signaling	
cascade.	This	makes	this	pathway	an	 interesting	candidate	for	T-ALL	therapy.	The	first	clinical	
trials	with	γ-secretase	inhibitors	(GSI)	that	strongly	reduce	NOTCH1-signaling,	had	to	be	termi-
nated	due	to	side	effects	and	therapy	resistance.	Since	then,	there	is	a	quest	to	better	define	
the	NOTCH1-signaling	pathway	to	find	novel,	T-ALL	specific,	targets	to	complement	a	low	dose	
GSI	treatment.	
The	role	of	protein	coding	genes	in	the	NOTCH1-pathway,	both	in	normal	T-cell	development	as	
in	T-ALL,	has	already	been	 thoroughly	described.	Therefore,	we	now	aimed	 to	perform	a	de-
tailed	landscaping	of	the	lncRNAs	that	are	transcriptionally	regulated	by	this	pathway	(paper	1,	
Haematologica,	2014).	We	generated	lncRNA	expression	profiles	after	GSI	treatment	of	T-ALL	
cell	 lines,	but	also	of	CD34+	T-cell	 subsets	 that	encountered	a	NOTCH1-activating	 ligand.	This	
was	further	complemented	by	lncRNA	profiling	of	healthy	donor	T-cell	subsets	and	primary	T-
ALL	patient	samples.		
AIM	2:	Unraveling	lncRNA	expression	patterns	in	the	different	T-ALL	subtypes	
Previously	 published	 micro-array	 gene	 expression	 profiling	 data	 of	 protein	 coding	 genes	 re-
vealed	a	specific	clustering	pattern	of	T-ALL	patient	samples	that	could	be	linked	to	specific	on-
cogenic	driver	events	and	differentiation	arrest	during	T-cell	development	at	a	specific	devel-
opmental	stage	with	subsequent	expansion	of	the	 lymphoblast	population.	To	also	unravel	T-
ALL	subtype	specific	lncRNA	expression	patterns,	RNA	of	64	T-ALL	patient	samples	was	profiled	
on	a	custom-designed	micro-array	platform,	detecting	the	expression	of	 lncRNAs	next	to	pro-
tein	coding	genes	(paper	2,	Leukemia,	2016).	In	this	way,	I	was	able	to	identify	a	set	of	lncRNAs	
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that	can	discriminate	the	various	known	T-ALL	subgroups	and	the	determination	of	lncRNA	pro-
files	from	sorted	healthy	donor	T-cell	subsets	could	further	support	the	elucidation	of	potential	
oncogenic	lncRNAs	amongst	the	T-ALL	subgroups	in	this	study.	Previous	studies	elucidating	the	
mRNA	expression	profiles	of	T-ALL	subgroups	could	identify	oncogenic	drivers	for	this	profiles,	
we	thus	hypothesize	that	some	of	the	subtype	specific	 lncRNAs	might	also	have	an	oncogenic	
function	in	T-ALL	development.		
Technological	 advances	 in	 next-generation	 sequencing	have	pushed	 forward	RNA-sequencing	
as	the	state-of-the-art	technology	to	generate	gene	expression	profiles	rather	than	micro-array	
technology.	Therefore	we	generated	in	this	study	novel	expression	profiles	of	our	T-ALL	patient	
cohort	by	means	of	poly(A)	RNA-sequencing	(paper	3,	in	preparation).	This	led	to	an	update	of	
the	 lncRNA	 profiles	 that	 can	 differentiate	 the	 distinct	 T-ALL	 subtypes	 and	 I	 could	 show	 that	
RNA-sequencing	is	indeed	a	better	option	for	lncRNA	profiling	as	compared	to	micro-arrays,	as	
it	 detects	 differentially	 expressed	 lncRNAs	more	 robustly	 and	 it	 also	 allows	 the	 detection	 of	
novel	lncRNAs.	Furthermore,	I	included	total	RNA-sequencing	of	a	small	group	of	T-ALL	patient	
samples	that	allowed	me	to	also	compare	both	RNA-sequencing	technologies.			
AIM	3:	Completing	the	T-ALL	subtype	specific	transcriptome	by	microRNA	profiling	
In	 the	 last	decade,	 several	miRNAs	have	been	 linked	 to	T-ALL	development.	These	are	either	
oncogenic	miRNAs	or	tumor	suppressive	miRNAs	that	target	respectively	known	tumorsuppres-
sor	 genes	 or	 oncogenes	 in	 T-ALL.	 These	 studies	made	 use	 of	 an	 RT-qPCR	 platform	 to	 detect	
miRNA	expression	levels	in	primary	T-ALL	cases,	but	could	never	define	a	subtype	specific	miR-
NA	signature.	We	therefore	measured	miRNA	expression	levels	in	48	T-ALL	patient	samples	of	
different	 subtypes	 by	 small	 RNA-sequencing	 (paper	 4,	 submitted).	 First	 of	 all,	 this	 detection	
method	allowed	to	pick	up	many	more	miRNAs	as	the	previously	used	platforms	and	secondly,	
this	also	identified,	for	the	first	time,	isomiR	expression	in	T-ALL	samples.	Next	to	that,	 in	this	
dataset	there	was	a	clear	subtype	specific	miRNA	expression	signature,	especially	for	the	imma-
ture	T-ALL	and	the	TAL-R	subtype.		
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1 DEFINING	THE	NOTCH1-REGULATED	LNCRNAOME	IN	T-ALL	
	
PAPER	1 	
The	Notch	driven	long	non-coding	RNA	repertoire	in	T-cell	acute	lymphoblastic	leukemia		
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ABSTRACT	
Genetic	studies	in	T-cell	acute	lymphoblastic	leukemia	have	uncovered	a	remarkable	complexi-
ty	 of	 oncogenic	 and	 loss-of-function	 mutations.	 Amongst	 this	 plethora	 of	 genetic	 changes,	
NOTCH1	activating	mutations	stand	out	as	the	most	frequently	occurring	genetic	defect,	identi-
fied	in	more	than	50%	of	T-cell	acute	lymphoblastic	leukemias,	supporting	a	role	as	an	essential	
driver	for	this	gene	in	T-cell	acute	lymphoblastic	leukemia	oncogenesis.	In	this	study,	we	aimed	
to	 establish	 a	 comprehensive	 compendium	of	 the	 long	non-coding	RNA	 transcriptome	under	
control	of	Notch	 signaling.	 For	 this	purpose,	we	measured	 the	 transcriptional	 response	of	 all	
protein	coding	genes	and	long	non-coding	RNAs	upon	pharmacological	Notch	inhibition	in	the	
human	 T-cell	 acute	 lymphoblastic	 leukemia	 cell	 line	 CUTLL1	 using	 RNA-sequencing.	 Similar	
Notch	dependent	profiles	were	established	for	normal	human	CD34+	thymic	T-cell	progenitors	
exposed	to	Notch	signaling	activity	in	vivo.	In	addition,	we	generated	long	non-coding	RNA	ex-
pression	 profiles	 (array	 data)	 from	 ex	 vivo	 isolated	 Notch	 active	 CD34+	 and	 Notch	 inactive	
CD4+CD8+	thymocytes	and	from	a	primary	cohort	of	15	T-cell	acute	lymphoblastic	leukemia	pa-
tients	with	known	NOTCH1	mutation	status.	Integration	of	these	expression	datasets	with	pu-
blicly	available	Notch1	ChIP-sequencing	data	 resulted	 in	 the	 identification	of	 long	non-coding	
RNAs	directly	regulated	by	Notch	activity	in	normal	and	malignant	T	cells.	Given	the	central	role	
of	Notch	in	T-cell	acute	lymphoblastic	 leukemia	oncogenesis,	these	data	pave	the	way	for	the	
development	of	novel	therapeutic	strategies	that	target	hyperactive	Notch	signaling	in	human	
T-cell	acute	lymphoblastic	leukemia.	
INTRODUCTION	
The	 Notch	 pathway	 comprises	 a	 highly	 con-
served	 signaling	 pathway	 that	 regulates	 va-
rious	 cellular	 processes	 in	 all	metazoans,	 in-
cluding	 stem	cell	maintenance,	 regulation	of	
cell	 fate	 decisions,	 cellular	 proliferation,	 dif-
ferentiation,	 cell	 death	 and	 adult	 tissue	 ho-
meostasis.1	 As	 such,	 Notch	 signaling	 is	 criti-
cally	involved	in	many	different	tissues	inclu-
ding	epithelial,	neuronal,	blood,	bone,	muscle	
and	endothelial	cells.2	Precise	regulation	and	
duration	of	Notch	signaling	activity	is	of	criti-
cal	 importance	 to	ensure	appropriate	execu-
tion	 of	 the	 various	 developmental	 cues	 and	
cellular	processes.	Consequently,	constitutive	
or	 acquired	 perturbation	 of	 Notch	 signaling	
frequently	 leads	 to	 human	 disease	 and	 can-
cer.1-4	
Notch	signaling	plays	multiple	roles	in	hema-
topoiesis	 and	 is	 essential	 for	 the	 establish-
ment	of	definitive	hematopoiesis	through	the	
generation	 of	 hematopoietic	 stem	 cells,5	 as	
well	as	for	their	subsequent	differentiation	in	
an	 expanding	 number	 of	 blood	 cell	 types.6-9		
The	role	of	Notch	signaling	has	been	particu-
larly	well	documented	 in	T-cell	 development	
where	Notch1/Dll4	interactions	are	crucial	to	
induce	T-lineage	differentiation	at	the	expen-
se	of	other	hematopoietic	lineages.10-14	
Subsequently,	 Notch	 signaling	 is	 imple-
mented	 in	 TCR-rearrangements,15,16	modula-
tion	 of	 TCR-αb	 versus	 –γδ	 development,17-21	
and	 in	 the	 support	of	proliferation	during	β-
selection.22-24		Sustained	activation	of	Notch1	
signaling	 beyond	 this	 developmental	 check-
point	 has	 been	 shown	 to	 cause	 T-cell	 acute	
lymphoblastic	 leukemia	 (T-ALL)	 and	NOTCH1	
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activating	 mutations	 are	 amongst	 the	 most	
frequently	observed	genetic	 alterations	 in	 T-
ALL.25,26	 Importantly,	 γ-secretase	 inhibitors	
(GSIs)	 that	 block	 S3	 cleavage	 of	 the	 Notch1	
receptor	and	subsequent	release	of	the	intra-
cellular	signaling	domain	(ICN)	are	the	subject	
of	 intensive	 investigation	 as	 novel	 drugs	 to	
combat	 T-ALL.	 However,	 single	 compound	
therapies	almost	invariably	lead	to	resistance.	
Therefore,	 a	 deeper	 understanding	 of	Notch	
signaling	 in	 normal	 thymocyte	 maturation27	
and	 in	 Notch1	 activated	 T-ALLs	 could	 yield	
novel	 insights	 that	 could	 make	 treatment	
more	effective.		
Activation	of	Notch1	 converts	 the	 intracellu-
lar	domain	(ICN1)	of	the	Notch1	receptor	into	
a	 transcriptional	 activator	 and	 ICN1	 subse-
quently	acts	as	a	direct	regulator	of	multiple	
target	 genes.28	 However,	 despite	 intensive	
investigation,	 the	 nature	 of	 these	 genes,	 as	
well	 as	 their	 context-dependent	 activation,	
remains	largely	elusive.	In	general,	oncogenic	
Notch	 signaling	 promotes	 leukemic	 T-cell	
growth	through	direct	transcriptional	upregu-
lation	of	multiple	 anabolic	 genes	 involved	 in	
ribosome	 biosynthesis,	 protein	 translation,	
and	 nucleotide	 and	 amino	 acid	 metabolism.	
Furthermore,	 Notch1	 positively	 regulates	
G1/S	 cell	 cycle	 progression	 in	 T-ALL29-31	 and	
up-regulates	 several	 cyclins	 and	 CDKs,30	 	 in	
addition	to	the	recurrent	oncogene	MYC.	
Furthermore,	 Notch	 signaling	 regulates	 cell	
size,	 glucose	 uptake	 and	 PI3K-AKT	 activated	
glycolysis	 through	 HES1-mediated	 PTEN	 re-
pression.	 Besides	 direct	 regulation	 of	 HES1,	
Notch1	is	also	implicated	in	the	control	of	es-
sential	 early	 T-cell	 genes	 such	 as	 pre-TCRα	
(PTCRA)	 and	 IL7R.32-34	 Taken	 together,	 these	
genes	and	pathways,	as	well	as	a	 further	ex-
panding	 list	 controlled	 by	 Notch1	 in	 T-ALL	
and	normal	T-cell	development,	illustrate	the	
complexity	 and	 vastness	 of	 the	 Notch1	 con-
trolled	regulatory	program.  
Recent	 transcriptome-wide	 profiling	 efforts	
have	 uncovered	 an	 unanticipated	 pervasive-
ness	 of	 transcription	 of	 the	 human	 genome,	
most	 of	 which	 is	 not	 translated	 into	 pro-
tein.35-38	Evidence	is	now	emerging	that	more	
than	 60%	 of	 the	 entire	 genome	 is	 transcri-
bed.39	 In	 addition	 to	 previously	 well-
characterized	 untranslated	 RNA	 molecules	
such	 as	 tRNAs,	 snoRNAs	 and	 microRNAs	
(miRNAs),	 thousands	 of	 so-called	 long	 non-
coding	RNAs	(lncRNAs)	have	been	annotated	
to	the	human	genome.40,	41	Although	functio-
nal	studies	still	need	to	be	carried	out	on	the	
vast	majority	of	these	lncRNA	sequences,	im-
portant	 cellular	 functions	 are	 rapidly	 being	
attributed	to	some	of	them,	including	roles	in	
disease	 processes	 such	 as	 cancer.42	 In	 con-
trast	 to	microRNAs,	 a	 picture	 is	 emerging	 in	
which	 lncRNAs	can	exhibit	a	myriad	of	diffe-
rent	 functions.	 These	 include	various	 regula-
tory	 mechanisms	 of	 gene	 transcription,	
splicing,	 post-transcriptional	 control,	 protein	
activity	and	nuclear	architecture.43-45	Despite	
this	initial	progress,	mechanisms	of	upstream	
regulation	 of	 lncRNAs	 have	 so	 far	 remained	
largely	unexplored.		
In	this	study,	we	investigate	the	role	of	Notch	
in	 the	 control	 of	 lncRNA	 transcription	 in	 the	
context	of	normal	T-cell	development	and	T-
ALL.	To	this	end,	lncRNA	expression	was	mea-
sured	 following	 modulation	 of	 Notch	 signa-
ling	in	the	T-ALL	cell	line	CUTLL1	as	well	as	in	
normal	human	 thymocytes,	and	 the	 recently	
published	data	on	genome-wide	Notch1	bin-
ding	sites	was	used	to	reveal	the	potential	for	
direct	 regulation.34	 Using	 this	 approach,	 we	
identified	a	total	of	40	Notch-driven	lncRNAs,	
thereby	revealing	a	novel	layer	in	the	molecu-
lar	machinery	that	mediates	Notch	signaling.	
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METHODS	
GSI	treatment	of	T-ALL	cell	lines	
HPB-ALL,	 TALL-1,	 ALL-SIL	 and	 CUTLL1	 cells	
(see	 also	 Online	 Supplementary	 Methods)	
were	 seeded	 at	 a	 density	 of	 1x106	 cells/mL	
and	 treated	 with	 either	 DMSO	 or	 1	 μM	 of	
Compound	E	 (Enzo	Life	Sciences).	Cells	were	
harvested	12	and	48	h	after	treatment.	
Human	 thymocytes	 and	 OP9-DLL1	 co-
cultures	
Pediatric	thymus	samples	were	obtained	and	
used	according	to	the	guidelines	of	the	Medi-
cal	Ethical	Commission	of	the	Ghent	Universi-
ty	Hospital,	Belgium.	CD34+	thymocytes	were	
purified	using	magnetic	activated	cell	sorting	
(MACS,	Miltenyi	 Biotec)	 to	 a	 purity	 of	more	
than	 98%	 and	 seeded	 onto	 confluent	 OP9-
GFP	 or	 OP9-DLL1	 plates	 for	 48	 h	 in	 α-MEM	
media	 supplemented	 with	 20%	 heat-
inactivated	FCS	plus	100	U/mL	penicillin,	100	
μg/mL	 streptomycin,	 2	mM	 L-glutamine	 and	
the	T-lineage	supporting	cytokines	SCF,	Flt3-L	
and	IL-7	at	5	ng/mL	each.20	Following	48	h	of	
OP9	 co-culture,	 cells	were	 harvested	 by	 for-
ceful	 pipetting	 and	 stained	 with	 CD45-PE	
(Miltenyi)	to	purify	CD45+	human	thymocytes	
through	 sorting	 to	 remove	 contaminating	
OP9	 stromal	 cells.	 For	 validation	 of	 selected	
lncRNAs,	 CD34	 MACS	 purified	 thymocytes	
were	labeled	with	CD34,	CD1	and	CD4	to	sort	
CD34+CD1–CD4–	 uncommitted	 and	
CD34+CD1+	 CD4–	 committed	 early	 thymo-
cytes,	 while	 CD4+	 CD8+CD3–	 and	
CD4+CD8+CD3+	 double	 positive	 thymocytes	
were	 sorted	 following	CD4,	CD8	and	CD3	 la-
beling	of	a	total	thymus	suspension.20	Sorted	
cells	were	lysed	in	700	μl	QIAzol	(Qiagen)	and	
stored	at	-70°C	prior	to	RNA	isolation.	
Clinical	samples	
Diagnostic	 blood	 samples	 of	 15	 individuals	
with	T-ALL	were	acquired	after	informed	con-
sent	from	the	Department	of	Pediatric	Hema-
to-Oncology	 at	 Ghent	 University	 Hospital,	
Belgium.	 This	 cohort	 includes	 8	 wild-type	
NOTCH1	 cases	 and	 7	mutant	NOTCH1	 cases	
(all	 FBXW7	 wild	 type).	 Sequencing	 was	 per-
formed	as	described	by	Mavrakis	et	al.46	Cor-
relation	 analysis	 was	 performed	 on	 bone	
marrow	 lymphoblast	 samples	 from	 64	 T-ALL	
patients	(unknown	NOTCH1	mutation	status),	
which	were	collected	after	 informed	consent	
according	to	the	Declaration	of	Helsinki	from	
Saint-Louis	Hospital,	Paris,	 France.	The	 study	
was	 approved	 by	 the	 Institut	 Universitaire	
d’Hématologie	 Institutional	 Review	 Board.	
This	 primary	 T-ALL	 cohort	 had	 been	 previ-
ously	investigated47	and	the	high-quality	RNA	
samples	 from	 this	 cohort	 were	 used	 for	
lncRNA	 micro-array	 based	 expression	 profi-
ling.		
RNA	sequencing	
RNA	 samples	 from	 the	 CUTLL1	 cells	 treated	
with	 GSI	 and	 thymocytes	 cultured	 on	 OP9-
GFP/DLL1	 were	 prepared	 (see	 also	 Online	
Supplementary	 Methods).	 RNA-seq	 was	 per-
formed	 after	 unstranded	 poly-A	 library	 prep	
with	an	average	coverage	of	130x106	paired-
end	 reads.	 Reads	were	mapped	 to	 the	 hg19	
reference	 genome	 using	 Tophat	 and	 trans-
cript	assembly	was	performed	with	Cufflinks.	
Normalizaton	and	differential	expression	ana-
lysis	 was	 carried	 out	 with	 DESeq2	 in	 R.	 The	
design	formula	was	adjusted	to	take	 into	ac-
count	the	paired	nature	of	the	data.	
Micro-array	based	gene	expression	profiling	
RNA	samples	(see	also	Online	Supplementary	
Methods)	were	profiled	on	a	custom	desig-	
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ned	 Agilent	 micro-array	 covering	 all	 protein	
coding	 genes	 and	 12,000	 lncRNAs	 (23,042	
unique	 lncRNA	 probes)	 as	 described	 by	 Vol-
ders	 et	 al.48	 The	 data-analysis	 workflow	 can	
be	 found	 in	 the	 Online	 Supplementary	 Me-
thods.	 The	data	discussed	 in	 this	publication	
have	 been	 deposited	 in	 the	 NCBI	 Gene	 Ex-
pression	 Omnibus49	 and	 are	 accessible	
through	 GEO	 Series	 accession	 number	
GSE62006.	 Complete	 details	 of	 study	 me-
thods	can	be	found	in	the	Online	Supplemen-
tary	Appendix.		
	
RESULTS	
Pharmacological	 Notch	 inhibition	 followed	
by	 RNA-sequencing	 reveals	 a	 set	 of	 Notch	
regulated	lncRNAs	in	T-ALL.	
To	 identify	 lncRNAs	 that	 are	 regulated	
through	 Notch	 signaling	 activity	 in	 the	 con-
text	 of	 T-ALL,	 we	 used	 the	 γ-secretase	 (GSI)	
Figure	 1.	 Pharmacological	 Notch	 inhibition	 followed	 by	 RNA-sequencing	 identifies	 a	 set	 of	 Notch	 regulated	
lncRNAs	 in	T-ALL.	(A)	Volcano	(left)	and	MA	plot	(right)	representation	of	the	differential	expression	of	protein	
coding	genes	 in	CUTLL1	cells	upon	GSI	treatment.	Red	dots	represent	the	significant	differentially	expressed	ge-
nes	(adjusted	P-value	<0.05).	(B)	Volcano	(left)	and	MA	plot	(right)	representation	of	the	differential	expression	of	
previously	annotated	lncRNAs	in	CUTLL1	cells	upon	GSI	treatment.	Red	dots	represent	the	significant	differential-
ly	expressed	genes	(adjusted	P-value<0.05;	n=2).	LncRNAs	names	depicted	 in	the	plots	are	the	top	differentially	
regulated	lncRNAs.	
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inhibitor	responsive	T-ALL	cell	 line	CUTLL1	as	
a	model	system,	since	genome-wide	informa-
tion	on	this	cell	 line	 is	available	with	respect	
to	 Notch1	 binding34	 and	 the	 Notch	 depen-
dent	expression	of	coding	genes.50	CUTLL1	T-
ALL	 cells	were	 treated	with	 GSI	 for	 12h	 and	
48h	 in	 triplicate.	 Genome-wide	 transcriptio-
nal	changes	determined	by	performing	diffe-
rential	 expression	 analysis	 on	 the	 RNA-seq	
data	 (see	alignment	 summary	 in	Online	Sup-
plementary	 Table	 S1)	with	DESeq2	using	 En-
sembl	 (release	 75)	 as	 a	 reference,	 showed	
robust	 downregulation	 of	 several	 of	 the	 ca-
nonical	 Notch1	 protein	 coding	 target	 genes	
(e.g.	DTX1,	NRARP,	NOTCH3)	upon	GSI	treat-
ment	(Figure	1A).	A	decrease	in	ICN1	protein	
levels	 was	 shown	 by	 Western	 blot	 analysis	
and	downregulation	of	 the	canonical	Notch1	
target	 gene	 DTX1	 upon	 GSI	 treatment	 was	
further	 validated	 by	 RT-qPCR	 (Online	 Sup-
plementary	 Figure	 S1).	 Amongst	 previously	
annotated	 lncRNAs48	we	could	detect	 signifi-
cant	differential	expression	(adjusted	P-value	
<0.05)	for	83	 lncRNAs,	using	a	basemean	cut	
off	of	100	(Figure	1B).	 In	total,	50	out	of	the	
83	 differentially	 expressed	 lncRNAs	 were	
downregulated	 after	 GSI	 treatment.	 Besides	
previously	annotated	lncRNAs,	we	also	detec-
ted	 differential	 expression	 of	 non-coding	
transcripts	 that	 had	 not	 been	 previously	 an-
notated	 in	 other	 databases	 (Gencode,	 lncR-
NAdb,	 Broad	 Institute	 and	 Ensembl	 release	
64).48	 Differentially	 expressed	 lncRNA	 loci	
with	a	basemean	higher	than	100	and	identi-
fied	 as	 “unknown,	 intergenic	 transcript”	 or	
“transfrag	 falling	 entirely	 within	 a	 reference	
intron”	 by	 Cuffcompare	 were	 retained	 for	
further	analysis.	This	led	to	a	selection	of	134	
lncRNA	loci	of	which	74	were	downregulated	
upon	GSI	treatment.		
Transcriptional	 regulation	 of	 Notch	 regula-
ted	 lncRNAs	 in	 immature	 normal	 human	
thymocytes	
Physiological	levels	of	Notch	signaling	are	es-
sential	during	the	earliest	stages	of	T-cell	de-
velopment,	but	no	information	is	available	on	
the	Notch	 dependent	 expression	 of	 lncRNAs	
in	these	cells.27	Therefore,	and	in	order	to	ha-
ve	an	independent	screening	method	in	addi-
tion	to	the	CUTLL1	cell	 line	to	 identify	Notch	
dependent	 lncRNAs,	 we	 used	 the	 in	 vitro	
OP9-DLL1	 co-culture	 system	 (Figure	 2A).	He-
re,	 ex	 vivo	 purified	 CD34+	 thymocytes	 from	
healthy	 human	 donors	 (n=2)	 were	 cultured	
on	a	 feeder	 layer	of	stromal	OP9	cells	either	
expressing	GFP	(as	a	negative	control)	or	the	
Notch1	ligand	DLL1	to	trigger	Notch	signaling.	
CD34+	 progenitor	 cells	 were	 collected	 after	
48h	 of	 co-culture	 and	 deep	 RNA-sequencing	
was	 performed	 (see	 alignment	 summary	 in	
Online	 Supplementary	 Table	 S2).	 The	 set	 of	
differentially	expressed	protein	coding	genes	
and	 lncRNAs	 was	 defined	 as	 above	 for	 the	
CUTLL1	 cells.	 Detection	 of	 differentially	 ex-
pressed	 protein	 coding	 genes	 known	 to	 be	
regulated	by	Notch	 signaling	 in	 early	 human	
thymocytes,20,27	 also	 validated	 our	 approach	
in	this	model	system	(Figure	2B).	Differential	
expression	 analysis	 for	 previously	 annotated	
lncRNAs	 revealed	 131	 significantly	 upregula-
ted	lncRNAs	as	a	consequence	of	Notch	acti-
vation	 (Figure	 2C).	 From	 these	 131	 lncRNAs,	
27	overlapped	with	the	set	of	downregulated	
lncRNAs	 upon	 GSI	 treatment	 of	 the	 CUTLL1	
cell	line	(Figure	2D	and	Online	Supplementary	
Table	 S3).	 Furthermore,	 we	 identified	 156	
unannotated	 lncRNA	 loci	 (base	 mean	 >100;	
adjusted	P-value	<0.05)	 in	CD34+	thymocytes	
that	 were	 upregulated	 by	 the	 Notch	 ligand	
DLL1.	In	total,	13	unique	unannotated	lncRNA	
loci	were	identified	to	be	positively	regulated	
by	Notch	in	both	normal	and	malignant	T-cell		
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Figure	 2.	 Transcriptional	 regulation	 of	Notch	 regulated	 lncRNAs	 in	 immature	 normal	 human	 thymocytes.	 (A)	
Schematic	overview	of	the	OP9-control	and	-DLL1	co-culture	system	used	to	manipulate	Notch	signaling	in	healthy	
human	 immature	CD34+	 thymocytes.	 (B)	Volcano	 (left)	 and	MAplot	 (right)	 representation	of	 the	differential	ex-
pression	of	protein	coding	genes	in	CD34+	cells	upon	Notch	signaling	induction	by	an	OP9-DLL1	feeder	layer.	Red	
dots	represent	the	significant	differentially	expressed	genes	(adjusted	P-value	<0.05;	n=2).	 (C)	Volcano	(left)	and	
MA	plot	(right)	representation	of	the	differential	expression	of	previously	annotated	lncRNAs	in	CD34+	cells	upon	
Notch	activation	by	an	OP9-DLL1	feeder	layer.	LncRNA	names	depicted	in	the	figure	are	the	top	differentially	regu-
lated	lncRNAs.	(D)	Venn	diagram	depicting	the	overlap	between	previously	annotated	lncRNAs	that	are	downregu-
lated	upon	GSI	treatment	of	the	CUTLL1	cell	line	and	up-regulated	upon	co-culturing	of	CD34+	thymocytes	on	the	
OP9-DLL1	feeder	layer.	(E)	Venn	diagram	depicting	the	overlap	between	previously	unannotated	lncRNAs	that	are	
downregulated	upon	GSI	 treatment	of	 the	CUTLL1	cell	 line	and	upregulated	upon	co-culturing	of	CD34+	 thymo-
cytes	on	OP9-DLL1	stromal	cells.	
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development	 (Figure	 2E	 and	 Online	 Supple-
mentary	 Table	 S4).	 Amongst	 the	 set	 of	 13	
overlapping	 Notch	 lncRNA	 loci,	 the	 recently	
described	 LUNAR151	 was	 present,	 thus	 sup-
porting	the	validity	of	our	approach.	 In	addi-
tion,	we	also	identified	33	annotated	lncRNAs	
to	 be	 up-regulated	 upon	 GSI	 treatment	 of	
CUTLL1	 cells	 by	 RNA-seq,	 18	 of	 them	 over-
lapping	with	the	set	of	 lncRNAs	downregula-
ted	in	CD34+	T-cell	progenitors	upon	DLL1	ex-
posure	in	the	OP9	in	vitro	culture	system	(366	
in	total)	(Online	Supplementary	Table	S5	and	
Figure	S2A).	In	a	similar	manner,	7	of	57	pre-
viously	 unannotated	 lncRNAs	 upregulated	
upon	GSI	 treatment	of	CUTLL1	 cells	overlap-
ped	with	the	set	of	320	unannotated	lncRNAs	
downregulated	 in	 CD34+	 thymocytes	 with	
DLL1	 exposure	 (Online	 Supplementary	 Table	
S6	 and	 Figure	 S2B).	 Furthermore,	 we	 hypo-
thesize	 that	 the	 Notch	 dependent	 lncRNAs	
(both	 annotated	 and	 unannotated)	 that	 are	
not	 shared	 between	 CUTLL1	 T-ALL	 cells	 and	
normal	 human	 thymocytes	 can	 be	 assumed	
to	 have	 very	 context-specific	 functions	 and	
should	be	regarded	as	potentially	 interesting	
for	 further	 exploration	 in	 future	 studies.	 For	
example,	 lncRNAs	expressed	exclusively	 in	T-
ALL	cells	could	be	restrictively	connected	to	a	
malignant	 context.	 To	 evaluate	 the	 putative	
protein	 coding	 potential	 of	 all	 unannotated	
lncRNA	 loci	 identified	 by	 RNA-seq	 in	 CUTLL1	
T-ALL	 cells	 and	 CD34+	 T-cell	 progenitors	 cul-
tured	on	OP9	stromal	cells,	Phylogenetic	Co-
don	Substitution	Frequency	(PhyloCSF)	scores	
for	all	loci	were	calculated	and	we	could	con-
firm	 that	more	 than	90%	of	 all	 unannotated	
lncRNA	loci	determined	are	truly	‘non-coding’	
(Online	 Supplementary	 Figure	 S3).	 Putative	
unannotated	 lncRNA	 loci	 with	 a	 PhyloCSF	
score	 higher	 than	 the	 determined	 threshold	
score	are	listed	and	thus	predicted	to	be	‘co-
ding’	 (Online	 Supplementary	 Tables	 S7	 and	
S8)	(see	also	Supplementary	Methods).		
Validation	of	Notch	regulated	lncRNAs	in	an	
extended	panel	of	T-ALL	cell	lines,	normal	T-
cell	subsets	and	primary	T-ALLs	
To	 further	 validate	 our	 data,	 we	 used	 a	
custom	designed	Agilent	micro-array48	 deve-
loped	in	house	that	contains	probes	for	15	of	
the	27	previously	annotated	lncRNAs	and	the	
recently	identified	LUNAR1	lncRNA	that	were	
shown	to	be	regulated	by	Notch	in	the	above	
described	 RNA-seq	 data	 from	 the	 T-ALL	 and	
normal	 thymocyte	models.	 First,	 we	 treated	
the	 T-ALL	 cell	 lines	 ALL-SIL,	 TALL-1,	 HPB-ALL	
and	DND-41	with	GSI	 (Supplementary	 Figure	
S4A	 and	 B)	 and	 carried	 out	 gene	 expression	
profiling	after	12	h	and	48	h.	Inclusion	of	the	
GSI-treated	CUTLL1	cell	 line	samples	and	the	
samples	 of	 4	 donors	 of	 CD34+	 thymocytes	
cultured	 on	OP9	 stromal	 cells,	 revealed	 that	
there	was	 a	 significant	 overlap	 between	 the	
RNA-sequencing	data	and	the	micro-array	da-
ta	 as	 validated	 by	 overlapping	 the	 protein-
coding	signatures	derived	from	both	datasets	
by	 Gene	 Set	 Enrichment	 Analysis	 (GSEA)	
(Supplementary	 Figure	 S4C	 and	 D).	 Nevert-
heless,	 few	 lncRNAs	were	significantly	Notch	
dependent	over	 all	 samples	of	 the	extended	
panel	 of	 T-ALL	 cell	 lines	 (ALL-SIL,	 HPB-ALL,	
DND-41	and	TALL-1),	probably	related	to	the	
difference	in	the	T-ALL	genetic	subgroup	and	
concomitant	differences	in	maturation	arrest	
of	 the	 different	 cell	 lines	 evaluated	 (Figure	
3A).	 From	 our	 selection,	 only	 lnc-PLEKHB2-1	
and	 lnc-UBXN4-1	 were	 differentially	 expres-
sed	at	 a	 significant	 level,	while	 lnc-GSDMC-2	
and	lnc-CA7-2	narrowly	failed	to	reach	signifi-
cance.	 As	we	were	 able	 to	 detect	 the	 previ-
ously	 unannotated	 and	 recently	 described	
lncRNA	 LUNAR151	 on	 our	 custom	 designed	
micro-array	platform,	this	lncRNA	was	one	of	
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the	 strongest	 overlapping	 and	 significantly	
differentially	expressed	lncRNAs	amongst	the	
four	GSI-treated	T-ALL	cell	lines	screened.	Se-
condly,	 we	 validated	 the	 Notch	 dependency	
of	selected	lncRNAs	in	normal	thymocytes	by	
analyzing	their	expression	in	the	most	imma-
ture	Notch	 dependent	 CD34+	 stages	 in	 com-
parison	 to	 the	Notch	 independent	CD4+CD8+	
double	positive	stages	of	human	T-cell	deve-
lopment.	 As	 is	 evident	 from	 the	 profiles	 of	
the	Notch	 target	gene	DTX1,	we	could	 show	
that	 in	 these	 two	 T-cell	 subpopulations	 LU-
NAR1	 follows	 the	 expression	 pattern	 of	 this	
canonical	 Notch	 target	 (Figure	 3B).	 Re-
markably,	9	out	of	15	lncRNAs	(and	LUNAR1)	
from	 this	 selection	 significantly	 correlated	
with	DTX1	expression	(Spearman	rho	correla-
tion),	 supporting	 their	 regulation	 by	 Notch	
during	early	stages	of	normal	T-cell	develop-
ment	 (Figure	 3C	 and	 Online	 Supplementary	
Table	S9).	
Moreover,	we	also	had	access	 to	15	primary	
T-ALL	samples	of	which	7	harbored	activating	
NOTCH1	 mutations	 while	 8	 were	 wild	 type	
(all	cases	are	FBXW7	wild	type).	There	was	a	
significant	 difference	 in	 expression	 of	 LU-
NAR1	 and	 lnc-FAM120AOS-1	 between	
NOTCH1	 wildtype	 and	 mutant	 cases	 (Figure	
3D	and	Online	Supplementary	Tables	S10	and	
S11).	By	 implying	an	additional	dataset	of	64	
primary	T-ALL	patient	samples,	we	could	cor-
relate	 the	 expression	of	 lncRNAs	 lnc-PGBD5-
2,	 lnc-FAM120AOS-1,	 lnc-c2orf55-1	 and	 LU-
NAR1	 with	 the	 Notch1	 positively	 regulated	
gene	 set	 Vilimas_NOTCH1	 _targets_up52	 by	
GSEA	(Figure	3E).	Overall,	these	independent	
experiments	 confirm	 the	 Notch	 dependent	
regulation	 of	 the	 selected	 lncRNAs,	 thereby	
validating	 the	 RNA-seq	 data	 from	 the	 GSI	
treated	CUTLL1	T-ALL	cell	 line	and	the	Notch	
perturbed	normal	human	thymocytes.	
Genome-wide	analysis	reveals	direct	Notch1	
binding	to	selected	lncRNAs	
To	further	validate	the	direct	regulation	of	se-
lected	 lncRNAs	 by	 Notch,	 publicly	 available	
ChIP	 sequencing	 (ChIP-seq)	 data	 from	 the	
CUTLL1	 cell	 line	 were	 analyzed	 for	 Notch1	
binding	 at	 specific	 loci.34	 From	 the	 Notch-
driven	 annotated	 lncRNAs	 that	 overlapped	
between	 normal	 and	 malignant	 thymocytes	
(Figure	 2D),	 13	 out	 of	 the	 27	 lncRNAs	 were	
bound	by	 ICN1	 (Online	Supplementary	Table	
S12)	 as	 illustrated	 for	 lnc-UBXN4-1	 and	 lnc-
PLEKHB2-1	 (Figure	4).	Remarkably,	12	out	of	
the	 13	 lncRNAs	 with	 a	 Notch1	 binding	 peak	
also	 show	 Brd4	 and	Med1	 binding.	 Notably,	
from	 the	 putative	 Notch	 regulated	 lncRNAs	
that	showed	correlated	expression	with	DTX1	
in	CD34+	and	CD4+CD8+	normal	thymocytes,	6	
out	of	9	 (Figure	4	and	Supplementary	Figure	
S5)	 showed	binding	 of	 ICN1,	 suggesting	 that	
the	majority	is	a	direct	Notch	target.	
In	 addition,	 we	 evaluated	 the	 presence	 of	
H3K27	 acetylation	 (H3K27ac)	 ChIP-seq	 signal	
at	these	lncRNA	loci,	a	histone	mark	indicati-
ve	 for	putative	enhancer	 regions.	For	18	out	
of	 the	 27	 selected	 lncRNAs,	 H3K27ac	 ChIP-
seq	 signal	 was	 present	 in	 close	 proximity	 of	
the	 promoter	 region	 (Online	 Supplementary	
Table	 S12),	 suggesting	 the	 presence	 of	 en-
hancer	sequences.		
Moreover,	 this	 public	 ChIP-seq	 data	 also	
showed	 LUNAR1	 to	 be	 directly	 bound	 by	
ICN1,	 Brd4,	 Med1	 and	 H3K27ac	 (Figure	 5).	
We	also	evaluated	ICN1	binding	at	annotated	
lncRNA	loci	up-regulated	upon	GSI	treatment	
of	 CUTLL1	 T-ALL	 cells	 and	 downregulated	 in	
CD34+	T-cell	progenitors	upon	DLL1	exposure	
in	 the	OP9	 in	vitro	 co-culture	system.	Only	4	
out	of	the	18	overlapping	annotated	lncRNAs	
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Figure	3.	Screening	expression	of	Notch	regulated	lncRNAs	in	an	extended	panel	of	T-ALL	cell	lines,	normal	T-
cells	 subsets	 and	 primary	 T-ALLs.	 (A)	 Volcano	 plot	 representation	 of	 the	 differential	 expression	 of	 lncRNAs	
upon	GSI	treatment	of	ALL-SIL,	TALL-1,	HPB-ALL	and	DND-41	cells.	Red	dots	represent	the	significant	differenti-
ally	expressed	genes	(adjusted	P-value	<0.05).	LUNAR1	was	amongst	the	top-differentially	expressed	 lncRNAs	
across	the	panel	of	GSI-treated	T-ALL	cell	lines.	The	other	lncRNA	names	depicted	in	the	figure	are	some	of	the	
selected	 lncRNAs	 from	 the	CUTLL1	GSI	 treatment	and	 the	OP9-DLL1	co-culture	 system.	 (B)	Plot	 representing	
the	expression	of	lncRNAs	in	selected	Notch-dependent	and	-independent	stages	of	normal	T-cell	development	
for	one	healthy	donor.	LUNAR1	expression	is	significantly	correlated	with	the	expression	of	DTX1	(see	also	On-
line	Supplementary	Table	S6)	and	the	data	are	representative	for	4	independent	donors.	(C)	Similar	analysis	as	
in	(B)	for	the	other	lncRNAs	that	are	significantly	correlated	with	the	expression	of	DTX1	(see	also	Online	Sup-
plementary	 Table	 S6);	 data	 are	 representative	 for	 4	 independent	 donors.	 (D)	 Expression	 of	 LUNAR1,	 lnc-
FAM120AOS-1	and	 lnc-UBXN4-1	 in	NOTCH1	wildtype	(WT)	versus	NOTCH1	mutant	(MUT)	primary	T-ALL	sam-
ples.	(Continued	on	the	next	page.)		
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that	are	negatively	 regulated	by	Notch	 (Sup-
plementary	 Figure	 S2A)	 showed	 direct	 bin-
ding	by	 ICN1.	 The	 same	analysis	was	perfor-
med	on	the	set	of	7	unannotated	lncRNAs	re-
pressed	 by	Notch1	 signaling	 (Supplementary	
Figure	S2B).	Only	3	out	of	these	7	lncRNA	loci	
showed	 ICN1	 binding	 in	 the	 proximity	 of	 its	
promoter	 region.	 Given	 the	 established	 pre-
dominant	 role	of	Notch1	as	a	 transcriptional	
activator,	 lncRNAs	 that	 are	 negatively	 affec-
ted	by	Notch1	signaling	may	actually	be	indi-
rect	targets.	
Attributing	 functional	 annotation	 to	 Notch	
regulated	 lncRNAs	 through	 guilt-by-
association	analysis	
As	described	above,	we	defined	a	core	set	of	
27	 Notch	 driven	 and	 previously	 annotated	
lncRNAs	by	considering	only	those	differenti-
ally	 expressed	 and	 positively	 regulated	 by	
Notch	signaling	in	the	GSI	perturbation	model	
in	CUTLL1	cells	and	the	 in	vitro	OP9-DLL1	co-
culture	 system.	As	 a	next	 step,	we	aimed	 to	
assign	 potential	 functionalities	 to	 each	 of	
these	candidates.	To	this	end,	we	used	the	so	
called	 ‘guilt-by-association’	 approach	 (see	
also	 Supplementary	Methods).	 As	 previously	
mentioned,	15	out	of	these	27	lncRNAs	(toge-
ther	with	LUNAR1)	were	detectable	by	a	pro-
be	on	our	custom	designed	micro-array	plat-
form.	 In	 a	 first	 step,	 we	 calculated	 the	 Spe-
arman	 correlation	 coefficients	 between	 the	
lncRNAs-of-interest	 and	 all	 protein	 coding	
genes	using	the	expression	data	of	a	primary	
T-ALL	 cohort	 of	 64	 patients	 from	 which	 we	
profiled	 all	 samples	 on	 the	 custom	designed	
Agilent	array.48	These	correlations	were	sub-
sequently	 used	 as	 an	 input	 for	 a	 GSEA	 pre-
ranked	analysis.	Next,	the	output	of	this	GSEA	
analysis	 was	 further	 refined	 into	 functional	
clusters	of	enriched	gene	sets	using	the	Cyto-
scape	plug-in	enrichment	mapping.	This	ana-
lysis	 yielded	 markedly	 different	 functional	
clustering	patterns	for	each	of	the	16	lncRNAs		
Figure	3	(Continued).	Screening	expression	of	Notch	regulated	lncRNAs	in	an	extended	panel	of	T-ALL	cell	li-
nes,	normal	T-cells	subsets	and	primary	T-ALLs.	(E)	Gene	set	enrichment	analysis	(GSEA)	using	the	public	gene	
set	 ‘VILIMAS_NOTCH1_TARGETS_UP’52	and	the	Spearman	correlations	between	all	protein	coding	genes	and	
the	set	of	15	selected	annotated	candidate	Notch	lncRNAs	was	performed.	This	NOTCH1	signature	was	signifi-
cantly	enriched	within	the	set	of	protein	coding	genes	positively	correlated	 to	the	expression	of	lnc-PGBD5-2,	
lnc-FAM120AOS-1	and	lnc-c2orf55-1.	This	enrichment	was	also	found	for	lncRNA	LUNAR1.	
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analyzed	 (including	 LUNAR1).	 Important	 pu-
tative	 functionalities	 were	 represented	 in	
each	of	 the	networks	as	exemplified	by	TCR-
signaling	 and	 phospholipid	 metabolism	 for	
lnc-PLEKHB2-1,	 DNA	 replication	 and	DNA	 re-
pair	for	 lnc-UBXN4-1	and	splicing	and	cell	cy-
cle	 regulation	 for	 LUNAR1	 (Figure	 6A-C	 and	
Supplementary	Figure	S6A-M).	
DISCUSSION	
Non-coding	RNAs	are	emerging	as	 important	
players	 in	 normal	 development	 and	 disease,	
including	 cancer.	 In	 previous	 studies,	 we	 in-
vestigated	the	role	of	miRNAs	 in	T-cell	acute	
lymphoblastic	 leukemia	 (T-ALL),	 thereby	
identifying	a	small	 set	of	miRNAs	that	 is	 res-
ponsible	 for	 the	 cooperative	 suppression	 of	
several	tumor	suppressor	genes.46		
These	miRNAs	produced	overlapping	and	co-
operative	effects	with	several	bona	fide	T-ALL	
tumor	 suppressor	 genes	 including	 IKZF1,	
PTEN,	BIM,	PHF6,	NF1	and	FBXW7,	and	more	
recently	 this	 network	 was	 expanded	 further	
with	PHF6.53	In	order	to	provide	some	insight	
into	 the	 genetic	 components	 driving	 long	
non-coding	RNAs	in	T-ALL	formation,	we	per-
formed	an	integrated	analysis	of	lncRNA	pro-
filing	 data	 sets	 from	 GSI	 inhibited	 Notch-
driven	 T-ALL	 cell	 lines	 and	 Notch-stimulated	
immature	 normal	 human	 thymocytes	 using	
the	OP9	co-culture	system,	together	with	pu-
blicly	available	genome-wide	data	on	Notch1	
binding	and	 specific	 chromatin	marks.	 In	ad-
dition,	 we	 correlated	 the	 expression	 of	
Notch-dependent	 lncRNAs	 with	 the	 Notch-
dependent	 stages	 of	 normal	 thymocytes	
during	 T-cell	 differentiation.	 Overall,	 our	
work	establishes	a	novel	lncRNA	network	that	
acts	downstream	of	Notch	during	normal	and	
malignant	thymocyte	development.	
Our	study	provides	a	number	of	fundamental	
new	 insights	 into	 Notch-dependent	 regula-
tion	 of	 lncRNAs	 in	 TALL	 and	 normal	 develo-
ping	 thymocytes.	 First,	 we	 unambiguously	
demonstrate	 that	 a	 significant	 number	 of	
lncRNAs	 are	 directly	 regulated	 by	Notch	 sig-
naling	 activity.	 Through	RNA-sequencing,	we	
identified	40	lncRNAs	that	are	positively	regu-	
Figure	4.	Notch1	ChIP-seq	reveals	direct	binding	of	Notch1	to	a	subset	of	regulated	lncRNAs.	Representation	of	
ChIP-sequencing	 tracks34	 for	Notch1,	 Brd4,	Med1	 and	H3K27ac	and	 representative	RNA-sequencing	 tracks	 for	
CUTLL1	DMSO/GSI	treatment	and	OP9-GFP/DLL1	of	lnc-UBXN4-1	and	lnc-PLEKHB2-1.	
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Figure	 5.	 Notch1	 ChIP-seq	 reveals	 direct	 binding	 of	 Notch1	 to	 LUNAR1.	 LUNAR151	 (lnc-IGF1R-1)	 was	 identified	
amongst	 the	 top	 differentially	 expressed	 novel,	 unannotated	 lncRNAs	 in	 both	GSI-treated	 CUTLL1	 cells	 and	 CD34+	
thymic	 progenitor	 cells	 exposed	 to	 DLL1-triggered	 Notch	 signaling.	 Publically	 available	 ChIP-seq	 tracks34	 for	 ICN1	
BRD4,	MED1	and	H3K27ac	as	well	as	representative	in	house	generated	RNA-seq	data	tracks	for	CUTLL1	DMSO/GSI	
treated	cells	and	OP9-GFP/DLL1	are	shown	at	the	LUNAR1	locus.	
	
		
	
	
105			 	
Figure	6.	Attributing	functional	annotation	to	selected,	annotated	lncRNAs	through	guilt-by-association	analy-
sis.	Enrichment	maps	of	gene	sets	correlated	with	the	expression	of	(A)	lnc-PLEKHB2-1,	 (B)	lnc-UBXN4-1	and	(C)	
LUNAR1.	Red	nodes	represent	the	positively	correlated	gene	sets	to	the	lncRNA	of	interest,	blue	nodes	the	nega-
tively	correlated	gene	sets.	The	size	of	the	nodes	depicts	the	size	of	the	gene	sets.	Nodes	that	are	clustered	re-
present	gene	sets	with	the	same	or	similar	functional	indication.	
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lated	by	Notch	in	both	normal	and	malignant	
T	 lymphocytes	 (annotated	 as	 well	 as	 previ-
ously	 unannotated	 lncRNAs),	 supporting	 an	
important	 role	 for	 these	 lncRNAs	 in	 Notch-
regulated	T-cell	biology.	This	could	be	related	
to	various	functions	of	Notch	signaling,	inclu-
ding	T-cell	 lineage	 specification	and	 commit-
ment,	 proliferation	 and	 differentiation.	 Im-
portantly,	 the	 recently	 identified	 lncRNA	LU-
NAR151	 was	 present	 amongst	 the	 most	 ro-
bustly	Notch	regulated	long	non-coding	RNAs	
in	 our	 data	 sets.	 LUNAR1	 was	 shown	 to	 be	
required	 for	efficient	T-ALL	growth	as	a	 con-
sequence	 of	 its	 role	 in	 enhancing	 IGF1R	
mRNA	expression	 to	sustain	 IGF1	signaling.51	
As	a	prelude	to	assigning	functional	annotati-
on	 to	 the	 newly	 assigned	 Notch-regulated	
lncRNAs	 in	 this	 study,	 we	 applied	 the	 so-
called	 ‘guilt-by-association’	 approach	 in	
which	 functions	 are	 predicted	 based	 upon	
correlation	with	known	protein	coding	genes	
and	 subsequent	 gene	 set	 enrichment	 analy-
sis.	 For	 the	 selected	 lncRNAs,	 various	 func-
tions	 were	 predicted,	 several	 of	 which	 are	
linked	 to	T-cell	biology	or	processes	 that	are	
perturbed	 in	 cancer.	 This	 marks	 these	
lncRNAs	as	prime	targets	 for	 further	 functio-
nal	studies	 in	order	to	unravel	their	mode	of	
action	and	assess	 to	what	extent	 they	might	
serve	as	 future	 therapeutic	 targets	 for	 treat-
ment	of	T-ALL.	
Not	 all	 of	 the	 40	 overlapping	 lncRNAs	 dis-
played	 ICN1	 binding,	 as	 is	 evident	 from	 the	
publicly	 available	 ChIP-seq	 data.34	 This	 may	
relate	to	the	complexity	of	the	chromosomal	
3D-structures	 that	 are	 generated	 when	
lncRNAs	 act	 as	 cis-regulatory	 elements,	 as	
well	 as	 to	 the	 sensitivity	 of	 the	Notch1	ChIP	
procedure.	However,	for	the	previously	anno-
tated	lncRNAs	directly	bound	by	ICN1,	all	but	
one	displayed	Brd4	and	Med1	binding.	Those	
lncRNAs	 that	 are	 characterized	 by	 Brd4	 and	
Med1	 ChIP-seq	 signal	 are	 also	 characterized	
by	 the	presence	of	H3K27ac	ChIP-seq	 signal,	
which	could	be	indicative	of	an	enhancer	ac-
tivity	of	these	loci.	
A	 second	 aspect	 of	 our	 study	 involved	 the	
identification	 of	 novel,	 previously	 unannota-
ted	 lncRNAs.	 Indeed,	 previous	 studies	 have	
shown	that	lncRNAs	are	often	shown	to	have	
a	very	restricted	expression	pattern,	but	with	
biologically	high	relevant	expression.40-45	This	
includes	expression	during	very	 specific	 time	
points	during	development	and/or	differenti-
ation,	 as	 well	 as	 restriction	 to	 very	 specific	
cell	 subsets.	 Typically,	 these	 lncRNAs	are	ex-
pressed	 at	 significant	 levels	 in	 these	 cells	
whereas	in	other	cell	types	their	expression	is	
very	low	or	absent.	Here,	we	identified	novel	
lncRNAs	 in	 the	 CUTLL1	 cell	 line	 and	 in	 the	
OP9-DLL1	co-culture	system.	Interestingly,	61	
of	 these	 lncRNAs	were	present	 in	T-ALL	cells	
only,	suggesting	that	their	ectopic	expression	
could	be	restricted	to	the	malignant	context.	
Likewise,	lncRNAs	only	present	in	thymocytes	
may	 be	 implicated	 in	 differentiation	 of	 nor-
mal	T	cells	which	is	disrupted	in	T-ALL	cells,	or	
may	reflect	differential	Notch3	activity	as	the	
DLL1	ligand,	to	which	CD34+	progenitor	T	cells	
are	 exposed	 in	 the	OP9-DLL1	 co-culture	 sys-
tem,	 can	 activate	 both	 Notch1	 and	 Notch3	
(Waegemans	E,	Van	de	Walle	I	and	Taghon	T,	
unpublished	 data	 on	 preferential	 Notch	 re-
ceptor-ligand	 interactions	 in	 human,	 2011)	
while	both	receptors	are	implicated	in	modu-
lating	human	T-cell	development.21	Both	sub-
sets	of	 lncRNAs	may,	 therefore,	 serve	as	no-
vel	therapeutic	targets	for	T-ALL	treatment.	It	
is	evident	that	our	work,	as	well	as	the	recent	
paper	 by	 Aifantis	 and	 colleagues,51	 strongly	
favors	 an	 important	 role	 for	 lncRNAs	 in	nor-
mal	T-cell	development	and	T-ALL	oncogene-
sis.	 Moreover,	 we	 show	 that	 the	 Notch1	
transcription	 factor	 directly	 controls	 the	
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transcription	 of	 many	 of	 these	 long	 non-
coding	RNAs.	Therefore,	one	can	predict	that	
other	oncogenic	transcription	factors	and	dri-
vers	 in	 T-ALL,	 such	 as	 TAL1,	 TLX1/TLX3,	
LMO1/2	 and	 HOXA	 genes,	 as	 well	 as	 other	
transcriptional	regulators	of	normal	T-cell	de-
velopment,	 will	 also	 perform	 similar	
transcriptional	 control.	 Therefore,	 specific	 T-
ALL	 subgroups	 and	 more	 distinct	 subsets	 of	
normal	 immature	developing	T	 cells	need	 to	
be	 analyzed	 in	 human	 for	 detection	 of	 all	
lncRNAs.	 We	 predict	 that	 this	 will	 further	
dramatically	 expand	 the	 lncRNA	 landscape	
for	 T-ALL	 and	 thymocyte	 maturation,	 and	
thus	provide	an	 important	 regulatory	 frame-
work	 for	 understanding	 some	 of	 the	 unique	
features	 that	 control	 human	T-cell	 biology.27	
Finally,	 given	 the	 central	 role	 of	 oncogenic	
Notch1	 activation	 in	 most	 if	 not	 all	 T-ALLs,	
and	the	current	limitations	of	targeted	thera-
py,	 further	exploration	of	the	new	therapeu-
tic	opportunities	offered	by	these	lncRNAs	in	
the	 context	 of	 their	 specific	 functionality	 is	
strongly	recommended.	
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SUPPLEMENTARY	METHODS	
Cell	lines	and	compound	treatment	
HPB-ALL,	 TALL-1	 and	ALL-SIL	 cells	were	 obtained	 from	 the	DSMZ	 cell	 line	 repository,	 CUTLL1	
cells	were	a	kind	gift	of	H.G.	Wendel	(Memorial	Sloan	Kettering	Cancer	Center,	New	York,	USA).	
Cells	were	maintained	 in	RPMI-.-1640	medium	 (Life	Technologies,	52400-025),	 supplemented	
with	 10%	 or	 20	 %	 (ALL-SIL	 and	 CUTLL1)	 fetal	 bovine	 serum	 (Biochrom	 AG,	 S0615),	 1	 %	 L-
glutamin	 (Life	 Technologies,	 1514-148)	 and	 1%	 penicillin/streptomycin	 (Life	 Technologies,	
15160-047).	 CUTLL1,	 HPB-ALL,	 TALL-1	 and	 ALL-SIL	 cells	 were	 seeded	 at	 a	 density	 of	 1*106	
cells/ml	and	treated	with	either	DMSO	or	1	μM	of	Compound	E	(Enzo	Life	Sciences).	Cells	were	
harvested	12	and	48	hours	after	treatment.	
RNA-isolation,	cDNA	synthesis	and	RT-qPCR	
Total	RNA	was	harvested	with	the	miRNeasy	minikit	(Qiagen)	with	DNase	treatment	on-column.	
RNA-concentrations	were	measured	 by	means	 of	 spectrophotometry	 (Nanodrop).	 cDNA	was	
synthesized	using	the	iScript	cDNA	synthesis	kit	(Biorad,	170-8891)	according	to	the	manufactu-
rers’	protocol,	starting	with	500ng	of	RNA,		followed	by	RT-qPCR	using	the	Light	Cycler	480	(Ro-
che).	Finally,	qPCR	data	was	analyzed	using	the	qBasePLUS	software	 (Biogazelle)	according	to	
the	ΔΔCt-method.	
	
Target	 Forward	primer	 Reverse	primer	
c-MYC	 GCCACGTCTCCACACATCAG	 TGGTGCATTTTCGGTTGTTG	
HES1	 TGTCAACACGACACCGGATAAA	 CCATAATAGGCTTTGATGACTTTCTG	
DTX1	 ACGAGAAAGGCCGGAAGGT	 GGTGTTGGACGTGCCGATAG	
HPRT	 TGACACTGGCAAAACAATGCA	 GGTCCTTTTCACCAGCAAGCT	
HMBS	 GGCAATGCGGCTGCAA	 GGGTACCCACGCGAATCAC	
TBP	 CACGAACCACGGCACTGATT	 TTTTCTTGCTGCCAGTCTGGAC	
B2M	 TGCTGTCTCCATGTTTGATGTATCT	 TCTCTGCTCCCCACCTCTAAGT	
	
	
Reaction	conditions	for	RT-qPCR	
Components	 Amount	
sSo	Advanced	2x	mastermix	 2,5	µl	
Forward	Primer	(5	µM)	 0,25	µl	
Reverse	Primer	(5	µM)	 0,25	µl	
cDNA	(2,5	ng/µl)	 2	µl	
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Thermocycling	parameters	
Step	 Temperature	 Time	 Cycles	
Enzyme	activation	 95	°C	 2	min	 1	
Amplification	 95	°C	
60	°C	
72	°C	
5	sec	
30	sec	
1	sec	
44	
Melting	cyclus	 95	°C	
60	°C	
95	°C	
5	sec	
1	min	
continuous	
1	
Cooling	 37	°C	 3	min	 1	
	
Western	blotting	
Total	protein	isolation	was	performed	with	RIPA-lysis	buffer,	supplemented	with	protease	inhi-
bitors	and	SDS-PAGE	was	performed	according	to	standard	protocols.	For	immunoblotting,	the	
rabbit	polyclonal	antibody	to	cleaved	NOTCH1	(Val	1744)	(Cell	Signaling,	2421S)	was	used	in	a	
1:500	dilution	in	BSA.	
Protein	coding	potential	calculation	
We	used	 PhyloCSF	 to	 identify	 putative	 protein	 coding	 	 transcripts	 in	 the	 unannotated,	 novel	
putative	 lncRNA	 loci	 obtained	 by	 RNA-seq.	 This	 algorithm	 employs	 codon	 substitution	
frequencies	in	whole-genome	multi-species	alignments	to	distinguish	between	coding	and	non-
coding	loci.	Whole-genome	alignments	of	46	species	are	obtained	from	the	UCSC	website	and	
processed	 using	 the	 PHAST	 package	 (version	 1.3)	 to	 obtain	 the	 required	 input	 format	 for	
PhyloCSF.		
To	 validate	 our	workflow,	we	 benchmarked	 PhyloCSF	with	 transcripts	 annotated	 in	 Ensembl	
(version	 75).	 Transcripts	 with	 biotype	 ‘lincRNA’	 or	 ‘antisense’	 (20,320	 transcripts)	 serve	 as	 a	
negative	set	while	transcripts	with	biotype	‘protein	coding’	and	an	annotated	coding	sequence	
(36,959	transcripts)	serve	as	a	positive	set.	Using	these	sets,	we	have	determined	41.2019	as	an	
optimal	treshold	for	the	PhyloCSF	score	(precision	of	95%	and	sensitivity	of	91%).	
Micro-array	based	gene	expression	profiling	
RNA	 samples	 from	 T-ALL	 cells	 treated	 with	 GSI,	 CD34+	 thymocytes	 cultured	 on	 the	 OP9-
GFP/DLL1	system,	sorted	T-cell	 subsets	 (CD34+	and	CD4+CD8+)	and	 two	primary	T-ALL	patient	
cohorts	of	which	one	cohort	including	samples	with	known	NOTCH1	mutation	status	(n=15)	(all	
FBXW7	wild	type)	and	a	larger	cohort	(n=64)	were	profiled	on	a	custom	designed	Agilent	micro-
array	covering	all	protein	coding	genes	and	12,000	lncRNAs	(23,042	unique	lncRNA	probes)	as	
described	by	Volders	et	al.46	Profiling	was	performed	according	to	the	manufacturers	protocol	
(One-color	Microarray-Based	Gene	Expression	Analysis,	Low	Input	Quick	Amp	Labeling,	Agilent	
Technologies),	with	100	ng	RNA	as	input.	Normalization	of	the	expression	data	was	performed	
with	the	VSN-package	(BioConductor	release	2.12)	in	R.	Expression	values	were	further	subjec-
ted	 to	background	 subtraction	by	 selecting	 those	probes	detecting	 a	 10	%	higher	 expression	
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than	the	negative	control	probes	of	the	array	design	in	at	least	one	treatment.	Differential	ex-
pression	analysis	was	performed	in	R	using	Limma.	A	multifactorial	design	was	used	to	control	
for	batch	effects.	
Correlation	analysis	for	functional	annotation	of	selected	lncRNAs	
Normalized	micro-array	based	gene	expression	profiles	were	generated	for	all	samples	of	the	
primary	T-ALL	patient	cohort	(n=64).	Spearman’s	rho	values	were	calculated	between	15	out	of	
the	set	of	27	overlapping	annotated	lncRNAs	(Figure	2E)	(and	also	for	LUNAR1	(lnc-IGF1R-1))	for	
which	a	probe	on	the	custom	micro-array46	was	available.	This	output	was	used	to	generate	a	
ranked	(.rnk)	file	and	used	as	an	input	for	a	GSEA	pre-ranked	analysis	using	the	c2v3.1	MsigDB	
collection	as	geneset	database.	The	output	files	were	subsequently	 loaded	into	Cytoscape.	By	
means	of	 the	Cytoscape	plug-in	 ‘enrichment	mapping’	 (Isserling	et	al.,	F1000Research,	2014),	
enrichment	maps	were	 built	 representing	 functional	 gene	 set	 clusters	 that	were	 significantly	
correlated	(red	nodes)	or	anti-correlated	(blue	nodes)	with	the	lncRNA-of-interest.			
	
SUPPLEMENTARY	TABLES	
The	supplementary	tables	can	be	found	in	the	online	version	of	the	paper:	
http://www.haematologica.org/content/99/12/1808.long	
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SUPPLEMENTARY	FIGURES	
	
	
Supplementary	 Figure	 1.	 Validation	 of	 the	 pharmacological	 Notch	 inhibition	 model	 in	 CUTLL1.	 (A)	 Down-
regulation	of	 ICN1	protein	 levels	upon	GSI	 treatment	 for	12h	and	48h	 in	CUTLL1	was	validated	by	Western	blot	
analysis.	(B)	RT-qPCR	could	confirm	down-regulation	of	DTX1	expression	upon	GSItreatment	of	CUTLL1	T-ALL	cells.	
	
	
	
	
Supplementary	 Figure	2.	Overlap	between	 lncRNAs	 that	 are	negatively	 correlated	with	Notch	 signaling	 in	GSI	
treatment	of	CUTLL1	cells	and	co-culturing	of	CD34+	thymocytes	on	the	OP9-DLL1	feeder	layer.	(A)	Venn	diagram	
depicting	 the	 overlap	 between	 previously	 annotated	 lncRNAs	 that	 are	 up-regulated	 upon	GSI	 treatment	 of	 the	
CUTLL1	 cell	 line	 and	down-regulated	upon	 co-culturing	of	CD34+	 thymocytes	on	 the	OP9-DLL1	 feeder	 layer.	 (B)	
Venn	 diagram	 depicting	 the	 overlap	 between	 previously	 unannotated	 lncRNAs	 that	 are	 upregulated	 upon	 GSI	
treatment	 of	 the	 CUTLL1	 cell	 line	 and	 downregulated	 upon	 co-culturing	 of	 CD34+	 thymocytes	 on	 the	OP9-DLL1	
feeder	layer.	
	 	
	
	
	
114	
	
	
Supplementary	Figure	3.	PhyloCSF	density	plot	to	evaluate	the	protein	coding	potential	of	novel,	unannotated	
lncRNA	 loci	by	RNA-seq.	The	putative	protein	coding	potential	of	unannotated	lncRNA	loci	 in	CUTLL1	T-ALL	cells	
and	CD34+	T-cell	progenitors	cultured	on	an	OP9	stromal	feeder	layer	was	calculated	using	the	PhyloCSF	algorithm.	
The	optimal	treshold	for	the	PhyloCSF	score	was	determined	as	41.2019	to	obtain	a	precision	of	95%	and	sensitivi-
ty	of	90%.	
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Supplementary	Figure	4.	Validation	of	Notch	regulated	lncRNAs	in	other	model	systems.	(A)	Western	blot	analy-
sis	confirms	down-regulation	of	 ICN1	in	HPB-ALL	and	ALL-SIL	cells	upon	GSI	treatment	for	12	h	and	48	h.	(B)	RT-
qPCR	shows	DTX1	down-regulation	upon	GSI	treatment	of	HPB-ALL	and	ALL-SIL	T-ALL	cells.	GSEA	shows	significant	
overlap	for	differentially	expressed	protein	coding	genes	found	by	RNA-seq	and	micro-array	data	of	(C)	GSI-treated	
CUTLL1	cells	and	(D)	CD34+	T-cell	progenitor	on	OP9-DLL1/GFP	co-cultures.	 	
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Supplementary	Figure	5.	Validation	of	direct	regulation	of	selected	lncRNAs	by	Notch1.	ChIP-seq	tracks	in	CUTLL1	
cells	of	Notch1,	Brd4,	Med1	and	H3K27ac	are	depicted	for	the	selection	of	annotated	lncRNAs	that	were	identified	
as	overlapping	Notch1	driven	 lncRNAs	 in	CUTLL1	cells	and	CD34+	progenitor	cells	 cultured	on	OP9	stromal	cells.	
Representative	RNA-seq	tracks	are	shown	for	both	in	vitro	model	systems.	
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Supplementary	 Figure	 6.	 Functional	 annotation	 of	 candidate	Notch	 driven	 lncRNAs	 in	 CUTLL1	 T-ALL	 cells	 and	
CD34+	thymic	progenitor	T-cells	through	enrichment	mapping.	(A-M)	Pairwise	Spearman’s	rho	correlations	were	
calculated	between	the	selected	Notch	driven	 lncRNAs	(with	probes	on	the	custom	array)	and	all	protein	coding	
genes	and	used	for	functional	annotation	of	each	of	the	candidate	lncRNAs	by	GSEA.	Followingly,	enrichment	maps	
were	generated	in	Cytoscape	for	all	selected	Notch	driven	lncRNAs	and	indicates	potential	clusters	of	functionali-
ties	 linked	 to	 each	 of	 the	 candidate	 lncRNAs	 such	 as	 involvement	 in	 the	 TCA-cycle,	meiosis,	 TCR-signaling.	 The	
thickness	of	the	edges	represent	the	overlap	of	genes	between	gene	sets	(nodes).	
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2 UNRAVELING	LONG	NONCODING	RNA	EXPRESSION		
PATTERNS	IN	THE	DIFFERENT	T-ALL	SUBTYPES	
	
PAPER	2 	
Long	noncoding	RNA	signatures	define	oncogenic	subtypes	 in	T-cell	acute	 lymphoblastic	
leukemia	
PAPER	3 	
RNA-sequencing	profiling	across	T-ALL	and	thymocyte	subsets	identifies	candidate	onco-
genic	lncRNAs	in	T-ALL		
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T-cell	acute	lymphoblastic	leukemia	(T-ALL)	is	
an	 aggressive	 hematologic	 malignancy	 of	
immature	 developing	 precursor	 T-cells	 and	
can	be	classified	 into	different	molecular	ge-
netic	 subgroups	 based	 on	 the	 aberrant	 acti-
vation	of	particular	transcription	factor	onco-
genes.	 In	 addition,	 these	 distinct	 molecular	
entities	 display	 specific	 gene	 expression	 sig-
natures	and	can	be	linked	to	certain	stages	of	
T-cell	development1-4.	Most	genetic	subtypes	
of	 human	 T-ALL	 are	 named	 after	 the	 tran-
scription	 factor	 oncogene	 that	 is	 predomi-
nantly	altered	in	these	hematological	tumors,	
i.e.	TAL/LMO,	TLX1	(HOX11),	TLX3	(HOX11L2)	
or	HOXA.	 However,	 immature	 T-ALLs,	 which	
generally	 lack	 a	 unifying	 molecular	 genetic	
alteration,	are	also	considered	as	a	 separate	
T-ALL	entity	with	putative	clinical	relevance.	
Long	 noncoding	 RNAs	 (lncRNAs)	 are	 a	 novel	
class	 of	 untranslated	 RNAs	 that	 are	 at	 least	
200	nucleotides	 in	size	and	are	 implicated	 in	
a	wide	 variety	 of	 cellular	 functions	 and	 spe-
cific	 developmental	 processes.	 Notably,	 re-
cent	 studies	 have	 shown	 that	 lncRNAs	 can	
drive	tumor	development5,	6	and,	 in	the	con-
text	 of	 T-ALL,	 it	 has	 been	 described	 that	
NOTCH1	 regulates	 the	 expression	 of	 several	
lncRNAs7,	 8.	 One	 interesting	 example	 is	 LU-
NAR1,	 which	 enhances	 the	 expression	 of	
IGF1R,	 leading	 to	 sustained	 IGF1	 signaling8.	
Thus	 far,	 lncRNAs	 remained	 unexplored	 as	
genetic	markers	for	distinct	T-ALL	subtypes.		
In	 this	 study,	 we	 defined	 the	 pattern	 of	
lncRNA	expression	 in	different	molecular	ge-
netic	subtypes	of	human	T-ALL.	Integration	of	
these	signatures	with	lncRNA	expression	in	T-
ALL	 cell	 lines	 and	 specific	 stages	 of	 normal	
human	 T-cell	 development	 provides	 a	 re-
source	 for	 the	 identification	of	oncogenic	or	
tumor	suppressive	 lncRNAs	 in	the	context	of	
T-cell	transformation.		
To	study	the	role	of	lncRNAs	in	the	molecular	
pathogenesis	 of	 human	 T-ALL,	we	 profiled	 a	
cohort	 of	 64	 T-ALL	 patient	 samples9	 using	 a	
custom	microarray	platform	detecting	13	000	
lncRNAs	 in	 addition	 to	 the	 protein	 coding	
mRNAs10.	This	cohort	consisted	of	RNA	of	15	
immature,	 17	 TLX1/TLX3,	 25	 TAL-R	 and	 7	
HOXA	 positive	 T-ALL	 patients.	 After	 VSN-
normalization,	 background	 subtraction	 was	
executed	by	 retaining	probes	 that	 showed	a	
10	%	higher	expression	 level	as	compared	to	
the	negative	 control	 probes	 in	 at	 least	 60	%	
of	 the	 samples	 of	 one	 particular	 molecular	
genetic	 subgroup.	 In	 keeping	 with	 previous	
reports1,	 2,	 distinct	 molecular	 genetic	 sub-
classes	showed	a	unique	mRNA	gene	expres-
sion	 signature	 (Figure	 1A,	 left	 panel).	 Next,	
we	 used	 the	 5190	 lncRNAs	 that	 showed	 ex-
pression	in	the	T-ALL	patient	cohort	to	define	
subtype	specific	lncRNA	signatures	of	human	
T-ALL.	 The	 top	 50	 differentially	 expressed	
lncRNAs	 for	 each	 subgroup	 are	 represented	
in	Figure	1A	(right	panel).	Of	note,	it	was	not	
possible	 to	 select	50	differentially	expressed	
lncRNAs	 for	 the	 HOXA	 subgroup,	 probably	
due	 to	 the	 small	 amount	of	patient	 samples	
(n=7).	 Forty	 percent	 of	 all	 subtype	 specific	
lncRNAs	 were	 characterized	 as	 ‘lincRNA’	
(long	intergenic	noncoding	RNAs)	in	Ensembl,	
whereas	 33	%	 were	 denoted	 as	 ‘antisense’	
(25	%	had	no	Ensembl	 ID	or	 no	biotype	was	
specified).	 Roughly	 half	 of	 the	 lncRNAs	
showed	 positive	 correlation	 in	 expression	
levels	 with	 one	 or	 more	 protein	 coding	
gene(s)	in	their	vicinity	(500	kb	up-	or	down-
stream	of	 the	 transcription	 start	 site;	 Spear-
man	 rho	 value	 >	 0.5;	 see	 Supplemental	 Ta-
ble).	In	contrast,	only	three	lncRNAs	were		
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Figure	1.	T-ALL	subgroups	can	be	characterized	by	a	specific	lncRNA	expression	pattern.	(A)	Heatmaps	showing	the	
top	50	most	differentially	expressed	mRNAs	(left)	and	lncRNAs	(right)	for	each	subgroup	(adjusted	p-value	<	0.05).	(B)	
Gene	set	enrichment	analysis	using	the	top	50	lncRNAs	upregulated	in	the	respective	genetic	T-ALL	subgroups	as	gene	
sets	within	a	panel	of	T-ALL	cell	lines.	(C)	For	each	subgroup,	one	lncRNA	from	the	core	enrichment	of	the	cell	lines	is	
visualized	with	RNA-sequencing	and	H3K27ac	ChIP-sequencing	tracks	for	LOUCY,	ALL-SIL	and	JURKAT.	
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negatively	correlated	with	a	neighboring	pro-
tein	coding	gene.	
In	 order	 to	 identify	 suitable	 in	 vitro	 model	
systems	 to	 study	 the	 functional	 role	 of	
lncRNAs	 in	human	T-ALL,	we	also	performed	
lncRNA	expression	profiling	in	a	subset	of	10	
human	T-ALL	cell	lines.	These	tumor	lines	ge-
netically	 resemble	most	of	 the	different	mo-
lecular	 subtypes	of	human	T-ALL	and	 includ-
ed	 immature	 (LOUCY),	 TLX1/TLX3	 positive	
(ALL-SIL,	DND41	and	HPB-ALL)	and	TAL-R	(PF-
382,	 JURKAT,	 KE-37	 and	 CCRF-CEM)	 tumor	
lines.	 Next,	 we	 used	 gene	 set	 enrichment	
analysis11	 to	 evaluate	 the	 potential	 overlap	
between	the	lncRNA	signatures	from	primary	
T-ALL	 patient	 samples	 and	 the	 established	
tumor	cell	lines	(Figure	1B	and	Supplemental	
Figure	1).	LncRNAs	highly	expressed	in	imma-
ture	 T-ALL	 patients,	 show	 a	 significant	 en-
richment	 in	 the	 immature	 T-ALL	 cell	 line	
LOUCY	 as	 compared	 to	 the	 other	 cell	 lines.	
Similarly,	 TLX1/3	 specific	 lncRNAs	 were	 en-
riched	 in	 ALL-SIL,	 DND-41	 and	 HPB-ALL,	
whereas	TAL-R	associated	lncRNAs	were	pre-
dominantly	 found	 in	 PF-382,	 JURKAT,	 KE-37	
and	CCRF-CEM.	Similar	results	were	obtained	
for	 downregulated	 lncRNAs	 and	 for	 protein	
coding	genes	 (Supplemental	Figure	1	and	2).	
For	 each	 subgroup,	 a	 representative	 lncRNA	
is	 visualized	 by	 means	 of	 RNA-Seq	 and	
H3K27ac	ChIP-Seq	data	of	the	LOUCY,	ALL-SIL	
and	 JURKAT	 T-ALL	 cell	 lines	 (Figure	 1C)12-14.	
Furthermore,	 the	 publically	 available	 RNA-
sequencing	of	8	T-ALL	cell	lines	(LOUCY,	DND-
41,	 HPB-ALL,	 ALL-SIL,	 PF-382,	 JURKAT,	 KE-37	
and	 CCRF-CEM)12	 has	 been	 remapped	 for	
lncRNAs	 and	 subsequently	 GSEA	 has	 been	
performed	 for	 the	 top	 selected	 mRNAs	 and	
lncRNAs	that	were	catalogued	in	the	Ensembl	
database.	 This	 revealed	 that,	 except	 the	
TLX1/3	 upregulated	 lncRNAs,	 all	 subgroup	
specific	gene	sets	were	enriched	in	the	RNA-
sequencing	 data	 of	 the	 corresponding	 T-ALL	
cell	 lines	 of	 that	 particular	 subtype	 (Supple-
mental	 Figure	 3),	 validating	 our	 microarray-
based	 data	 by	 RNA-sequencing.	 We	 hereby	
conclude	that	lncRNA	signatures	in	T-ALL	cell	
lines	 mimic	 those	 observed	 in	 primary	 leu-
kemia	samples	indicating	that	these	cell	lines	
represent	 reliable	 in	 vitro	model	 systems	 to	
study	the	role	of	these	lncRNAs	in	the	patho-
genesis	of	this	disease.		
To	 identify	putative	oncogenic	 lncRNAs	 in	T-
ALL	 development,	 we	 collected	 sorted	 sub-
sets	 of	 healthy	 thymocytes	 (Supplemental	
Methods).	Normal	thymopoiesis	is	a	carefully	
regulated	process	with	 each	of	 the	 interme-
diate	stages	being	characterized	by	a	distinct	
transcriptional	 profile	 and	 a	 combination	 of	
surface	markers	allowing	for	selection	of	the-
se	maturing	T-cell	subsets15.	During	this	mat-
uration	 process,	 several	 oncogenic	 lesions	
can	 occur,	 blocking	 differentiation	 and	 driv-
ing	 these	 immature	 thymocytes	 into	 an	 un-
controlled	 expansion	 towards	 full-blown	 T-
ALL.	 The	 above-described	 T-ALL	 subgroups	
largely	 resemble	 an	 arrest	 of	 thymocytes	 at	
specific	 stages	 of	 T-cell	 development.	 More	
specifically,	 the	 immature	 T-ALL	 patients	
have	an	arrest	in	the	early	stages	of	T-cell	de-
velopment,	 i.e.	 CD34+	 thymocytes.	 In	 con-
trast,	the	leukemic	cells	of	TAL-R	patients	re-
semble	 later	 stages	 of	 T-cell	 development,	
typically	 at	 the	 CD4+CD8+	 double	 positive	
stage.	 Given	 that	 the	 transcriptomes	 of	 the	
different	 genetic	 T-ALL	 subtypes	 strongly	 re-
capitulate	those	of	normal	 immature	thymo-
cytes,	we	also	explored	 the	 lncRNAome	of	6	
CD34+	 thymocyte	 populations	 and	 7	
CD4+CD8+	 thymocyte	samples	obtained	 from	
4	independent	donors.	
Interestingly,	24	out	of	the	top	50	upregulat-
ed	lncRNAs	in	immature	T-ALL	(Supplemental		
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Figure	2.	Comparison	with	healthy	thymocytes	reveals	lncRNAs	with	a	role	in	T-cell	development	and	poten-
tially	 oncogenic	 lncRNAs.	 (A)	 (left)	Heatmap	 representing	 lncRNAs	of	the	 top	50	 lncRNAs	upregulated	 in	the	
immature	 T-ALL	 patients	 that	 are	 also	 significantly	 higher	 expressed	 in	 CD34+	 thymocytes	 compared	 with	
CD4+CD8+	thymocytes	(adjusted	p-value	<	0.05).	(right)	Heatmap	representing	lncRNAs	of	the	top	50	upregulat-
ed	lncRNAs	in	the	TAL-R	group	that	are	significantly	higher	expressed	in	CD4+CD8+	thymocytes	compared	with	
CD34+	thymocytes	(adjusted	p-value	<	0.05).	(B)	Boxplots	representing	2	lncRNAs	that	are	ectopically	expressed	
in	immature	T-ALL	patients	compared	with	healthy	thymocytes	and	2	lncRNAs	that	are	ectopically	expressed	in	
TAL-R	 T-ALL	 patients	 compared	 with	 healthy	 thymocytes.	 (C)	 Density	 plots	 representing	 the	 average	 of	 the	
normalized	expression	of	all	lncRNAs	and	mRNAs	detected	by	the	array	in	all	patients	(left),	the	top	50	upregu-
lated	lncRNAs	for	each	subgroup	in	all	patients	(middle)	and	the	50	upregulated	lncRNAs	for	each	subgroup	in	
patients	of	that	particular	subgroup	(right).	
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Figure	 4A)	 were	 also	 significantly	 higher	 ex-
pressed	 in	 the	 CD34+	 thymocytes	 as	 com-
pared	 to	 CD4+CD8+	 T-cells	 (Figure	 2A,	 left),	
providing	 a	 link	 between	 immature	 T-ALLs	
and	their	cell	of	origin.	In	contrast,	18	of	the	
top	 50	 showed	 significant	 higher	 expression	
levels	 in	 immature	 T-ALL	 patients	 as	 com-
pared	 to	 CD34+	 thymocytes,	 suggesting	 that	
these	 lncRNAs	 might	 act	 as	 putative	 onco-
genes	in	the	biology	of	this	disease	(Figure	2B	
and	Supplemental	Figure	5A).	Ten	of	these	18	
lncRNAs	were	also	in	the	core	enrichment	of	
the	 immature	 T-ALL	 cell	 line	 LOUCY,	making	
them	 top	 candidates	 for	 further	 in	 depth	
study.	
A	similar	analysis	was	performed	for	the	TAL-
R	 subgroup	 in	 relation	 to	 CD4+CD8+	 healthy	
donor	counterparts.	Thirteen	 lncRNAs	of	 the	
top	 50	 upregulated	 in	TAL-R	 T-ALLs	 (Supple-
mental	 Figure	 4B)	 were	 significantly	 higher	
expressed	 in	 the	 CD4+CD8+	 thymocytes	 as	
compared	 to	CD34+	 thymocytes,	 reflecting	 a	
role	 during	 normal	 T-cell	 development	 (Fig-
ure	2A,	right).	On	the	other	hand,	29	lncRNAs	
of	 the	 selection	 are	 potentially	 oncogenic,	
because	 they	 are	 signifycantly	 higher	 ex-
pressed	 in	 the	 TAL-R	 T-ALL	 patients	 com-
pared	with	the	CD4+CD8+	thymocytes	(Figure	
2B	 and	 Supplemental	 Figure	 5B),	 of	which	 9	
are	also	 in	the	core	enrichment	of	the	TAL-R	
T-ALL	cell	lines.		
We	 could	 also	 detect	 possible	 tumor	 sup-
pressive	 lncRNAs	 by	 performing	 the	 reverse	
analysis.	Sixteen	lncRNAs	of	the	top	50	down-
regulated	 lncRNAs	 in	 the	 immature	 patients	
were	 significantly	 higher	 expressed	 in	 the	
CD34+	 thymocytes,	 whereas	 15	 lncRNAs	 of	
the	 top	 50	 downregulated	 lncRNAs	 in	 the	
TAL-R	 patients	 were	 significantly	 higher	 ex-
pressed	 in	 the	 CD4+CD8+	 thymocytes	 (Sup-
plemental	Figure	6).	The	same	analyses	have	
been	 performed	 for	 protein	 coding	 genes,	
which	 led	 to	 similar	 conclusions.	 These	 re-
sults	can	be	found	in	Supplemental	Figures	7	
–	10.		
LncRNAs	are	known	 to	have	a	 lower	expres-
sion	 level	 as	 compared	 to	 mRNAs,	 this	 also	
holds	true	for	our	data	as	can	be	seen	in	the	
distribution	plot	in	Figure	2C	(left).	The	aver-
age	normalized	expression	of	 the	top	50	up-
regulated	lncRNAs	for	each	subgroup	follows	
the	pattern	of	all	lncRNAs	detected	by	the	ar-
ray	(Figure	2C,	middle).	However,	the	expres-
sion	 patterns	 of	 the	 top	 50	 upregulated	
lncRNAs	 for	 each	 subgroup	 in	 the	 patients	
from	 that	 specific	 subgroup	 is	 shifted	 to	
higher	 levels,	 suggesting	 that	 these	 lncRNAs	
might	 be	 truly	 functional	 in	 the	 context	 of	
that	particular	subgroup	(Figure	2C,	right).		
In	conclusion,	this	study	provides	a	first	land-
scaping	of	 lncRNAs	that	can	discriminate	the	
distinct	 T-ALL	 subgroups	 and	 provides	 a	 re-
source	 for	 further	 biomarker	 discovery	 and	
novel	targets	for	patient-stratified	therapy.		
SUPPLEMENTAL	DATA	
The	supplemental	data	contain	a	detailed	de-
scription	 of	 the	materials	 and	methods	 that	
were	 used,	 extra	 figures	 and	 tables	 of	 the	
performed	 differential	 analysis	 and	 correla-
tion	analysis.	
ACCESS	TO	DATA	
The	 cell	 line	 expression	 data	 and	 ChIP-Seq	
data	of	the	LOUCY	cell	line	has	been	deposit-
ed	in	GEO	(GSE74312).		
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SUPPLEMENTARY	DATA	
Study	design	
Bone	 marrow	 lymphoblast	 and	 blood	 samples	 from	 T-ALL	 patients	 were	 collected	 after	 in-
formed	 consent	 according	 to	 the	 Declaration	 of	 Helsinki	 from	 Saint-Louis	 Hospital,	 Paris,	
France.	This	study	was	approved	by	the	Institut	Universitair	d’Hématologie	Institutional	Review	
Board	and	the	Ethical	committee	of	Ghent	University	Hospital.	This	primary	T-ALL	cohort	was	
previously	 investigated1	and	 the	high-quality	RNA	 samples	were	used	 for	 lncRNA	micro-array	
based	expression	profiling2.	Subgroup	annotation	of	the	T-ALL	patient	samples	can	be	found	in	
the	table	below.	
Thymocytes	were	purified	from	healthy	donors.	CD34	MACS	purified	thymocytes	were	labeled	
with	CD34,	CD1	and	CD4	to	sort	CD34+CD1-CD4-	uncommitted	and	CD34+CD1+CD4-	committed	
early	 thymocytes.	 A	 total	 thymus	 suspension	 was	 labeled	 with	 CD4,	 CD8	 and	 CD3	 to	 sort	
CD4+CD8+CD3-	and	CD4+CD8+CD3+	double	positive	thymocytes.	
The	 T-ALL	 cell	 lines	 LOUCY,	 KARPAS-45,	 PEER,	DND-41,	 ALL-SIL,	HPB-ALL,	 PF-382	 and	 JURKAT	
were	purchased	from	DSMZ.	KE-37	and	CCRF-CEM	were	a	kind	gift	of	respectively	the	Cools	Lab	
and	the	Barrata	lab.	
Total	RNA	from	T-ALL	patient	samples,	sorted	human	thymocytes	and	T-ALL	cell	 lines	was	iso-
lated	using	the	miRNeasy	mini	kit	(Qiagen)	and	the	RNA	quality	was	evaluated	on	Experion	(Bio-
Rad).	RNA	samples	(100	ng)	were	profiled	on	a	custom	designed	microarray	platform	covering	
all	protein	coding	genes	and	13,000	 lncRNAs	as	described	by	Volders	et	al.3	and	according	 to	
the	manufacturers	instructions	with	oligo-dT	primers	for	cDNA	synthesis.	Normalization	of	the	
data	was	performed	with	 the	VSN-package	 (BioConductor	 release	3.1)	 in	R.	Background	 sub-
traction	in	the	T-ALL	patient	cohort	was	executed	by	retaining	probes	that	showed	a	10	%	high-
er	expression	level	as	compared	to	negative	control	probes	in	at	 least	60	%	of	the	samples	of	
one	 subgroup.	 Differential	 expression	 analysis	 was	 performed	 in	 R	 using	 Limma.	 Correlation	
analysis	between	protein	coding	genes	and	lncRNAs	was	performed	by	means	of	Spearman	cor-
relation.	Expression	profiling	data	have	been	deposited	in	the	NCBI	Gene	Expression	Omnibus4	
and	 are	 accessible	 through	 GEO	 accession	 numbers	 GSE61866	 (T-ALL	 patient	 samples2),	
GSE61873	(sorted	human	thymocytes2)	and	GSE74312	(T-ALL	cell	 lines).	The	results	of	the	dif-
ferential	expression	analysis	and	the	correlation	analysis	can	be	found	in	supplemental	tables.	
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T-ALL	subgroup	annotation	for	the	samples	used	in	Durinck	et	al.,	2014	(GSE61866)	2	
Sample	 Subgroup	 Sample	 Subgroup	 Sample	 Subgroup	
TALL_JS_1	 TAL-R	 TALL_JS_23	 HOXA	 TALL_JS_45	 TLX	
TALL_JS_2	 IMM	 TALL_JS_24	 TAL-R	 TALL_JS_46	 IMM	
TALL_JS_3	 TLX	 TALL_JS_25	 TAL-R	 TALL_JS_47	 TAL-R	
TALL_JS_4	 IMM	 TALL_JS_26	 TLX	 TALL_JS_48	 TAL-R	
TALL_JS_5	 IMM	 TALL_JS_27	 IMM	 TALL_JS_49	 TAL-R	
TALL_JS_6	 HOXA	 TALL_JS_28	 TLX	 TALL_JS_50	 TAL-R	
TALL_JS_7	 IMM	 TALL_JS_29	 IMM	 TALL_JS_51	 TAL-R	
TALL_JS_8	 TAL-R	 TALL_JS_30	 IMM	 TALL_JS_52	 TAL-R	
TALL_JS_9	 TLX	 TALL_JS_31	 TLX	 TALL_JS_53	 TAL-R	
TALL_JS_10	 TLX	 TALL_JS_32	 TAL-R	 TALL_JS_54	 TAL-R	
TALL_JS_11	 HOXA	 TALL_JS_33	 IMM	 TALL_JS_55	 TLX	
TALL_JS_12	 TAL-R	 TALL_JS_34	 TAL-R	 TALL_JS_56	 TLX	
TALL_JS_13	 TAL-R	 TALL_JS_35	 HOXA	 TALL_JS_57	 TLX	
TALL_JS_14	 HOXA	 TALL_JS_36	 TAL-R	 TALL_JS_58	 TLX	
TALL_JS_15	 TAL-R	 TALL_JS_37	 TLX	 TALL_JS_59	 TLX	
TALL_JS_16	 TAL-R	 TALL_JS_38	 IMM	 TALL_JS_60	 TLX	
TALL_JS_17	 IMM	 TALL_JS_39	 TLX	 TALL_JS_61	 HOXA	
TALL_JS_18	 IMM	 TALL_JS_40	 HOXA	 TALL_JS_62	 TLX	
TALL_JS_19	 TLX	 TALL_JS_41	 TAL-R	 TALL_JS_63	 IMM	
TALL_JS_20	 IMM	 TALL_JS_42	 TAL-R	 TALL_JS_64	 TAL-R	
TALL_JS_21	 TAL-R	 TALL_JS_43	 TAL-R	 	 	
TALL_JS_22	 IMM	 TALL_JS_44	 TAL-R	 	 	
	
H3K27ac	ChIP-sequencing	in	LOUCY	
The	LOUCY	cell	line	was	obtained	from	the	DSMZ	cell	line	repository.	Cells	were	maintained	in	
RPMI-1640	medium	supplemented	with	10	%	fetal	bovine	serum,	1%	of	L-glutamine	and	1	%	of	
penicillin/streptomycin.	The	ChIP-protocol	has	been	performed	as	described	by	Durinck	et	al.5	
In	brief,	10	million	cells	were	cross-linked	with	1,1%	formaldehyde	for	10	min	at	room	tempera-
ture.	The	cross-linking	reaction	was	quenched	with	glycine	(125	mM	final	concentration).	Nuclei	
were	 isolated	and	the	chromatin	was	purified	by	chemical	 lysis.	Next,	purified	chromatin	was	
fragmented	by	sonication	to	200-300	bp	fragments	(Covaris).	Chromatin	 immunoprecipitation	
was	 performed	 by	 incubation	 of	 the	 chromatin	 fraction	 overnight	 with	 100	 µl	 of	 protein-A	
coated	beads	 (Thermo-Scientific,	 catalog	number	53139)	 and	10	μg	of	H3K27ac-specific	 anti-
body	 (Abcam,	 ab4729).	 The	 next	 day,	 beads	 were	 washed	 to	 remove	 non-specific	 binding	
events	and	the	enriched	chromatin	fragments	were	eluted	from	the	beads,	followed	by	reverse	
cross-linking	by	overnight	 incubation	at	65°C.	DNA	was	purified	by	phenol/chloroform	extrac-
tion,	assisted	by	phase	lock	gel	tubes	(5Prime).	DNA	obtained	from	the	ChIP-assays	was	adap-
tor-ligated,	amplified	and	analyzed	by	Illumina	Hiseq	2000.	Raw	sequencing	data	was	mapped	
to	the	human	reference	genome	(GRCh37/h19)	using	Bowtie.	Peak	calling	was	performed	using	
MACS.	ChIP	seq	data	has	been	deposited	in	the	GEO	database	(GSE74312).	
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Supplemental	tables	
Supplementary	 tables	 can	 be	 downloaded	 through	 the	 Leukemia	 website	 or	 directly	 via:	
http://www.nature.com/leu/journal/vaop/ncurrent/suppinfo/leu201682s1.html?url=/leu/journal/vaop/ncurrent/f
ull/leu201682a.html	
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SUPPLEMENTAL	FIGURES	
	
	
	
	
Supplemental	Figure	1.	T-ALL	subgroup	lncRNA	signatures	are	mirrored	in	T-ALL	cell	lines.	(A-C)	Heatmap	repre-
senting	 the	core	enrichment	of	 the	gene	set	enrichment	analysis	performed	 in	 figure	1B.	 (D-F)	Gene	set	enrich-
ment	analysis	of	the	T-ALL	subgroup	specific	down	regulated	lncRNAs	in	the	T-ALL	cell	lines	with	a	heatmap	of	the	
core	enrichment.	(A+D)	LOUCY	as	a	representative	cell	line	for	the	immature	T-ALL	subgroup.	(B+E)	DND-41,	HPB-
ALL	and	ALL-SIL	as	representative	cell	lines	for	the	TLX1/3	T-ALL	subgroup.	(C+F)	PF-382,	JURKAT,	KE-37	and	CCRF-
CEM	as	representative	cell	lines	for	the	TAL-R	subgroup.	
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Supplemental	Figure	2.	T-ALL	subgroup	mRNA	signatures	are	mirrored	in	T-ALL	cell	lines.	(A-C)	Gene	set	enrich-
ment	analysis	of	the	T-ALL	subgroup	specific	upregulated	mRNAs	in	the	T-ALL	cell	lines	with	a	heatmap	of	the	core	
enrichment.	(D-F)	Gene	set	enrichment	analysis	of	the	T-ALL	subgroup	specific	downregulated	mRNAs	in	the	T-ALL	
cell	lines	with	a	heatmap	of	the	core	enrichment.	(A+D)	LOUCY	as	a	representative	cell	line	for	the	immature	T-ALL	
subgroup.	(B+E)	DND-41,	HPB-ALL	and	ALL-SIL	as	representative	cell	lines	for	the	TLX1/3	T-ALL	subgroup.	(C+F)	PF-
382,	JURKAT,	KE-37	and	CCRF-CEM	as	representative	cell	lines	for	the	TAL-R	subgroup.		
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Supplemental	Figure	3.	T-ALL	subgroup	signatures	defined	by	microarray	are	reflected	in	RNA-sequencing	data.	
(A)	Gene	set	enrichment	analysis	of	the	T-ALL	subgroup	specific	upregulated	mRNAs	selected	by	microarray	analy-
sis	 in	RNA-sequencing	data	of	8	TALL	 cell	 lines.	 (B)	Gene	 set	enrichment	analysis	of	 the	T-ALL	 subgroup	specific	
downregulated	mRNAs	selected	by	microarray	analysis	 in	RNA-sequencing	data	of	8	TALL	cell	 lines.	 (C)	Gene	set	
enrichment	analysis	of	 the	T-ALL	subgroup	specific	upregulated	 lncRNAs	selected	by	microarray	analysis	 in	RNA-
sequencing	data	of	8	TALL	cell	lines.	(D)	Gene	set	enrichment	analysis	of	the	T-ALL	subgroup	specific	downregulat-
ed	 lncRNAs	selected	by	microarray	analysis	 in	RNA-sequencing	data	of	8	TALL	cell	 lines.	 (A-D)	LOUCY	as	a	repre-
sentative	cell	 line	for	the	immature	T-ALL	subgroup.	DND-41,	HPB-ALL	and	ALL-SIL	as	representative	cell	 lines	for	
the	TLX1/3	T-ALL	subgroup.	PF-382,	 JURKAT,	KE-37	and	CCRF-CEM	as	representative	cell	 lines	 for	the	TAL-R	sub-
group.	
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Supplemental	 Figure	 4.	 Top	 50	 upregulated	 lncRNAs	 in	 the	 immature	 and	 the	 TAL-R	 T-ALL	 subgroups.(A)	
Heatmap	showing	the	top	50	upregulated	lncRNAs	in	the	immature	T-ALL	subgroup	compared	with	the	other	T-ALL	
subgroups.	(B)	Heatmap	showing	the	top	50	upregulated	lncRNAs	in	the	TAL-R	T-ALL	subgroup	compared	with	the	
other	T-ALL	subgroups.	
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Supplemental	Figure	5.	Comparative	analysis	of	immature	thymocytes	and	the	T-ALL	lncRNAome	reveals	poten-
tial	oncogenic	lncRNAs.	(A)	Heatmap	representing	lncRNAs	from	the	top	50	upregulated	lncRNAs	in	the	immature	
T-ALL	 subgroup	 that	 are	 also	 significantly	 higher	 expressed	 in	 the	 immature	 T-ALL	 patients	 compared	with	 the	
CD34+	thymocytes	(p.adj	<	0.05).	(B)	Heatmap	representing	lncRNAs	from	the	top	50	upregulated	lncRNAs	in	the	
TAL-R	T-ALL	subgroup	that	are	also	significantly	higher	expressed	in	the	TAL-R	T-ALL	patients	compared	with	the	
CD4+CD8+	thymocytes	(p.adj	<	0.05).	
	
	
	
	
	
Supplemental	Figure	6.	Comparative	analysis	of	immature	thymocytes	and	the	T-ALL	lncRNAome	reveals	poten-
tial	 tumor	 suppressive	 lncRNAs.	 (A)	Heatmap	representing	 lncRNAs	 from	the	 top	50	downregulated	 lncRNAs	 in	
the	immature	T-ALL	subgroup	that	are	significantly	lower	expressed	in	the	immature	T-ALL	patients	compared	with	
the	CD34+	thymocytes	(p.adj	<	0.05).	(B)	Heatmap	representing	lncRNAs	from	the	top	50	downregulated	lncRNAs	
in	the	TAL-R	T-ALL	subgroup	that	are	also	significantly	lower	expressed	in	the	TAL-R	T-ALL	patients	compared	with	
the	CD4+CD8+	thymocytes	(p.adj	<	0.05).	
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Supplemental	 Figure	 7.	 Top	 50	 upregulated	 mRNAs	 in	 the	 immature	 and	 the	 TAL-R	 T-ALL	 subgroups.	 (A)	
Heatmap	showing	the	top	50	upregulated	mRNAs	in	the	immature	T-ALL	subgroup	compared	with	the	other	T-ALL	
subgroups.	(B)	Heatmap	showing	the	top	50	upregulated	mRNAs	in	the	TAL-R	T-ALL	subgroup	compared	with	the	
other	T-ALL	subgroups.	
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Supplemental	Figure	8.	Comparison	with	healthy	thymocytes	reveals	mRNAs	with	a	role	in	T-cell	development.	
(A)	Heatmap	representing	mRNAs	of	the	top	50	upregulated	mRNAs	in	the	immature	T-ALL	patients	that	are	also	
significantly	 higher	 expressed	 in	 CD34+	 thymocytes	 compared	 with	 CD4+CD8+	 thymocytes	 (p.adj	 <	 0.05).	 (B)	
Heatmap	representing	mRNAs	of	 the	top	50	upregulated	mRNAs	 in	the	TAL-R	group	that	are	significantly	higher	
expressed	in	CD4+CD8+	thymocytes	compared	with	CD34+	thymocytes	(p.adj	<	0.05).	
	
	
	
Supplemental	Figure	9.	Comparative	analysis	of	immature	thymocytes	and	the	T-ALL	mRNAome	reveals	poten-
tial	oncogenic	mRNAs.	(A)	Heatmap	representing	mRNAs	from	the	top	50	upregulated	mRNAs	in	the	immature	T-
ALL	subgroup	that	are	also	significantly	higher	expressed	in	the	immature	T-ALL	patients	compared	with	the	CD34+	
thymocytes	(p.adj	<	0.05).	(B)	Heatmap	representing	mRNAs	from	the	TOP	50	upregulated	mRNAs	in	the	TAL-R	T-
ALL	subgroup	that	are	also	significantly	higher	expressed	in	the	TAL-R	T-ALL	patients	compared	with	the	CD4+CD8+	
thymocytes	(p.adj	<	0.05).	
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Supplemental	Figure	10.	Comparative	analysis	of	immature	thymocytes	and	the	T-ALL	mRNAome	reveals	poten-
tial	 tumor	suppressive	mRNAs.	 (A)	Heatmap	representing	mRNAs	from	the	top	50	downregulated	mRNAs	in	the	
immature	T-ALL	subgroup	that	are	significantly	lower	expressed	in	the	immature	T-ALL	patients	compared	with	the	
CD34+	thymocytes	(p.adj	<	0.05).	(B)	Heatmap	representing	mRNAs	from	the	top	50	downregulated	mRNAs	in	the	
TAL-R	T-ALL	subgroup	that	are	also	significantly	 lower	expressed	 in	 the	TAL-R	T-ALL	patients	compared	with	 the	
CD4+CD8+	thymocytes	(p.adj	<	0.05).	
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ABSTRACT	
Long	noncoding	RNAs	are	emerging	as	 important	players	 in	cancer.	 In	order	to	identify	candi-
date	oncogenic	lncRNAs,	we	have	performed	a	broad	and	in	depth	comparative	landscaping	of	
the	lncRNAomes	of	all	genetic	T-ALL	subtypes	and	normal	counterpart	T-cell	subsets.	First,	we	
validated	 our	 previous	 lncRNA	 T-ALL	 subgroup	 classification	 and	 showed	 that	 poly(A)	 RNA-
sequencing	 allows	more	 robust	 classification	 as	 compared	 to	 array-based	 analysis.	 Next,	 we	
identified	 ectopically	 expressed	 candidate	 oncogenic	 lncRNAs	 in	 immature	 and	 TAL-R	 T-ALL,	
which	represent	valid	targets	for	functional	studies.	In	addition,	using	total	RNA-sequencing	on	
a	 smaller	 subset	 of	 samples,	we	 investigated	 the	 full	 spectrum	 of	 long	 noncoding	 RNAs	 and	
identified	 a	 set	 of	 novel	 and	 previously	 unannotated	 lncRNAs	 in	 T-ALL.	 Taken	 together,	 our	
study	offers	a	unique	resource	of	data	on	lncRNAs	expressed	in	T-ALL	and	normal	thymocytes	
for	further	data	mining	and	functional	exploration.	
	
INTRODUCTION	
T-cell	acute	lymphoblastic	leukemia	(T-ALL)	is	
an	aggressive	hematological	malignancy	aris-
ing	from	a	differentiation	arrest	during	T-cell	
development.	T-ALL	patients	can	be	classified	
into	 different	 genetic	 subtypes	 based	 upon	
their	 aberrant	 expression	 of	 specific	 tran-
scription	 factor	 oncogenes	 (TAL,	 TLX1,	 TLX3	
or	HOXA)	 that	 demarcates	 a	 developmental	
arrest	at	a	specific	stage	of	T-cell	differentia-
tion1-4.	 More	 than	 a	 decade	 ago,	 a	 unique	
mRNA	 expression	 signature	 characterizing	
these	 genetic	 subgroups	 was	 reported1,	 2.	
More	recently,	we	showed	that	long	noncod-
ing	RNAs	also	exhibit	genetic	subtype	specific	
expression	patterns5.			
Previous	 studies	 describing	 T-ALL	 signatures	
were	 based	 on	 the	 profiling	 of	 the	 T-ALL	
samples	by	micro-array	platforms,	with	a	cus-
tom	 designed	 micro-array	 platform	 for	 the	
detection	 of	 lncRNAs5,	 6.	 	 Currently,	 RNA-
sequencing	offers	 a	more	powerful	platform	
for	 sensitive	 detection	 of	 lncRNAs	 including	
those	 who	 have	 not	 been	 previously	 anno-
tated.		
Here,	we	analyzed	poly(A)	RNAseq	mRNA	and	
lncRNA	 profiles	 of	 60	 primary	 T-ALL	 patient	
samples	 from	 four	 different	 genetic	 T-ALL	
subtypes	 (immature,	 TLX1/3,	 TAL-R	 and	
HOXA	overexpressing	T-ALL)	by	poly(A)	RNA-
seq.	We	 validated	 our	 dataset	 through	 sub-
group	 classification	 and	 show	 more	 robust	
separation	by	RNA-seq	as	compared	to	array-
data.	 Next,	 we	 identified	 ectopically	 ex-
pressed	 candidate	 oncogenic	 lncRNAs	
through	 comparison	 with	 normal	 thymo-
cytes.	Finally,	we	detect	novel	T-ALL	lncRNAs,	
in	particular	in	a	subset	of	25	primary	match-
ing	 T-ALL	 patient	 samples	 analyzed	 by	 total	
RNA-seq.	
MATERIALS	AND	METHODS	
Primary	human	T-ALL	patient	samples	
Blood	 samples	 and	 bone	 marrow	 lympho-
blast	from	T-ALL	patients	were	collected	after	
informed	 consent	 according	 to	 the	 Declara-
tion	 of	 Helsinki	 from	 Saint-Louis	 Hospital,	
Paris,	 France.	 This	 study	 was	 approved	 by	
both	 the	 Institut	 Universitair	 d’Hématologie	
Institutional	 Review	 Board	 and	 the	 Ethical	
Committee	of	Ghent	University	Hospital.	To-
tal	RNA	was	isolated	using	the	miRNeasy	mini	
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kit	 (Qiagen).	These	samples	are	part	of	a	co-
hort	 previously	 investigated	 by	 mRNA8	 and	
lncRNA	profiling5,	9.		
Thymocyte	subset	selection	
Thymus	 tissue	was	 derived	 from	 a	 child	 un-
dergoing	 cardiac	 surgery	 (UZ	Gent)	 and	was	
obtained	 and	 used	 according	 to	 the	 guide-
lines	 of	 the	 Medical	 Ethical	 Commission	 of	
Ghent	 University	 Hospital	 (Ghent,	 Belgium).	
Immature	 CD34+	 thymocytes	 were	 purified	
based	 on	MACS	 purification	 using	 CD34	mi-
crobeads	(Miltenyi	Biotec)10	and	were	subse-
quently	sorted	into	a	CD1	negative	and	posi-
tive	 subpopulation.	 On	 the	 other	 hand,	 the	
CD4+CD8+	double	positive	subset	was	isolated	
using	 CD4	 and	 CD8	 labeled	 antibodies	 and	
was	 further	 divided	 into	 the	 CD3	 negative	
and	the	more	mature	CD3	positive	subpopu-
lations.	 All	 sorts	 were	 performed	 using	 a	
FACSAriaIII	 (BDBiosciences).11	 The	 purity	 of	
each	subset	was	at	least	98%.	Total	RNA	was	
isolated	 using	 the	 miRNeasy	 mini	 kit	 (Qi-
agen).	
Poly(A)	and	total	RNA-sequencing	
For	poly(A)	RNA-seq,	libraries	were	prepared	
using	 the	 TruSeq	 Stranded	 mRNA	 sample	
prep	 kit	 (Illumina).	 100	 ng	 of	 total	 RNA	was	
enriched	 using	 the	 oligodT	 bead	 system	 (Il-
lumina).	The	isolated	mRNA	was	subsequent-
ly	 fragmented	 using	 enzymatic	 fragmenta-
tion.	 Libraries	 for	 total	 RNA-seq	 were	 pre-
pared	 using	 the	 TruSeq	 Stranded	 total	 RNA	
(with	RiboZero	Gold)	sample	prep	kit	 (Illumi-
na).	 100	 ng	 of	 total	 RNA	 was	 depleted	 of	
rRNAs	 using	 Ribo-Zero	 Gold	 magnetic	 bead	
based	 capture-probe	 system	 (Illumina).	 The	
remaining	 RNA	 was	 subsequently	 purified	
(RNAcleanXP)	 and	 fragmented	 using	 enzy-
matic	fragmentation.	
First	 and	 second	 strand	 synthesis	 was	 per-
formed	and	double	stranded	cDNA	was	puri-
fied	 (Agencourt	 AMPure	 XP).	 The	 cDNA	was	
end-repaired,	 3’adenylated	 and	 Illumina	 se-
quencing	 adapters	 were	 ligated	 followed	 by	
purification.	 The	 mRNA	 stranded	 libraries	
were	 pre-amplified	 with	 PCR	 and	 purified	
(Agencourt	 AMPure	 XP).	 The	 quality	 of	 the	
libraries	was	 inspected	 on	 the	 2100	 Bioana-
lyzer	(high	sensitivity	DNA	chip,	Agilent).	High	
quality	 libraries	 were	 quantified	 using	 the	
Qubit	 Fluorometer	 (Life	 Technologies).	 After	
concentration	 normalization,	 single-end	 se-
quencing	was	performed	on	the	NextSeq500	
instrument	 (Illumina)	 according	 to	manufac-
turer	instructions.	
RNA-seq	data-processing	
Reads	 were	 mapped	 to	 the	 reference	 ge-
nome	GRCh38	with	 STAR	 v2.4.2a.	 STAR	was	
also	 used	 for	 gene	 expression	 quantification	
on	Gencode	v23	GTF.	For	each	sample,	tran-
script	 assembly	 was	 performed	 with	 String-
Tie.	 Subsequently	 Cuffmerge	 was	 used	 to	
merge	 all	 transcript	 assemblies	 into	 one	 su-
perset	containing	all	transcripts	present	in	at	
least	one	 sample.	Expression	 levels	are	visu-
alized	 as	 Transcripts	 Per	 Kilobase	 Million	
(TPM),	which	is	calculated	by	first	dividing	all	
read	counts	by	their	gene	length	in	kilobases	
(RPK,	 reads	 per	 kilobase)	 and	 subsequently	
by	the	scaling	factor	per	sample.	This	scaling	
factor	 was	 determined	 by	 summing	 up	 all	
RPK	values	per	sample	and	dividing	this	by	1	
million.		
To	 identify	 unannotated	 transcripts,	 the	
merged	GTF	file	was	compared	with	different	
annotation	 GTF	 files	 (Gencode23,Refseq78,	
Ensembl81	 and	 lncipedia3.1)	 using	 Cuffcom-
pare.	
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Differential	expression	analysis	
Gencode	mRNA	and	 lncRNA	expression	data	
was	 filtered	 with	 a	 background	 correction	
that	 only	 retained	 the	 genes	 detected	 by	 at	
least	4	reads	in	at	least	60%	of	samples	from	
one	T-ALL	subgroup	or	in	at	least	all	samples	
from	 one	 thymocyte	 subset.	 Differential	 ex-
pression	 analysis	 was	 performed	 using	 the	
DESeq2	algorithm	in	R12.		
RESULTS	
Validation	 of	 the	 poly(A)	 RNA-sequencing	
dataset	of	T-ALL	patient	samples	through	T-
ALL	genetic	subtype	classification			
Poly(A)	 RNA-sequencing	 was	 performed	 for	
60	primary	T-ALL	patient	samples	with	an	av-
erage	 sequencing	 depth	 of	 51	 million	 reads	
per	 sample,	 of	which	65%	 could	be	mapped	
to	 the	 Gencode	 v23	 database13,14.	 The	 60	
samples	are	divided	over	the	four	main	T-ALL	
subtypes:	 13	 immature,	 17	 TLX1/3	 overex-
pressing,	 23	 TAL-rearranged	 and	 7	 HOXA	
overexpressing	 cases	 (Figure	 1A).	 To	 correct	
for	 background	 detection,	 only	 genes	 that	
were	detected	by	at	 least	 four	 reads	 in	60%	
of	the	samples	of	one	particular	genetic	sub-
type	 were	 retained	 (14,447	 protein	 coding	
genes	 and	 3,264	 lncRNAs	 (‘lincRNA	 or	 ‘anti-
sense’	 biotype)).	 The	expression	 level	 of	 the	
lncRNAs	is,	as	expected,	much	lower	than	for	
protein	 coding	genes,	 as	 can	be	appreciated	
from	the	density	plot	(Figure	1B).		
Principal	 Component	Analysis	 (PCA)	 shows	a	
clustering	 of	 the	 samples	 according	 to	 sub-
type	for	both	the	mRNA	(Supplementary	Fig-
ure	 1A)	 and	 lncRNA	 (Figure	 1C)	 expression,	
with	 the	 only	 exception	 for	 the	HOXA	 sam-
ples	 which	 are	 broadly	 dispersed.	 Hierar-
chical	clustering	of	the	samples,	using	the	top	
1000	 mRNAs	 or	 top	 1000	 lncRNAs	 with	 the	
largest	standard	deviation,	also	shows	a	sep-
aration	of	most	of	 the	 immature,	TAL-R	 and	
TLX1/3	patient	samples	to	the	expected	sub-
type	 based	 on	 clinical	 data	 (Supplementary	
Figure	2).	Notably,	lncRNA	expression	profiles	
yield	a	similar	qualitative	separation	of	T-ALL	
subtypes	 as	 hierarchical	 clustering	 based	 on	
protein	coding	gene	expression	profiles.		
To	 identify	 the	 subtype	 specific	 lncRNAs	 in	
our	 poly(A)	 RNA-seq	 dataset,	 we	 performed	
DESeq2	 differential	 expression	 analysis12	 us-
ing	 iterations	 of	 one-to-three	 comparisons.	
We	validated	this	method	based	on	the	pro-
tein	 coding	 gene	 expression	 and	 detected	
several	 specific	 mRNAs	 that	 were	 already	
identified	by	previous	groups	(Supplementary	
Figure	 1B,	 Supplementary	 Table	 1)1,2.	 The	
heatmap	 in	 Figure	1D	 represents	 the	 top	50	
most	 differentially	 expressed	 lncRNAs	 per	
subgroup.	 Again,	 this	 pattern	 is	 less	 distinct	
for	the	HOXA	group	as	only	48	HOXA-specific	
lncRNAs	 could	 be	 identified.	 For	 the	 other	
subtypes,	 at	 least	 550	 lncRNAs	 were	 signifi-
cantly	 up	 or	 downregulated	 (p.adj	 <	 0.05)	
(Supplementary	Table	2).	
T-ALL	 subtype	 specific	 lncRNAs	 in	T-ALL	 cell	
lines	
T-ALL	cell	lines	are	extensively	used	for	func-
tional	tests	in	genetic	studies.	As	a	prelude	to	
further	 functional	 analysis	 of	 candidate	 on-
cogenic	 lncRNAs,	 we	 therefore	 analyzed	
lncRNA	profiles	of	commonly	used	T-ALL	cell	
lines	 in	 a	 publicly	 available	 poly(A)	 RNA-seq	
data15.	 The	 LOUCY	 cell	 line	 is	 representative	
for	 the	 immature	 T-ALL	 patients,	 whereas	
HPB-ALL	(TLX3+),	DND-41	(TLX3+)	and	ALL-SIL	
(TLX1+)	 represent	 the	TLX1/3	 T-ALL	 subtype.	
The	 TAL-R	 subtype	 can	 be	 linked	 to	 the	 cell	
lines	 JURKAT,	 PF-382,	 KE-37	 and	 CCRF-CEM.	
In	Figure	2	and	Supplementary	Figure	3,	 the	
density	plots	represent	the	lncRNA	expres-	
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sion	levels	in	these	cell	lines,	with	the	expres-
sion	of	the	top	10	highest	expressed	and	up-
regulated	 lncRNAs	 for	 the	 immature,	TLX1/3	
or	TAL-R	subgroups	represented	by	the	verti-
cal	 black	 bars.	 We	 therefore	 conclude	 that	
nearly	all	of	selected	overexpressed	 lncRNAs	
are	 also	 detected	 at	 relatively	 high	 levels	 in	
the	 representative	 cell	 lines	 validating	 their	
use	for	further	study	of	the	oncogenic	effect.		
To	further	explore	the	T-ALL	subtype	specific	
lncRNAs	 in	 T-ALL	 cell	 lines,	 we	 performed	
Gene	 Set	 Enrichment	 Analysis	 (GSEA)	 with	
the	top	50	up-	or	downregulated	lncRNAs	per	
subtype	 as	 genesets	 (Supplementary	 Figure	
4).	All	genesets	containing	the	50	downregu-
lated	 lncRNAs	per	 subtype	were	significantly	
enriched	in	the	cell	lines	not	resembling	that	
subtype.	 For	 the	 upregulated	 lncRNAs	 per	
subtype,	 there	was	only	 a	 significant	enrich-
ment	for	the	TAL-R	 lncRNAs	in	the	TAL-R	cell	
lines.	 For	 the	 immature	 and	TLX1/3	 upregu-
lated	 lncRNAs,	 several	 were	 also	 higher	 ex-
pressed	 in	 their	 representative	 cell	 lines	 as	
compared	to	the	others,	but	the	full	geneset	
could	 not	 be	 significantly	 linked	 to	 the	 cell	
lines.	
Figure	1.	Poly(A)	RNA-seq	reveals	a	T-ALL	subtype	specific	lncRNA	expression	profile.	(A)	Overview	of	the	sam-
ples	used	in	this	study.	(B)	Density	plot	representing	the	expression	level	of	mRNAs	and	lncRNAs	in	the	T-ALL	pa-
tient	samples.	(C)	Principal	Component	Analysis	for	the	lncRNAs	detected	by	poly(A)	RNA-seq.	(D)	Heatmap	rep-
resenting	the	top	50	most	differentially	expressed	lncRNAs	for	each	subtype	in	comparison	to	the	others	(p.adj	<	
0.05).	
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Poly(A)	 RNA-sequencing	 detects	 subtype	
specific	 lncRNAs	more	 robustly	 than	micro-
array	profiling	
We	previously	published	the	subtype	specific	
mRNA	 and	 lncRNA	 signatures	 of	 these	 pa-
tients	based	on	micro-array	expression	profil-
ing5.	 If	we	 compare	both	 signatures	 for	pro-
tein	coding	genes,	we	 find	50-80%	of	signifi-
cant	 subtype	 specific	 mRNAs	 detected	 by	
poly(A)	 RNA-seq	 also	 in	 our	 microarray	 da-
taset	(Supplementary	Figure	5A).	This	overlap	
is	 however	 smaller	 (less	 than	 30%)	 for	 the	
HOXA-specific	 mRNAs,	 but	 again,	 this	 might	
be	 due	 to	 the	 low	 number	 of	 patient	 sam-
ples.	 However,	 with	 poly(A)	 RNA-seq,	 much	
more	 HOXA-specific	 mRNAs	 were	 detected.	
Remarkably,	if	we	compared	the	mRNAs	that	
were	 subtype	 specific	 by	 both	methods,	 the	
detected	fold	change	was	significantly	(Paired	
students	t-test;	p	<	0,01)	larger	for	the	micro-
array	 profiling	 of	 the	 immature,	 TLX1/3	 and	
HOXA	signatures	(Supplementary	Figure	5B).		
To	 compare	 the	 lncRNA	 signatures	 obtained	
from	both	methods,	we	had	to	cope	with	the	
different	 annotation	 of	 the	 micro-array	
probes	compared	to	our	poly(A)	RNA-seq	da-
taset.	As	a	consequence,	we	could	only	con-
vincingly	 compare	 860	 Gencode	 defined	
lncRNAs	 (‘lincRNA’	 and	 ‘antisense’	 biotype)	
with	probes	on	the	micro-array	and	took	only	
these	lncRNAs	into	account	for	further	analy-
sis.	 For	 the	 T-ALL	 subtype	 specific	 lncRNAs,	
we	 detected	 an	 overlap	 of	 about	 50%	 be-
tween	both	methods	(Figure	3A).	In	compari-
son	 to	 the	 protein	 coding	 genes,	 the	 fold	
change	of	the	subtype	specific	lncRNAs	in	the	
overlap	 between	 the	 2	methods	was	 signifi-
cantly	higher	for	the	RNA-sequencing	dataset	
as	compared	to	the	micro-array	data	(Paired	
student’s	 t-test;	p	<	0.01;	Figure	3B).	 In	con-
clusion,	 our	 poly(A)	 RNA-seq	 dataset	 gives	
the	advantage	over	the	micro-array	data	that	
it	detects	the	same	subtype	specific	lncRNAs,	
but	with	a	larger	difference	in	expression.		
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Figure	2.	Poly(A)	RNA-seq	of	T-ALL	cell	lines.	Density	plots	of	lncRNA	expression	in	the	LOUCY	cell	line,	a	cell	line	
representative	for	IMM	T-ALL	(A),	the	HPB-ALL	cell	line,	for	the	TLX1/3	subgroup	(B)	and	the	JURKAT	cell	line	for	
the	TAL-R	subgroup	(C).	The	vertical	bars	represent	the	top	10	lncRNAs	that	are	significantly	higher	expressed	in	
the	representative	subgroup	compared	to	the	others.	
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Poly(A)	RNA-seq	detects	previously	unanno-
tated	T-ALL	lncRNAs	
We	 next	 took	 advantage	 of	 the	 power	 of	
RNA-sequencing	 for	 the	 detection	 of	 novel	
lncRNAs.	 To	 this	 end,	 we	 aligned	 our	 RNA-
sequencing	 reads	with	 the	 STAR	 algorithm16	
to	 the	 hg38	 genome,	 followed	 by	 transcript	
assembly	 with	 StringTie17.	 These	 transcript	
assemblies	 per	 sample	were	 then	 combined	
with	Cuff-Compare18	 leading	 to	 the	 in-house	
establishment	 of	 a	 T-ALL	 transcriptome	 (an-
notated	 with	 XLOC	 codes).	 This	 led	 to	 the	
identification	of	12,524	genes	 that	were	not	
present	 in	Gencode	 (v23)13,	Ensembl	 (v81)19,	
RefSeq	(v78)20	and	lncipedia	(v3.1)21.	To	elim-
inate	 very	 low	 expressed	 genes,	 we	 per-
formed	a	background	correction	in	which	we	
only	 retained	 the	 3303	 genes	 that	were	 de-
tected	by	 at	 least	 4	 reads	 in	 at	 least	 5	 sam-
ples.	 Furthermore,	 there	 is	 more	 evidence	
that	a	gene	 is	 truly	 functional	 if	at	 least	one	
splicing	 event	 occurs,	 so	 we	 filtered	 out	
genes	 with	 only	 one	 exon.	 Of	 those	 932	
genes,	526	genes	have	no	protein	coding	po-
tential	as	calculated	by	the	‘Coding	Potential		
A
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Figure	3.	Poly(A)	RNA-seq	detects	subtype	specific	 lncRNAs	more	 robustly	than	micro-arrays.	 (A)	Overview	of	
the	 amount	 of	 subtype	 specific	 lncRNAs	 detected	 only	 by	 micro-array	 profiling	 (dark	 blue),	 only	 by	 RNA-
sequencing	 (light	 blue)	 or	 by	 both	 methods	 (red).	 (B)	 Comparison	 between	 micro-array	 profiling	 and	 RNA-
sequencing	of	the	fold	change	detected	for	the	significant	lncRNAs	identified	by	both	methods.	The	red	line	rep-
resents	the	distribution	if	the	fold	change	would	be	equal	(x=y).	
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Calculator’	 (CPC)	algorithm	(Figure	4A)22	and	
these	 genes	 are	 thus	 considered	 as	 novel	
lncRNAs	 (Supplementary	 table	 3).	 Of	 these	
526	lncRNAs,	511	were	intergenic,	3	were	an-
tisense	 and	 12	 were	 bi-directional	 (having	
their	 transcription	 start	 site	 closer	 than	 100	
bp	 from	the	transcription	start	site	of	a	pro-
tein	coding	gene).		
We	 repeated	 the	 differential	 expression	
analysis	 for	 lncRNAs	between	the	T-ALL	sub-
types,	 but	 this	 time,	 we	 added	 the	 novel	
identified	 lncRNAs	 to	 these	 already	 included	
by	Gencode	(v23)13,	14.	Several	of	these	puta-
tively	 novel	 lncRNAs	 were	 also	 significantly	
up-	 or	 downregulated	 in	 a	 specific	 subtype	
and	interestingly,	some	of	these	were	repre-
sented	 in	 the	 top	 50	 most	 significantly	 up-
regulated	 lncRNAs.	 For	 each	 subtype,	 the	
most	 significant	 upregulated	 novel	 lncRNA,	
which	 was	 also	 present	 in	 the	 top	 50	 of	 all	
lncRNAs,	 is	 shown	 in	 Figure	4B.	 It	 should	be	
noted	 that	 these	 novel	 lncRNAs	 have	 very	
low	expression	 levels,	but	their	subtype	spe-
cific	expression	 is	quite	clear.	As	an	 interest-
ing	example,	XLOC_539213	 is	upregulated	 in	
the	 TLX1/3	 subtype	 and	 detected	 at	 quite	
high	 rates	 in	 the	 HPB-ALL	 and	 DND41	 cell	
lines	(TLX3+,	data	not	shown).	Also	the	other	
novel	 subtype	 specific	 lncRNAs	 are	 repre-
sented	in	the	cell	lines,	however	at	a	low	lev-
el.		
Comparative	 analysis	 of	 normal	 thymocyte	
versus	 T-ALL	 lncRNA	 transcriptomes	 identi-
fies	oncogenic	lncRNAs	
T-ALL	 occurs	 from	 a	 malignant	 transfor-
mation	of	maturing	T-cells	in	the	thymus.	The	
lymphoblasts	 of	 the	 immature	 T-ALL	 cases	
show	a	differentiation	arrest	very	early	dur-	
Figure	4.	Poly(A)	RNA-seq	can	link	previously	unannotated	lncRNAs	to	specific	T-ALL	subtypes.	(A)	Overview	
of	 the	 selection	 method	 to	 identify	 novel	 long	 noncoding	 RNA	 genes.	 (B)	 Boxplots	 representing	 one	 novel	
lncRNA	per	T-ALL	subgroup	that	is	significantly	upregulated	in	that	subgroup	compared	to	the	others.	
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ing	 T-cell	 development,	 at	 the	 CD34+	 stage.	
The	TAL-R	 cases	however,	have	had	a	differ-
entiation	arrest	at	a	later	stage	during	devel-
opment,	 from	 the	 CD4+CD8+	 double	 positive	
stage	on.	To	 identify	oncogenic	 lncRNAs,	we	
profiled	 the	 lncRNA	 expression	 of	 2	 CD34+	
and	 2	 CD4+CD8+	 subsets	 from	 a	 healthy	 do-
nor	by	poly(A)	RNA-sequencing.			
By	 means	 of	 differential	 RNA-seq	 analysis	
(DESeq2),	 we	 identified	 276	 lncRNAs	 that	
were	 upregulated	 in	 immature	 T-ALL	 com-
pared	 to	 the	 CD34+	 healthy	 donor	 subsets	
(Figure	 5A,	 Supplementary	 Table	 4).	 Sixteen	
of	 these	 lncRNAs	were	 also	 identified	 in	 the	
top	 50	 upregulated	 lncRNAs	 in	 immature	 T-
ALL	compared	to	the	other	subtypes	(two	ex-
amples	 in	 Figure	 5B).	 These	 16	 lncRNAs	 are	
thus	 potential	 oncogenic	 drivers	 for	 imma-
ture	 T-ALL.	 Furthermore,	 475	 lncRNAs	 were	
upregulated	 in	 TAL-R	 T-ALL	 as	 compared	 to	
Figure	 5.	 Comparison	with	 thymocyte	 subsets	 detects	 oncogenic	 subtype	 specific	 lncRNAs.	 (A)	Diagonal	plot	
comparing	 the	 expression	 of	 lncRNAs	 between	 IMM	 T-ALL	 samples	 and	 CD34+	 T-cell	 subsets.	 Red	 dots	 are	
lncRNAs	significantly	upregulated	in	IMM	T-ALL	and	blue	dots	are	the	significantly	downregulated	lncRNAs	(p.adj	
<	0.05).	 (B)	Two	examples	of	 IMM	T-ALL	upregulated	 lncRNAs	 that	are	also	upregulated	 in	 IMM	T-ALL	as	 com-
pared	to	their	healthy	donor	counterparts.	(C)	Diagonal	plot	comparing	the	expression	of	lncRNAs	between	TAL-R	
T-ALL	 samples	 and	 CD4+CD8+	T-cell	 subsets.	Red	dots	are	 lncRNAs	 significantly	upregulated	 in	 TAL-R	T-ALL	and	
blue	dots	are	the	significantly	downregulated	lncRNAs	(p.adj	<	0.05).	(B)	Two	examples	of	TAL-R	T-ALL	upregulat-
ed	lncRNAs	that	are	also	upregulated	in	TAL-R	T-ALL	as	compared	to	their	healthy	donor	counterparts.	
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the	CD4+CD8+	subsets	(Figure	5C,	Supplemen-
tary	Table	4),	with	15	of	these	also	in	the	top	
50	 upregulated	 lncRNAs	 in	TAL-R	 T-ALL	 (Fig-
ure	5D).		
Comparison	 of	 poly(A)	 and	 total	 RNA	 se-
quencing	data	sets	for	unannotated	lncRNAs	
As	 a	 last	 part	 of	 this	 study,	 we	 evaluated	
whether	 additional	 information	 can	 be	 ob-
tained	on	lncRNA	expression	profiles	of	T-ALL	
samples	by	means	of	 total	RNA-seq	 (with	 ri-
bodepletion)	 as	 compared	 to	 poly(A)	 RNA-
seq.	A	first	 incentive,	 is	 that	several	 lncRNAs	
do	 not	 have	 a	 poly(A)	 tail,	 so	 these	 will,	 by	
definition,	 not	 be	 detected	 by	 poly(A)	 RNA-
seq.	It	should	however	be	stated	that	we	de-
tect	some	known	non-poly(A)	genes	(ex.	his-
tone	 genes	 and	 MALAT1	 lncRNA)	 in	 our	
poly(A)	 dataset	 as	 some	 random	 priming	
might	occur	during	 library	preparation,	how-
ever	 these	genes	are	only	detected	at	a	 low	
ratio.	 One	 disadvantage	 of	 total	 RNA-seq	 is	
the	cost,	as	 the	sequencing	depth	should	be	
increased,	 to	 correct	 for	 the	 reads	mapping	
to	introns	of	mRNAs.	
We	performed	a	pilot	study	with	25	samples	
(5	immature,	10	TLX1/3,	5	TAL-R	and	5	HOXA	
overexpressing	 T-ALL	 cases)	 also	 profiled	 by	
poly(A)	RNA-seq.	 The	average	 read	depth	of	
the	total	RNA-seq	was	103	million	reads,	with	
45	million	 reads	mapping	 to	Gencode	 (v23).	
To	perform	an	optimal	 comparison	between	
both	technologies,	we	also	selected	only	the	
matching	 25	 samples	 out	 of	 our	 poly(A)	 da-
taset.	 The	 same	mapping	 and	 analysis	 were	
performed	as	described	above	and	this	led	to	
the	 identification	of	1108	novel	multi-exonic	
genes	with	a	log2(TPM)	expression	level	of	at	
least	0.1	in	5	samples	for	the	poly(A)	dataset	
and	1288	for	the	total	RNA-seq	dataset.	Pro-
tein	 coding	 potential	 calculation	 (CPC22)	 fur-
ther	 identified	 712	 novel	 lncRNAs	 in	 the	
poly(A)	data	and	831	novel	lncRNAs	in	the	to-
tal	 RNA-seq	 data,	 with	 an	 overlap	 of	 611	
lncRNAs	(Figure	6,	Supplementary	Table	5).	In	
this	 respect,	 it	 might	 be	 interesting	 to	 per-
form	 total	RNA-seq	as	 it	detects	more	novel	
lncRNAs	than	poly(A)	RNA-seq.	If	we	also	look	
at	 the	annotated	mRNAs	and	 lncRNAs	 in	the	
Gencode	 database,	 we	 also	 detect	 more	
genes	 in	 total	 RNA-seq	 after	 a	 background	
correction	 (more	 than	 four	 reads	 in	 at	 least	
two	 samples	 of	 one	 T-ALL	 subtype).	 With	
poly(A)	RNA-seq	we	detected	15,858	protein	
coding	genes	and	4,720	lncRNAs	and	with	to-
tal	 RNA-seq	 there	were	 16,388	 protein	 cod-
ing	 genes	 and	 5,759	 lncRNAs.	 A	 pairwise	
comparison	 between	 the	 samples	 also	 re-
vealed	 that	 total	 RNA-seq	 detected	 signifi-
cantly	more	mRNAs	and	lncRNAs	with	4	reads	
or	more	(Students	t-test,	p-value	<	0.001	for	
both	mRNAs	and	 lncRNAs).	So	total	RNA-seq	
does	 not	 only	 detect	more	novel	 genes,	 but	
also	more	known	genes.		
Figure	6.	Total	RNA-sequencing	detects	more	previ-
ously	 unannotated	 lncRNAs	 compared	 to	 poly(A)	
RNA-seq.	Venn	 diagram	 representing	 the	amount	 of	
previously	 unannotated	 lncRNAs	 detected	 by	 both	
methods.	
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DISCUSSION	
T-ALL	 genetic	 subtypes	 have	 already	 been	
linked	 in	 the	 past	 to	 specific	 mRNA	 profiles	
and	more	 recently	our	 research	 team	estab-
lished	 subgroup	 specific	 lncRNA	 expression	
profiles	by	micro-array	technology1,	2,	5.	In	this	
study,	 we	 profiled	 gene	 expression	 of	 60	 T-
ALL	patient	samples	divided	over	the	several	
subtypes	 by	 poly(A)	 RNA-sequencing.	 First,	
we	could	confirm	that	patients	from	a	specif-
ic	subtype	cluster	together	by	their	gene	ex-
pression	 profiles,	 either	 for	 mRNAs	 or	 for	
lncRNAs	and	defined	an	updated	lncRNA	sig-
nature	for	the	subtypes	(Figure	1).	By	using	a	
publically	 available	 unstranded	 poly(A)	 RNA-
seq	dataset	of	T-ALL	cell	 lines,	we	could	also	
verify	 the	expression	of	 the	 subtype	 specific	
lncRNAs	in	matching	T-ALL	cell	lines.	Most	of	
the	 denoted	 signatures	 were	 linked	 to	 the	
subtype	 specific	 cell	 lines,	 however	 there	
were	 some	 exceptions	 (Figure	 2).	 These	 ex-
ceptions	might	be	due	to	the	different	nature	
of	the	RNA-sequencing	datasets,	as	our	T-ALL	
patient	 cohort	 was	 a	 stranded	 poly(A)	 da-
taset	and	the	publicly	available	T-ALL	cell	line	
data	 was	 unstranded.	 Furthermore,	 using	
poly(A)	 RNA-seq	 data	 of	 healthy	 donor	 thy-
mocytes	 we	 could	 identify	 ectopically	 ex-
pressed	 subtype	 specific	 lncRNAs	 for	 imma-
ture	T-ALL	and	TAL-R	T-ALL	(Figure	5)	
We	could	compare	this	dataset	with	the	pre-
viously	 published	 micro-array	 data5,	 as	 the	
same	 patient	 cohort	 was	 used.	 For	 protein	
coding	 genes,	 there	 was	 a	 big	 overlap	 be-
tween	 the	 2	 datasets	 and	 for	 this	 analysis,	
poly(A)	RNA-sequencing	did	not	 immediately	
give	 an	 advantage.	However,	 it	might	 be	 in-
teresting	 to	 check	 this	 poly(A)	 dataset	 for	
specific	 transcripts	 or	 splicing	 variants	 of	
mRNAs	present	in	the	subtypes,	but	this	falls	
beyond	 the	 scope	 of	 this	 paper.	 In	 terms	 of	
lncRNAs,	 the	overlap	between	both	datasets	
was	 quite	 difficult	 and	 we	 could	 only	 com-
pare	 a	 small	 amount	 of	 lncRNAs.	 Still,	 there	
was	 quite	 some	 overlap	 between	 both	 sub-
type	specific	signatures.	Remarkably,	lncRNAs	
that	 were	 denoted	 as	 significant	 by	 both	
methods	 had	 a	 larger	 fold	 change	 in	 the	
poly(A)	 RNA-seq	 dataset.	 This	 could	 imply	
that	 poly(A)	 RNA-seq	 has	 the	 possibility	 to	
better	 determine	 the	 differential	 expression	
for	 lncRNAs	 than	 micro-arrays	 have	 (Figure	
3).	
Another	 advantage	 of	 poly(A)	 RNA-
sequencing	over	micro-array	data	 is	the	pos-
sibility	 to	detect	novel,	unanotated	 lncRNAs.	
This	 can	 be	 very	 interesting,	 as	 lncRNAs	 are	
known	to	be	 tissue	or	even	cell-type	specifi-
cally	 expressed	 at	 rather	 low	 levels.	 This	
could	 imply	that	 lncRNAs	with	a	specific	role	
in	T-cell	development	or	T-ALL	(subtype	spe-
cific)	oncogenesis	have	not	been	detected	by	
any	 other	 RNA-seq	 study.	 In	 our	 poly(A)	 da-
taset	 of	 60	 T-ALL	 samples,	we	 detected	 526	
potential	 novel	 interesting	 lncRNAs,	 that	
were	not	present	in	Gencode	(v23),	Ensemble	
(v81)	RefSeq	(v78)	and	lncipedia	(v3.1)13,	14,	19-
21.	Other	criteria	we	took	 into	account	 is	the	
expression	 level	 (at	 least	 4	 reads	 in	 5	 sam-
ples),	 the	 need	 for	 a	 splicing	 event	 and	 no	
protein	 coding	 potential	 (calculated	 with	
CPC22).	It	should	be	noted	that	unspliced,	sin-
gle-exon	 transcripts	 might	 also	 be	 interest-
ing,	as	they	can	for	example	be	linked	to	the	
class	 of	 enhancer	 RNAs23.	 Several	 novel	
lncRNAs	 are	 also	 subtype	 specifically	 ex-
pressed	 and	 are	 even	 present	 in	 the	 top	 50	
most	 significant	 lncRNAs	 (annotated	 and	
novel)	 for	 a	 subtype	 (Figure	 4).	 However,	 it	
should	be	 interesting	 to	also	add	CAGE	 (Cap	
Analysis	 Gene	 Expression)	 data	 and	 histone	
marks	 (ex.	 H3K4me3	 for	 active	 promoters	
and	H3K27ac	for	enhancers)	to	further	identi-
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fy	these	novel	lncRNAs	and	to	claim	that	the-
se	are	independent	transcripts.	
We	also	set	up	a	pilot	 study	with	25	patient	
samples	 to	 test	 if	 total	 RNA-sequencing	
would	give	an	extra	benefit	over	poly(A)	RNA-
seq	 to	 detect	 lncRNAs	 in	 T-ALL.	 With	 total	
RNA-sequencing,	more	known	protein	coding	
genes	 and	 lncRNAs	 were	 detected	 and	 we	
could	 also	 show	 that	more	 novel	 previously	
unannotated	 lncRNAs	 were	 detected.	 Fur-
thermore,	total	RNA-seq	could	be	interesting	
to	 possibly	 detect	 circular	 RNAs24	 or	 other	
non	poly-adenylated	RNA	transcripts	 (for	ex.	
snoRNAs).		
With	 this	 study,	we	updated	 the	 lncRNA	sig-
natures	 of	 T-ALL	 subtypes	 by	 poly(A)	 RNA-
sequencing	and	could	show	that	poly(A)	RNA-
seq	 has	 an	 advantage	 over	 the	 previously	
used	micro-array	 profiling.	 Next	 to	 that,	 we	
also	 identified	 several	 novel,	 previously	 un-
annotated	 lncRNAs	 that	 could	be	of	 interest	
for	further	analysis	as	they	might	be	lncRNAs	
that	are	only	expressed	in	a	T-ALL	context.			
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SUPPLEMENTARY	FIGURES	
	
	
	
	
Supplementary	Figure	1.	Subtype	specific	expression	pattern	of	mRNAs	detected	by	poly(A)	RNA-seq	of	60	T-
ALL	 patients	 samples.	 (A)	 Principal	 Component	 Analysis	 for	 the	 mRNAs	 detected	 by	 poly(A)	 RNA-seq.	 (B)	
Heatmap	representing	the	top	50	most	differentially	expressed	mRNAs	for	each	subtype	in	comparison	to	the	
others	(p.adj	<	0.05).	
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Supplementary	Figure	2.	Unsupervised	clustering	of	T-ALL	patient	samples	divides	the	samples	according	
to	 subtype.	 (A)	Hierarchical	 clustering	 of	 the	 1000	mRNAs	with	 the	 highest	 standard	 deviation	 over	 all	
samples.	(B)	Hierarchical	clustering	of	the	1000	lncRNAs	with	the	highest	standard	deviation	over	all	sam-
ples.	
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Supplementary	 Figure	 3.	 Poly(A)	 RNA-seq	 of	 T-ALL	 cell	 lines.	Density	plots	of	 lncRNA	expression	 in	 the	
DND-41	and	ALL-SIL	 cell	 line,	 as	cell	 lines	 representative	 for	 the	TLX1/3	 subgroup	and	the	PF-382,	KE-37	
and	CCRF-CEM	cell	lines		for	the	TAL-R	subgroup.	The	vertical	bars	represent	the	top	10	lncRNAs	that	are	
significantly	higher	expressed	in	the	representative	subgroup	compared	to	the	others.	
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Supplementary	Figure	4.	Gene	set	enrichment	analysis	for	the	T-ALL	cell	lines.	Gene	set	enrichment	anal-
ysis	using	the	top	50	lncRNAs	up-	or	downregulated	in	the	respective	genetic	T-ALL	subgroups	as	gene	sets	
within	a	panel	of	T-ALL	cell	lines.	
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Supplementary	Figure	5.	Poly(A)	RNA-seq	has	no	major	advantage	over	micro-array	data	for	subtype	specific	
mRNA	detection.	(A)	Overview	of	the	amount	of	subtype	specific	mRNAs	detected	only	by	micro-array	profiling	
(dark	 blue),	 only	 by	 RNA-sequencing	 (light	 blue)	 or	 by	 both	methods	 (red).	 (B)	 Comparison	 between	micro-
array	profiling	and	RNA-sequencing	of	 the	fold	 change	detected	for	 the	 significant	mRNAs	 identified	by	both	
methods.	The	red	line	represents	the	distribution	if	the	fold	change	would	be	equal	(x=y).	
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ABSTRACT	
T-cell	acute	lymphoblastic	leukemia	(T-ALL)	is	a	genetically	heterogeneous	disease	that	can	be	
classified	 into	different	molecular	genetic	 subtypes	according	 to	 their	mRNA	gene	expression	
profile.	In	this	study,	we	applied	RNA	sequencing	to	investigate	the	full	spectrum	of	miRNA	ex-
pression	in	primary	T-ALL	patient	samples,	T-ALL	leukemia	cell	lines	and	healthy	donor	thymo-
cytes.	Notably,	this	analysis	revealed	that	genetic	subtypes	of	human	T-ALL	also	display	unique	
miRNA	expression	signatures,	which	are	largely	conserved	in	human	T-ALL	cell	lines	with	corre-
sponding	genetic	background.	Furthermore,	 small	RNA-sequencing	also	unraveled	 the	variety	
of	isoforms	that	are	expressed	for	each	miRNA	in	T-ALL	and	showed	that	a	significant	number	
of	miRNAs	are	actually	represented	by	an	alternative	isomiR.	Finally,	comparison	of	CD34+	and	
CD4+CD8+	healthy	donor	thymocytes	and	T-ALL	miRNA	profiles	allowed	identifying	several	novel	
miRNAs	with	putative	oncogenic	or	tumor	suppressor	functions	in	T-ALL.	Altogether,	this	study	
provides	a	comprehensive	overview	of	miRNA	expression	in	normal	and	malignant	T-cells	and	
sets	the	stage	for	functional	evaluation	of	novel	miRNAs	in	T-ALL	disease	biology.		
	
INTRODUCTION	
T-cell	acute	lymphoblastic	leukemia	(T-ALL)	is	
an	aggressive	hematological	malignancy	 that	
is	 classified	 into	 different	 genetic	 subtypes	
based	 upon	 the	 aberrant	 expression	 of	 spe-
cific	 transcription	 factor	 oncogenes	 (TAL,	
TLX1,	TLX3	or	HOXA)	or	the	arrest	at	a	specif-
ic	stage	of	T-cell	differentiation	(immature	T-
ALL).1-4	 Notably,	 these	 molecular	 subgroups	
are	 characterized	by	unique	mRNA	and	 long	
noncoding	RNA	expression	signatures,	which	
partially	reflect	their	putative	cell	of	origin.1,	2,	
5	
MicroRNAs	 (miRNAs)	 are	 short	 noncoding	
RNAs	 that	 function	 as	 post-transcriptional	
repressors	of	specific	target	genes.6,	7	Several	
studies	 have	 previously	 described	 a	 role	 for	
miRNAs	 in	 malignant	 T-cell	 transformation,	
including	 the	 identification	of	both	an	onco-
genic	 (miR-19b,	 mir-20a,	 miR-26a,	 miR-92	
and	miR-223)	8	as	well	as	a	tumor	suppressor	
(miR-150,	 miR-155,	 miR-200	 and	 miR-193b-
3p)	9,	10	miRNA	network	involved	in	T-ALL	dis-
ease	 biology.	 However,	 studies	 that	 ad-
dressed	 the	 role	 of	miRNAs	 in	 human	 T-ALL	
have	 largely	been	focused	on	previously	rec-
ognized	miRNA	molecules	as	they	consistent-
ly	used	RT-qPCR	or	microarrays	as	detection	
platforms.	
More	 recently,	 small	 RNA-sequencing	
emerged	 as	 a	more	 comprehensive	 technol-
ogy	 that	 enables	 unbiased	 detection	 of	 the	
full	 spectrum	of	small	RNA	molecules.	 In	ad-
dition,	it	also	provides	information	on	specific	
isoforms	 that	 differ	 from	 canonical	 miRNAs	
by	 the	 addition	 or	 deletion	 of	 one	 or	 more	
nucleotides	 at	 the	 5’	 or	 3’	 end	 of	 the	
miRNA.11,	 12	 Notably,	 this	 heterogeneity	 in	
miRNA	sequences,	which	is	thought	to	result	
from	 RNA-editing,	 exonuclease	 activity	 or	
imprecise	 cleavage	 by	DICER	 or	DROSHA	 (ri-
bonucleases	 involved	 in	 the	 miRNA	 pro-
cessing)	 13,	 could	 be	 functionally	 relevant	 as	
shown	for	a	number	of	miRNAs.14-17	
Here,	 we	 used	 small	 RNA-sequencing	 to	
study	 the	 full	 spectrum	 of	 miRNAs	 that	 are	
expressed	 in	 human	 T-ALL	 samples.	 We	
demonstrate,	for	the	first	time,	that	molecu-
lar	 genetic	 subtypes	 of	 human	 T-ALL	 are	
characterized	 by	 unique	 miRNA	 expression	
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signatures,	 delineate	 the	 pattern	 of	 miRNA	
isoforms	 that	 are	 expressed	 in	malignant	 T-
cells	 and	 use	 small	 RNA	 sequencing	 profiles	
of	normal	T-cell	subsets	to	identify	novel	pu-
tative	 oncogenic	 or	 tumor	 suppressive	 miR-
NAs	in	the	context	of	human	T-ALL.		
MATERIALS	AND	METHODS	
Study	design	
Small	RNA-sequencing	was	performed	on	48	
primary	 T-ALL	 patient	 samples,	 7	 T-ALL	 cell	
lines	 and	 2	 CD34+	 and	 2	 CD4+CD8+	 healthy	
donor	 thymocyte	 subsets,	 to	 profile	 the	 full	
T-ALL	miRNA	transcriptome	(Figure	1a).	
Primary	human	T-ALL	patient	samples	and	T-
ALL	cell	lines	
Blood	 samples	 and	 bone	 marrow	 lympho-
blast	from	T-ALL	patients	were	collected	after	
informed	 consent	 according	 to	 the	 Declara-
tion	 of	 Helsinki	 from	 Saint-Louis	 Hospital,	
Paris,	 France.	 This	 study	 was	 approved	 by	
both	 the	 Institut	 Universitair	 d’Hématologie	
Institutional	 Review	 Board	 and	 the	 Ethical	
Committee	of	Ghent	University	Hospital.	To-
tal	RNA	was	isolated	using	the	miRNeasy	mini	
kit	 (Qiagen).	These	samples	are	part	of	a	co-
hort	previously	 investigated	by	mRNA	18	and	
lncRNA	 profiling.5,	 19	 The	 T-ALL	 cell	 lines	
LOUCY,	 DND-41,	 HPB-ALL,	 ALL-SIL,	 PF-382	
and	JURKAT	were	purchased	from	DSMZ.	KE-
37	was	a	kind	gift	from	the	Cools	lab.		
Thymocyte	subset	selection	
Thymus	tissue	was	derived	from	children	un-
dergoing	 cardiac	 surgery	 (UZ	Gent)	 and	was	
obtained	 and	 used	 according	 to	 the	 guide-
lines	 of	 the	 Medical	 Ethical	 Commission	 of	
Ghent	 University	 Hospital	 (Ghent,	 Belgium).	
Both	 thymocyte	 subsets	 were	 each	 purified	
from	two	different	healthy	donors	in	order	to	
obtain	 two	 independent	 replicates	 for	 each	
subset.	 Immature	 CD34+	 thymocytes	 were	
purified	 based	 on	 MACS	 purification	 using	
CD34	 microbeads	 (Miltenyi	 Biotec)	 20	 while	
CD4	 and	 CD8	 labeling	 was	 used	 to	 sort	 the	
CD4+CD8+	 double	 positive	 subset	 using	 a	
FACSAriaIII	 (BDBiosciences).21	 The	 purity	 of	
each	subset	was	at	least	98%.	Total	RNA	was	
isolated	 using	 the	 miRNeasy	 mini	 kit	 (Qi-
agen).	
MicroRNA	 profiling	 by	 small	 RNA-
sequencing	
The	 libraries	 for	 small	 RNA-sequencing	were	
prepared	using	 the	TruSeq	small	RNA	 library	
kit	 from	 Illumina	with	50	ng	of	 total	RNA	as	
input	 for	 T-ALL	 samples	 and	 100	 ng	 of	 total	
RNA	as	 input	 for	T-ALL	cell	 lines	and	 thymo-
cyte	subset	samples.	According	to	the	manu-
facturer’s	 use,	 3’	 and	 5’	 RNA	 adapters	were	
ligated	to	the	RNA	followed	by	reverse	tran-
scription	 and	 PCR	 amplification	 (with	 bar-
coded	primers).	The	PCR	products	were	sepa-
rated	using	 a	Pippin	Prep	 System	 to	 recover	
the	147	nt	 and	157	nt	 fractions.	 Sequencing	
of	the	small	RNA	libraries	was	performed	on	
a	NextSeq500	 (Illumina),	with	 an	 average	 of	
14.4	 million	 reads	 per	 sample.	 After	 read	
quality	 control	 and	 adapter	 trimming,	 reads	
were	 mapped	 to	 the	 reference	 genome	
(GRCh38)	 using	 Bowtie.22	 Raw	 data	 files	 are	
submitted	 into	the	GEO	database	23	with	ac-
cession	number	GSE89978.	
Differential	expression	analysis	
MicroRNA	expression	data	was	filtered	with	a	
background	correction	that	only	retained	mi-
RNAs	detected	by	at	 least	4	reads	 in	at	 least	
60	%	of	samples	from	one	T-ALL	subgroup	or	
in	 at	 least	 all	 samples	 from	 one	 thymocyte	
subset.	 Differential	 expression	 analysis	 was	
performed	using	the	DESeq2	algorithm	in	R.24	
The	expression	was	normalized	using	de	Var-
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iance	 Stabilizing	 Transformation	 from	 the	
DESeq2	algorithm.		
RESULTS	
Small	RNA-sequencing	of	T-ALL	patient	sam-
ples,	 healthy	 donor	 thymocytes	 and	 T-ALL	
cell	lines		
To	 study	 the	 full	 spectrum	 of	 miRNAs	 in-
volved	 in	normal	and	malignant	T-cell	devel-
opment,	 we	 performed	 small	 RNA-
sequencing	on	48	primary	T-ALL	patient	sam-
ples	 of	 different	 T-ALL	 subgroups	 (13	 imma-
ture,	 14	 TLX1+	 or	 TLX3+,	 15	 TAL-rearranged	
and	 6	 HOXA-overexpressing	 T-ALL	 samples),	
CD34+	and	CD4+CD8+	normal	thymocyte	sub-
sets	from	healthy	donors	and	a	panel	of	7	T-
ALL	cell	lines	(Figure	1a).	While	1816	miRNAs	
were	initially	detected	in	the	total	panel	of	T-
ALL	patient	samples,	we	further	only	consid-
Fig	1.	Small	RNA-sequencing	of	T-ALL	samples,	healthy	thymocytes	and	cell	lines	detects	novel	T-ALL	miRNAs	and	
isomiRs.	(a)	Overview	of	samples	profiled	by	small	RNA-sequencing.	(b)	Dot	plot	representing	the	mean	normalized	
expression	 levels	of	all	574	miRNAs	detected	by	small	RNA-sequencing	of	the	48	T-ALL	patient	samples.	Each	dot	
represents	one	miRNA	and	the	miRNAs	are	ranked	from	highest	to	lowest	mean	expression.	Black	dots	are	miRNAs	
that	were	already	detected	by	a	qRT-PCR	platform	from	previous	studies.	Red	dots	are	the	novel	miRNAs	detected	
in	T-ALL	samples.	(c)	Bar	plot	visualizing	the	distribution	of	the	miRNAs	by	means	of	the	amount	of	isomiRs	they	are	
represented	by.	(d)	Correlation	plot	between	the	mean	expression	level	of	the	miRNAs	and	their	amount	of	isomiR	
forms.	(e)	Table	representing	the	isomiR	form	that	was	represented	by	the	highest	expression	level	for	each	of	the	
detected	miRNAs.	The	first	column	denotes	the	5’	overhangs	or	deletions,	the	second	column	the	3’	overhang	or	
deletions	of	the	isomiR	in	comparison	to	the	canonical	miRNA.	The	third	column	shows	the	amount	of	miRNAs	of	
which	the	highest	expressed	miRNA	had	that	isomiR	form.	(Graphics	from	www.somersault1824.com)	
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ered	 the	 574	 miRNAs	 for	 which	 four	 reads	
were	present	in	at	least	60%	of	patients	from	
one	T-ALL	subtype	(Figure	1b).		
Given	that	for	this	same	T-ALL	patient	cohort	
miRNA	 expression	 profiling	 was	 done	 previ-
ously	using	an	RT-qPCR	approach	10,	we	were	
able	 to	 directly	 compare	 the	 absolute	 num-
ber	 of	 detected	 miRNAs	 between	 the	 RT-
qPCR	 and	 small	 RNA-sequencing	 platforms.	
Using	a	similar	background	selection	as	men-
tioned	above,	283	miRNAs	were	detected	by	
RT-qPCR	 10,	 which	 reflects	 about	 half	 of	 the	
miRNA	 transcripts	 that	 were	 identified	 by	
small	 RNA-sequencing.	 Next,	 we	 converted	
the	 miRNA	 annotation	 of	 the	 RT-qPCR	 plat-
form	 to	 the	most	 recent	 annotation	 in	miR-
Base	 by	 using	 the	miRBaseTracker	 25,	 which	
resulted	in	248	unique	miRNAs.	There	was	an	
overlap	 of	 198	 miRNAs	 with	 small	 RNA-
sequencing,	 implying	 that	 the	 RT-qPCR	 also	
detects	50	miRNAs	 that	were	not	present	 in	
the	small	RNA-sequencing	dataset.	
In	Figure	1b,	the	mean	expression	values	for	
the	 574	 miRNAs,	 detected	 by	 small	 RNA-
sequencing	 in	 primary	 T-ALL	 patients,	 are	
plotted,	with	the	black	dots	representing	the	
280	 miRNAs	 that	 were	 previously	 identified	
by	 RT-qPCR	 and	 the	 red	 dots	 representing	
the	miRNAs	detected	 for	 the	 first	 time	 in	 T-
ALL	 samples.	 Most	 of	 the	 formerly	 known	
miRNAs	 reside	 amongst	 the	most	 highly	 ex-
pressed	 in	human	T-ALL	 (Figure	1b).	Howev-
er,	some	of	the	newly	T-ALL	identified	miRNA	
transcripts	 also	 show	a	 very	 high	 expression	
pattern	 (the	 top	 10	 of	 highest	 expressed	
novel	 miRNAs	 are	 annotated	 in	 Figure	 1b),	
suggesting	that	they	might	possess	oncogenic	
potential	in	the	context	of	T-ALL	disease	biol-
ogy.	 Nevertheless,	 the	 average	 expression	
level	of	most	novel	 T-ALL	miRNAs	 that	were	
exclusively	 detected	 by	 small	 RNA-
sequencing	is	median	to	low.		
Small	 RNA-sequencing	 also	 enables	 the	 de-
tection	 of	 so-called	 isomiRs,	 i.e.	 miRNA	
isoforms	 that	deviate	 from	the	canonical	 se-
quence	by	one	or	a	few	nucleotide(s).11,	12	 In	
our	small	RNA-sequencing	dataset,	we	identi-
fied	 2139	 isomiRs	 covering	 481	 different	
miRNAs,	 losing	 some	 very	 low	 expressed	
miRNAs	 from	 the	 analysis	 above.	 	 Although	
154	 miRNAs	 were	 only	 represented	 by	 one	
isomiR,	 some	 others	 showed	 expression	 of	
more	 than	10	different	 isomiR	 forms	 (Figure	
1c).	 We	 observed	 a	 positive	 correlation	 be-
tween	the	number	of	 isomiRs	detected	for	a	
specific	 miRNA	 and	 its	 expression	 level	 in	
human	T-ALL	(r	=	0.89,	Figure	1d).	For	exam-
ple,	 we	 detected	 39	 different	 isomiR	 forms	
for	miR-181a-5p,	 the	miRNA	 that	 shows	 the	
highest	average	expression	in	T-ALL.	Remark-
ably,	for	106	out	of	481	miRNAs,	the	canoni-
cal	miRNA	was	 not	 expressed	 in	 our	 patient	
series.	 In	 addition,	 for	 only	 half	 of	 the	miR-
NAs	 (246	 out	 of	 481),	 the	 canonical	 isoform	
showed	the	highest	expression	level,	suggest-
ing	that	a	substantial	amount	of	miRNAs	are	
mainly	 represented	 by	 alternative	 isomiRs.	
The	 distribution	 of	 isomiRs	 that	 show	 the	
highest	expression	 for	each	miRNA	 is	 shown	
in	Figure	1e.		
Small	 RNA-sequencing	 reveals	 a	 subtype	
specific	 expression	 pattern	 of	 miRNAs	 in	
human	T-ALL	
Previous	 studies	 have	 convincingly	 shown	
that	molecular	genetic	subtypes	of	human	T-
ALL	 display	 unique	 mRNA	 1,	 2	 and	 lncRNA	 5	
expression	signatures.	Here,	we	used	the	574	
miRNAs	 detected	 by	 small	 RNA-sequencing	
to	define	 subtype	 specific	miRNA	expression	
signatures	in	human	T-ALL	(adjusted	p-value		
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Fig	2.	Small	RNA-sequencing	of	primary	T-ALL	samples	reveals	a	subtype	specific	expression	pattern	of	miRNAs.	
(a)	Heatmap	representing	the	top	50	most	significantly	up-	or	downregulated	miRNAs	per	subgroup	 in	compari-
son	to	the	other	subgroups	(adjusted	p-value	<	0.05).	 (b)	PCA-plot	showing	the	distribution	of	the	patient	sam-
ples.	The	different	colors	denote	patient	samples	from	a	different	subgroup.	(c)	Table	representing	the	selection	
of	10	miRNAs	per	subgroup.	These	were	the	highest	expressed	miRNAs	that	were	significantly	upregulated	in	that	
subgroup	compared	to	the	other	subgroups.	MiRNAs	denoted	in	red	were	not	detected	by	a	previously	used	qRT-
PCR	platform.	(d)	Density	plots	representing	the	distribution	of	the	miRNA	expression	in	the	LOUCY,	HPB-ALL	and	
JURKAT	cell	 line.	Vertical	bars	show	the	expression	 level	of	the	top	10	miRNAs	selected	for	the	subgroup	these	
cell	lines	represent.	LOUCY	represents	the	immature	T-ALL	subgroup,	HPB-ALL	the	TLX1/3	subgroup	and	JURKAT	
the	TAL-R	subgroup.		
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<	 0.05;	 Figure	 2a;	 Supplementary	 Table	 1).	
Principal	Component	Analysis	confirmed	that	
the	 most	 pronounced	 differences	 in	 miRNA	
expression	 are	 observed	 between	 immature	
and	TAL-R	T-ALL	patient	samples	(Figure	2b).	
The	10	miRNAs	that	show	the	highest	expres-
sion	level	in	each	of	the	genetic	subtypes	are	
shown	in	Figure	2c.	The	miRNAs,	which	were	
not	previously	detected	by	the	RT-qPCR	plat-
form,	are	depicted	in	red	(Figure	2c).	
As	 mentioned	 above,	 small	 RNA-sequencing	
was	also	performed	on	a	panel	of	7	human	T-
ALL	 cell	 lines.	 These	 in	 vitro	 model	 systems	
reflect	most	of	the	different	genetic	subtypes	
of	human	T-ALL	and	included	TLX1/3	positive	
(ALL-SIL,	DND41	and	HPB-ALL),	TAL-R	positive	
(PF-382,	 JURKAT	 and	 KE-37)	 and	 imma-
ture/HOXA	 overexpressing	 (LOUCY)	 tumor	
lines.	 Notably,	 subtype	 specific	 miRNAs,	
which	 were	 identified	 in	 primary	 T-ALL	 pa-
tient	samples,	also	showed	high	expression	in	
the	T-ALL	cell	 lines	 from	their	corresponding	
genetic	 subtype	 (Figure	 2d	 and	 Supplemen-
tary	Figure	1).	Therefore,	the	subtype	specific	
tumor	 lines	 can	 be	 used	 as	 valuable	 in	 vitro	
tools	to	evaluate	the	role	of	specific	miRNAs	
in	the	pathogenesis	of	this	disease.		
MiRNA	 profiling	 of	 normal	 thymocyte	 sub-
sets	 reveals	 oncogenic	 subtype	 specific	
miRNAs	
Small	 RNA-sequencing	 was	 also	 performed	
on	 CD34+	 and	 CD4+CD8+	 normal	 thymocyte	
samples	 from	 two	 healthy	 donor	 controls.	
First,	 DESeq2	 analysis	 revealed	 190	 miRNAs	
that	 show	 significant	 differential	 expression	
between	 these	 CD34+	 and	 CD4+CD8+	 normal	
T-cell	subsets	(126	high	in	CD34+	and	64	high	
in	CD4+CD8+;	adjusted	p-value	<	0.05;	Figure	
3a	and	Supplementary	Table	2).	The	 top	 ten	
most	 significant	 miRNAs	 are	 listed	 in	 Figure	
3b,	 with	 the	 miRNAs	 depicted	 in	 red	 those	
that	 were	 not	 covered	 in	 previous	 RT-qPCR	
analyses.	Of	note,	small	RNA-sequencing	data	
Fig	 3.	 MiRNA	 profiling	 of	 healthy	 thymocyte	 subsets	 reveals	 different	 miRNA	 expression	 profiles	 between	
CD34+	and	CD4+CD8+	subsets.	(a)	Diagonal	plot	showing	the	expression	of	the	miRNAs	in	the	different	thymocyte	
subsets.	Red	dots	represent	miRNAs	that	are	significantly	higher	expressed	in	the	CD34+	subset,	blue	dots	are	the	
miRNAs	significantly	higher	expressed	in	the	CD4+CD8+	subset.	(b)	Top	10	most	significantly	upregulated	miRNAs	
for	 the	CD34+	 subset	and	 for	 the	CD4+CD8+	 subset.	MiRNAs	denoted	 in	 red	were	not	detected	 by	a	previously	
used	qRT-PCR	platform.	(c)	Dot	plots	of	two	representative	miRNAs	for	the	subsets.	**:	significant	difference	with	
an	adjusted	p-value	<	0.001.	
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were	 highly	 concordant	 between	 both	 do-
nors	 for	 each	 subset	 (Figure	 3c	 and	 Supple-
mentary	Figure	2).		
Next,	we	integrated	these	miRNA	expression	
data	obtained	 from	healthy	donors	with	 the	
subtype	specific	miRNAs	that	were	identified	
in	 the	 primary	 T-ALL	 patient	 cohort.	 For	 ex-
ample,	 4	miRNAs	 (hsa-miR-222-3p,	 hsa-miR-
146a-5p,	 hsa-mir-221-3p	 and	 hsa-miR-126-
5p)	 from	the	top	10	 immature	T-ALL	specific	
miRNAs	 (Figure	 2c)	 also	 showed	 significant	
higher	 expression	 in	 CD34+	 vs.	 CD4+CD8+	 T-
cell	 subsets	 (Figure	4a).	Similarly,	 three	miR-
NAs	 (hsa-miR-16-5p,	 hsa-miR-16-2-3p	 and	
hsa-miR-450b-5p)	from	the	top	10	TAL-R	spe-
cific	miRNAs	 (Figure	 2c)	 are	 significantly	 up-
regulated	 in	 CD4+CD8+	 T-cell	 subsets	 (Figure	
4b).	Therefore,	 these	miRNAs	most	probably	
reflect	 the	 specific	 T-cell	 maturation	 arrest	
associated	with	these	molecular	genetic	sub-
types	 of	 T-ALL	 and	 their	 respective	 cell	 of	
origin.		
In	 order	 to	 identify	miRNAs	with	 true	 onco-
genic	 potential	 in	 specific	 T-ALL	 subgroups,	
we	 also	 performed	 differential	 expression	
analysis	between	immature	T-ALLs	and	CD34+	
thymocytes,	 and	 between	 TAL-R	 T-ALLs	 and	
CD4+CD8+	 thymocytes,	 as	 these	 thymocyte	
subsets	represent	the	stage	of	differentiation	
arrest	 during	 T	 cell	 development	 leading	 to	
these	 specific	 T-ALL	 subtypes	 	 (Supplemen-
tary	Tables	3	and	4).	From	the	top	ten	imma-
ture	specific	miRNAs,	three	miRNAs	(hsa-miR-
21-5p,	 hsa-miR-222-3p	 and	 hsa-miR-101-3p)	
were	 significantly	 upregulated	 in	 the	 imma-
ture	 samples	 compared	 to	 the	 healthy	 con-
trol	 CD34+	 samples.	 Remarkably,	 hsa-miR-
222-3p	 was	 also	 significantly	 upregulated	 in	
the	CD34+	subset,	but	its	expression	is	further	
increased	 in	 immature	 T-ALLs	 (Figure	 4c).	
Similarly,	 three	 miRNAs	 (hsa-miR-182-5p,	
Fig	4.	Subtype	specific	miRNAs	can	be	either	oncogenic	or	representative	for	the	differentiation	arrest	of	lym-
phoblasts.	 (a+c)	Box	plots	showing	the	expression	of	the	 immature	T-ALL	specific	miRNAs	hsa-miR-126-5p	and	
hsa-miR-222-3p	in	the	immature	T-ALL	patients	and	the	thymocyte	subsets.	(b+d)	Box	plots	showing	the	expres-
sion	of	the	TAL-R	T-ALL	specific	miRNAs	hsa-miR-16-2-3p	and	hsa-miR-450b-5p	 in	the	TAL-R	T-ALL	patients	and	
the	thymocyte	subsets.	*:	Significant	difference	with	an	adjusted	p-value	<	0.05;	**:	Significant	difference	with	
an	adjusted	p-value	<	0.001.	
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hsa-miR-29c-3p	 and	 hsa-miR-450b-5p),	 from	
the	 TAL-R	 subtype	 specific	 signature,	 show	
significant	 higher	 expression	 in	 the	 TAL-R	 T-
ALLs	 as	 compared	 to	 their	 CD4+CD8+	normal	
counterparts.	Here,	hsa-miR-450b-5p	was	al-
ready	higher	expressed	in	the	CD4+CD8+	dou-
ble	positive	subset,	but	showed	a	further	 in-
crease	 in	 activity	 in	TAL-R	 rearranged	 leuke-
mias	(Figure	4d).		
Small	 RNA-sequencing	 reveals	 putative	 on-
cogenic	miRNAs	in	human	T-ALL		
Finally,	 we	 aimed	 to	 identify	 novel	 T-ALL	
miRNAs	 with	 potential	 oncogenic	 activity	 in	
human	T-ALL	irrespective	of	the	genetic	sub-
types.	 Differential	 expression	 analysis	 be-
tween	 48	 T-ALL	 samples	 and	 four	 normal	
thymocyte	 samples	 (Supplementary	 Table	5)	
resulted	in	the	identification	of	87	significant-
ly	upregulated	miRNAs	and	69	downregulat-
ed	miRNAs	 in	human	T-ALL	 (Figure	5a).	 Sev-
eral	miRNAs	with	a	known	oncogenic	 role	 in	
T-ALL	 8,	26	were	 recovered	 from	 this	 analysis	
and	are	depicted	 in	 Figure	5a.	However	 and	
most	notably,	this	analysis	also	identified	dif-
ferent	 miRNAs,	 which	 were	 not	 previously	
detected	in	the	context	of	normal	and	malig-
nant	T	cell	development,	and	which	could	po-
tentially	act	as	novel	oncomiRs	or	tumor	sup-
pressor	 miRNAs	 involved	 in	 the	 biology	 of	
this	disease	(Figure	5b-c).		
DISCUSSION	
More	than	a	decade	ago,	Ferrando	et	al.	and	
Soulier	 et	 al.	 described	 different	 T-ALL	 sub-
types	 according	 to	 specific	 transcriptional	
profiles.1,	2	 Last	 year,	we	were	 able	 to	 show	
that	 these	 molecular	 genetic	 subtypes	 of	
human	 T-ALL	 also	 display	 unique	 long	 non-
coding	RNA	expression	signatures.5	Here,	we	
performed	 small	 RNA-sequencing	 on	 48	 T-
ALL	patient	samples	to	finalize	the	transcrip-
tional	 characterization	 of	 human	 T-ALL	 by	 a	
comprehensive	analysis	of	miRNA	expression	
in	this	disease.		
Small	RNA-sequencing	enabled	the	detection	
of	twice	as	many	miRNAs	as	compared	to	RT-
qPCR	platforms.10	Although	most	of	the	new-
Fig	5.	Novel	oncogenic	miRNAs	are	detected	by	small	RNA-sequencing.	(a)	Diagonal	plot	showing	the	expression	
of	the	miRNAs	in	T-ALL	compared	to	healthy	donor	thymocytes.	Red	dots	represent	miRNAs	that	are	significantly	
higher	expressed	in	the	T-ALL	patient	samples,	blue	dots	are	the	miRNAs	significantly	higher	expressed	in	thymo-
cyte	 subsets.	 (b)	Top	10	most	 significantly	upregulated	miRNAs	 in	 the	T-ALL	patients	 and	 in	 the	healthy	donor	
samples.	MiRNAs	denoted	in	red	were	not	detected	by	a	previously	used	qRT-PCR	platform.	(c)	Dot	plots	of	two	
representative	miRNAs	from	the	table.	**:	Significant	difference	with	an	adjusted	p-value	<	0.001.	
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ly	 detected	miRNAs	 were	 expressed	 at	 very	
low	 levels,	 we	 also	 identified	 a	 selection	 of	
novel	 T-ALL	 miRNAs	 with	 very	 high	 expres-
sion	levels	in	T-ALL	patient	samples,	including	
hsa-miR-181b-5p,	 hsa-miR-423-3p,	 hsa-miR-
486-5p	 and	 hsa-miR-92b-3p	 (Figure	 1b).	 In-
terestingly,	some	of	these	miRNAs	have	pre-
viously	been	associated	with	malignant	trans-
formation	in	different	tumor	entities.	For	ex-
ample,	 hsa-miR-181b-5p	 is	 a	 known	 onco-
gene	 in	 several	 cancer	 types	 as	 reviewed	by	
Liu	et	al..27	 In	the	context	of	 leukemia,	over-
expression	of	hsa-miR-181b-5p	was	shown	to	
enhance	 proliferation	 in	 acute	 myeloid	 leu-
kemia	by	 targeting	MLK2.	 Furthermore,	hsa-
miR-92b-3p	was	 identified	 as	 an	 oncomiR	 in	
glioblastoma	 by	 targeting	 SMAD3	 (ref.	 28),	
which	is	known	to	be	lost	 in	several	cases	of	
pediatric	T-ALL	(ref.	29),	and	PTEN	(ref.	30),	a	
well-established	 T-ALL	 oncosuppressor.31,	 32	
In	addition,	hsa-miR-92b-3p	is	also	specifical-
ly	 higher	 expressed	 in	 TLX1/3	 T-ALL	 com-
pared	to	the	other	T-ALL	subtypes.	
Interestingly,	 small	 RNA-sequencing	 also	 de-
tects	 deviations	 from	 canonical	 miRNA	 se-
quences.	 Indeed,	our	 analysis	 revealed	2139	
different	isomiR	forms,	corresponding	to	481	
miRNAs.	Remarkably,	for	only	half	of	the	mi-
RNAs,	the	canonical	form	showed	the	highest	
expression	 (Figure	 1e).	 In	 addition,	 most	
highly	expressed	 isomiRs	displayed	modifica-
tions	at	their	3’	end,	suggesting	that	these	al-
terations	 would	 not	 affect	 the	 miRNA	 seed	
sequence	and,	 therefore,	have	no	 functional	
effect	 on	 target	 recognition.	Nevertheless,	 a	
number	of	 studies	have	shown	that	 these	3’	
modifications	might	 impact	 target	 specificity	
and	stability	of	the	miRNA.17,	33	
Finally,	 small	 RNA	 sequencing	 of	 human	
CD34+	and	CD4+CD8+	thymocytes	enabled	the	
identification	 of	 subtype	 specific	 and	 onco-
genic	miRNAs	in	the	context	of	human	T-ALL.	
An	 interesting	 example	 is	hsa-miR-486.	Hsa-
miR-486-5p	 is	 one	 of	 the	 highest	 expressed	
newly	 identified	miRNAs	 in	T-ALL	 (Figure	1b)	
and,	 together	 with	 hsa-miR-486-3p,	 it	 also	
shows	higher	expression	 in	T-ALL	samples	as	
compared	to	healthy	donor	thymocytes.	Hsa-
miR-486-5p	is	an	oncomiR	in	Down	syndrome	
myeloid	 leukemias,	 where	 it	 is	 regulated	 by	
GATA1	 (ref.	 34).	 Hsa-miR-486-3p	 has	 also	
been	linked	to	erythroid	development	down-
stream	of	MYB,	a	known	oncogene	 in	T-ALL,	
and	targeting	MAF	(ref.	35).	
	
Altogether,	this	study	provides	the	first	com-
prehensive	overview	of	miRNA	expression	 in	
molecular-genetic	 subtypes	 of	 human	 T-ALL.	
Integration	 of	 these	 signatures	 with	 miRNA	
expression	 profiles	 in	 normal	 T-cell	 subsets	
provides	 a	 unique	 resource	 to	 study	 novel	
miRNAs	 that	 are	 implicated	 in	 T-ALL	 disease	
biology.		
Supplementary	 tables	 can	 be	 requested	 via		
e-mail.	
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SUPPLEMENTARY	FIGURES	
	
	
	
Supplementary	Figure	1.	Subtype	specific	miRNAs	are	also	represented	in	the	T-ALL	cell	lines.	Density	plots	rep-
resenting	the	distribution	of	the	miRNA	expression	in	the	T-ALL	cell	lines	DND-41,	ALL-SIL,	PF-382	and	KE-37.	Verti-
cal	bars	show	the	expression	level	of	the	top	10	miRNAs	selected	for	the	subgroup	these	cell	lines	represent.	DND-
41	(a)	and	ALL-SIL	(b)	for	the	TLX	subgroup	and	PF-382	(c)	and	KE-37	(d)	for	the	TAL/LMO	subgroup.	
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Supplementary Figure 1. Subtype specific miRNAs are also represented in the T-ALL cell lines. Den-
sity plots representing the distribution of the miRNA expression in the T-ALL cell lines DND-41, ALL-SIL, 
PF-382 and KE-37. Vertical bars show the expression level of the top 10 miRNAs selected for the subgroup 
these cell lines represent. DND-41 (A) and ALL-SIL (B) for the TLX subgroup and PF-382 (C) and KE-37 (D) 
for the TAL/LMO subgroup.
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Supplementary	Figure	2.	miRNA	expression	 is	highly	correlated	 in	2	different	donors.	Scatterplots	representing	
the	log2	normalized	expression	of	the	miRNAs	profiled	by	small	RNA-sequencing	for	2	different	donors	of	CD34+	
thymocytes	(a)	and	CD4+CD8+	thymocytes	(b).	
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Supplementary Figure 2. miRNA expression is highly correlated in 2 different donors. Scatterplots 
representing the log2 normalized expression of the miRNAs profiled by small RNA-sequencing for 2 different 
donors of CD34+ thymocytes (A) and CD4+CD8+ thymocytes (B).
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DISCUSSION	
In	the	past	decades,	the	genetic	basis	of	T-cell	acute	leukemia	has	been	extensively	investigat-
ed,	 first	 by	 cytogenetic	 and	 molecular	 cytogenetic	 techniques	 and	 more	 recently	 by	 next-
generation	 sequencing	 technologies.	 This	 led	 to	 the	 identification	 of	 several	 key	 oncogenic	
driver	mutations	and	allowed	to	identify	several	T-ALL	genetic	subtypes.	Also,	the	identification	
of	the	genes	implicated	in	T-ALL	provided	fundamental	insights	into	the	process	of	normal	and	
perturbed	 thymocyte	differentiation	 and	oncogenesis.	 Importantly,	 this	work	 also	offered	 in-
sights	into	novel	therapeutic	targets.	In	addition	to	protein	coding	genes,	the	role	of	noncoding	
RNAs	in	T-ALL	has	also	received	growing	attention.	Previous	studies	of	the	host	lab	and	others	
have	shed	 light	on	 the	 role	of	multiple	miRNAs	 in	T-ALL	 leukemogenesis.	 In	 this	PhD	thesis,	 I	
aimed	to	further	explore	the	potential	role	of	noncoding	RNAs	in	T-ALL,	including	a	novel	class	
of	noncoding	RNAs,	the	so-called	long	noncoding	RNAs	(lncRNAs)	that	recently	gained	much	in-
terest	in	the	field	of	cancer	research.	
First,	 I	elucidated	the	set	of	 lncRNAs	driven	by	NOTCH1-signaling	both	 in	T-ALL	and	normal	T-
cell	development	(paper	1).	For	this	study,	64	primary	T-ALL	patient	samples	were	profiled	on	a	
custom	designed	micro-array	detecting	the	expression	of	mRNAs	and	lncRNAs.	Secondly,	 I	ex-
plored	this	dataset	in	more	depth	to	unravel	subtype	specific	expression	patterns	of	lncRNAs	in	
those	primary	T-ALLs,	as	it	was	already	described	that	the	distinct	T-ALL	subgroups	are	defined	
by	a	 subtype	 specific	 gene	expression	profile	 (paper	 2).	As	next-generation	 sequencing	 tech-
nologies	 became	 cheaper	 in	 the	 last	 years,	 RNA-sequencing	 is	 now	 the	preferred	 technology	
over	micro-array	gene	expression	profiling.	Because	of	this,	I	reprofiled	60	samples	of	the	pre-
vious	dataset	by	poly(A)	RNA-sequencing	and	25	samples	by	total	RNA-sequencing	to	(1)	define	
a	novel	T-ALL	subtype	specific	lncRNA	expression	profile	and	(2)	compare	technologies	(paper	
3).	We	also	hypothesized	that	there	should	be	a	subtype	specific	expression	pattern	for	some	
miRNAs,	as	they	are	described	to	be	regulated	by	T-ALL	genes	or	to	regulate	T-ALL	genes	them-
selves.	 However,	 previous	 studies	 could	 not	 define	 these	 profiles	 after	 RT-qPCR	 profiling	 of	
miRNA	 expression	 in	 a	 primary	 T-ALL	 patient	 cohort.	 Therefore,	 I	 performed	 small	 RNA-
sequencing	on	48	primary	patient	samples	to	detect	a	broader	range	of	miRNAs	than	previous	
studies	and	with	this	dataset	I	was	then	able	to	find	miRNAs	with	a	specific	expression	in	T-ALL	
patient	subgroups	 (paper	4).	An	overview	of	 the	matching	samples	used	 in	the	different	pro-
jects	can	be	found	in	Figure	11.	
micro-array 1,2
poly(A) RNA-seq 3
total RNA-seq 3
small RNA-seq 4
IMMATURE TLX1/3 TAL-R HOXA
Figure	11.	Overview	of	the	primary	T-ALL	patient	samples	used	in	this	thesis.	The	patient	samples	from	the	same	
cohort	were	used	 to	 study	 the	expression	of	 lncRNAs	 (micro-array,	poly(A)	and	 total	RNA-seq)	and	miRNAs	 (small	
RNA-seq)	in	T-ALL	subtypes.	1,2,3,4:	papers	in	which	these	datasets	are	used.	
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Defining	the	NOTCH1-regulated	lncRNAome	in	T-ALL	
The	NOTCH1-signaling	pathway	 is	of	major	 interest	 in	T-ALL	 research	as	 it	 is	overactivated	 in	
more	 than	 half	 of	 T-ALL	 patients,	 making	 it	 a	 strong	 candidate	 therapeutic	 target1.	 The	
NOTCH1-receptor	is	present	at	the	membrane	of	the	immature	T-cell	and	is	activated	through	
its	ligand(s)	in	the	thymus	microenvironment.	This	leads	to	a	signaling	cascade	necessary	in	the	
first	steps	towards	T-cell	commitment	and	cell	proliferation	in	the	early	stages	of	T-cell	devel-
opment2.	Overactivation	of	this	signaling	pathway	or	 ligand	 independent	signaling	 leads	how-
ever	 to	 the	 uncontrolled	 proliferation	 of	 these	 immature	 thymocytes	 and	 aberrant	 signaling	
through	the	NOTCH1	receptor	has	been	shown	sufficient	to	drive	T-cell	leukemia	development	
in	vivo3.	
Pharmacological	inhibition	of	hyperactive	NOTCH1-signaling	has	been	explored	in	the	past	dec-
ade	by	the	use	of	GSIs	(γ-secretase	inhibitors)	and	has	been	tested	in	the	clinic.	Although	prom-
ising	results	were	obtained	through	 in	vitro	evaluation	of	GSIs,	clinical	trials	have	been	termi-
nated	due	to	gastro-intestinal	toxicity	and	treatment	resistance4,	5.	This	gastro-intestinal	toxicity	
is	 due	 to	 the	 presence	 of	 the	 NOTCH1	 and	 NOTCH2	 receptors	 on	 the	 intestinal	 epithelium,	
which	are	both	targeted	by	GSIs.	In	this	PhD	thesis,	I	used	a	GSI	(Compound	E)	as	a	tool	to	inhib-
it	NOTCH1-signaling	 in	vitro	 in	the	T-ALL	cell	 line	CUTLL1	and	evaluated	the	transcriptional	ef-
fects	on	downstream	lncRNA	expression	(see	paper	1).	Next	to	that,	we	activated	NOTCH	sig-
naling	 in	 CD34+	 T-cells	 by	 growing	 them	 on	 a	 feeder	 layer	 containing	 the	 DLL1-ligand.	 The	
NOTCH1-activated	lncRNAs	were	further	studied	in	different	T-ALL	cell	lines,	T-ALL	patient	sam-
ples	and	T-cell	subsets	that	were	profiled	by	a	custom	designed	micro-array	platform	detecting	
the	 expression	 of	 mRNAs	 and	 lncRNAs.	 Publicly	 available	 ICN1	 (activated	 NOTCH1)	 ChIP-
sequencing	 data	 allowed	 me	 to	 determine	 the	 lncRNAs	 that	 were	 directly	 regulated	 by	
NOTCH1,	of	which	almost	all	also	had	BRD4	and	MED1	binding	and	H3K27	acetylation,	hinting	
towards	a	possible	enhancer	locus.	It	should	however	be	noted	that	some	recent	publications	
question	the	function	of	eRNAs	or	cis-acting	lncRNAs,	as	only	the	act	of	transcription	at	that	lo-
cus	is	important	and	not	the	transcript	itself6,	7.	The	use	of	this	ICN1	ChIP-sequencing	data	could	
also	filter	out	 lncRNAs	that	were	downregulated	after	GSI	treatment	due	to	the	regulation	by	
other	NOTCH	receptors	instead	of	the	NOTCH1	receptor.	The	NOTCH3	receptor	is	also	present	
at	the	T-ALL	cell	membranes,	but	at	lower	levels	than	NOTCH1.	This	could	however	also	lead	to	
an	extra	effect	of	the	GSI,	however	this	is	expected	to	be	modest.	Also	the	other	pathways	that	
could	be	targeted	by	GSIs	(eg.	Beta-Amyloid)	are	not	expressed	in	the	T-ALL	cells.	
Further	in	depth	study	should	give	more	insights	on	the	real	function	and	importance	of	these	
lncRNAs.	By	the	lncRNA	and	mRNA	profiling	of	64	T-ALL	patient	samples,	we	could	perform	the	
so-called	 ‘guilt-by-association’	analysis	 to	 identify	 the	pathways	 these	 lncRNAs	are	 correlated	
with,	 showing	 that	 several	 of	 the	 NOTCH1-activated	 lncRNAs	 might	 be	 involved	 in	 cancer-
related	pathways	or	in	T-cell	development.		
At	the	same	time	of	our	study,	the	Aifantis	lab	(New	York,	USA)	published	the	identification	and	
mechanism-of-action	of	the	T-cell	specific	lncRNA	‘Leukemia	Induced	Noncoding	Activator	RNA	
1’	 (LUNAR1),	 a	NOTCH1-activated	 lncRNA	 that	 regulates	 the	 expression	 of	 IGF1R	 (Insulin-like	
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Growth	Factor	1	Receptor)	in	T-ALL8.	IGF1R	was	previously	identified	as	regulated	by	NOTCH1-
signaling	and	pharmacological	inhibition	of	IGF1R	could	block	the	growth	and	viability	of	T-ALL	
cells9.	LUNAR1	was	also	found	in	our	dataset	as	the	top-candidate	amongst	the	set	of	NOTCH1-
activated	lncRNAs	both	in	the	applied	in	vitro	models	for	T-ALL	and	normal	T-cell	development	
as	well	as	 in	the	dataset	of	the	primary	T-ALL	patient	cohort,	underscoring	the	validity	of	our	
analyses.	The	research	team	of	prof.	Aifantis	could	show	that	there	was	a	physical	interaction	
between	 the	 LUNAR1	 promoter	 and	 an	 active	 enhancer	 in	 the	 last	 intron	 of	 its	 neighboring	
gene	IGF1R.	The	knockdown	of	LUNAR1,	but	not	its	overexpression,	could	modulate	the	IGF1R	
expression,	 showing	 a	 cis-regulatory	 effect.	 Furthermore,	 it	was	 shown	 that	 LUNAR1	was	 in-
volved	in	the	recruitment	of	the	Mediator	complex	and	RNAPII	to	the	IGF1R	enhancer,	leading	
to	increased	IGF1R	expression.		
Briefly	 after	 the	 discovery	 of	 LUNAR1,	 another	 lncRNA	 was	 linked	 to	 the	 NOTCH1-pathway	
(NOTCH1-associated	 lncRNA	 in	 T-ALL	 or	 NALT).	 The	 NALT	 transcript	 is	 bi-directionally	 tran-
scribed	from	the	NOTCH1	locus10.	The	knockdown	of	NALT	in	vitro	and	in	vivo	inhibited	cell	pro-
liferation,	potentially	due	 to	cis-regulation	of	NOTCH1	mRNA	 transcription	as	 it	 showed	a	 re-
duction	in	the	NOTCH1	downstream	targets.	This	study	thus	further	provides	another	example	
that	lncRNAs	might	play	a	crucial	role	in	NOTCH1-driven	signaling.	NALT	knockdown	might	be	a	
novel	 therapeutical	 approach,	 however	 the	 expression	 level	 and	 function	 of	 NALT	 in	 other	
NOTCH1-dependent	tissues	should	be	checked	to	avoid	off-target	effect.	
The	identification	of	lncRNAs	with	a	role	in	NOTCH1-signaling	in	T-ALL	can	also	be	of	interest	for	
other	cancer	types.	NOTCH1	and	other	NOTCH-receptors	have	been	described	as	oncogenes	in	
different	hematological	malignancies,	with	 the	exception	of	acute	myeloid	 leukemia	 (AML)	 in	
which	NOTCH1	plays	a	tumor	suppressive	role11.	Also	in	solid	tumors,	for	example	breast	cancer	
and	lung	adenocarcinoma,	NOTCH1	overactivation	has	been	linked	to	an	increased	proliferation	
and	a	restricted	differentiation12.	In	these	other	cancer	types,	several	groups	have	recently	also	
studied	the	role	of	lncRNAs	in	NOTCH1-signaling.	For	example,	in	glioma,	the	‘Taurine	Upregu-
lated	Gene	1’	(TUG1)	lncRNA	is	activated	by	NOTCH1	and	acts	as	a	sponge	for	miR-145,	increas-
ing	the	expression	of	stemness	related	genes	SOX2	and	MYC.	The	knockdown	of	TUG1	induces	
apoptosis	 in	 glioma	 stem	 cells	 in	 vitro	 and	 could	 inhibit	 tumorigenesis	 in	 vivo	more	 strongly	
than	GSIs13.		
In	this	study,	we	thus	explored	lncRNAs	with	a	potential	role	in	the	NOTCH1-signaling	cascade	
in	malignant	and	normal	T-cell	development.	This	might	aid	in	the	identification	of	novel	drug-
gable	 lncRNAs	 to	 inhibit	 the	 oncogenic	mechanism	 of	NOTCH1	 in	 T-ALL.	One	 example	 is	 LU-
NAR1	that	was	also	put	forward	as	a	valuable	target	in	our	study.		
Unraveling	T-ALL	subtype	specific	expression	of	long	noncoding	RNAs	
Whereas	NOTCH1	mutations	are	recurrent	in	all	T-ALL	patient	subgroups,	key	driver	oncogenes	
have	 been	 described	 that	 define	 the	 signature	 of	 a	 particular	 subtype	 such	 as	 TLX1	 or	 TLX3	
overexpression,	 TAL1-rearrangements	 or	 HOXA	 overexpression.	 These	 oncogenic	 events	 are	
mutually	 exclusive.	 The	 research	 teams	 of	 prof.	 Ferrando	 (NY,	 USA)	 and	 prof.	 Soulier	 (Paris,	
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France)	previously	published	a	detailed	analysis	of	protein-coding	gene	expression	in	primary	T-
ALL	patient	samples	by	micro-array	based	profiling	and	could	show	that	these	expression	pro-
files	clustered	together	according	to	their	oncogenic	driver	event	and	in	the	meantime	revealed	
TLX3	 and	 the	HOXA	 genes	as	novel	T-ALL	oncogenes14,	15.	 These	 subtypes	do	not	only	have	a	
specific	gene	expression	profile,	but	also	resemble	a	specific	stage	of	differentiation	arrest	dur-
ing	T-cell	development.	 In	comparison	to	the	previously	stated	subtypes	with	a	specific	onco-
genic	driver	event,	one	subtype,	immature	T-ALL,	is	solely	identified	by	a	differentiation	arrest	
very	early	during	T-cell	development	at	 the	CD34+	 stage.	Nevertheless,	also	 this	group	of	pa-
tients	shows	a	subtype	specific	clustering	of	mRNA	expression	profiles	compared	to	the	other	
groups14.		
We	hypothesized	that	lncRNA	expression	profiles	in	T-ALL	patients	might	also	allow	to	discrimi-
nate	the	previously	established	T-ALL	subtypes	and	that	subtype	specific	lncRNAs	might	be	po-
tent	candidates	as	novel	players	 in	T-ALL	development.	Therefore,	 I	dissected	 lncRNA	expres-
sion	profiles	obtained	from	64	primary	T-ALL	patients	by	means	of	a	custom	in-house	designed	
micro-array	platform	 (paper	 2).	 This	was	 the	 first	 time	 that	 a	 large	T-ALL	patient	 cohort	was	
profiled	for	lncRNA	expression	and	the	first	time	that	a	comprehensive	study	was	performed	on	
the	lncRNA	expression	in	T-ALL	subtypes.	Next	to	that,	I	also	had	access	to	expression	profiles	
of	healthy	donor	T-cells	from	the	CD34+	or	CD4+CD8+	subsets	as	controls.		
First,	I	validated	our	dataset	from	the	primary	T-ALL	cohort	by	evaluating	known	subset	specific	
expression	patterns	of	protein	coding	genes.	One	disadvantage	of	our	dataset	appeared	to	be	
the	underrepresentation	of	HOXA-overexpressing	cases	(7	out	of	64)	making	it	more	difficult	to	
identify	genes	up-	or	downregulated	for	this	subtype.	Nevertheless,	several	HOXA-genes	were	
identified	as	 significantly	upregulated	 in	 the	HOXA	 subtype.	Repeating	 the	 same	analyses	 for	
the	 lncRNAs	detected	on	 the	micro-array	platform,	 also	 allowed	 to	detect	 a	 subtype	 specific	
expression	pattern,	but	with	only	a	small	amount	of	 lncRNAs	 in	 the	HOXA	signature.	Further,	
mRNA	 and	 lncRNA	 expression	 profiles	 of	 different	 T-ALL	 cell	 lines,	 linked	 to	 the	 immature,	
TLX1/3	or	TAL-R	 subtype	were	also	 included	allowing	 to	validate	 in	 those	 in	vitro	models	 the	
subtype	specific	 lncRNA	expression	patterns	 identified	 from	patient	samples.	Finally,	by	using	
the	 expression	 profiles	 of	 healthy	 donor	 T-cell	 subsets,	 I	 could	 identify	 specific	 oncogenic	
lncRNAs	for	the	 immature	T-ALL	subtype	(compared	to	CD34+	T-cell	subsets)	and	for	TAL-R	T-
ALL	(compared	to	CD4+CD8+	T-cell	subsets).	
Similar	as	to	our	study,	also	in	other	leukemias	lncRNA	expression	patterns	could	be	identified	
by	micro-array	profiling	and	linked	to	a	specific	subtype.	For	example,	Garzon	et	al.	could	cou-
ple	 the	expression	of	 lncRNAs	 to	a	 specific	mutation	status	of	AML	 (acute	myeloid	 leukemia)	
samples	and	identified	a	48	lncRNA	signature	that	was	related	to	event	free	survival16.	Also	in	
AML,	Diaz-Beya	et	al.	revealed	a	subtype	specific	lncRNA	expression	profile	and	could	link	the	
transcription	factor	GATA2	to	the	lncRNAs	of	the	t(8;16)	subtype17.	In	B-ALL,	it	was	shown	that	
the	 subtypes	 defined	 by	 mRNA	 profiling	 had	 specific	 lncRNA	 expression	 profiles	 and	 these	
lncRNA	profiles	could	also	predict	the	subtype	of	a	validation	cohort.	Furthermore,	they	identi-
fied	BALR-2		(‘B-ALL	associated	long	RNA-2’)	as	an	lncRNA	linked	to	poor	prognosis	and	reduced	
prednisone	 treatment	 response18.	Quite	 remarkably,	based	on	 lncRNA	expression	profiling,	 it	
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was	shown	that	the	expression	of	only	two	lncRNAs	could	form	a	risk	model	in	CLL19.	Also	in	sol-
id	tumors	lncRNA	expression	followed	the	known	subtypes	and	the	lncRNA	expression	profiles	
could	be	linked	to	prognosis	(as	recently	reviewed	by	Flippot	et	al.20).	
Micro-arrays	were	the	method	of	choice	for	gene	expression	profiling	for	many	years,	but	more	
recently	RNA-sequencing	has	become	the	golden	standard	as	both	sequencing	and	data	mining	
has	become	robust	and	reliable.	Moreover,	important	advantages	of	RNA-sequencing	are	that	
low	abundant	transcripts	can	be	detected	more	easily	as	well	as	splice	variants	and	novel	tran-
scripts.	These	topics	are	of	specific	 interest	for	 lncRNA	research	as	 lncRNA	are	expressed	at	a	
much	lower	level	than	most	protein	coding	genes	and	several	novel	lncRNAs	are	being	detected	
as	they	are	only	expressed	in	a	specific	tissue	or	disease.	
Taking	the	major	advantages	of	RNA-sequencing	 for	 lncRNA	research	 into	account,	we	repro-
filed	60	T-ALL	samples	from	the	previous	cohort	by	poly(A)	RNA-sequencing	(see	paper	3).	At	
the	level	of	protein-coding	genes,	it	was	clear	that	for	our	analysis	both	the	data	generated	by	
micro-array	and	the	poly(A)	RNA-sequencing	were	equally	fit	for	the	purpose	of	our	study.	With	
respect	to	landscaping	of	lncRNA	expression	profiles,	the	comparison	between	micro-array	and	
RNA-seq	 based	 generation	 of	 expression	 profiles	 was	 more	 challenging.	 However,	 from	 the	
matching	lncRNAs	I	could	identify	several	that	were	significantly	differentially	expressed	in	a	T-
ALL	 subtype	 compared	 to	 the	 others	 by	 both	methods.	 Interestingly,	 the	 lncRNAs	 that	were	
subtype	specific	in	both	methods,	were	identified	with	a	larger	fold	change	in	the	poly(A)	RNA-
sequencing	dataset	compared	to	the	micro-array	dataset.	This	is	consistent	with	previous	publi-
cations	 that	 also	 detected	 a	 larger	 difference	with	 RNA-sequencing	 technologies.	One	of	 the	
major	advantages	of	RNA-sequencing	in	lncRNA	research	is	the	possibility	to	detect	novel,	pre-
viously	 unannotated	 lncRNAs.	 In	 this	 dataset,	 I	 discovered	 526	 novel	 multi-exonic	 lncRNAs	
without	protein	coding	potential.	Some	of	these	novel	lncRNAs	are	also	specific	for	a	T-ALL	sub-
type,	implying	that	they	might	have	a	very	specific	role	in	subtype	specific	T-ALL	oncogenesis.	It	
should	however	also	be	noted	that	these	novel	lncRNAs	are	detected	at	very	low	levels,	which	
can	question	the	relevance	in	leukemogenesis.	It	 is	also	not	sure	that	these	detected	lncRNAs	
are	independent	transcripts;	therefore	several	other	experiments	should	be	performed.	CAGE-
sequencing	(Cap	Analysis	of	Gene	Expression)21	of	a	T-ALL	cell	line	could	first	of	all	identify	the	
possible	transcription	start	sites	in	the	cell	line	and	ATAC-seq	(Assay	for	Transposase-Accessible	
Chromatin,	detects	open	chromatin)22	and	histone	marks	 (ex.	H3K4me3	for	active	promoters,	
H3K36me3	for	active	gene	bodies	and	H3K27ac	for	enhancer	regions)	can	inform	on	the	chro-
matin	status	of	a	given	chromosomal	locus.	
Of	the	above-mentioned	60	patient	samples,	we	selected	25	for	which	RNA	was	remaining	to	
profile	RNA	expression	with	total	RNA-sequencing	for	the	discovery	of	novel	previously	unan-
notated	lncRNAs.	 Indeed,	as	 it	has	been	estimated	that	about	one	third	of	all	 lncRNAs	do	not	
have	a	poly(A)	tail,	a	significant	additional	number	of	lncRNAs	should	be	detected	using	this	ap-
proach.	 As	 a	 side	 note,	 it	 should	 be	 mentioned	 that	 also	 some	 known	 non-polyadenylated	
mRNAs	 and	 lncRNAs	were	 present	 in	 the	 poly(A)	 dataset,	 as	 also	 random	 priming	 occurs	 in	
poly(A)	RNA-seq.	From	our	analysis,	and	in	keeping	with	previous	reports,	it	seems	that	the	ma-
jor	advantage	of	total	RNA-sequencing	is	indeed	the	detection	of	novel	lncRNAs.	We	detected	
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17	%	more	novel	 lncRNAs	 than	poly(A)	RNA-seq	and	next	 to	 that,	 total	RNA-seq	also	detects	
more	annotated	lncRNAs.	It	might	also	be	interesting	to	check	for	the	presence	of	circular	RNAs	
(circRNAs)	 in	 this	 total	RNA-seq	dataset,	as	 these	are	not	detected	by	poly(A)	RNA-seq.	Total	
RNA-seq	 has	 however	 some	 disadvantages;	 one	 example	 is	 the	 detection	 of	 pre-mRNA	
(unspliced	mRNA)	leading	to	a	lot	of	reads	present	from	introns.	This	 implies	that	more	reads	
are	necessary	to	detect	the	same	amount	of	genes	and	could	lead	to	more	noise	in	the	detec-
tion	of	novel	lncRNAs.		
With	the	datasets	provided	here,	a	lot	of	novel	insights	in	T-ALL	could	be	explored.	First	of	all,	
the	subtype	specific	expression	of	lncRNAs	could	be	linked	to	protein	coding	genes	and	might	
reveal	some	novel	T-ALL	oncogenic	networks.	As	an	example,	we	are	now	further	exploring	the	
lncRNAs	directly	regulated	by	TLX1	and	we	are	also	elucidating	possible	enhancer	regions	and	
eRNAs	 involved	 in	TLX1	driven	T-ALL	oncogenesis.	Using	the	RNA-sequencing	dataset,	we	can	
also	look	for	(novel)	ectopically	expressed	lncRNAs	with	an	oncogenic	role	in	several	cases.	Such	
lncRNAs	 could	 lead	 to	 novel	 therapies	 with	 less	 off-target	 effects	 compared	 to	 the	 current	
treatments.	It	should	also	be	noted	that	this	is	the	first	time	that	such	a	large	T-ALL	patient	co-
hort	is	profiled	with	poly(A)	RNA-sequencing	and	this	might	also	be	used	to	look	for	specific	or	
novel	transcripts	of	protein	coding	genes	and	give	more	 insights	 in	the	role	of	protein	coding	
genes	in	T-ALL.		
The	hurdles	to	take	in	lncRNA	research	
In	Chapter	1	of	this	thesis	I	already	elaborated	on	several	questions	that	arose	during	the	first	
decade	of	lncRNA	research,	such	as	the	lack	of	conservation	of	lncRNA	loci,	the	binding	of	ribo-
somes	to	lncRNAs	and	the	fact	that	some	lncRNAs	are	mere	by-products	of	mRNA	transcription.	
Despite	these	issues,	several	lncRNAs	are	nowadays	already	identified	to	have	a	bona	fide	role	
in	(cancer)	cell	biology,	with	the	melanoma-specific	lncRNA	SAMSSON	as	an	exciting	example23.	
However,	several	studies	question	the	importance	of	lncRNAs	as	they	might	be	coding	for	mi-
cro-peptides	or	as	 they	might	be	by-products	of	 transcription	of	nearby	genes.	A	very	 recent	
paper	by	the	Proudfoot	team	studied	the	transcription	and	RNA-processing	of	lincRNAs	(inter-
genic	lncRNAs)	and	identified	several	differences	in	comparison	to	pre-mRNA	transcription	and	
processing.	 Of	 particular	 interest,	 they	 state	 that	 lincRNAs	 are	 unstable	 and	 cleaved	 during	
transcription24.	This	is	one	of	the	papers	that	illustrates	that	lncRNA	research	is	only	a	very	re-
cent	 scientific	 field	 and	 a	 lot	 remains	 to	 be	 explored.	 Certainly,	 not	 all	 detected	ncRNAs	will	
have	a	 function,	but	their	detection	might	 for	example	still	be	 interesting	as	a	biomarker.	On	
the	other	hand,	there	is	a	rapidly	growing	list	of	 lncRNAs	with	a	function	in	the	cell	and/or	 in	
development	(Table	3),	clearly	 indicating	the	biological	role	of	at	 least	a	significant	portion	of	
the	currently	annotated	lncRNAs.	
The	study	of	lncRNAs	poses	several	challenges.	First,	many	lncRNAs	are	not	or	poorly	annotated	
and	need	to	be	studied	 in	detail	by	other	technologies,	 for	example	CAGE-seq	to	 identify	 the	
transcription	start	site	and	 ‘rapid	amplification	of	cDNA	ends’	 (RACE)	to	 identify	the	exact	se-
quence	of	the	lncRNA.	Furthermore,	there	is	no	unique	lncRNA	annotation	method,	so	different	
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databases	make	use	of	different	 identifiers	 for	 the	same	 lncRNA	 locus,	which	 further	compli-
cates	lncRNA	research.		
A	crucial	next	step	towards	 the	 identification	of	 the	 function	of	an	 lncRNA	 is	 through	 in	vitro	
knockdown	or	knockout	of	lncRNA	expression.	For	knockdown,	the	use	of	the	RNA	interference	
machinery	with	siRNAs	(short	 interfering	RNAs)	or	shRNAs	(short	hairpin	RNAs)	may	not	work	
as	 they	make	use	of	 the	DICER	machinery	of	 the	miRNA	biogenesis	pathway,	which	 is	mostly	
functional	 in	the	cytoplasm.	Therefore,	 the	use	of	antisense	oligonucleotides	(ASOs)	 is	a	valid	
alternative	option,	as	these	are	 functional	 in	the	nucleus	by	using	the	RNaseH	enzyme	to	de-
grade	the	RNA	molecule.	CRISPR-mediated	knockout	is	another	option	but	may	be	hampered	in	
subsequent	phenotypic	 interpretation	as	 lncRNAs	 can	overlap	with	protein	 coding	 genes	 (ex.	
antisense	 lncRNAs)	 or	with	 regulatory	 regions	 (ex.	 enhancers).	 Alternatively,	 lncRNAs	 can	 be	
overexpressed	 through	 viral	 transduction,	 but	 again	 pitfalls	 may	 occur.	 First	 of	 all,	 the	
knowledge	of	the	exact	transcript	sequence	is	necessary	and	secondly	cis-regulatory	functions	
cannot	be	studied.	For	both	the	knockdown	and	the	overexpression	there	might	however	be	a	
solution	using	a	modified	CRISPR/Cas9	system.	Here,	a	Cas9	molecule	could	be	used	that	has	
lost	its	ability	to	cut	the	DNA	sequence	(dCas9)	but	that	has	an	extra	functional	domain	that	can	
either	activate	or	repress	the	transcription	of	the	targeted	locus25-27.		
Yet	another	difficulty	 in	 lncRNA	research	 in	comparison	 to	mRNA	research	 is	 that	 for	protein	
coding	genes	the	amino	acid	sequence	of	the	proteins	might	already	hint	towards	a	function,	
for	example	a	DNA-binding	domain,	but	for	lncRNAs	there	is	very	little	information	that	can	be	
extracted	from	its	sequence	and	RNA	secondary	structure	prediction	algorithms	remain	predic-
tions	and	do	not	provide	extra	information	on	possible	interaction	partners.	To	test	the	interac-
tion	between	an	lncRNA	and	a	protein	or	genomic	locus,	several	in	vitro	tools	are	already	avail-
able	(ex.	ChIRP,	CHART	and	RIP)28-30,	however	they	remain	challenging	to	introduce	in	the	lab.	
Next	to	the	challenges	for	 in	vitro	research,	the	low	species	conservation	of	 lncRNAs	makes	it	
difficult	to	check	the	effects	of	lncRNAs	in	model	organisms.	The	introduction	of	human	lncRNA	
transcripts	 in	overexpression	models	or	the	use	of	primary	xenografts,	are	two	possibilities	to	
partially	 overcome	 this.	 Taken	 together,	 while	 lncRNAs	 hold	 promise	 for	 discovery	 of	 novel	
roles	in	biology	and	disease,	many	technical	hurdles	currently	hamper	the	deciphering	of	their	
function	and	slow	down	the	discovery	process.	
Completing	the	T-ALL	subtype	specific	transcriptome	by	microRNA	profiling	
The	role	of	miRNAs	in	T-ALL	is	already	more	broadly	described	than	lncRNAs,	with	proven	in	vi-
vo	oncogenic	effects	(see	review	in	Chapter	1).	Most	of	the	described	miRNAs	with	a	role	in	T-
ALL	oncogenesis	could	be	linked	to	several	known	T-ALL	oncogenes	or	tumor	suppressors	either	
as	 activators	 of	miRNA	 transcription	or	 as	 targets	 for	 the	miRNAs.	No	 studies	were	however	
present	that	described	the	subtype	specific	expression	pattern	of	the	miRNAs	in	T-ALL,	but	we	
hypothesized	that	there	should	be	at	least	some	miRNAs	with	a	T-ALL	subtype	specific	role,	as	
there	are	several	of	the	miRNAs	linked	to	subtype	specific	T-ALL	oncogenes	(ex.	TLX1,	TLX3	and	
TAL1).	One	example	is	miR-223	that	is	activated	by	the	TAL1	oncogene	and	can	downregulate	
the	expression	of	the	T-ALL	tumor	suppressor	gene	FBXW7	(see	Chapter	1)31,	32.	We	profiled	for	
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the	 first	 time	 the	 miRNA	 expression	 of	 a	 large	 cohort	 of	 primary	 T-ALL	 patient	 samples	 by	
means	 of	 small	 RNA-sequencing	 instead	 of	 the	 RT-qPCR	 or	micro-array	 platforms	 previously	
used	(see	paper	4).	Within	our	dataset	I	could	identify	miRNAs	that	were	not	detected	on	the	
RT-qPCR	platforms	and	I	could	also	delineate	different	isomiR	forms	of	the	miRNAs,	which	was	
not	possible	with	the	previous	platforms.		
Several	 of	 the	 highest	 expressed	 novel	 detected	miRNAs	 in	 T-ALL	 in	 general	 are	 known	 on-
comiRs	in	other	cancer	entities,	for	example	hsa-miR-181b-5p	that	enhances	AML	proliferation	
and	hsa-miR-92b-3p	that	was	identified	as	an	oncomiR	in	glioblastoma	and	that	targets	SMAD3,	
which	is	known	to	be	lost	in	several	pediatric	T-ALL	cases.	Next	to	that,	I	detected	that	in	each	
subtype	several	miRNAs	were	specifically	up-	or	downregulated	 in	comparison	with	the	other	
subtypes.	However,	this	was	the	most	obvious	for	the	immature	T-ALL	and	the	TAL-R	subgroup.	
Several	 of	 these	miRNAs	 also	 appear	 to	 be	differentially	 expressed	 in	 comparison	 to	 healthy	
donor	subsets,	making	them	ideal	candidates	for	further	T-ALL	research.		
Remarkably,	for	several	miRNAs,	it	was	not	the	canonical	miRNA	sequence	that	was	the	highest	
expressed,	which	is	something	that	should	be	taken	into	account	for	further	in	vitro	and	in	vivo	
analysis	of	these	miRNAs.	Isomeric	forms	of	a	miRNA	can	occur	due	to	the	imprecise	cleavage	
by	DROSHA	or	DICER,	by	exonuclease	activity	at	the	miRNA	ends	or	by	post-transcriptional	ad-
dition	of	one	or	more	bases	at	the	3’	end	of	the	miRNA.	A	miRNA	interacts	with	its	target	mRNA	
by	its	seed	region,	which	starts	at	the	second	nucleotide	at	the	5’	end	and	is	6-8	nucleotides	in	
length.	This	means	that	if	there	is	a	shift	in	the	miRNA	sequence	at	the	5’	end	(addition	or	dele-
tion),	 the	seed	sequence	changes,	which	has	a	major	 impact	on	the	target	 recognition	of	 the	
miRNA.	However,	in	this	dataset,	I	mostly	detected	isomiR	forms	that	have	an	addition	or	dele-
tion	of	one	or	more	nucleotides	at	 the	3’	end,	which	does	not	 immediately	affect	 the	 target	
recognition	 site	of	 the	miRNA.	 The	3’	 end	 isomiR	 variants	 are	 also	 in	other	 studies	 the	most	
common	detected	modifications33-36,	but	their	functional	mechanism	is	less	clear	than	for	the	5’	
isomiRs.	 It	was	however	discovered	that	3’	 isomiRs	can	have	a	different	affinity	 for	 the	AGO-
complexes	as	the	canonical	miRNAs,	which	can	have	an	effect	on	the	mRNA	modulation	(as	for	
example	only	AGO2	is	able	to	cleave	the	target	mRNA)33.	Furthermore,	it	was	already	described	
in	plant	biology	 that	3’	 isomiRs	have	a	different	half-life	compared	to	 the	canonical	miRNA37,	
which	is	however	not	yet	proven	in	animals.	The	presence	of	isomiRs	also	has	an	effect	on	fol-
low-up	studies,	as	specific	RT-qPCR	primers	should	be	designed	to	detect	their	expression	level	
and	also	specific	ASO	inhibitors	are	necessary	to	target	5’	isomirs	as	they	must	bind	nucleotides	
2-20	of	the	miRNA.		
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FUTURE	PERSPECTIVES	
With	this	PhD	thesis,	I	generated	a	panoramic	landscape	of	noncoding	RNA	expression	in	T-ALL,	
thus	providing	a	unique	resource	for	further	exploration	and	data	mining	by	other	researchers.	
The	raw	data	for	paper	1	and	paper	2	are	publically	available	through	the	Gene	Expression	Om-
nibus	(GEO)	database	(GSE62006	and	GSE74272)	and	upon	publication	of	the	two	other	papers,	
these	datasets	will	also	be	oploaded	to	the	GEO	database.	Furthermore,	the	results	of	the	dif-
ferential	 expression	 analyses	 are	 available	 as	 supplementary	materials	 for	 the	 papers,	which	
makes	these	results	available	for	a	quick	examination.	
This	study	was	the	first	RNA-seq	based	characterization	of	a	large	T-ALL	patient	cohort	for	both	
miRNA	 and	 lncRNA.	 Further,	 the	 poly(A)	 and	 total	 RNA-sequencing	 data	 can	 also	 be	 used	 to	
check	 specific	 splice	 variants	 of	 protein	 coding	 genes	or	 circular	RNAs,	which	was	out	 of	 the	
scope	of	this	PhD	thesis.	Finally,	an	in	depth	study	comparing	poly(A)	and	total	RNA-sequencing	
in	our	T-ALL	patient	cohort	will	be	performed	as	a	follow-up	on	this	project.		
In	addition	to	the	above,	a	further	challenge	is	the	integration	of	the	currently	available	mRNA,	
lncRNA	and	miRNA	datasets	in	order	to	gain	further	insights	into	the	biology	of	the	disease	and	
the	 interconnection	 of	 regulatory	 networks	 and	 integrated	 perturbed	 biological	 processes.	 A	
first	example	could	be	the	negative	correlation	between	a	miRNA	and	an	mRNA/lncRNA	in	the	
subtype	specific	profiles,	which	could	identify	potential	targets	of	the	miRNA	(Figure	12	A).	Mi-
croRNA	target	prediction	algorithms	could	aid	 in	this	analysis,	however	there	are	some	disad-
vantages	as	different	 tools	give	different	 results,	 several	 special	miRNA-mRNA	 target	 interac-
tions	are	described	(for	example	G-bulges)	and	isomiR	forms	can	have	different	target	prefer-
ences.	AGO2-pull	down	or	reporter	assays	could	on	the	other	hand	be	used	for	in	vitro	identifi-
cation	of	miRNA-mRNA/lncRNA	interaction.	A	second	interesting	focus	could	be	the	identifica-
tion	of	transcription	factor	binding	sites	near	the	promoters	of	lncRNAs	and	miRNAs	that	could	
explain	 a	 possible	 activation	 or	 repression	 of	 the	 subtype	 specific	 lncRNA/miRNA	 by	mRNAs	
linked	 to	 the	same	subtype	 (Figure	12	B).	A	 third	and	 final	example	 I	would	 like	 to	point	out	
here	 is	 the	 identification	 of	 competing	 endogenous	 RNAs	 (ceRNAs),	 which	 are	 lncRNAs	 that	
bind	miRNAs,	acting	as	sponges	and	titrating	them	away	from	their	mRNA	target,	leading	to	the	
increased	expression	of	 the	mRNA,	 as	has	been	described	 for	 the	PTENP1	 lncRNA	 (Figure	12	
C)38.	This	could	be	identified	by	mRNAs	and	lncRNAs	that	are	upregulated	in	the	same	subtype	
and	that	can	be	targeted	by	the	same	miRNAs.	An	extra	clue	would	be	the	presence	of	multiple	
binding	sites	for	the	same	miRNA	in	the	lncRNA.	
Further	insights	into	T-ALL	biology	might	lead	to	novel	therapeutic	targets	as	even	lncRNAs	and	
miRNAs	are	nowadays	already	druggable	with	some	clinical	trials	using	antisense	oligonucleo-
tide	ongoing	(see	Chapter	1).	Despite	the	fact	that	there	is	no	specific	link	between	T-ALL	sub-
types	and	prognosis	(as	discussed	in	Chapter	1),	these	subtype	specific	pathways	might	still	be	
of	interest	in	clinic.	For	example,	the	relative	highest	amount	of	NOTCH1-oncogenic	mutations	
(druggable	with	GSIs)	is	present	in	TLX1	T-ALL1	and	oncogenic	IL7R	pathway	mutations	that	are	
associated	with	a	poor	outcome	are	mostly	detected	 in	 immature	and	TLX3	 T-ALL39.	 Further-
more,	the	comparison	with	healthy	donor	thymocyte	subsets	remains	important	as	these	might	
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Figure	12.	Future	research	directions	using	 the	datasets	provided	 in	 this	 thesis.	 (A)	Negative	correlation	with	a	
miRNA	might	point	at	a	miRNA	target.	(B)	Positive	or	negative	correlation	with	a	transcription	factor	might	indicate	
transcriptional	 regulation.	 (C)	An	mRNA	and	 lncRNA	that	are	both	upregulated	 in	a	specific	group	and	that	have	
binding	 sites	 for	 the	 same	 miRNA	 might	 identify	 the	 lncRNA	 as	 a	 ceRNA.	 (Illustrations	 from	
www.somersault1824.com)		
help	in	identifying	true	oncogenic	pathways.	Next	to	that,	online	available	gene-expression	da-
tasets	 might	 aid	 in	 the	 identification	 of	 cancer	 type	 or	 tissue	 type	 specific	 lncRNAs.	 For	
example,	 ‘The	 Cancer	 Genome	 Atlas’	 (TCGA)	 contains	 RNA-seq	 data	 for	 33	 different	 cancer	
types	which	could	be	queried	for	a	lncRNA	of	interest.	A	T-ALL	lncRNA	that	is	not	expressed	in	
any	other	cancer	type	might	indicate	a	specific	T-cell	leukemogenic	function.	
Nowadays,	the	major	challenges	for	T-ALL	in	the	clinic	are	the	patients	that	show	initial	therapy	
resistance	or	the	patients	that	relapse,	as	their	prognosis	is	very	dismal.	It	is	therefore	very	im-
portant	 to	 quickly	 identify	 these	 patients	 and	 find	 novel	 druggable	 targets	 and	 combination	
therapies	might	aid	in	improving	their	survival.	
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SUMMARY	
Normal	T-cell	development	 is	a	hierarchically	orchestrated	process	and	 requires	 strict	 regula-
tion	of	underlying	gene	expression	programs.	Various	genomic	lesions	can	lead	to	either	aber-
rant	expression/activation	of	proto-oncogenes	or	repression/loss	of	tumor	suppressors	that	in-
duces	a	differentiation	arrest	 at	 a	 specific	developmental	 T-cell	 stage,	 thereby	 increasing	 the	
risk	for	transformation	of	arrested	progenitor	thymocytes	to	T-cell	acute	lymphoblastic	 leuke-
mia	(T-ALL).	
The	prognosis	of	T-ALL	patients	has	increased	in	the	last	decades	due	to	intensified	therapies,	
but	for	patients	with	relapse	and	therapy	resistance	outcome	with	current	treatment	regimens	
is	very	poor.	These	hurdles,	as	well	as	the	problem	of	 long-term	side	effects	of	current	harsh	
treatment	protocols,	underscore	the	importance	of	further	research	to	discover	novel,	more	ef-
ficient	 and	 less	 toxic	 targeted	 therapies.	 During	my	 PhD	mandate,	 I	 explored	 the	 expression	
patterns	of	two	types	of	noncoding	RNAs,	lncRNAs	and	miRNAs,	in	T-ALL	patient	samples,	sort-
ed	 T-cell	 subsets	 and	 T-ALL	 in	 vitro	 models	 as	 their	 functional	 role	 in	 cancer	 biology	 has	
emerged	strongly	in	the	last	decades	and,	particularly	for	lncRNAs,	their	role	in	T-ALL	remained	
largely	 unexplored.	 This	 thesis	 provides	 a	 unique	 resource	 depicting	 the	miRNA	 and	 lncRNA	
landscape	of	a	well-annotated	series	of	primary	T-ALL	samples	and	provides	 the	 first	steps	 in	
exploring	the	putative	role	of	selected	candidate	novel	lncRNAs	and	miRNAs	implicated	in	T-ALL	
with	potential	as	biomarkers	or	as	novel	therapeutic	targets.		
Given	the	key	role	of	 the	NOTCH1-signaling	pathway	 in	both	normal	and	malignant	T-cell	de-
velopment,	this	cascade	has	been	exploited	in	the	treatment	of	T-ALL	patients	through	the	use	
of	the	NOTCH1	inhibitor	GSI.	Although	the	use	of	GSIs	in	in	vitro	studies	seemed	very	promising,	
clinical	 trials	unfortunately	 failed	as	a	consequence	of	 therapy	resistance	and	gastrointestinal	
toxicity	 issues.	Hence,	 other	 components	 of	 the	 pathway	 should	 be	more	 properly	 dissected	
and	characterized	to	pinpoint	novel	targets	for	innovative	treatment	regimens.	During	the	first	
part	of	my	thesis,	I	therefore	identified	lncRNAs	directly	regulated	by	NOTCH1	in	T-ALL	and	in	
normal	T-cell	development.	
Interestingly,	T-ALL	cases	can	be	classified	in	different	genetic	subtypes	based	on	a	specific	on-
cogenic	driver	event	and/or	stage	of	differentiation	arrest	during	T-cell	development.	Further-
more,	 the	mRNA	 expression	 profiles	 of	 T-ALL	 cases	 cluster	 together	 according	 to	 subtype.	 I	
aimed	 in	 the	 second	part	of	my	PhD	 thesis	 to	explore	 the	expression	of	 lncRNAs	next	 to	 the	
protein	coding	gene	expression	for	each	of	the	known	T-ALL	subtypes	by	means	of	micro-array	
technology	 and	 I	 could	 show	 that	 the	 T-ALL	 subgroups	 are	 also	 characterized	 by	 a	 specific	
lncRNA	 expression	 profile,	 adding	 a	 novel	 layer	 of	 gene	 signatures	 that	 characterize	 these	
groups.	Through	a	comparative	analysis	with	lncRNA	expression	profiles	of	sorted	healthy	do-
nor	 T-cell	 subsets,	 I	 could	 further	 delineate	 the	 subtype	 specific	 and	 in	 T-ALL	 ectopically	 ex-
pressed	lncRNAs,	which	are	of	particular	interest	for	in	depth	research	on	oncogenic	lncRNAs.	
Next-generation	sequencing	techniques	have	dramatically	boosted	our	ability	to	explore	tran-
scriptome	profiling	in	more	depth.	In	this	respect,	RNA-sequencing	has	now	become	the	meth-
od	of	choice	 for	gene	expression	profiling.	Therefore,	 I	 reprofiled	a	 large	set	of	T-ALL	patient	
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samples,	 that	we	previously	 screened	by	means	of	micro-array	 technology,	using	poly(A)	and	
total	RNA-sequencing.	Comparative	analysis	with	the	array	based	technology	showed	that	RNA-
sequencing	allows	detection	of	differentially	expressed	lncRNAs	with	a	larger	fold	change	thus	
offering	 a	 broader	 detection	 range	 than	 micro-arrays.	 Another	 advantage	 of	 the	 RNA-
sequencing	technologies,	specifically	in	the	context	of	studying	lncRNA	expression,	is	the	possi-
bility	to	detect	novel,	previously	unannotated	lncRNAs,	which	is	of	particular	interest	as	these	
might	be	lineage	specific	lncRNAs	that	could	be	used	for	targeted	therapy.	
In	the	last	part	of	this	thesis,	I	focused	on	the	subtype	specific	expression	pattern	of	miRNAs	in	
T-ALL.	Different	 research	 teams,	 including	 the	host	 lab,	 already	 studied	 the	 role	of	 individual	
miRNAs	and	mRNA-miRNA	networks	 in	T-ALL.	 In	 this	 thesis,	a	pioneering	study	was	set	up	to	
evaluate	 subtype	 specific	 miRNA	 expression	 patterns	 of	 T-ALL	 patient	 samples	 by	 means	 of	
small	 RNA-sequencing.	 In	 contrast	 to	 previously	 developed	 RT-qPCR	 based	 and	 micro-array	
platforms,	we	were	able	to	scrutinize	a	much	wider	spectrum	of	miRNAs	and	were	also	able	for	
the	first	time	to	detect	and	evaluate	isomiR	expression	in	T-ALL.	This	dataset	allowed	me	to	de-
fine	a	subtype	specific	miRNA	profile	for	T-ALL	cases	and	to	identify	novel	potential	oncogenic	
miRNAs	by	comparing	these	profiles	with	miRNA	expression	profiles	from	healthy	donor	T-cell	
subsets.		
To	 conclude,	 with	 this	 PhD	 project	 I	 established	 unique	 noncoding	 RNA	 expression	 datasets	
(miRNA	 and	 lncRNA)	 and	 identified	 potential	 oncogenic	 miRNAs	 and	 lncRNAs	 in	 T-ALL	 that	
could	be	used	 for	 further	 in	depth	exploration	on	both	a	 functional	and	therapeutic	 level.	As	
several	therapies	for	noncoding	RNAs	(miRNAs	and	lncRNAs)	are	already	in	(pre-)	clinical	trials,	
the	identification	of	a	miRNA	or	lncRNA	with	a	specific	oncogenic	role	in	T-ALL,	NOTCH1-driven	
T-ALL	or	a	specific	T-ALL	subtype	might	lead	to	the	establishment	of	a	novel	targeted	therapy	in	
T-ALL.		
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SAMENVATTING	
De	ontwikkeling	van	T-cellen	in	de	thymus	is	een	hiërarchisch	proces	dat	een	strikte	regulatie	
van	gen	expressie	programma’s	eist.	Verscheidene	genetische	defecten	kunnen	leiden	tot	ener-
zijds	een	overexpressie/activatie	van	proto-oncogenen	of	anderzijds	een	onderdrukking/verlies	
van	tumor	suppressor	genen	die	een	differentiatie	stop	in	de	normale	T-cel	ontwikkeling	kun-
nen	introduceren,	waardoor	het	risico	tot	de	ontwikkeling	van	T-cel	acute	lymfatische	leukemie	
(T-ALL)	verhoogt.	Door	een	 intensieve	behandeling	 is	de	prognose	voor	T-ALL	patiënten	 in	de	
laatste	 decennia	 sterk	 gestegen,	maar	 de	 patiënten	die	 hervallen	 of	 resistentie	 tegen	de	be-
handeling	vertonen	hebben	nog	steeds	een	slechte	overlevingskans.	Dit,	maar	ook	de	neven-
werkingen	op	lange	termijn	van	de	intensieve	behandelingsschema’s	tonen	het	belang	aan	van	
verder	onderzoek	naar	nieuwe,	meer	efficiënte	en	minder	toxische	doelgerichte	therapieën.		
Tijdens	 mijn	 doctoraatsproject	 onderzocht	 ik	 het	 expressie	 patroon	 van	 twee	 types	 niet-
coderende	RNAs,	miRNAs	en	lncRNAs,	 in	T-ALL	patiënten	stalen,	verscheidene	T-cel	ontwikke-
lingsstadia	en	T-ALL	in	vitro	model	systemen,	aangezien	hun	rol	in	kankerbiologie	in	het	laatste	
decennium	aangetoond	is	en,	vooral	voor	lncRNAs,	hun	rol	in	T-ALL	nog	zeer	weinig	beschreven	
is.	Deze	thesis	brengt	een	unieke	dataset	aan	die	het	miRNA	en	lncRNA	landschap	van	primaire	
T-ALL	patiëntenstalen	in	kaart	brengt	en	een	eerste	stap	aanbiedt	richting	het	onderzoeken	van	
een	 functionele	 rol	 voor	 kandidaat	miRNAs	en	 lncRNAs	betrokken	 in	T-ALL	als	mogelijke	bio-
merkers	of	nieuwe	therapeutische	doelwitten.	
Door	 de	 sleutelrol	 van	 NOTCH1-signalisatie	 in	 zowel	 normale	 als	maligne	 T-cel	 ontwikkeling,	
werd	deze	signalisatie	gebruikt	in	het	onderzoek	naar	behandelingen	voor	T-ALL	patiënten	door	
middel	van	de	NOTCH1-inhibitor	GSI.	De	in	vitro	testen	met	GSIs	waren	veelbelovend,	maar	de	
klinische	studies	moesten	helaas	vroegtijdig	stopgezet	worden	wegens	resistentie	en	toxische	
reacties	 in	 het	 spijsverteringsstelsel.	 Hierdoor	 zouden	 andere	 componenten	 in	 de	 NOTCH1-
signalisatie	grondiger	onderzocht	en	gekarakteriseerd	moeten	worden	om	nieuwe	doelwitten	
voor	 innovatieve	therapieën	te	kunnen	aanduiden.	Daarom	heb	ik	tijdens	het	eerste	deel	van	
mijn	doctoraatsstudie	lncRNAs	geïdentificeerd	die	direct	gereguleerd	worden	door	NOTCH1	in	
T-ALL	en	normale	T-cel	ontwikkeling.	
T-ALL	patiënten	kunnen	ook	ingedeeld	worden	in	verschillende	genetische	subtypes	gebaseerd	
op	een	specifiek	oncogeen	defect	en/of	het	stadium	van	differentiatie	arrest	tijdens	T-cel	ont-
wikkeling.	Daarnaast	 is	ook	aangetoond	dat	de	mRNA	expressieprofielen	van	T-ALL	patiënten	
samen	clusteren	naargelang	het	subtype.	In	het	tweede	deel	van	mijn	doctoraatsstudie	heb	ik	
de	 lncRNA	 expressie	 in	 deze	 T-ALL	 subtypes	 in	 kaart	 gebracht	 door	 middel	 van	 micro-array	
technologie	en	kon	ik	aantonen	dat	de	T-ALL	subtypes	ook	gekarakteriseerd	worden	door	speci-
fieke	lncRNA	expressieprofielen,	waardoor	deze	subtypes	nu	door	een	extra	niveau	van	genex-
pressie	gekarakteriseerd	zijn.	Door	het	vergelijken	van	deze	data	met	de	lncRNA	expressiepro-
fielen	in	gesorteerde	T-cel	stadia	van	gezonde	donoren,	kon	ik	de	subtype	specifieke	en	ecto-
pisch	geëxpresseerde	lncRNA’s	identificeren,	wat	interessant	is	voor	verder	onderzoek	naar	on-
cogene	lncRNA’s	in	T-ALL.	Door	de	nieuwe	generatie	van	sequeneringstechnologiën	is	de	moge-
lijkheid	 tot	 het	 grondig	 onderzoeken	 van	 transcriptoom	 profielen	 gegroeid,	 waardoor	 RNA-
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sequenering	nu	de	voorkeur	krijgt	op	micro-arrays	voor	genexpressieprofilering.	Hiervoor	heb	
ik	een	groot	deel	van	de	T-ALL	patiënten	stalen	uit	vorig	micro-array	onderzoek	opnieuw	gepro-
fileerd	door	middel	van	poly(A)	en	totale	RNA-sequenering.	Een	vergelijkende	analyse	met	de	
array	 technologie	 toonde	 aan	 dat	 RNA-sequenering	 de	 differentieel	 geëxpresseerde	 lncRNAs	
met	een	groter	verschil	 in	expressie	detecteerde	en	dus	een	groter	detectie	gebied	heeft	dan	
de	micro-arrays.	Een	extra	voordeel	van	RNA-sequenering,	vooral	in	de	context	van	lncRNA	ex-
pressie,	is	de	mogelijkheid	om	nieuwe	lncRNAs	te	identificeren	die	nog	niet	geannoteerd	zijn	in	
databanken,	wat	zeer	interessant	is	voor	de	detectie	van	T-ALL	specifieke	lncRNAs	die	kunnen	
gebruikt	worden	voor	doelgerichte	therapieën.	
In	het	laatste	deel	van	deze	thesis,	heb	ik	mijn	focus	gelegd	op	het	subtype	specifieke	expres-
siepatroon	van	miRNA’s	in	T-ALL.	Verschillende	onderzoeksgroepen,	waaronder	het	labo	waar	
ik	mijn	doctoraatsstudie	heb	uitgevoerd,	hebben	al	de	 rol	 van	 individuele	miRNAs	en	mRNA-
miRNA	netwerken	 in	T-ALL	bestudeerd.	 In	deze	thesis	werd	een	eerste	studie	opgezet	om	de	
subtype	 specifieke	miRNA	 expressiepatronen	 in	 primaire	 T-ALL	 patiëntenstalen	 te	 evalueren	
door	middel	van	een	RNA-sequeneringstechnologie	gericht	op	de	detectie	van	korte	RNA	mole-
culen.	In	tegenstelling	tot	vroeger	ontwikkelde	RT-qPCR	en	micro-array	platformen,	waren	we	
nu	in	staat	om	een	veel	breder	spectrum	van	miRNAs	te	detecteren	en	konden	we	ook,	voor	de	
eerste	keer,	isomiR	expressie	detecteren	en	evalueren.	Deze	dataset	liet	me	daarnaast	ook	toe	
om	subtype-specifieke	miRNA	profielen	voor	T-ALL	patiënten	te	definiëren	en,	door	een	verge-
lijking	met	miRNA	profielen	van	gezonde	T-cel	donoren,	mogelijke	nieuwe	oncogene	miRNAs	in	
T-ALL	te	identificeren.	
Samengevat	 heb	 ik	met	 dit	 doctoraatsproject	 unieke	 niet-coderende	 RNA	 expressie	 datasets	
(miRNAs	en	lncRNAs)	gegenereerd	en	mogelijke	oncogene	miRNAs	en	lncRNAs	in	T-ALL	geïden-
tificeerd	 die	 gebruikt	 kunnen	 worden	 voor	 verder	 functioneel	 en	 therapeutisch	 onderzoek.	
Aangezien	er	al	voor	verscheidene	therapieën	gericht	tegen	niet-coderende	RNAs	(miRNAs	en	
lncRNAs)	(pre-)	klinische	studies	opgestart	zijn,	kan	de	identificatie	van	miRNAs	en	lncRNAs	met	
een	specifieke	oncogene	rol	 in	T-ALL,	NOTCH1-gedreven	T-ALL	of	 in	een	T-ALL	subtype	 leiden	
tot	de	ontwikkeling	van	nieuwe	doelgerichte	therapieën	in	T-ALL.	
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Verder	wil	ik	enkele	collega’s	specifiek	bedanken.	Eerst	en	vooral	het	steeds	kleiner	wordende	
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paper	bijvoorbeeld?).	Ook	wil	 ik	al	mijn	bureaugenootjes	bedanken:	Kaat,	Karen,	Aline,	Jolien,	
Pieter,	Joni,	Sofie,	Béa,	Filip,	Gloria,	Els,	Suzanne,	Evelien	en	Nadine.	Bedankt	voor	de	vele	we-
tenschappelijke	reflecties	bij	‘acute’	problemen	of	toch	alvast	de	mogelijkheid	om	even	frustra-
ties	te	uiten,	vooraleer	er	weer	met	volle	moed	in	te	vliegen.	Maar	ook	zeker	en	vast	bedankt	
voor	de	grappige	momenten	en	de	ontspannende	gesprekken	tussendoor.	Daarnaast	wil	ik	ook	
Wouter	Van	Loocke	bedanken	voor	zijn	onmisbare	hulp	bij	de	bio-informatica	analyses,	team	Jo	
voor	de	interessante	discussies	omtrent	lncRNA	problemen	en	Tom	Taghon	voor	de	samenwer-
king	omtrent	normale	T-cel	ontwikkeling;	zonder	jullie	input	was	mijn	werk	helemaal	niet	zoals	
het	nu	is.	Ook	alle	CMGG	collega’s	wil	ik	bedanken	voor	de	ontspannende	lunchgesprekken,	de	
leuke	 congres	 uitstappen	 en	 de	 georganiseerde	 activiteiten	 (ik	 denk	 dan	 bv.	 aan	 C4CC,	 de	
monthly	drinks,	de	lab	retreats	etc.).	Door	jullie	kan	ik	terugkijken	op	een	zeer	toffe	periode	en	
ik	zal	nog	vaak	aan	deze	momenten	moeten	denken	tijdens	de	nieuwe	uitdagingen	die	ik	nu	te-
gemoet	ga.	Een	speciaal	woordje	van	dank	wil	ik	ook	richten	aan	mijn	paranimfen	Karen,	Jolien	
en	Celine,	die	me	 in	de	 laatste	eindspurt	van	mijn	doctoraat	hebben	bijgestaan	om	heel	wat	
praktische	zaken	te	regelen.		
Tot	slot	wil	ik	ook	een	woordje	van	dank	richten	aan	mijn	familie	en	vrienden.	Bedankt	om	inte-
resse	te	tonen	in	iets	wat	voor	velen	onder	jullie	redelijk	abstract	is	en	om	voor	de	nodige	ont-
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spanning	 te	 zorgen.	De	 steeds	 terugkomende	vragen	 “Wat	 is	het	nu	weer	 juist	dat	 je	onder-
zoekt?”	en	“Is	er	al	een	datum	die	we	moeten	vastzetten	voor	je	doctoraatsverdediging?”	zijn	
nu	hopelijk	beantwoord.	In	het	bijzonder	wil	ik	ook	mijn	ouders,	mijn	broer	en	Laurens	bedan-
ken	voor	hun	onvoorwaardelijke	steun,	niet	alleen	tijdens	mijn	doctoraat	maar	ook	in	de	vele	
jaren	ervoor.		
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between	 lncRNAs	 and	 the	 major	 T-ALL	 genetic	 subgroups.	Wallaert	 A,	 Durinck	 K,	Van	
Loocke	W,	Volders	PJ,	Van	de	Walle	I,	Benoit	Y,	Poppe	B,	Mestdagh	P,	Vandesompele	J,	Tag-
hon	T,	Soulier	J,	Cools	J,	Rondou	P,	Van	Vlierberghe	P,	Speleman	F.	
Non-Coding	RNA	–	From	Basic	Mechanisms	to	Cancer,	Heidelberg,	Germany	(22-25/6/2014)	
	
• The	immature	phenotype	T-ALL	long	noncoding	RNAome	as	a	prelude	to	novel	therapeu-
tic	 targeting.	Wallaert	 A,	Durinck	 K,	Van	 Loocke	W,	Volders	 PJ,	Van	 de	Walle	 I,	 Benoit	 Y,	
Poppe	B,	Mestdagh	P,	Vandesompele	 J,	Taghon	T,	Soulier	 J,	Cools	 J,	Rondou	P,	Van	Vlier-
berghe	P	and	Speleman	F.	
International	Conference	on	the	Long	&	the	Short	of	Non-Coding	RNAs,	Crete,	Greece	(14-
19/6/2015)	
	
• The	 lncRNAomes	 of	 T-cell	 acute	 lymphoblastic	 leukemia	 and	 normal	 immature	 thymo-
cyte	subsets	through	combined	poly-A	and	total	RNA-sequencing.	Wallaert	A,	Durinck	K,	
Van	Loocke	W,	Van	de	Walle	I,	Rondou	P,	Soulier	J,	Van	Vlierberghe	P,	Taghon	T	and	Spele-
man	F.	
Noncoding	 RNAs	 in	 Health	 and	 Disease,	 Santa	 Fe,	 United	 States	 of	 America	 (21-
24/02/2016)	
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Conferences	
• Next	Generation	Sequencing	and	Recent	Advances	in	Genetics,	BeSHG,	Liège,	Belgium	
(02/03/2012)	
• Cancer	Seminar,	UZ	Gasthuisberg,	Leuven,	Belgium	(25/09/2012)	
• Noncoding	RNAs	in	Development	and	Cancer,	Keystone	Symposia,	Vancouver,	Canada	(20-
25/01/2013)		
• Genetics	of	Human	Development	Exposed,	BeSHG,	Brussels,	Belgium	(15/03/2013)	
• Second	ESH-EHA	Scientific	Workshop	on	T-Cell	Acute	Lymphoblastic	Leukemia,	Lisbon,	Por-
tugal	(22-24/03/2013)	
• Genome	Engineering	and	Synthetic	Biology:	Tools	and	Technologies,	VIB,	Ghent,	Belgium	
(16-17/09/2013)	
• EMBO/EMBL	Symposium,	The	Non-Coding	Genome,	Heidelberg,	Germany	(9-12/10/2013)	
• 55th	ASH	Annual	Meeting	and	Exposition,	New	Orleans,	United	States	of	America	(7-
10/12/2013)	
• 2nd	Oncopoint	meeting,	UZ	Ghent,	Ghent,	Belgium	(6/2/2014)	
• Translational	Genetics:	from	cage	over	bench	to	bed,	BeSHG,	Antwerp,	Belgium	(7/2/2014)	
• Course	and	Master	Classes	on	Molecular	Aspects	of	Hematological	Disorders,	Rotterdam,	
The	Netherlands	(10-12/6/2014)	
• 19th	EHA	congress,	Milan,	Italy	(12-15/6/2014)	
• Non-Coding	RNA	–	From	Basic	Mechanisms	to	Cancer,	Heidelberg,	Germany	(22-
25/6/2014)	
• 3rd		Oncopoint	meeting,	Ghent,	Belgium	(11/2/2015)	
• Research	Day,	Faculty	of	Medicine	and	Health	Sciences,	Ghent,	Belgium	(05/03/2015)	
• IAP	Progress	meeting	2015,	Ghent,	Belgium	(08/06/2015)	
• Course	and	Master	Classes	on	Molecular	Aspects	of	Hematological	Disorders,	Rotterdam,	
the	Netherlands	(09-10/06/2015)	
• International	Conference	on	the	Long	&	the	Short	of	Non-Coding	RNAs,	Crete,	Greece	(14-
19/6/2015)	
• Genome	Engineering	and	Synthetic	Biology:	Tools	and	Technologies,	VIB,	Ghent,	Belgium	
(28-29/01/2016)	
• First	joint	meeting	BeSHG/NVHG,	Genetics	and	Society,	Leuven,	Belgium	(04-05/02/2016)	
• Noncoding	RNAs	in	Health	and	Disease,	Santa	Fe,	United	States	of	America	(21-
24/02/2016)	
• Research	Day,	Faculty	of	Medicine	and	Health	Sciences,	Ghent,	Belgium	(16/03/2016)	
• Course	and	Master	Classes	on	Molecular	Aspects	of	Hematological	Disorders,	Rotterdam,	
The	Netherlands	(07-08/6/2016)	
• Light	at	the	dark	side	of	the	genome,	fTales,	Ghent,	Belgium	(15-16/09/2016)	
	
Student	Guidance	
2014	
• Lucas	Verniers,	2nd	bachelor	Medicine,	“Z-lijn”	paper	
Importance	of	NOTCH1	as	a	target	for	future	therapy	in	T-ALL.	
• Karen	Verboom,	1st	Master	Biomedical	Sciences,	Internship	
Study	of	long	noncoding	RNAs	in	T-cell	acute	lymphoblastic	leukemia.	
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2015	
• Nienke	Heireman,	Nathalie	Peeters	and	Maaike	Van	Trimpont,	Project	Writing	Coaching,	
course	of	Cancergenetics	of	Prof.	Frank	Speleman,	1st	Master	Biomedical	Sciences	
	 The	role	of	JAK/STAT	signaling	on	downstream	lncRNAs	in	ETP-ALL.	
• Karen	Verboom,	2nd	Master	Biomedical	Sciences,	Masterthesis	
Study	of	long	noncoding	RNAs	in	T-cell	acute	lymphoblastic	leukemia.	
• Laura	Keersmaekers	and	Maxim	De	Maere,	2nd	bachelor	Medicine,	“Z-lijn”	paper	
Prognostic	factors	in	T-ALL.	
	
2016	
• Tessa	Van	Steenstraete	and	Michiel	Vercruysse,	2nd	bachelor	Medicine,	“Z-lijn”	paper	
Noncoding	RNAs	as	biomarkers	in	Cancer.	
	
	
	
	
	
